Following The Patents: Covid-19 & Medical Tyranny
Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.
The
National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit. (Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”
(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was
ever detected in humans!
Against
this backdrop, they noted the unusual patent prosecution efforts of the CDC,
when on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This
legality did not deter CDC in their efforts. Their application, updated in
2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not
licensed by their patent from manipulating SARS CoV, developing tests or kits
to measure SARS coronavirus in humans or working with their patented virus for
therapeutic use. Work associated with this virus by their select collaborators
included considerable amounts of chimeric engineering, gain-of-function
studies, viral characterization, detection, treatment (both vaccine and
therapeutic intervention), and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted
without permission or infringement.
It
was noted that gain-of-function specialist, Dr. Ralph Baric, was both the
recipient of millions of dollars of U.S. research grants from several federal
agencies but also sat on the World Health Organization’s International
Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study
Group (CSG). In this capacity, he was both responsible for determining
“novelty” of clades of virus species but directly benefitted from determining
declarations of novelty in the form of new research funding authorizations and
associated patenting and commercial collaboration. Together with CDC, NIAID, WHO,
academic and commercial parties (including Johnson & Johnson; Sanofi and
their several coronavirus patent holding biotech companies; Moderna; Ridgeback;
Gilead; Sherlock Biosciences; and, others), a powerful group of interests
constituted what we would suggest are “interlocking directorates” under U.S.
anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.
35 U.S.C. § 101
Section
101 of the Patent Act: "Whoever
invents or discovers any new and useful ... composition of matter, or any new
and useful improvement thereof, may obtain a patent therefor, subject to the
conditions and requirements of this title." 35 U.S.C. § 101.
We
have "long held that this provision contains an important implicit
exception[:] Laws of nature, natural phenomena, and abstract ideas are not
patentable." Mayo, 566 U.S., at , 132 S.Ct., at 1293 (internal
quotation marks and brackets omitted). Rather, "`they are the basic tools
of scientific and technological work'" that lie beyond the domain of
patent protection. Id., at ,
132 S.Ct., at 1293. As the Court has explained, without this exception, there
would be considerable danger that the grant of patents would "tie up"
the use of such tools and thereby "inhibit future innovation premised upon
them." Id., at _, 132
S.Ct., at 1301. This would be at odds with the very point of patents, which
exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct.
2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and
"`manifestations... of nature [are] free to all men and reserved
exclusively to none'").(Source: Association
for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))
In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.
When
they filed their patent application on April 25, 2003, their first claim (and
the only one that survived to ultimate issuance over the objection of the
patent examiner in 2006 and 2007) was the genome for SARS CoV.
While
this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC
insist on its granting over non-final and final rejections, but they also
continued to pay maintenance fees on the patent after the 2013 Supreme Court
decision confirmed that it was illegal.
In
addition, the CDC patented the detection of SARS CoV using a number of methods
including reverse transcription polymerase chain reaction (RT-PCR). With this
patent, they precluded anyone outside of their licensed or conspiring interest
from legally engaging in independent verification of their claim that they had
isolated a virus, that it was a causative agent for SARS, or that any therapy
could be effective against the reported pathogen.
It
is important to note that the CDC’s patent applications were also rejected in
non-final and final rejections for ineligibility under 35 U.S.C. § 102 for
being publicly disclosed prior to their own filing.
In the first non-final rejection, the USPTO stated that the CDC’s genome was
published in four Genbank accession entries on April 14, 18, and 21, 2003 with
identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO
Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew,
and failed to disclose evidence that the CDC patent was illegal, based on work
he had funded in the years leading up to the SARS outbreak.
After
seeking an illegal patent, petitioning to override the decision of an examiner
to reject it, and ultimately prevailing with the patent’s grant, the CDC lied
to the public by stating they were controlling the patent so that it would be
“publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0)
Tragically, this public statement is falsified by the simple fact that their
own publication in Genbank had, in fact, made it public domain and thereby
unpatentable. This fact, confirmed by patent examiners, was overridden by CDC
in a paid solicitation to override the law.
While
not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is
detailed below. Of note, however, is his willful and deceptive use of the term
“vaccine” in patents and public pronouncements to pervert the meaning of the
term for the manipulation of the public.
In the 1905 Jacobson v. Mass case, the court was clear that a
PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor
Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts,
197 U.S. 11 (1905), the court held that the context for their opinion rested on
the following principle:
“This court has more than once recognized it as a fundamental
principle that 'persons and property are subjected to all kinds of restraints
and burdens in order to secure the general comfort, health, and prosperity of
the state…”
The Moderna and Pfizer “alleged vaccine” trials have explicitly
acknowledged that their gene therapy technology has no impact on viral
infection or transmission whatsoever and merely conveys to the recipient the
capacity to produce an S1 spike protein endogenously by the introduction of a
synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and
the Supreme Court’s determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV
vaccine made the following statement supporting their rejection of his bogus
"invention"
18 U.S.C. §2339 C et seq. – Funding and Conspiring to
Commit Acts of Terror
Indirectly, unlawfully, and willfully provides or collects funds
with the intention that such funds be used, or with the knowledge that such
funds are to be used, in full or in part, in order to carry out—
- an act
which constitutes an offense within the scope of a treaty specified in
subsection (e)(7), as implemented by the United States, or
- any
other act intended to cause death or serious bodily injury to a civilian,
or to any other person not taking an active part in the hostilities in a
situation of armed conflict, when the purpose of such act, by its nature
or context, is to intimidate a population, or to compel a government or
an international organization to do or to abstain from doing any act….
By
no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the
association of SARS with bioterror potential. Leveraging the fear of the
anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic
terror had directed towards his budget. He specifically stated that NIAID was
actively funding research on a “SARS Chip” DNA microarray to rapidly detect
SARS (something that was not made available during the current “pandemic”) and
two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his
employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least
one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/
) This team, part of the Vaccine Research Center at NIAID, was primarily
focused on HIV vaccine development but was tasked to identify SARS vaccine
candidates as well. Working in collaboration with Sanofi, Scripps Institute,
Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as
a primary intervention for several designated “infectious diseases” precluded proven
therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)
The
CDC and NIAID led by Anthony Fauci entered into trade among States (including,
but not limited to working with EcoHealth Alliance Inc.) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences) through the 2014 et seq National Institutes of Health Grant
R01AI110964 to exploit their patent rights. This research was known to
involve surface proteins in coronavirus that had the capacity to directly
infect human respiratory systems. In flagrant violation of the NIH
moratorium on gain of function research, NIAID and Ralph Baric persisted in
working with chimeric coronavirus components specifically to amplify the
pathogenicity of the biologic material.
By
October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein
was described in NIAID’s funded work in China.
This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth
Alliance. This work, funded under R01AI079231, was pivotal in isolating and
manipulating viral fragments selected from sites across China which contained
high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et
al. Isolation and characterization of a bat SARS-like coronavirus that uses
the ACE2 receptor. Nature 503, 535–538 (2013).)
By
March 2015, both the virulence of the S1 spike protein and the ACE II receptor
was known to present a considerable risk to human health. NIAID,
EcoHealth Alliance and numerous researchers lamented the fact that the public
was not sufficiently concerned about coronavirus to adequately fund their
desired research.(Source: Forum on Medical and Public Health Preparedness for
Catastrophic Events; Forum on Drug Discovery, Development, and Translation;
Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global
Health; Institute of Medicine; National Academies of Sciences, Engineering, and
Medicine. Rapid Medical Countermeasure Response to Infectious Diseases:
Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector
Partnerships: Workshop Summary. Washington (DC): National Academies Press (US);
2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)
Dr.
Peter Daszak of EcoHealth Alliance offered the following assessment:
“Daszak
reiterated that, until an infectious disease crisis is very real, present, and
at an emergency threshold, it is often largely ignored. To sustain the funding
base beyond the crisis, he said, we need to increase public understanding of
the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key
driver is the media, and the economics follow the hype. We need to use that
hype to our advantage to get to the real issues. Investors will respond if they
see profit at the end of process, Daszak stated.”
Economics
will follow the hype.
The
CDC and NIAID entered into trade among States (including, but not limited to
working with University of North Carolina, Chapel Hill) and with foreign
nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place
during a time when the work being performed was prohibited by the United States
National Institutes of Health.
The
public was clearly advised of the dangers being presented by NIAID-funded
research by 2015 and 2016 when the Wuhan Institute of Virology material was
being manipulated at UNC in Ralph Baric’s lab.
“The
only impact of this work is the creation, in a lab, of a new, non-natural
risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at
Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are
long-standing critics of gain-of-function research.
In
their paper, the study authors also concede that funders may think twice about
allowing such experiments in the future. "Scientific review panels may
deem similar studies building chimeric viruses based on circulating strains too
risky to pursue," they write, adding that discussion is needed as to
"whether these types of chimeric virus studies warrant further
investigation versus the inherent risks involved”.
But
Baric and others say the research did have benefits. The study findings “move
this virus from a candidate emerging pathogen to a clear and present danger”,
says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the
EcoHealth Alliance, an international network of scientists, headquartered in
New York City, that samples viruses from animals and people in
emerging-diseases hotspots across the globe.
Studies
testing hybrid viruses in human cell culture and animal models are limited in
what they can say about the threat posed by a wild virus, Daszak agrees. But he
argues that they can help indicate which pathogens should be prioritized for
further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )
Knowing
that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID,
and their funded laboratories and commercial partners) had patents on each
proposed element of medical counter measures and their funding, Dr. Fauci, Dr.
Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to
commit acts of terror on the global population – including the citizens of the
United States – when, in September 2019, they published the following mandate:
“Countries,
donors and multilateral institutions must be prepared for the worst. A
rapidly spreading pandemic due to a lethal respiratory pathogen (whether
naturally emergent or accidentally or deliberately released) poses
additional preparedness requirements. Donors and multilateral institutions must
ensure adequate investment in developing innovative vaccines and therapeutics,
surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical
interventions. All countries must develop a system for immediately sharing
genome sequences of any new pathogen for public health
purposes along with the means to share limited medical countermeasures across
countries.
Progress
indicator(s) by September 2020
A. Donors and countries commit and
identify timelines for: financing and development of a universal influenza
vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its
Member States develop options for standard procedures and timelines for sharing
of sequence data, specimens, and medical countermeasures for pathogens other
than influenza.
B. Donors, countries and multilateral
institutions develop a multi-year plan and approach for strengthening R&D
research capacity, in advance of and during an epidemic.
C. WHO, the United Nations Children’s
Fund, the International Federation of Red Cross and Red Crescent Societies,
academic and other partners identify strategies for increasing capacity and
integration of social science approaches and researchers across the entire
preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf
(page 8) )
As
if to confirm the utility of the September 2019 demand for “financing and development
of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019,
Dr. Fauci began gloating that his fortunes for additional funding were likely
changing for the better. In a February 2020 interview in STAT, he
was quoted as follows:
““The
emergence of the new virus is going to change that figure, likely considerably,
Fauci said. “I don’t know how much it’s going to be. But I think it’s going to
generate more sustained interest in coronaviruses because it’s very clear that
coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting
in death of American Citizens
Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded
the definition of terrorism to cover "domestic," as opposed to
international, terrorism. A person engages in domestic terrorism if they do an
act "dangerous to human life" that is a violation of the criminal
laws of a state or the United States, if the act appears to be intended to: (i)
intimidate or coerce a civilian population; (ii) influence the policy of a
government by intimidation or coercion;
Dr.
Anthony Fauci has intimidated and coerced a civilian population and sought to
influence the policy of a government by intimidation and coercion.
With
no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives
) Professor Neil Ferguson’s computer simulation derived claims that,
“The
world is facing the most serious public health crisis in generations. Here we
provide concrete estimates of the scale of the threat countries now face.
“We
use the latest estimates of severity to show that policy strategies which aim
to mitigate the epidemic might halve deaths and reduce peak healthcare demand
by two-thirds, but that this will not be enough to prevent health systems being
overwhelmed. More intensive, and socially disruptive interventions will
therefore be required to suppress transmission to low levels. It is likely such
measures – most notably, large scale social distancing – will need to be in
place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)
Reporting
to the President that as many as 2.2 million deaths may result from a pathogen
that had not yet been isolated and could not be measured with any accuracy, Dr.
Fauci intimidated and coerced the population and the government into reckless,
untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source:
https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline)
Neither the Imperial College nor the “independent” Institute for Health
Metrics and Evaluation (principally funded by the Bill and Melinda Gates
Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement)
had any evidence of success in estimating previous burdens from
coronavirus but, without consultation or peer-review, Dr. Fauci adopted their
terrifying estimates as the basis for interventions that are explicitly against
medical advice.
a. The imposition of social
distancing was based on computer simulation and environmental models with NO
disease transmission evidence whatsoever.
b. The imposition of face mask
wearing was directly against controlled clinical trial evidence and against the
written policy in the Journal of the American Medical Association.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)
c. In both the Imperial College and
the IHME simulations, quarantines were modeled for the sick, not the
healthy.
Insisting
on vaccines while blockading the emergency use of proven pharmaceutical
interventions may have contributed to the death of many patients and otherwise healthy
individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)
Using
the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively
suppressed proven medical countermeasures used by, and validated in scientific
proceedings, that offered alternatives to the products funded by his conspiring
entities for which he had provided direct funding and for whom he would receive
tangible and intangible benefit.
18 U.S.C. § 1001 – Lying to Congress
Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—
- falsifies, conceals, or covers up by any trick, scheme, or
device a material fact;
- makes any materially false, fictitious, or fraudulent
statement or representation; or
- makes or uses any false writing or document knowing the
same to contain any materially false, fictitious, or fraudulent
statement or entry;
shall
be fined under this title, imprisoned not more than 5 years or, if the offense
involves international or domestic terrorism (as defined in section 2331),
imprisoned not more than 8 years, or both. If the matter relates to an offense
under chapter 109A, 109B, 110, or 117, or section 1591, then the term of
imprisonment imposed under this section shall be not more than 8 years.
On
October 22, 2020, the United States Government Accountability Office (GAO)
published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly
Report More Information about the Licensing of Its Intellectual Property.
In this document, the
authors reported that the National Institutes of Health (NIH) received, “up to
$2 billion in royalties from its contributions to 34 drugs sold from
1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)
A
casual review of the NIH Office of Technology Transfer report of active
licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics)
appears to conflict with the GAO report on several important facts.
Conspicuously absent from the GAO report are over 30 patents associated with
active compounds generating billions of dollars in revenue. Why would it be
that the GAO and the NIH couldn’t agree on something as simple as drugs
generating income for NIH?
Since
the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally
funded research has been an economic bonanza for U.S. universities, federal
agencies, and their selected patronage. For the first decade following Bayh
Dole, NIH funding
doubled from $3.4 billion to $7.1 billion. A decade later, it
doubled again to $15.6 billion. In the wake of September 2001, the
National Institute for Allergy and Infectious Diseases (NIAID) saw its direct
budget increase over 300%, without accounting for DARPA, funds of as much as
$1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41
billion.
What
has become of the $763 billion of taxpayer funds allocated to making America
healthier since inventors have been commercially incentivized? Who has been
enriched?
The
answer, regrettably, is that no accountability exists to answer these questions.
The NIH is the named owner of at least 138 patents since 1980.
The
United States Department of Health and Human Services is the named owner of at
least 2,600 patents.
NIAID
grants or collaboration have resulted in 2,655 patents and patent applications
of which only 95 include an assignment to the Department of Health and Human
Services as an owner. Most of these patents are assigned to universities
thereby making the ultimate commercial beneficiaries entirely opaque. One
of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly
reporting close affiliation with NIAID, is not referenced in the NIH GAO
report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing
its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before
exiting to commercial ventures. While their technology is clearly derived
from NIAID science, the company reports revenue from NIAID but no royalty or
commercial payments to NIH or any of its programs.
NIAID’s
Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents.
None of them are reported in NIAID, NIH, or GAO reports of active licensing
despite the fact that Dr. Fauci reportedly was compelled to get paid for his
interleukin-2 “invention” – payments he reportedly donated to an unnamed
charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)
Of
the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange
book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are
listed. Furthermore, none of the NIAID patents are listed despite clear
evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of
Johnson & Johnson) have generated over $2 billion annually from sales that
were the direct result of NIAID funded science. Missing from the GAO report
are 2 patents for Velclade® which has been generating sales in excess of $2.18
billion annually for several years. None of the patents for Yescarta® are
listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO
report. None of the Kepivance® patents are listed in the GAO report. In
violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in
the GAO report fail to disclose government interest despite being the direct
result of NIH funding.
Dr.
Anthony Fauci’s Own Patent Track Record:
US
Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent
interleukin-2 therapy:
A
method for activating a mammalian immune system entails a series of IL-2
administrations that are affected intermittently over an extended period. Each
administration of IL-2 is sufficient to allow spontaneous DNA synthesis in
peripheral blood or lymph node cells of the patient to increase and peak, and
each subsequent administration follows the preceding administration in the
series by a period of time that is sufficient to allow IL-2 receptor expression
in peripheral or lymph node blood of the patient to increase, peak and then
decrease to 50% of peak value. This intermittent IL-2 therapy can be combined
with another therapy which targets a specific disease state, such as an anti-retroviral
therapy comprising, for example, the administration of AZT, ddI or interferon
alpha. In addition, IL-2 administration can be employed to facilitate in situ
transduction of T-cells in the context of gene therapy. By this approach the
cells are first activated in vivo via the aforementioned IL-2 therapy, and
transduction then is affected by delivering a genetically engineered retroviral
vector directly to the patient.
This
application is a continuation of U.S. patent application Ser. No. 08/487,075,
filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S.
patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S.
Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May
26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage
filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of
which are incorporated herein by reference.
Filed
May 19, 1993
Issued
a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998
and April 12, 1999. Reduced and modified claims granted May 8, 2000.
This
family of patents was the basis of Fauci’s lie to the British Medical
Journal in which he falsely stated:
“Dr
Anthony Fauci told the BMJ that as a government employee he was required by law
to put his name on the patent for the development of interleukin 2 and was also
required by law to receive part of the payment the government received for use
of the patent. He said that he felt it was inappropriate to receive payment and
donated the entire amount to charity.”
US Patent 6,911,527 - HIV related peptides:
This
invention is the discovery of novel specific epitopes and antibodies associated
with long term survival of HIV-1 infections. These epitopes and antibodies have
use in preparing vaccines for preventing HIV-1 infection or for controlling
progression to AIDS.
Filed
May 6, 1999
Rejected
as unpatentable January 22, 2003. Issued with a final rejection on July 15,
2004 after submitting reconsideration requests. Modified and restricted claims
allowed September 29, 2004.
US
Patent 7,368,114 - Fusion protein including of CD4:
Novel
recombinant polypeptides are disclosed herein that include a CD4 polypeptide
ligated at its C-terminus with a portion of an immunoglobulin comprising a
hinge region and a constant domain of a mammalian immunoglobulin heavy chain.
The portion or the IgG is fused at its C-terminus with a polypeptide comprising
a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara
tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also
disclosed herein are methods for using these CD4 fusion proteins.
Filed
October 24, 2002
Rejected
as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings
February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants
further narrowed the construction of what was clearly not a patent and the
USPTO granted less than half the claims that had been sought in the original
filing.
US
Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the
interaction between HIV GP120 and .alpha.4.beta.7 integrin:
Methods
are provided for the treatment of a HIV infection. The methods can include
administering to a subject with an HIV infection a therapeutically effective
amount of an agent that interferes with the interaction of gp120 and .alpha.4
integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist,
thereby treating the HIV infection. In several examples, the .alpha.4 integrin
antagonist is a monoclonal antibody that specifically binds to a .alpha.4,
.beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino
acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or
infection. The methods include contacting a cell with an effective amount of an
agent that interferes with the interaction of gp120 and .alpha.4 integrin, such
as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods
are provided for determining if an agent is useful to treat HIV.
Rejected
May 22, 2017 as Double Patenting. In their response, the applicants acknowledge
the illegal act and seek only those components of their application that extend
beyond the life of the issued patents. On October 11, 2017, the limited claims
were issued.
A
sample of the convoluted flow of funds that evades public disclosure.
U.S.
Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby,
British Columbia. In their patent, they disclose that their research was
supported by a grant from the National Institute of Allergy and Infectious
Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was
awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam
Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics |
Technology Networks)
In
2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes
including a $1 billion damages claim for “relentless and egregious”
misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest
priority of November 10, 2008, there is no public record stating Tekmira as the
beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle
technology developed from this grant is the technology now used in the Moderna
COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a
license to technology from Arbutus – formerly Tekmira – which has accused
Acuitas of misappropriating trade secrets and licensing them to Moderna and
Pfizer’s collaboration with BioNTech.
Additional
references can be found at:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22
15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity
Every
contract, combination in the form of trust or otherwise, or conspiracy, in
restraint of trade or commerce among the several States, or with foreign
nations, is declared to be illegal. Every person who shall make any contract or
engage in any combination or conspiracy hereby declared to be illegal shall be
deemed guilty of a felony, and, on conviction thereof, shall be punished by
fine not exceeding $100,000,000 if a corporation, or, if any
other
person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said
punishments, in the discretion of the court.
The
National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at
the University of North Carolina at Chapel Hill (officially classified as
affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for
the express purpose of general research, pathogenic enhancement, detection,
manipulation, and potential therapeutic interventions targeting the same. As
early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of
the coronavirus family for their commercial benefit.(Source: U.S. Provisional
Application No. 60/206,537, filed May 21, 2000) In one of the several papers
derived from work sponsored by this grant, Dr. Baric published what he reported
to be the full length cDNA of SARS CoV in which it was clearly stated that SAR
CoV was based on a composite of DNA segments.
“Using
a panel of contiguous cDNAs that span the entire genome, we have assembled a
full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly
cloned SARS viruses (infectious clone SARS-CoV) that contained the expected
marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)
On
April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher
M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent
7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an
infectious, replication defective, coronavirus.” This work was supported by the
NIH grant referenced above and GM63228. In short, the U.S. Department of Health
and Human Services was involved in the funding of amplifying the infectious
nature of coronavirus between 1999 and 2002 before SARS was ever
detected in humans.
Against
this backdrop, we noted the unusual patent prosecution efforts of the CDC, when
on April 25, 2003 they sought to patent the SARS coronavirus isolated from
humans that had reportedly transferred to humans during the 2002-2003 SARS
outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did
not deter CDC in their efforts. Their application, updated in 2007, ultimately
issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS
coronavirus in humans or working with their patented virus for therapeutic use.
Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral
characterization, detection, treatment (both vaccine and therapeutic intervention),
and weaponization inquiries.
In
short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852
patent (Claim 1), no research in the United States could be conducted without
permission or infringement.
We
noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient
of millions of dollars of U.S. research grants from several federal agencies
but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In
this capacity, he was both responsible for determining “novelty” of clades of
virus species but directly benefitted from determining declarations of novelty
in the form of new research funding authorizations and associated patenting and
commercial collaboration. Together with CDC, NIAID, WHO, academic and
commercial parties (including Johnson & Johnson; Sanofi and their several
coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead;
Sherlock Biosciences; and, others), a powerful group of interests constituted
what we would suggest are “interlocking directorates” under U.S. anti-trust
laws.
·
1986-1990 NIAID Grant AI
23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant
Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
The
paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
·
1990 Pfizer files U.S.
Patent 6,372,224 on a vaccine for the S-protein on coronavirus November
14, 2000 which was abandoned April 2010 making it public domain.
· 1990s Work focused on CoV association with cardiomyopathy (see above)
Early
reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
·
2000 Ralph Baric AI23946
and GM63228 from the National Institutes of Health actively working recombinant
CoV
·
2001 National Institute
of Health, Allergy and Infectious diseases. “Reverse Genetics with a
Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total
costs/yr. RS Baric, PI
·
2002 Asia CoV SARS
outbreak
· 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.
Dr.
Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand
Challenges Scientific Advisory Board (served through 2010).
·
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response
and patent US7,151,163 https://www.sbir.gov/node/305319
· July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana
Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to
neutralize SARS CoV. This research is supported by several NIH grants including
National Institutes of Health Grants A128785, A148436, and A1053822.
·
2004 January 6, 2004 – SARS
and Bioterrorism linked at Bioterrorism and Emerging Infectious
Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At
this conference, the term “The New Normal” was introduced by Merck
FAUCI
AND BARIC start making money!!! National Institutes of Health,
Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7
million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project
develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV
replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV
to mice, producing a pathogenic mouse model for SARS-CoV infection.
National
Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS
Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09.
$2.1 million
·
November 22, 2004
University of Hong Kong patents SARS associated spike protein on CoV and
pursues patent US 7,491,489
·
2005 DARPA gets in on the
game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies,
June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Review
timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U
and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
·
2008 Biodefense Grant U54
AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
·
2009 Biodefense Grant U54
AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)
Patent
issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued
patents.
·
August 6, 2010, Moderna (prior to its establishment) files U.S.
Patent 9,447,164 which attracted the investment of (and “inventorship” for)
venture capitalists at Flagship Ventures. This patent grew out of the work of
Dr. Jason P. Schrum of Harvard Medical School supported by National Science
Foundation Grant #0434507. While the application claims priority to August 2010, the application
didn’t get finalized until October, 2015. On November 4, 2015, the USPTO
issued a non-final rejection on this original patent rejecting all claims.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507
with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
·
2011 Crucell joined the
Janssen Pharmaceutical Companies of Johnson & Johnson in February taking
with it all of its SARS technology.
Biodefense
Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill
(non-competitive grant from NIAID)
·
2012 MERS isolated in
Egypt
Biodefense
Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive
grant from NIAID)
·
2013 Biodefense Grant U54
AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant
from NIAID)
· 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435
·
2015 Moderna signs a
vaccine development agreement with NIAID and executes it with the lead on the
mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
·
2016 NIH through Scripps
Institute and Dartmouth College file patent application WO 2018081318A1
“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology
that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en
Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person
at NIH that Moderna “e-mailed” to get the sequence for SARS
CoV-2
according to Moderna’s report here (“In January
2020, once it was discovered that the infection in Wuhan was caused by a novel
coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the
Vaccine Research Center at the National Institutes of Health, asking him to
send the genetic sequence for the virus.”)
https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In
addition, co-inventor Jason McLellan worked with Graham on a vaccine patent
jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
·
2017 August – Sanofi buys
Protein Science Corp with considerable SARS patent holdings
·
2018 June – Sanofi buys
Ablynx with considerable SARS patent holdings
·
2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by
Open Philanthropy – the same organization that would be the financial sponsor
of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan
in October 2019.
15 U.S.C. §8 – Market Manipulation and Allocation
Every combination, conspiracy, trust, agreement, or contract is
declared to be contrary to public policy, illegal, and void when the same is
made by or between two or more persons or corporations, either of whom, as
agent or principal, is engaged in importing any article from any foreign
country into the United States, and when such combination, conspiracy, trust,
agreement, or contract is intended to operate in restraint of lawful trade, or
free competition in lawful trade or commerce, or to increase the market price
in any part of the United States of any article or articles imported or
intended to be imported into the United States, or of any manufacture into
which such imported article enters or is intended to enter. Every person who
shall be engaged in the importation of goods or any commodity from any foreign
country in violation of this section, or who shall combine or conspire with
another to violate the same, is guilty of a misdemeanor, and on conviction
thereof in any court of the
United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.
Through
non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of
the Bio-Safety Level 4 laboratory locations, to the setting of prices for
Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S.
Department of Health and Human Services have been involved in allocating
Federal funds to conspiring parties without independent review.
Around
March 12, 2020, in an effort to enrich their own economic interests by way of
securing additional funding from both Federal and Foundation actors, the CDC
and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by
capricious symptom presentation alone. Forcing the public to rely on The
COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates
Foundation and presented by a media outlet (The Atlantic) – not a public health agency – Dr. Fauci used
fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive
PCR tests in the living while insisting that COVID deaths be counted by
symptoms alone. This perpetuated a market demand for his desired vaccine agenda
which was recited by him and his conspiring parties around the world until the
present. Not surprisingly, this was necessitated by the apparent fall in cases
that constituted Dr. Fauci’s and others’ criteria for depriving citizens of
their 1st Amendment rights.
15 U.S.C. § 19 – Interlocking Directorates
No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—
- engaged in whole or in part in commerce; and
- by virtue of their business and location of operation,
competitors, so that the elimination of competition by agreement between
them would constitute a violation of any of the antitrust laws; if each
of the corporations has capital, surplus, and undivided profits
aggregating more than $10,000,000 as adjusted pursuant to paragraph (5)
of this subsection.
Dr. Fauci is on the Leadership Council
of the Bill and Malinda Gates Global Vaccine Action Plan
Dr.
Fauci while controlling the economic dispensation of Federal research funding,
Dr. Fauci has been, and continues to be, on the World Health Organization’s
Global Preparedness Monitoring Board. He is joined on this board by the
conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias
and the State Council of China’s Dr. George
F.
Gao of the Chinese CDC. This GPMB stipulated that all member states must take
part in a global simulation of the release of a respiratory pathogen.
Dr.
Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4
facility and sits on the International Committee on Taxonomy of Virus Coronaviridae
Working Group tasked to confirm the presence of absence of the pathogen for
which he is directly compensated.
As
referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous
undisclosed commercial relationships exist between funded researchers, their
funding agencies, and commercial interests in which disclosed and undisclosed
commercial terms exist. A complete list of all potential implicated parties
is listed in the section below entitled “The Commercial Actors”.
It
appears that during the period of patent enforcement and after the Supreme
Court ruling confirming that patents on genetic material were illegal, the CDC
and National Institute of Allergy and Infectious Diseases led by Anthony Fauci
(hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade
among States (including, but not limited to working with Ecohealth Alliance
Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology
and the Chinese Academy of Sciences) through the 2014 et seq National
Institutes of Health Grant R01AI110964 to exploit their patent rights.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on genetic material was illegal,
the CDC and National Institute of Allergy and Infectious Diseases (hereinafter
“NIAID”) entered into trade among States (including, but not limited to working
with University of North Carolina, Chapel Hill) and with foreign nations
(specifically, the Wuhan Institute of Virology and the Chinese Academy of
Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric),
U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China
Award 81290341 (Zheng-Li Shi) et al. 2015-2016.
It
further appears that during the period of patent enforcement and after the
Supreme Court ruling confirming that patents on generic material was illegal,
the CDC and NIAID entered into trade among States (including, but not limited
to working with University of North Carolina, Chapel Hill) and with foreign
nations to conduct chimeric construction of novel coronavirus material with
specific virulence properties prior to, during, and following the determination
made by the National Institutes for Health in October 17, 2014 that this work
was not sufficiently understood for its biosecurity and safety standards.
In
this inquiry, it is presumed that the CDC and its associates were: a) fully
aware of the work being performed using their patented technology; b) entered
into explicit or implicit agreements including licensing, or other consideration;
and, c) willfully engaged one or more foreign interests to carry forward the
exploitation of their proprietary technology when the U.S. Supreme Court
confirmed that such patents were illegal and when the National Institutes of
Health issued a moratorium on such research.
Reportedly,
in January 2018, the U.S. Embassy in China sent investigators to Wuhan
Institute of Virology and found that, “During interactions with scientists
at the WIV laboratory, they noted the new lab has a serious shortage of
appropriately trained technicians and investigators needed to safely operate
this high-containment laboratory.” The Washington Post reported that this
information was contained in a cable dated 19 January 2018. Over a year later,
in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army
Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and
ordered it closed after alleging that their inspection found biosafety hazards.
A report in the journal Nature in 2003 (423(6936): 103) reported cooperation
between CDC and USAMRIID on coronavirus research followed by considerable
subsequent collaboration. The CDC, for what appear to be the same type of
concern identified in Wuhan, elected to continue work with the Chinese
government while closing the U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.
35 U.S.C. §200 - 206 – Disclosure of Government Interest
35 U.S.C. §202 (c)(6)
An
obligation on the part of the contractor, in the event a United States patent
application is filed by or on its behalf or by any assignee of the contractor,
to include within the specification of such application and any patent issuing
thereon, a statement specifying that the invention was made with Government
support and that the Government has certain rights in the invention.
Over 5000 patents and patent
applications have included reference to SARS Coronavirus dating back to
priority dates of 1998. They are summarized below.
On
July 23, 2020, the Patent Trial and Appeal Board of the United States Patent
and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent
8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by
Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver
an mRNA vaccine. Some of the core technology was based on work originally done
at the University of British Columbia and was first licensed in 1998.
mRNA-1273
– the experimental vaccine developed by Moderna for COVID-19 – uses the LNP
technology that Moderna thought it had licensed from Acuitas Therapeutics Inc.,
a firm developed by a former principal of Arbutus’ prior company Tekmira. That
license did not authorize Moderna to use the technology for the COVID-19
vaccine.
M·CAM
and Knowledge Ecology International have independently confirmed that Moderna
has violated U.S. law in failing to disclose the U.S. government’s funding
interest in their patents and patent applications.
While this negligence impacts all of Moderna’s over 130 granted U.S. patents,
it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the
patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open
reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein
subunit formulated in a lipid nanoparticle.” The specific claims addressing the
pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS
CoV-2 outbreak! Both the patent and the DARPA funding
for the technology were disclosed in scientific publication (New England
Journal of Medicine) but the government funds were not acknowledged in the
patent.
In 2013, the Autonomous Diagnostics to Enable Prevention and
Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for
the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was
W911NF-13-1-0417. The company used that technology to develop its
COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source:
https://crsreports.congress.gov/product/pdf/IN/IN11446)
Under
the Federal Acquisition Regulation (FAR) rules, contractor to the Federal
Government must provide information regarding intellectual property
infringement issues as part of their contract. Under FAR §27.201-1(c) and (d),
the Government both requires a notice of infringement or potential infringement
as well as retention of economic liability for patent infringements. Specifically,
in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its
officers, agents, and employees against liability, including costs for
infringement of any United States Patent…”. In addition to the patents cited by
the USPTO in their examination of ‘600, M·CAM has identified fourteen other
issued patents preceding the ‘600 patent which were used by patent examiners to
limit patents arising from the same funded research including patents sought by
CureVac.
In
short, while Moderna enjoys hundreds of millions of dollars of funding,
allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception,
it has been engaged in illegal patent activity and demonstrated contempt for
U.S. Patent law. To make matters worse, the U.S. Government has given it
financial backing in the face of undisclosed infringement risks potentially
contributing to the very infringement for which they are indemnified.
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial
It
is unlawful to conduct medical research (even in the case of emergency) without
a series of steps taken to:
- Establish
the research with a duly authorized and independent institutional review
board;
- Secure
informed consent of all participants including a statement of risks and
benefits; and,
- Engage
in consultation with the community in which the study is to be conducted.
Dr.
Anthony Fauci has forced upon the healthy population of the United States an
unlawful clinical trial in which the U.S. Department of Health and Human
Services are extrapolating epidemiologic data. No informed consent has been
sought or secured for any of the “medical countermeasures” forced upon the
population and no independent review board – as defined by the statute – has
been empaneled.
Through
April 2020, the official recommendation by the Journal of the American
Medical Association was unambiguous.
“Face
masks should not be worn by healthy individuals to protect themselves from
acquiring respiratory infection because there is no evidence to suggest that
face masks worn by healthy individuals are effective in preventing people from
becoming ill.”(Source: Medical Masks
| Infectious Diseases | JAMA | JAMA Network)
Part
of that lack of evidence in fact showed that cloth facemasks actually increased
influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)
In
contravention to established science, States, municipalities, and
businesses have violated the legal requirements for the promulgation of medical
counter measures during a public health emergency stating a “belief” that face
masks limit the spread of SARS CoV-2. To date, not a single study has confirmed
that a mask prevented the transmission of, or the infection by SARS CoV-2.
All
parties mandating the use of facemasks are not only willfully ignoring
established science but are engaging in what amounts to a whole population clinical
trial. This conclusion is reached by the fact that facemask use and COVID-19
incidence are being reported in scientific opinion pieces promoted by the
United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)
Social
distancing of up to 6 feet has been promoted as a means of preventing
person-to-person transmission of influenza-like viruses. While one study
hypothesized that infection could happen in a 6 foot range, the study
explicitly states that person-to-person transfer was not tested and
viability of the virus at 6 feet was not even a subject of the investigation.(Source:
Werner E. Bischoff, Katrina Swett, Iris Leng,
Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient
Care, The Journal of Infectious Diseases,
Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773)
That did not stop the misrepresentation of the study to be used as the basis
for an unverified medical counter measure of social distancing. To date, no
study has established the efficacy of social distancing to modify the
transmission of SARS CoV-2. Public health officials have referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.
|
|
It
is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a
product or service can prevent, treat, or cure human disease unless you possess
competent and reliable scientific evidence, including, when appropriate, well-
controlled human clinical studies, substantiating that the claims are true at
the time they are made. As a result, every party promoting the use of face
masks is violating the FTC Act.
The Commercial Actors
SARS coronavirus is a new topic for many individuals. Since 1999,
the ability to manipulate and exploit coronavirus for a variety of purposes has
attracted the attention of individuals, institutions and commercial
organizations in public, private, and not-for-profit sectors.
The following is a list of over 4,000 patents and patent
applications filed for the express purpose of controlling some aspect of the
SARS coronavirus.
PATENT |
Title |
Owner |
Priority |
File Date |
Issue Date |
US9995706 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9995705 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
30- Sep -14 |
12- Jun- 18 |
US9994558 |
Multicyclic
compounds and methods of using same |
Karyopharm
Therapeutics Inc. |
20- Sep- 13 |
19- Sep -14 |
12- Jun- 18 |
US9994550 |
Heterocyclic
modulators of lipid synthesis for use against cancer and viral infections |
3-V
Biosciences, Inc. |
7- Jan- 14 |
7- Jan -15 |
12- Jun- 18 |
US9993543 |
Immunogenic
compositions comprising silicified virus and methods of use |
Portland
State University |
31- Jan- 13 |
31- Jan -14 |
12- Jun- 18 |
US9982257 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
29- May -18 |
US9982241 |
Recombinant
HCMV and RHCMV vectors and uses thereof |
Oregon
Health & Science University |
14- May- 10 |
1- Oct -15 |
29- May -18 |
US9982025 |
Monomeric
griffithsin tandemers |
The
United States of America, as represented by the Secretary, Department of Health
and Human Services |
5- Jun-
13 |
5- Jun -14 |
29- May -18 |
US9981036 |
Compositions,
comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics
and methods of using the same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
12- Dec- 11 |
26- Feb -16 |
29- May -18 |
US9975885 |
Broad-spectrum
non-covalent coronavirus protease inhibitors |
PURDUE
RESEARCH FOUNDATION |
28- Apr- 16 |
28- Apr -17 |
22- May -18 |
US9974850 |
Immunogenic
compositions and uses thereof |
BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
25- Mar- 15 |
25- Mar -16 |
22- May -18 |
US9974848 |
Tetanus
toxoid and CCL3 improve DC vaccines |
Duke
University |
14- Nov- 13 |
14- Nov -14 |
22- May -18 |
US9974845 |
Combination
of vaccination and inhibition of the PD-1 pathway |
CureVac
AG |
22- Feb- 13 |
21- Feb -14 |
22- May -18 |
US9970061 |
Bioagent
detection oligonucleotides |
IBIS
BIOSCIENCES, INC. |
27- Dec- 11 |
27- Dec -12 |
15- May -18 |
US9969793 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
Biologics, Inc. |
28- Oct- 14 |
13- Nov -17 |
15- May -18 |
US9963718 |
LCMV-GP-VSV-pseudotyped
vectors and tumor-infiltrating virus- producing cells for the therapy of
tumors |
VIRATHERAPEUTICS
GMBH |
8- Oct-
08 |
7- Apr -17 |
8- May -18 |
US9963611 |
Composition
for use in decreasing the transmission of human pathogens |
Innonix
Technologies, Incorporated |
29- May- 09 |
21- May -10 |
8- May -18 |
US9963427 |
Dithiol
mucolytic agents |
PARION
SCIENCES, INC. |
23- Aug- 13 |
11- Mar -16 |
8- May -18 |
US9962439 |
Injectable
vaccine composition |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
8- May -18 |
US9957302 |
Treating
cancer with viral nucleic acid |
Mayo
Foundation for Medical Education and Research |
20- Feb- 07 |
6- Jul- 15 |
1- May -18 |
US9957300 |
Virus-like
particles, methods of preparation, and immunogenic compositions |
Emory
University |
17- May- 02 |
4- May -15 |
1- May -18 |
US9957238 |
Arylalkyl-and
aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
1- Mar -17 |
1- May -18 |
US9951317 |
Highly
efficient influenza matrix (M1) proteins |
NOVAVAX,
INC. |
11- Jul-03 |
6- Oct -16 |
24- Apr- 18 |
US9951124 |
Antibody
producing non-human mammals |
MERUS
N.V. |
27- Jun- 08 |
25- Jan -13 |
24- Apr- 18 |
US9951122 |
Antibodies
against influenza virus and methods of use thereof |
BURNHAM
INSTITUTE FOR MEDICAL RESEARCH |
6- Dec-
07 |
12- Aug -13 |
24- Apr- 18 |
US9950062 |
Compounds
and compositions as TLR activity modulators |
GLAXOSMITHKLINE
BIOLOGICALS SA |
2- Sep-
09 |
1- Sep -10 |
24- Apr- 18 |
US9945856 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
AMSTERDAM
INSTITUTE OF VIRAL GENOMICS B.V. |
18- Aug- 03 |
13- Aug -14 |
17- Apr- 18 |
US9945780 |
Use of a
fluorescent material to detect failure or deteriorated performance of a
fluorometer |
GEN-PROBE
INCORPORATED |
14- Jun- 12 |
7- Jun -13 |
17- Apr- 18 |
US9944928 |
Construction
of pool of interfering nucleic acids covering entire RNA target sequence and
related compositions |
York
Yuan Yuan Zhu |
23- Jul-07 |
2- Jul- 15 |
17- Apr- 18 |
US9944695 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
30- Apr -14 |
17- Apr- 18 |
US9944686 |
Treatment
of tumors with recombinant interferon alpha |
SUPERLAB
FAR EAST LIMITED |
28- Feb- 01 |
5- Sep -13 |
17- Apr- 18 |
US9944649 |
Compounds
and compositions as toll-like receptor 7 agonists |
Novartis
Ag |
1- May-
14 |
29- Apr -15 |
17- Apr- 18 |
US9943614 |
Cationic
steroid antimicrobial diagnostic, detection, screening and imaging methods |
BRIGHAM
YOUNG UNIVERSITY |
17- Jun- 08 |
16- Jun -09 |
17- Apr- 18 |
US9938300 |
Isothiazolopyrimidinones,
pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific
protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb- 15 |
4- Feb -16 |
10- Apr- 18 |
US9938275 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
23- Jan -17 |
10- Apr- 18 |
US9938258 |
Substituted
2,3-dihydrobenzofuranyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Nov- 12 |
27- Nov -13 |
10- Apr- 18 |
US9932351 |
Thienopyrimidinones
as ubiquitin-specific protease 7 inhibitors |
Forma
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
3- Apr-
18 |
US9932323 |
Therapeutic
hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
Rutgers,
The State University of New Jersey |
11- Sep- 12 |
13- Jan -17 |
3- Apr-
18 |
US9931316 |
Antiviral
activity from medicinal mushrooms and their active constituents |
Not
Available |
31- Mar- 15 |
14- Sep -15 |
3- Apr-
18 |
US9926340 |
NAD
analogs and methods of using said NAD analogs in determining ribosylation of
proteins with PARP mutants |
Biolog
Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH |
8- Apr-
15 |
1- Apr -16 |
27- Mar -18 |
US9925215 |
Anionically
modified polyallylamine derivative, use of anionically modified
polyallylamine derivative as medicine, particularly for propylaxis and
treatment of infections of respiratory tract caused by human metapneumovirus
(hMPV), human rhinoviruses (HRV), and infection by influenza virus type A
(IAV) and pharmaceutical composition comprising the anionically modified
polyallylamine derivative |
UNIWERSYTET
JAGIELLONSKI |
29- Jul-14 |
25- Oct -17 |
27- Mar -18 |
US9920314 |
Compositions
for and methods of identifying antigens |
President
and Fellows of Harvard College |
21- Feb- 06 |
6- May -15 |
20- Mar -18 |
US9920128 |
Synthetic
antiserum for rapid-turnaround therapies |
The
Johns Hopkins University |
28- Jan- 15 |
20- Jan -16 |
20- Mar -18 |
US9919034 |
Methods
of treating and prophylactically protecting mammalian patients infected by
viruses classified in Baltimore group V |
TAMIR
BIOTECHNOLOGY, INC. |
28- Mar- 14 |
10- Jun -15 |
20- Mar -18 |
US9915613 |
Systems
and methods for distinguishing optical signals of different modulation
frequencies in an optical signal detector |
GEN-PROBE
INCORPORATED |
24- Feb- 11 |
21- Mar -14 |
13- Mar -18 |
US9914976 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA AGRICULTURAL
AND MECHANICAL UNIVERSITY (FA |
25- Mar- 11 |
27- May -16 |
13- Mar -18 |
US9913801 |
Treatment
of evolving bacterial resistance diseases including Klebsiella pneumoniae
with liposomally formulated glutathione |
YOUR
ENERGY SYSTEMS, LLC |
15- Feb- 13 |
15- Mar -13 |
13- Mar -18 |
US9909176 |
Efficient
deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq) |
The
Johns Hopkins University |
8- Sep-
14 |
1- Sep -15 |
6- Mar -18 |
US9908946 |
Generation
of binding molecules |
Merus
N.V. |
26- Sep- 11 |
16- Sep -15 |
6- Mar -18 |
US9908675 |
Powdered
pouch and method of making same |
MONOSOL,
LLC |
16- Apr- 12 |
19- Jul- 16 |
6- Mar -18 |
US9907796 |
Methods
of treating tumoral diseases, or bacterial or viral infections |
INHIBIKASE
THERAPEUTICS, INC. |
4- Oct-
12 |
15- Sep -16 |
6- Mar -18 |
US9895692 |
Sample-to-answer
microfluidic cartridge |
Micronics,
Inc. |
29- Jan- 10 |
5- Aug -15 |
20- Feb -18 |
US9895411 |
Analogs
of C5a and methods of using same |
BOARD
OF REGENTS OF THE UNIVERSITY OF NEBRASKA |
29- Jun- 10 |
29- Jun -11 |
20- Feb -18 |
US9895341 |
Inflammation
and immunity treatments |
Ocean
Spray Cranberries, Inc. |
1- Apr-
11 |
30- Mar -12 |
20- Feb -18 |
US9894888 |
Transgenic
immunodeficient mouse expressing human SIRP-alpha |
INSTITUT
PASTEUR |
26- Mar- 12 |
26- Mar -13 |
20- Feb -18 |
US9890419 |
Nanoreporters
and methods of manufacturing and use thereof |
NanoString
Technologies, Inc. |
23- Dec- 05 |
20- May -16 |
13- Feb -18 |
US9890408 |
Multiple
displacement amplification |
IBIS
BIOSCIENCES, INC. |
15- Oct- 09 |
15- Oct -10 |
13- Feb -18 |
US9890362 |
Compositions,
methods and uses for inducing viral growth |
Takeda
Vaccines, Inc. |
5- Dec-
08 |
19- Sep -14 |
13- Feb -18 |
US9890361 |
Methods
for increasing the infectivity of viruses utilizing alkyne- modified fatty acids |
LIFE
TECHNOLOGIES CORPORATION |
26- Jan- 12 |
25- Jan -13 |
13- Feb -18 |
US9890206 |
H1N1
flu virus neutralizing antibodies |
Medigen
Biotechnology Corporation |
20- Aug- 15 |
20- Aug -15 |
13- Feb -18 |
US9890169 |
Triazolinone
compounds as HNE inhibitors |
CHIESI
FARMACEUTICI S.P.A. |
14- Dec- 15 |
12- Dec -16 |
13- Feb -18 |
US9890124 |
Benzazepine
sulfonamide compounds |
Hoffmann-La
Roche Inc. |
15- Dec- 15 |
14- Jun -17 |
13- Feb -18 |
US9889194 |
Immunogenic
composition for MERS coronavirus infection |
New
York Blood Center, Inc. |
1- Mar-
13 |
28- Feb -14 |
13- Feb -18 |
US9885092 |
Materials
and methods for detection of HPV nucleic acids |
QIAGEN
GAITHERSBURG INC. |
24- Feb- 11 |
23- Feb -12 |
6- Feb -18 |
US9885082 |
Embodiments
of a probe and method for targeting nucleic acids |
University
of Idaho |
19- Jul-11 |
19- Jul- 12 |
6- Feb -18 |
US9885037 |
Chiral
control |
WAVE
LIFE SCIENCES LTD. |
13- Jul-12 |
12- Jul- 13 |
6- Feb -18 |
US9884895 |
Methods
and compositions for chimeric coronavirus spike proteins |
The
University of North Carolina at Chapel Hill |
20- Mar- 14 |
20- Mar -15 |
6- Feb -18 |
US9884876 |
Anti-viral
compounds, pharmaceutical compositions, and methods of use thereof |
Kineta,
Inc. |
9- May-
14 |
8- May -15 |
6- Feb -18 |
US9884129 |
Release
of agents from cells |
The
Brigham and Women's Hospital, Inc. |
15- Oct- 09 |
5- Jan -15 |
6- Feb -18 |
US9884032 |
Esters of
short chains fatty acids for use in the treatment of immunogenic disorders |
PROPONENT
BIOTECH GMBH |
3- Oct-
12 |
3- Mar -16 |
6- Feb -18 |
US9884026 |
Modular
particles for immunotherapy |
YALE
UNIVERSITY |
1- Nov-
13 |
31- Oct -14 |
6- Feb -18 |
US9880151 |
Method of
determining, identifying or isolating cell-penetrating peptides |
Phylogica
Limited |
23- May- 11 |
23- May -12 |
30- Jan- 18 |
US9879026 |
Substituted
spirocycles |
Boehringer
Ingelheim International GmbH |
12- Sep- 14 |
29- Nov -16 |
30- Jan- 18 |
US9879003 |
Host
targeted inhibitors of dengue virus and other viruses |
Dana-Farber
Cancer Institute, Inc. |
11- Apr- 12 |
15- Mar -13 |
30- Jan- 18 |
US9878988 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
PARION
SCIENCES, INC. |
29- May- 12 |
5- Jan -16 |
30- Jan- 18 |
US9873678 |
Chemical
compounds |
AstraZeneca
AB |
18- Mar- 14 |
17- Mar -15 |
23- Jan- 18 |
US9873674 |
C-Rel
inhibitors and uses thereof |
CORNELL
UNIVERSITY |
21- Sep- 12 |
19- Sep -13 |
23- Jan- 18 |
US9872900 |
Nucleic
acid vaccines |
ModernaTX,
Inc. |
23- Apr- 14 |
5- Apr -16 |
23- Jan- 18 |
US9872898 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Founation |
24- Apr- 12 |
3- Oct -16 |
23- Jan- 18 |
US9872895 |
TLR5
ligands, therapeutic methods, and compositions related thereto |
Emory
University |
24- Sep- 10 |
20- Sep -11 |
23- Jan- 18 |
US9868952 |
Compositions
and methods for “resistance-proof†SiRNA therapeutics for influenza |
Sirnaomics,
Inc. |
8-Jul- 12 |
7- Jul- 13 |
16- Jan- 18 |
US9868740 |
Pyrimidinone
compounds which are HNE inhibitors |
CHIESI
FARMACEUTICI S.p.A. |
12- Jun- 14 |
12- Jun -14 |
16- Jan- 18 |
US9868736 |
Deubiquitinase
inhibitors and methods for use of the same |
THE
REGENTS OF THE UNIVERSITY OF MICHIGAN |
10- Oct- 13 |
10- Oct -14 |
16- Jan- 18 |
US9867882 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
25- Aug -15 |
16- Jan- 18 |
US9867877 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
22- Nov -16 |
16- Jan- 18 |
US9862706 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
9- Jan-
18 |
US9861614 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
23- Jun -15 |
9- Jan-
18 |
US9856254 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
13- Jun -16 |
2- Jan-
18 |
US9856241 |
Substituted
benzofuranyl and benzoxazolyl compounds and uses thereof |
Karyopharm
Therapeutics Inc. |
3-Jul- 13 |
3- Jul- 14 |
2- Jan-
18 |
US9856228 |
Peptidyl
nitril compounds as dipeptidyl peptidase I inhibitors |
PROZYMEX
A/S |
9- Sep-
13 |
8- Sep -14 |
2- Jan-
18 |
US9856224 |
Stable
sodium channel blockers |
PARION
SCIENCES, INC. |
30- Jun- 14 |
30- Jan -17 |
2- Jan-
18 |
US9855287 |
Anti-viral
azide containing compounds |
LIFE
TECHNOLOGIES CORPORATION |
28- Jul-10 |
20- Aug -15 |
2- Jan-
18 |
US9855284 |
Pharmaceutical
compositions and methods |
Pop
Test Oncology LLC |
3- Aug-
15 |
6- Dec -16 |
2- Jan-
18 |
US9849143 |
Broad
spectrum antiviral and methods of use |
The
Burlington HC Research Group, Inc. |
17- Apr- 06 |
16- Feb -17 |
26- Dec -17 |
US9845342 |
Fusion
proteins, recombinant bacteria, and methods for using recombinant bacteria |
Spogen
Biotech Inc. |
17- Sep- 14 |
17- Sep -15 |
19- Dec -17 |
US9840731 |
Preservation
of biological materials in non-aqueous fluid media |
Gentegra,
LLC |
14- Mar- 13 |
14- Mar -14 |
12- Dec -17 |
US9840719 |
Variant
AAV and compositions, methods and uses for gene transfer to cells, organs and
tissues |
The
Children's Hospital of Philadelphia |
22- Jul-13 |
22- Jul- 14 |
12- Dec -17 |
US9840491 |
Quinazolinones
and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
FORMA
Therapeutics, Inc. |
5- Feb-
15 |
4- Feb -16 |
12- Dec -17 |
US9839687 |
Acetylenedicarboxyl
linkers and their uses in specific conjugation of a cell-binding molecule |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
15- Jul- 15 |
12- Dec -17 |
US9834812 |
Probe
kit for detecting a single strand target nucleotide sequence |
Fondazione
Istituto Italiano Di Tecnologia |
27- Dec- 12 |
27- Dec -13 |
5- Dec -17 |
US9834791 |
CRISPR-related
methods and compositions with governing gRNAS |
Editas
Medicine, Inc. |
7- Nov-
13 |
7- Nov -14 |
5- Dec -17 |
US9834757 |
Hand,
foot, and mouth vaccines and methods of manufacture and use thereof |
Takeda
Vaccines, Inc. |
7- Nov-
14 |
6- Nov -15 |
5- Dec -17 |
US9834595 |
Amino
acid sequences directed against envelope proteins of a virus and polypeptides
comprising the same for the treatment of viral diseases |
Ablynx
N.V. |
5- Jun- 08 |
29- Oct -15 |
5- Dec -17 |
US9833504 |
Virus-like
particles and process for preparing same |
Folia
Biotech Inc. |
13- May- 11 |
1- May -12 |
5- Dec -17 |
US9833492 |
Combinations
of a caspase inhibitor and an antiviral agent |
Centre
National de la Recherche Scientifique |
2- Nov-
07 |
15- May -15 |
5- Dec -17 |
US9832998 |
Antiviral
compositions |
Long
Island University |
30- May- 07 |
19- Mar -15 |
5- Dec -17 |
US9828382 |
Pyrimidinone
compounds as human neutrophil elastase inhibitors |
Chiesi
Farmaceutici S.p.A. |
18- Dec- 12 |
10- May -16 |
28- Nov -17 |
US9828379 |
Pyrrolo-pyrrole
carbamate and related organic compounds, pharmaceutical compositions, and
medical uses thereof |
ABIDE
THERAPEUTICS, INC. |
3-Jul- 13 |
1- Jul- 14 |
28- Nov -17 |
US9828370 |
Compositions
and methods for inhibiting kinases |
INHIBIKASE
THERAPEUTICS, INC. |
23- Apr- 15 |
22- Apr -16 |
28- Nov -17 |
US9828346 |
N-myristoyl
transferase inhibitors |
University
of Dundee |
2- Sep-
08 |
31- Aug -15 |
28- Nov -17 |
US9828342 |
Isatin
derivatives, pharmaceutical compositions thereof, and methods of use thereof |
CITY
OF HOPE |
24- Feb- 12 |
25- Feb -13 |
28- Nov -17 |
US9827190 |
Intradermal
delivery of immunological compositions comprising toll- like receptor 7
agonists |
GLAXOSMITHKLINE
BIOLOGICALS SA |
1- Feb-
13 |
30- Jan -14 |
28- Nov -17 |
US9822339 |
Means and
methods for influencing the stability of antibody producing cells |
ACADEMISCH
MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM |
9- Dec-
05 |
26- Aug -15 |
21- Nov -17 |
US9822173 |
Heterodimeric
immunoglobulins |
AMGEN
INC. |
21- Nov- 12 |
21- Nov -13 |
21- Nov -17 |
US9822165 |
Hydrocarbon
stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external
region |
DANA-FARBER
CANCER INSTITUTE, INC. |
18- Jun- 09 |
18- Jun -10 |
21- Nov -17 |
US9822155 |
Method of
preventively treating a subject at the risk of developing infections of a
respiratory virus |
Xiangxue
Group (Hong Kong) Company Limited |
9- May-
13 |
23- Aug -16 |
21- Nov -17 |
US9822127 |
GAK
modulators as antivirals |
The Board
of Trustees of the Leland Stanford Junior University |
23- Jul-14 |
23- Jul- 15 |
21- Nov -17 |
US9822065 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
14- Feb -17 |
21- Nov -17 |
US9821052 |
Reverse
genetics systems |
Seqirus
UK Limited |
31- Jul-09 |
30- Jul- 10 |
21- Nov -17 |
US9821051 |
Reducing
hospitalization in elderly influenza vaccine recipients |
Seqirus
UK Limited |
28- Oct- 10 |
21- Oct -11 |
21- Nov -17 |
US9816078 |
Compositions
for increasing polypeptide stability and activity, and related methods |
SOLIS
BIODYNE OÜ |
19- Nov- 09 |
11- Mar -16 |
14- Nov -17 |
US9815886 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
8- Jan -15 |
14- Nov -17 |
US9815805 |
Certain
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as
dipeptidyl peptidase 1 inhibitors |
ASTRAZENECA
AB |
24- Jan- 14 |
8- Nov -16 |
14- Nov -17 |
US9814777 |
Targeting
lipids |
Arbutus
Biopharma Corporation |
4- Dec-
07 |
22- Oct -13 |
14- Nov -17 |
US9810683 |
Use of
live cell inteferometry with reflective floor of observation chamber to
determine changes in mass of mammalian cells |
The
Regents of the University of California |
6- May-
09 |
25- Nov -13 |
7- Nov -17 |
US9809845 |
Methods
and reagents for amplifying nucleic acids |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
6- Aug-
12 |
6- Aug -12 |
7- Nov -17 |
US9809796 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
18- May -17 |
7- Nov -17 |
US9809632 |
Universal
protein tag for double stranded nucleic acid delivery |
University
of Washington Through its Center for Commercialization |
23- Oct- 13 |
22- Oct -14 |
7- Nov -17 |
US9809591 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
5- Oct -15 |
7- Nov -17 |
US9808490 |
Induced
hepatocytes and uses thereof |
ACCELERATED
BIOSCIENCES CORP. |
26- Nov- 14 |
25- Nov -15 |
7- Nov -17 |
US9803236 |
Microarray-based
assay integrated with particles for analyzing molecular interactions |
CapitalBio
Corporation |
6- Aug-
10 |
6- Aug -10 |
31- Oct- 17 |
US9803197 |
Particle-nucleic
acid conjugates and therapeutic uses related thereto |
Emory
University |
25- Jun- 12 |
27- Feb -13 |
31- Oct- 17 |
US9802937 |
Substituted
pyrazolo{4,3-D}pyrimidines as kinase inhibitors |
ORIGENIS
GMBH |
21- Apr- 11 |
23- Apr -12 |
31- Oct- 17 |
US9802919 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
31- May- 16 |
26- May -17 |
31- Oct- 17 |
US9801948 |
Antimicrobial
compositions and methods of use thereof |
Yale
University |
21- Sep- 11 |
21- Sep -12 |
31- Oct- 17 |
US9801947 |
Methods
and compositions for enhancing immune response |
3M
INNOVATIVE PROPERTIES COMPANY |
10- Apr- 03 |
6- Oct -14 |
31- Oct- 17 |
US9801935 |
Soluble
needle arrays for delivery of influenza vaccines |
SEQIRUS
UK LIMITED |
20- Aug- 10 |
11- Oct -16 |
31- Oct- 17 |
US9801897 |
Delivery
of RNA to trigger multiple immune pathways |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
6- Jul- 11 |
31- Oct- 17 |
US9797000 |
Non-target
amplification method for detection of RNA splice-forms in a sample |
QIAGEN
GAITHERSBURG INC. |
1- May-
09 |
30- Apr -10 |
24- Oct- 17 |
US9796979 |
Oligonucleotide
modulators of the toll-like receptor pathway |
Quark
Pharmaceuticals Inc. |
3- Mar-
11 |
28- Jul- 16 |
24- Oct- 17 |
US9796735 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
20- Jun- 07 |
7- Nov -14 |
24- Oct- 17 |
US9795669 |
Lipidated
immune response modifier compound compositions, formulations, and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
17- Aug- 10 |
15- Dec -15 |
24- Oct- 17 |
US9795668 |
Delivery
of self-replicating RNA using biodegradable polymer particles |
GlaxoSmithKline
Biologicals S.A. |
6-Jul- 10 |
23- Nov -15 |
24- Oct- 17 |
US9795666 |
High-yield
transgenic mammalian expression system for generating virus-like particles |
Academia
Sinica |
5- Sep-
06 |
11- Feb -15 |
24- Oct- 17 |
US9791437 |
Multianalyte
assay |
Nexus
Dx, Inc. |
30- Apr- 07 |
15- Jun -15 |
17- Oct- 17 |
US9789180 |
D-amino
acid derivative-modified peptidoglycan and methods of use thereof |
The
Regents of the University of California |
30- Nov- 12 |
31- Mar -16 |
17- Oct- 17 |
US9786050 |
Stain-free
histopathology by chemical imaging |
The
Board of Trustees of the University of Illinois |
15- Mar- 13 |
14- Mar -14 |
10- Oct- 17 |
US9783595 |
Neutralizing
GP41 antibodies and their use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
7- Nov-
11 |
2- Aug -16 |
10- Oct- 17 |
US9782470 |
Method
of obtaining thermostable dried vaccine formulations |
Merck
Sharp & Dohme Corp. |
16- Oct- 13 |
13- Oct -14 |
10- Oct- 17 |
US9782434 |
Methods
of treating or preventing inflammation and hypersensitivity with oxidative
reductive potential water solution |
Sonoma
Pharmaceuticals, Inc. |
20- Jan- 06 |
7- Jul- 15 |
10- Oct- 17 |
US9770504 |
Generating
peptoid vaccines |
The
Board of Regents of the University of Texas System |
3- May-
13 |
2- May -14 |
26- Sep -17 |
US9770463 |
Delivery
of RNA to different cell types |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
7- Jun -11 |
26- Sep -17 |
US9765395 |
System
and method for DNA sequencing and blood chemistry analysis |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
10- Apr -15 |
19- Sep -17 |
US9765133 |
Antibody
producing non-human mammals |
Merus
N.V. |
27- Jun- 08 |
29- Apr -14 |
19- Sep -17 |
US9765071 |
Substituted
imidazo ring systems and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
25- Nov- 03 |
14- Mar -16 |
19- Sep -17 |
US9764027 |
Outer
membrane vesicles |
GLAXOSMITHKLINE
BIOLOGICALS SA |
18- Sep- 12 |
18- Sep -13 |
19- Sep -17 |
US9759723 |
B-cell
antigen presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
21- Mar -16 |
12- Sep -17 |
US9758840 |
Parasite
detection via endosymbiont detection |
IBIS
BIOSCIENCES, INC. |
14- Mar- 10 |
11- Mar -11 |
12- Sep -17 |
US9758820 |
Organism
identification panel |
BioFire
Diagnostics, LLC |
2- Apr-
07 |
1- Apr -08 |
12- Sep -17 |
US9758775 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
14- Apr -14 |
12- Sep -17 |
US9758568 |
Oligopeptide-free
cell culture media |
Baxalta
GmbH |
4- Jan- 06 |
16- Nov -15 |
12- Sep -17 |
US9758553 |
Yeast
strain for the production of proteins with terminal alpha-1,3- linked
galactose |
MERCK
SHARP & DOHME CORP. |
30- May- 08 |
2- Jul- 14 |
12- Sep -17 |
US9757478 |
Mutant
protease biosensors with enhanced detection characteristics |
Promega
Corporation |
11- May- 10 |
7- Jan -16 |
12- Sep -17 |
US9757470 |
Peptides
for assisting delivery across the blood brain barrier |
Children's
Medical Center Corporation |
22- May- 06 |
30- Apr -14 |
12- Sep -17 |
US9757446 |
Influenza
virus vectors and uses therefor |
FLUGEN,
INC. |
17- Mar- 14 |
13- Mar -15 |
12- Sep -17 |
US9757407 |
Treatment
of viral infections by modulation of host cell metabolic pathways |
The
Trustees of Princeton University |
1- Jun-
07 |
21- Dec -15 |
12- Sep -17 |
US9751945 |
Sortase-modified
VHH domains and uses thereof |
Whitehead
Institute for Biomedical Research |
13- Apr- 12 |
15- Apr -13 |
5- Sep -17 |
US9750798 |
Bunyaviruses
with segmented glycoprotein precursor genes and methods for generating these
viruses |
STICHTING
WAGENINGEN RESEARCH |
21- May- 13 |
21- May -14 |
5- Sep -17 |
US9750797 |
Sustained
release vaccine composition |
VIRBAC
CORPORATION |
16- Jun- 04 |
16- Jun -05 |
5- Sep -17 |
US9750690 |
Circulation
of components during microfluidization and/or homogenization of emulsions |
NOVARTIS
AG |
3- Dec-
09 |
5- Sep -14 |
5- Sep -17 |
US9746985 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
25- Feb- 08 |
20- Apr -11 |
29- Aug -17 |
US9746459 |
Antigen
presenting cell assay |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
8- Apr-
10 |
11- Oct -13 |
29- Aug -17 |
US9745306 |
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-
D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one
derivatives and their use as phosphoinositide 3-kinase inhibitors |
Respivert
Limited |
15- Mar- 13 |
14- Mar -14 |
29- Aug -17 |
US9744231 |
Quality
control methods for oil-in-water emulsions containing squalene |
NOVARTIS
AG |
8- Nov-
06 |
27- Aug -13 |
29- Aug -17 |
US9744229 |
Vaccines
and immunotherapeutics using IL-28 and compositions and methods of using the
same |
THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
4- Apr-
08 |
28- Apr -14 |
29- Aug -17 |
US9744183 |
Nucleic
acid prodrugs and methods of use thereof |
WAVE
LIFE SCIENCES LTD. |
6-Jul- 09 |
6- Jul- 10 |
29- Aug -17 |
US9738894 |
Short
interfering RNA (siRNA) analogues |
Roche
Innovation Center Copenhagen A/S |
21- Mar- 03 |
28- Mar -16 |
22- Aug -17 |
US9738624 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
21- Jun- 13 |
20- Jun -14 |
22- Aug -17 |
US9737618 |
Adeno-associated
virus (AAV) glades, sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
30- Sep- 03 |
20- Jul- 15 |
22- Aug -17 |
US9737593 |
Carbon
nanotube compositions and methods of use thereof |
Yale
University |
19- Mar- 08 |
15- Mar -13 |
22- Aug -17 |
US9730997 |
Alphavirus
vectors for respiratory pathogen vaccines |
Novartis
Vaccines and Diagnostics, Inc. |
21- May- 04 |
20- Aug -14 |
15- Aug -17 |
US9730912 |
Pharmaceutical
compounds |
ASTEX
THERAPEUTICS LIMITED |
12- Oct- 06 |
12- Oct -07 |
15- Aug -17 |
US9727810 |
Spatially
addressable molecular barcoding |
Cellular
Research, Inc. |
27- Feb- 15 |
26- Feb -16 |
8- Aug -17 |
US9726607 |
Systems
and methods for detecting multiple optical signals |
GEN-PROBE
INCORPORATED |
10- Mar- 05 |
3- Mar -14 |
8- Aug -17 |
US9725770 |
Methods
and compositions for identification of source of microbial contamination in a
sample |
The
Regents of the University of California |
6- Mar-
12 |
6- Mar -13 |
8- Aug -17 |
US9725487 |
Compositions
and methods for measles virus inhibition |
Autoimmune
Technologies, LLC |
4- Nov-
03 |
13- May -15 |
8- Aug -17 |
US9719106 |
Tissue
preferential codon modified expression cassettes, vectors containing same,
and uses thereof |
The
Trustees of the University of Pennsylvania |
29- Apr- 13 |
29- Apr -14 |
1- Aug -17 |
US9719083 |
Bioagent
detection methods |
IBIS
BIOSCIENCES, INC. |
8- Mar-
09 |
8- Mar -10 |
1- Aug -17 |
US9718774 |
Indole
carboxamide derivatives as P2X7 receptor antagonist |
IDORSIA
PHARMACEUTICALS LTD |
12- Dec- 12 |
11- Dec -13 |
1- Aug -17 |
US9717755 |
Method
of treating inflammation |
Cytosorbents
Corporation |
1- Apr-
10 |
1- Apr -11 |
1- Aug -17 |
US9717749 |
Production
of stable non-polyadenylated RNAs |
Massachusetts
Institute of Technology |
16- Oct- 12 |
16- Oct -13 |
1- Aug -17 |
US9717732 |
Drug
combination |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
1- Aug -17 |
US9714411 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
30- Nov -15 |
25- Jul- 17 |
US9714283 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
2- Jul- 15 |
25- Jul- 17 |
US9714226 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
13- Nov -15 |
25- Jul- 17 |
US9713641 |
Anti-TIGIT
antigen-binding proteins and methods of use thereof |
Potenza
Therapeutics, Inc. |
13- Feb- 17 |
13- Feb -17 |
25- Jul- 17 |
US9713606 |
Methods
for treating pulmonary emphysema using substituted 2-
Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
1- Dec -15 |
25- Jul- 17 |
US9708375 |
Inhibitory
polypeptides specific to WNT inhibitors |
Amgen
Inc. |
15- Mar- 13 |
14- Mar -14 |
18- Jul- 17 |
US9707278 |
Methods
of modulating immune responses by modifying Akt3 bioactivity |
Augusta
University Research Institute, Inc. |
17- Apr- 14 |
17- Apr -15 |
18- Jul- 17 |
US9701736 |
Influenza
hemagglutinin-specific monoclonal antibodies for preventing and treating
influenza virus infection |
New
York Blood Center, Inc. |
20- Oct- 10 |
9- Oct -14 |
11- Jul- 17 |
US9701638 |
Therapeutic
hydroxyquinolones |
Rutgers,
The State University of New Jersey |
9- Nov-
12 |
8- Nov -13 |
11- Jul- 17 |
US9700616 |
Arranging
interaction and back pressure chambers for microfluidization |
NOVARTIS
AG |
3- Dec-
09 |
22- Mar -16 |
11- Jul- 17 |
US9700614 |
Intranasal
vaccination dosage regimen |
Eurocine
Vaccines AB |
17- Dec- 12 |
17- Dec -13 |
11- Jul- 17 |
US9700558 |
Drug
combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
11- Jul- 17 |
US9696247 |
Sample
fixation and stabilisation |
RNASSIST
LTD. |
1- Mar-
13 |
28- Feb -14 |
4- Jul- 17 |
US9695445 |
Method
for production of reprogrammed cell using chromosomally unintegrated virus
vector |
ID
Pharma Co., Ltd. |
16- Jul-08 |
29- Jul- 15 |
4- Jul- 17 |
US9695135 |
Therapeutic
catechols |
Rutgers,
The State University of New Jersey |
12- May- 14 |
11- May -15 |
4- Jul- 17 |
US9695134 |
3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-
2-carboxamide compounds |
Parion
Sciences, Inc. |
17- Dec- 12 |
8- Jan -15 |
4- Jul- 17 |
US9689018 |
Mixed
cell diagnostic systems for detection of respiratory, herpes and enteric
viruses |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
4- Aug -14 |
27- Jun- 17 |
US9688982 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
11- Oct -13 |
27- Jun- 17 |
US9687536 |
Methods
and compositions for intranasal delivery |
SHIN
NIPPON BIOMEDICAL LABORATORIES, LTD. |
15- Apr- 10 |
15- Apr -11 |
27- Jun- 17 |
US9683256 |
Biological
specimen collection and transport system |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
15- Dec -15 |
20- Jun- 17 |
US9683017 |
Inhibitory
peptides of viral infection |
UNIVERSITY
TENNESSEE RESEARCH FOUNDATION |
17- Jul-14 |
16- Jul- 15 |
20- Jun- 17 |
US9682133 |
Disrupted
adenovirus-based vaccine against drugs of abuse |
CORNELL
UNIVERSITY |
17- Mar- 10 |
17- Mar -11 |
20- Jun- 17 |
US9677089 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
30- Mar -16 |
13- Jun- 17 |
US9676867 |
Chimeric
T cell receptor comprising carbonic anhydrase IX (G250) antibody |
Dana-Farber
Cancer Institute Inc. |
2- Dec-
05 |
8- May -13 |
13- Jun- 17 |
US9676857 |
Soluble
engineered monomeric Fc |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
16- Mar- 12 |
14- Mar -13 |
13- Jun- 17 |
US9676727 |
Myxovirus
therapeutics, compounds, and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
24- Oct- 11 |
7- Jul- 16 |
13- Jun- 17 |
US9675550 |
Methods
for inducing an immune response via buccal and/or sublingual administration
of a vaccine |
BOARD
OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
26- Jul-10 |
25- Jan -13 |
13- Jun- 17 |
US9670507 |
Directed
evolution and in vivo panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
28- Jun -16 |
6- Jun-
17 |
US9670166 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
6- Feb-
13 |
5- Aug -16 |
6- Jun-
17 |
US9669092 |
Antagonism
of the VIP signaling pathway |
Emory
University |
2- Feb-
11 |
31- Jan -12 |
6- Jun-
17 |
US9669089 |
Nucleic
acid comprising or coding for a histone stem-loop and a poly(A) sequence or a
polyadenylation signal for increasing the expression of an encoded pathogenic
antigen |
CureVac
AG |
15- Feb- 12 |
15- Feb -13 |
6- Jun- 17 |
US9669088 |
Vaccination
with multiple clades of H5 influenza A virus |
Seqirus
UK Limited |
26- Nov- 07 |
25- Nov -08 |
6- Jun-
17 |
US9661856 |
Synergy
of plant antimicrobials with silver |
The
Arizona Board of Regents on Behalf of The University of Arizona |
24- Aug- 12 |
26- Aug -13 |
30- May -17 |
US9657278 |
Methods
to produce bunyavirus replicon particles |
Stichting
Dienst Landbouwkundig Onderzoek |
20- Sep- 10 |
10- Jul- 15 |
23- May -17 |
US9657076 |
GM-CSF
and IL-4 conjugates, compositions, and methods related thereto |
Children's
Healthcare of Atlanta, Inc. |
23- Oct- 12 |
23- Oct -13 |
23- May -17 |
US9657048 |
Enantiomers
of the 1′,6′-isomer of neplanocin A |
Auburn
University |
4- Aug-
14 |
4- Aug -15 |
23- May -17 |
US9657015 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
23- May -17 |
US9655896 |
Chemically
and metabolically stable dipeptide possessing potent sodium channel blocker
activity |
PARION
SCIENCES, INC. |
27- Jun- 11 |
12- Jan -15 |
23- May -17 |
US9655845 |
Oil-in-water
emulsions that contain nucleic acids |
GlaxoSmithKline
Biologicals, S.A. |
6-Jul- 11 |
6- Jul- 12 |
23- May -17 |
US9655367 |
Disinfecting
composition and wipes with reduced contact time |
LONZA,
INC. |
6- Nov-
13 |
4- Nov -14 |
23- May -17 |
US9651543 |
Malaria
antigen screening method |
The
United States of America as Represented by the Secretary of the Navy |
31- Aug- 05 |
19- Apr -13 |
16- May -17 |
US9650685 |
Selective
detection of human rhinovirus |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
5- Dec-
08 |
15- Dec -14 |
16- May -17 |
US9650649 |
LCMV-GP-VSV-pseudotyped
vectors and tumor-infiltrating virus- producing cells for the therapy of
tumors |
VIRATHERAPEUTICS
GMBH |
8- Oct-
08 |
8- Oct -09 |
16- May -17 |
US9649324 |
Use
of tylvalosin as antiviral agent |
CAMBRIDGE
UNIVERSITY TECHNICAL SERVICES |
13- Jul-06 |
8- Jun -15 |
16- May -17 |
US9649309 |
Therapeutic
uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
16- May -17 |
US9644180 |
Synthetic
membrane-receiver complexes |
RUBIUS
THERAPEUTICS, INC. |
18- Nov- 13 |
12- Jun -15 |
9- May -17 |
US9642876 |
Method of
preventing or treating sinusitis with oxidative reductive potential water
solution |
SONOMA
PHARMACEUTICALS, INC. |
30- Dec- 03 |
27- Oct -15 |
9- May -17 |
US9642873 |
Combinations
of TGFβ and COX-2 inhibitors and methods for their therapeutic application |
Sirnaomics,
Inc. |
4- May-
10 |
4- May -11 |
9- May -17 |
US9637524 |
Proteolysis-resistant
capsid of chimeric hepatitis E virus as an oral delivery vector |
The
Regents of the University of California |
27- Feb- 09 |
5- Nov -14 |
2- May -17 |
US9637491 |
Pyrazolo[4,3-D]pyrimidines
as kinase inhibitors |
ORIGENIS
GMBH |
19- Oct- 12 |
18- Oct -13 |
2- May -17 |
US9636410 |
Cationic
oil-in-water emulsions |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 11 |
6- Jul- 12 |
2- May -17 |
US9636397 |
Adjuvant
compositions and related methods |
Vaxliant,
LLC |
24- Mar- 15 |
24- Mar -16 |
2- May -17 |
US9636370 |
AAV
vectors targeted to oligodendrocytes |
The
University of North Carolina at Chapel Hill |
28- Sep- 12 |
27- Sep -13 |
2- May -17 |
US9629907 |
Compositions
for and methods of inducing mucosal immune responses |
The
Trustees of the University of Pennsylvania |
19- Nov- 04 |
28- Oct -11 |
25- Apr- 17 |
US9624173 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
19- Mar -15 |
18- Apr- 17 |
US9623040 |
Immunomodulation
by controlling expression levels of microRNAs in dendritic cells |
The Board
of Trustees of the Leland Stanford Junior University |
14- Jul-14 |
10- Jul- 15 |
18- Apr- 17 |
US9618508 |
Flow
cytometry analysis of materials adsorbed to metal salts |
GlaxoSmithKline
Biologicals SA |
14- Dec- 10 |
14- Dec -11 |
11- Apr- 17 |
US9618476 |
System
and method for electronic biological sample analysis |
NANOMEDICAL
DIAGNOSTICS, INC. |
28- Apr- 14 |
28- Apr -14 |
11- Apr- 17 |
US9618429 |
Polymer
stabilization of chromogen solutions |
Ventana
Medical Systems, Inc. |
23- Jan- 12 |
18- Jan -13 |
11- Apr- 17 |
US9611481 |
Chimeric
polynucleotides and polypeptides enabling the secretion of a polypeptide of
interest in combination with exosomes and uses thereof |
UNIVERSITE
DE MONTPELLIER |
24- Sep- 09 |
23- Sep -10 |
4- Apr- 17 |
US9611474 |
Double-stranded
oligonucleotide molecules to DDIT4 and methods of use thereof |
QUARK
PHARMACEUTICALS, INC. |
12- Sep- 12 |
12- Sep -13 |
4- Apr-
17 |
US9605276 |
Replication
defective adenovirus vector in vaccination |
Etubics
Corporation |
24- Aug- 12 |
15- Mar -13 |
28- Mar -17 |
US9603864 |
Substituted
nucleosides, nucleotides and analogs thereof |
Alios
BioPharma, Inc. |
24- Jun- 14 |
22- Jun -15 |
28- Mar -17 |
US9603850 |
MerTK-specific
pyrazolopyrimidine compounds |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
28- Mar -17 |
US9599606 |
ADP-ribose
detection reagents |
The
Board of Regents of the University of Texas System |
10- Jun- 14 |
9- Jun -15 |
21- Mar -17 |
US9598459 |
Pharmaceutical
compositions and methods |
Pop
Test Oncology LLC |
3- Aug-
15 |
28- Jul- 16 |
21- Mar -17 |
US9597333 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
28- Sep -16 |
21- Mar -17 |
US9593334 |
Use of
the chromosome 19 microRNA cluster (C19MC) for treating viral disease and
promoting authophagy |
University
of Pittsburgh—Of the Commonwealth System of Higher Education |
7- Mar-
12 |
6- Mar -13 |
14- Mar -17 |
US9593331 |
Double-stranded
nucleic acid molecule for gene expression control |
Osaka
City University |
2- Nov-
11 |
1- Nov -12 |
14- Mar -17 |
US9593084 |
Chloro-pyrazine
carboxamide derivatives with epithelial sodium channel blocking activity |
Parion
Sciences, Inc. |
17- Dec- 12 |
13- Dec -13 |
14- Mar -17 |
US9592284 |
Immunization
regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost |
The
Trustees of the University of Pennsylvania |
28- Apr- 04 |
27- Apr -05 |
14- Mar -17 |
US9592277 |
Compositions
with modified nucleases targeted to viral nucleic acids and methods of use
for prevention and treatment of viral diseases |
Avirid,
Inc. |
14- Apr- 04 |
14- Apr -05 |
14- Mar -17 |
US9588069 |
Methods
for performing thermal melt analysis |
GEN-PROBE
INCORPORATED |
31- Jul-12 |
31- Jul- 13 |
7- Mar -17 |
US9587250 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
Trustees
of the University of Pennsylvania |
17- Dec- 01 |
16- Jan -15 |
7- Mar -17 |
US9586998 |
Methods
of propagating monkey adenoviral vectors |
GenVec,
Inc. |
9- Nov-
09 |
4- Aug -15 |
7- Mar -17 |
US9586911 |
Arylalkyl-
and aryloxyalkyl-substituted epthelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
19- Dec -14 |
7- Mar -17 |
US9586910 |
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-
pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra
zine-2-carboxamide |
Parion
Sciences, Inc. |
27- Jun- 11 |
18- Dec -13 |
7- Mar -17 |
US9585968 |
Hydrazino
1H-imidazoquinolin-4-amines and conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
14- Aug -15 |
7- Mar -17 |
US9585953 |
Immunogenic
compositions in particulate form and methods for producing the same |
MUCOSIS
B.V. |
22- Mar- 11 |
22- Mar -12 |
7- Mar -17 |
US9585874 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
6- Jan -16 |
7- Mar -17 |
US9585849 |
Broad
spectrum antiviral and methods of use |
The
Burlington HC Research Group, Inc. |
17- Apr- 06 |
17- Apr -07 |
7- Mar -17 |
US9580474 |
Polyionic
papilloma virus-like particle (VLP) vaccines |
THE
JOHNS HOPKINS UNIVERSITY |
8- Sep-
10 |
8- Sep -11 |
28- Feb -17 |
US9580468 |
Methods
and reagents for efficient and targeted delivery of therapeutic molecules to
CXCR4 cells |
CENTRE
DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA
(CIBER BBN) |
13- Jan- 11 |
13- Jan -12 |
28- Feb -17 |
US9580429 |
Pyrrolo[3,2-D]pyrimidin-4-one
derivatives and their use in therapy |
AstraZeneca
AB |
6- Dec-
04 |
15- Sep -14 |
28- Feb -17 |
US9574189 |
Enzymatic
encoding methods for efficient synthesis of large libraries |
Nuevolution
A/S |
1- Dec-
05 |
1- Dec -06 |
21- Feb -17 |
US9574181 |
Influenza
virus reassortment method |
Seqirus
UK Limited |
21- May- 10 |
24- Oct -14 |
21- Feb -17 |
US9573955 |
Compounds |
Chiese
Farmaceutici S.p.A. |
16- Dec- 13 |
16- Dec -14 |
21- Feb -17 |
US9573938 |
Therapeutic
hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
Rutgers,
The State University of New Jersey |
11- Sep- 12 |
11- Sep -13 |
21- Feb -17 |
US9572899 |
Compositions
for enhancing transport of molecules into cells |
AVI
BIOPHARMA, INC. |
29- Apr- 03 |
5- Nov -08 |
21- Feb -17 |
US9572864 |
Compositions
and uses of lectins |
Emory
University |
12- Feb- 10 |
11- Dec -15 |
21- Feb -17 |
US9572823 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
5- Apr -16 |
21- Feb -17 |
US9567336 |
Conjugated
TLR7 and/or TLR8 and TLR2 agonists |
INVIVOGEN |
19- Nov- 12 |
15- Mar -13 |
14- Feb -17 |
US9566326 |
Adjuvanted
influenza vaccines for pediatric use |
Seqirus
UK Limited |
22- Feb- 08 |
21- Jun -13 |
14- Feb -17 |
US9566291 |
Nutritional
composition comprising indigestible oligosaccharides |
N.V.
Nutricia |
24- Aug- 04 |
24- Aug -05 |
14- Feb -17 |
US9566290 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
20- Apr -16 |
14- Feb -17 |
US9566289 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
17- Feb -16 |
14- Feb -17 |
US9565857 |
Antimicrobial
solutions |
Board
of Regents, The University of Texas System |
10- Sep- 10 |
9- Sep -11 |
14- Feb -17 |
US9562110 |
Bispecific
antibody |
Wuhan
YZY Biopharma Co., Ltd. |
21- Nov- 12 |
21- Nov -12 |
7- Feb -17 |
US9561263 |
Treatment
of inflammatory illnesses with ACE2 |
Apeiron
Biologics AG |
18- Dec- 07 |
18- Dec -08 |
7- Feb -17 |
US9556237 |
Antiviral
rift valley fever virus peptides and methods of use |
The
United States of America, as represented by the Secretary of the Army, on
behalf of the U.S. Army Medical Research
Institute of Infectious Diseases |
6- Dec-
12 |
4- Jun -15 |
31- Jan- 17 |
US9556229 |
Modification
of peptides using a bis(thioether)arylbridge approach |
The
Regents of the University of California |
18- May- 12 |
17- May -13 |
31- Jan- 17 |
US9556184 |
Phosphoinositide
3-kinase inhibitors |
Respivert,
Ltd. |
15- Mar- 13 |
4- Dec -15 |
31- Jan- 17 |
US9556117 |
Indole
carboxamide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
18- Dec- 12 |
17- Dec -13 |
31- Jan- 17 |
US9555031 |
Therapeutic
uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
31- Jan- 17 |
US9555030 |
Therapeutic
uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase
activity |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
3- Apr -15 |
31- Jan- 17 |
US9550773 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
13- Apr -15 |
24- Jan- 17 |
US9550757 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
5- Mar-
10 |
28- Jun -13 |
24- Jan- 17 |
US9549949 |
Antiviral
agent |
NBC
MESHTEC, INC. |
3- Sep-
08 |
31- Aug -09 |
24- Jan- 17 |
US9549938 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
11- Mar -16 |
24- Jan- 17 |
US9546371 |
Chimeric
polynucleotides and polypeptides enabling secretion of a polypeptide of
interest in association with exosomes and use thereof for the production of
immunogenic compositions |
CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
18- Mar- 08 |
18- Mar -09 |
17- Jan- 17 |
US9546184 |
Alkyloxy
substituted thiazoloquinolines and thiazolonaphthyridines |
3M
INNOVATIVE PROPERTIES COMPANY |
13- Aug- 08 |
8- Jun -15 |
17- Jan- 17 |
US9546150 |
Substituted
quinazolin-4-ones for inhibiting ubiquitin specific protease 7 |
HYBRIGENICS
SA |
2- Sep-
11 |
29- Aug -12 |
17- Jan- 17 |
US9545440 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
23- Oct -15 |
17- Jan- 17 |
US9540373 |
Substituted
spirocycles |
Boehringer
Ingelheim International GmbH |
12- Sep- 14 |
10- Sep -15 |
10- Jan- 17 |
US9539321 |
HMGB1-derived
peptides enhance immune response to antigens |
The
Regents of the University of California |
27- Jul-10 |
9- Mar -15 |
10- Jan- 17 |
US9539217 |
Nanoparticle
compositions |
Allertein
Therapeutics, LLC |
3- Apr-
13 |
3- Apr -14 |
10- Jan- 17 |
US9533978 |
Pyrimidine
derivatives and their use in the treatment of cancer and further diseases |
Sumitomo
Dainippon Pharma Co., Ltd |
21- May- 09 |
26- Aug -14 |
3- Jan-
17 |
US9533037 |
Methods
for designing and preparing vaccines comprising directed sequence polymer
compositions via the directed expansion of epitopes |
Declion
Holdings LLC |
16- Oct- 07 |
16- Oct -08 |
3- Jan- 17 |
US9529974 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
25- Feb- 08 |
27- Jul- 11 |
27- Dec -16 |
US9527903 |
Engineered
antibody constant domain molecules |
The
United States of America, as represent by the Secretary, Department of Health
and Human Services |
31- Jan- 08 |
1- Oct -13 |
27- Dec -16 |
US9526803 |
Diagnostic
chewing gum for pathogens |
Julius-Maximilians-Universitaet
Wuerzburg |
8- Mar-
12 |
8- Mar -13 |
27- Dec -16 |
US9526700 |
Composition
for inactivating an enveloped virus |
VIROBLOCK
SA |
19- May- 06 |
17- Nov -14 |
27- Dec -16 |
US9522962 |
Peptides,
conjugates and method for increasing immunogenicity of a vaccine |
Academisch
Ziekenhuis Leiden h.o.d.n. LUMC |
15- Mar- 10 |
15- Mar -11 |
20- Dec -16 |
US9522894 |
Certain
(2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as
dipeptidyl peptidase 1 inhibitors |
AstraZeneca
AB |
24- Jan- 14 |
21- Jan -15 |
20- Dec -16 |
US9522171 |
EV576 for
use in the treatment of viral infections of the respiratory tract |
Volution
Immuno Pharmaceuticals SA |
8- Jan- 10 |
2- Jan -15 |
20- Dec -16 |
US9518093 |
Topical
formulation of arginine-rich cyclic antimicrobial peptides |
NOVABIOTICS
LIMITED |
24- Feb- 06 |
9- Nov -15 |
13- Dec -16 |
US9518083 |
Gadd45beta
targeting agents |
Imperial
Innovations Limited |
22- Oct- 09 |
10- Feb -15 |
13- Dec -16 |
US9517263 |
Benzonaphthyridine-containing
vaccines |
GlaxoSmithKline
Biologicals SA |
10- Jun- 09 |
10- Jun -10 |
13- Dec -16 |
US9517205 |
Soluble
needle arrays for delivery of influenza vaccines |
Seqirus
UK Limited |
20- Aug- 10 |
19- Aug -11 |
13- Dec -16 |
US9512471 |
Methods
and kits for detecting human papillomavirus |
DIACARTA
Inc |
30- Jun- 10 |
30- Jun -10 |
6- Dec -16 |
US9512443 |
Recombinant
expression of multiprotein complexes using polygenes |
ETH
ZURICH |
8- Nov-
05 |
6- Nov -06 |
6- Dec -16 |
US9512181 |
Fusion
proteins of ciliate granule lattice proteins, granular protein particles
thereof, and uses therefor |
Tetragenetics,
Inc. |
27- May- 11 |
29- May -12 |
6- Dec -16 |
US9511070 |
Heterocyclyl
carboxamides for treating viral diseases |
NovaDrug,
LLC |
31- Aug- 12 |
30- Aug -13 |
6- Dec -16 |
US9506063 |
SiRNA
compositions and methods for treatment of HPV and other infections |
Sirnaomics,
Inc. |
29- Jul-10 |
29- Jan -13 |
29- Nov -16 |
US9504747 |
Lipids
and lipid compositions for the delivery of active agents |
Novartis
AG |
8- Mar-
13 |
7- Mar -14 |
29- Nov -16 |
US9504673 |
Agent for
the prophylaxis and treatment of highly pathogenic infectious diseases |
LTD
“Valenta-Intellekt†|
21- May- 09 |
10- May -10 |
29- Nov -16 |
US9504255 |
Physical
antimicrobial method |
NMS
TECHNOLOGIES CO., LTD. |
1- Aug-
12 |
16- Jul- 13 |
29- Nov -16 |
US9499799 |
Cells and
methodology to generate non-segmented negative-strand RNA viruses |
Centre
National De La Recherche Scientifique |
22- Dec- 06 |
15- Oct -13 |
22- Nov -16 |
US9499535 |
Kinase
inhibitors |
ORIGENIS
GMBH |
21- Apr- 11 |
23- Apr -12 |
22- Nov -16 |
US9499489 |
Myxovirus
therapeutics, compounds, and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
24- Oct- 11 |
24- Oct -12 |
22- Nov -16 |
US9498548 |
Method of
using oxidative reductive potential water solution in dental applications |
Oculus
Innovative Sciences, Inc. |
2- May-
05 |
2- May -06 |
22- Nov -16 |
US9498544 |
Genetically
modified human umbilical cord perivascular cells for prophylaxis against or
treatment of biological or chemical agents |
Tissue
Regeneration Therapeutics Inc. |
21- Apr- 08 |
13- Mar -15 |
22- Nov -16 |
US9498527 |
Vaccine
composition |
NITTO
DENKO CORPORATION |
4- Apr-
12 |
3- Apr -13 |
22- Nov -16 |
US9494571 |
Methods
of testing for intracellular pathogens |
Novartis
AG |
8- Mar-
10 |
7- Mar -11 |
15- Nov -16 |
US9493788 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
16- Jan -15 |
15- Nov -16 |
US9493572 |
GITR
antibodies and methods of inducing or enhancing an immune response |
GITR,
Inc. |
25- Mar- 05 |
23- Mar -15 |
15- Nov -16 |
US9493518 |
Compositions
and methods for treating clostridium difficile- associated diseases |
National
Health Research Institutes |
14- Mar- 13 |
13- Mar -14 |
15- Nov -16 |
US9492528 |
Influenza
virus-like particles (VLPS) comprising hemagglutinin |
MEDICAGO
INC. |
13- Jul-07 |
2- Jul- 09 |
15- Nov -16 |
US9492413 |
Use of
salt of an acetylsalicylic acid for the treatment of viral infections |
Ventaleon
GMBH |
14- Jan- 08 |
14- Jan -09 |
15- Nov -16 |
US9489495 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
GEORGETOWN
UNIVERSITY |
25- Feb- 08 |
28- Aug -08 |
8- Nov -16 |
US9487838 |
Oligonucleotide
probe for the detection of adenovirus |
QIAGEN
HAMBURG GMBH |
28- Dec- 10 |
28- Dec -10 |
8- Nov -16 |
US9487837 |
Exosome-mediated
diagnosis of hepatitis virus infections and diseases |
MOREHOUSE
SCHOOL OF MEDICINE |
6- Oct-
08 |
21- Jan -14 |
8- Nov -16 |
US9487778 |
Oligonucleotide
modulators of the toll-like receptor pathway |
QUARK
PHARMACEUTICALS, INC. |
3- Mar-
11 |
1- Mar -12 |
8- Nov -16 |
US9487749 |
Use
of methylsulfonylmethane (MSM) to modulate microbial activity |
Biogenic
Innovations, LLC |
30- Oct- 09 |
12- Aug -14 |
8- Nov -16 |
US9487528 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
9- Jun-
14 |
5- Jun -15 |
8- Nov -16 |
US9486479 |
Antimicrobial
solutions containing dichloride monoxide and methods of making and using the
same |
Oculus
Innovative Sciences, Inc. |
13- Mar- 07 |
21- Jul- 14 |
8- Nov -16 |
US9481912 |
Compositions
and methods for detecting and identifying nucleic acid sequences in
biological samples |
Longhorn
Vaccines and Diagnostics, LLC |
12- Sep- 06 |
8- Oct -13 |
1- Nov -16 |
US9481724 |
hDC-sign
binding peptides |
Sloan-Kettering
Institute for Cancer Research |
19- Dec- 11 |
10- Dec -12 |
1- Nov -16 |
US9481630 |
Ingenane-type
diterpene compound, and pharmaceutical composition for treating or preventing
viral infectious diseases containing same |
KOREA
RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
19- Oct- 11 |
28- Sep -12 |
1- Nov -16 |
US9476090 |
Signal
propagation biomolecules, devices and methods |
STC.UNM |
21- May- 13 |
21- May -14 |
25- Oct- 16 |
US9476032 |
Attenuated
viruses useful for vaccines |
The Research
Foundation for The State University of New York |
30- Mar- 07 |
31- Mar -08 |
25- Oct- 16 |
US9475872 |
Nucleic
acid molecules encoding moonoclonal antibodies speceific for IL17F |
ImmunoQure
AG |
28- Dec- 11 |
2- Jan -13 |
25- Oct- 16 |
US9475862 |
Neutralizing
GP41 antibodies and their use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
7- Nov-
11 |
7- Nov -12 |
25- Oct- 16 |
US9475832 |
Phosphonates
with reduced toxicity for treatment of viral infections |
The
Regents of the University of California |
14- Apr- 10 |
29- Sep -14 |
25- Oct- 16 |
US9475804 |
Heterobifunctional
linkers with polyethylene glycol segments and immune response modifier
conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
1- Jun -12 |
25- Oct- 16 |
US9475779 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
25- Oct- 16 |
US9475775 |
Benzazepine
dicarboxamide compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
4- Mar -16 |
25- Oct- 16 |
US9474844 |
Methods
for pathogen inactivation in blood using UV irradiation while minimizing heat
transfer thereto |
Hemalux
LLC |
22- Oct- 14 |
29- Dec -15 |
25- Oct- 16 |
US9474759 |
Broad-spectrum
antivirals against 3C or 3C-like proteases of picornavirus-like supercluster:
picornaviruses, caliciviruses and coronaviruses |
Kansas
State University Research Foundation |
27- Sep- 11 |
27- Sep -12 |
25- Oct- 16 |
US9469876 |
Circulating
biomarkers for metastatic prostate cancer |
Caris
Life Sciences Switzerland Holdings GmbH |
6- Apr-
10 |
6- Apr -11 |
18- Oct- 16 |
US9464276 |
Highly
efficient influenza matrix (M1) proteins |
Novavax,
Inc. |
11- Jul-03 |
23- Feb -15 |
11- Oct- 16 |
US9464123 |
Peptides
having activity of inhibiting infections of respiratory viruses and use of
the same |
XIANGXUE
GROUP (HONG KONG) COMPANY LIMITED |
9- May-
13 |
21- Feb -14 |
11- Oct- 16 |
US9463240 |
Arranging
interaction and back pressure chambers for microfluidization |
NOVARTIS
AG |
3- Dec-
09 |
11- Jul- 14 |
11- Oct- 16 |
US9459247 |
Quantitative
measurement of nano/micro particle endocytosis with cell mass spectrometry |
Academia
Sinica |
29- Mar- 10 |
29- Mar -11 |
4- Oct-
16 |
US9459233 |
Amperometric
gas sensor |
Steris
Corporation |
25- Jun- 12 |
26- Feb -13 |
4- Oct-
16 |
US9458492 |
Methods
and cells for identifying RIG-I pathway regulators |
Kineta,
Inc. |
25- Feb- 11 |
23- Feb -12 |
4- Oct-
16 |
US9458470 |
Recombinant
influenza virus-like particles (VLPs) produced in transgenic plants
expressing hemagglutinin |
MEDICAGO
INC. |
21- Jan- 08 |
23- Jan -13 |
4- Oct-
16 |
US9458184 |
Compositions
of TLR7 and/or TLR8 agonists conjugated to lipids |
INVIVOGEN |
15- Jun- 12 |
15- Mar -13 |
4- Oct-
16 |
US9458113 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
4- Oct-
16 |
US9457074 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Foundation |
24- Apr- 12 |
23- Feb -15 |
4- Oct-
16 |
US9453043 |
Nucleic
acid chemical modifications |
ALNYLAM
PHARMACEUTICALS, INC. |
2- Mar-
09 |
22- Jan -15 |
27- Sep -16 |
US9452973 |
Modulators
of the relaxin receptor 1 |
THE
FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES |
4- May-
12 |
15- Mar -13 |
27- Sep -16 |
US9452210 |
Influenza
virus-like particles (VLPS) comprising hemagglutinin produced within a plant |
MEDICAGO
INC. |
13- Jul-07 |
4- Jan -13 |
27- Sep -16 |
US9447462 |
Methods
for concurrent identification and quantification of an unknown bioagent |
IBIS
BIOSCIENCES, INC. |
18- Feb- 04 |
27- Jan -14 |
20- Sep -16 |
US9447132 |
Highly
active nucleoside derivative for the treatment of HCV |
Achillion
Pharmaceuticals, Inc. |
12- Apr- 13 |
14- Apr -14 |
20- Sep -16 |
US9447097 |
4-amino-imidazoquinoline
compounds |
Hoffmann-La
Roche Inc. |
22- Apr- 14 |
7- Apr -16 |
20- Sep -16 |
US9446062 |
Methods
of treating ischemia-reperfusion injury with siRNAs |
Quark
Pharmaceuticals, Inc. |
25- Oct- 06 |
8- Jan -15 |
20- Sep -16 |
US9442107 |
Antibody-nanoparticle
conjugates and methods for making and using such conjugates |
Ventana
Medical Systems, Inc. |
27- Apr- 10 |
21- Apr -15 |
13- Sep -16 |
US9441247 |
TC-83-derived
alphavirus vectors, particles and methods |
ALPHAVAX,
INC. |
18- May- 04 |
6- Jul- 15 |
13- Sep -16 |
US9440960 |
Substituted
oxetanes and their use as inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
1- Aug-
14 |
31- Jul- 15 |
13- Sep -16 |
US9440930 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
13- Sep -16 |
US9435795 |
Enhanced
deposition of chromogens utilizing pyrimidine analogs |
Ventana
Medical Systems, Inc. |
30- Dec- 10 |
6- Oct -14 |
6- Sep -16 |
US9435000 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
20- Sep -13 |
6- Sep -16 |
US9434997 |
Methods,
compounds and systems for detecting a microorganism in a sample |
Lawrence
Livermore National Security, LLC |
24- Aug- 07 |
21- Aug -08 |
6- Sep -16 |
US9434769 |
Peptide
compositions and methods for inhibiting herpesvirus infection |
The
Administrators of the Tulane Educational Fund |
30- Oct- 09 |
9- Jul- 14 |
6- Sep -16 |
US9433672 |
Compositions
and methods for activating innate and allergic immunity |
ID
Biomedical Corporation of Quebec |
26- Apr- 12 |
28- Apr -14 |
6- Sep -16 |
US9430610 |
Re-sequencing
pathogen microarray |
The
United States of America, as represented by the Secretary of the Navy |
2-Jul- 04 |
10- Apr -08 |
30- Aug -16 |
US9428739 |
Norovirus
and Sapovirus antigens |
NOVARTIS
VACCINES AND DIAGNOSTICS, INC. |
24- Mar- 01 |
27- Nov -12 |
30- Aug -16 |
US9428574 |
Polypeptides
and uses thereof for treatment of autoimmune disorders and infection |
COMPUGEN
LTD. |
30- Jun- 11 |
1- Jul- 12 |
30- Aug -16 |
US9428571 |
Antibodies
and processes for preparing the same |
TAIGA
BIOTECHNOLOGIES, INC. |
16- May- 08 |
18- Mar -15 |
30- Aug -16 |
US9428490 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
26- Jul- 12 |
30- Aug -16 |
US9428439 |
Hydrobenzamide
derivatives as inhibitors of Hsp90 |
ASTEX
THERAPEUTICS LTD. |
12- Oct- 06 |
7- Jan -14 |
30- Aug -16 |
US9426989 |
Organic
peroxide compounds for microorganism inactivation |
NOVARTIS
AG |
6- May-
10 |
6- May -11 |
30- Aug -16 |
US9422367 |
Antigenic
GM-CSF peptides and antibodies to GM-CSF |
Morphotek,
Inc. |
7- Feb-
06 |
26- Nov -13 |
23- Aug -16 |
US9421254 |
Immunostimulatory
combinations of TLR ligands and methods of use |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
24- Sep- 07 |
24- Sep -08 |
23- Aug -16 |
US9416416 |
Biological
specimen collection/transport compositions and methods |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
16- Dec -11 |
16- Aug -16 |
US9416409 |
Capture
primers and capture sequence linked solid supports for molecular diagnostic
tests |
IBIS
BIOSCIENCES, INC. |
31- Jul-09 |
30- Jul- 10 |
16- Aug -16 |
US9416396 |
Covalently
linked thermostable kinase for decontamination process validation |
The
Secretary of State for Health |
20- Feb- 08 |
18- Feb -09 |
16- Aug -16 |
US9415392 |
Slip
chip device and methods |
The
University of Chicago |
24- Mar- 09 |
23- Mar -10 |
16- Aug -16 |
US9415087 |
Compositions
and methods for treating coronavirus infection |
Ludwig-Maximilians-Universitaet
Muenchen |
11- Mar- 14 |
8- May -15 |
16- Aug -16 |
US9415033 |
Esters of
short chains fatty acids for use in the treatment of immunogenic disorders |
PROPONENT
BIOTECH GMBH |
3- Oct-
12 |
3- Oct -13 |
16- Aug -16 |
US9409987 |
Polypeptides
and polynucleotides, and uses thereof for treatment of immune related
disorders and cancer |
COMPUGEN
LTD |
15- Apr- 11 |
16- Apr -12 |
9- Aug -16 |
US9409917 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
20- Jan- 12 |
18- Jan -13 |
9- Aug -16 |
US9409870 |
Compounds |
CHIESI
FARMACEUTICI S.p.A. |
15- Dec- 14 |
27- Nov -15 |
9- Aug -16 |
US9408908 |
Combination
adjuvant formulation |
Not
Available |
16- Oct- 08 |
15- Feb -13 |
9- Aug -16 |
US9408907 |
Homogenous
suspension of immunopotentiating compounds and uses thereof |
GlaxoSmithKline
Biologicals SA |
15- Dec- 09 |
15- Dec -10 |
9- Aug -16 |
US9404160 |
Methods
for the detection of microorganisms |
Becton,
Dickinson and Company |
22- Dec- 09 |
21- Dec -10 |
2- Aug -16 |
US9403868 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
5- Mar -15 |
2- Aug -16 |
US9402921 |
Directed
evolution and in vitro panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
22- Oct -14 |
2- Aug -16 |
US9402878 |
Depsipeptide
and uses thereof |
NovoBiotic
Pharmaceuticals, LLC |
3- Dec-
12 |
1- Jul- 15 |
2- Aug -16 |
US9402812 |
Methods
for the preparation of liposomes |
Indu
Javeri |
23- Sep- 09 |
23- Sep -10 |
2- Aug -16 |
US9394092 |
Powdered
pouch and method of making same |
MONOSOL,
LLC |
16- Apr- 12 |
14- Mar -13 |
19- Jul- 16 |
US9393564 |
Bioagent
detection systems, devices, and methods |
IBIS
BIOSCIENCES, INC. |
30- Mar- 09 |
30- Mar -10 |
19- Jul- 16 |
US9393295 |
Nanoparticles
for use in pharmaceutical compositions |
Novartis
AG |
28- Apr- 08 |
28- Apr -09 |
19- Jul- 16 |
US9393215 |
Nanoparticles
for use in immunogenic compositions |
Novartis
AG |
2- Dec-
05 |
1- Dec -06 |
19- Jul- 16 |
US9388429 |
Method
for propagating adenoviral vectors encoding inhibitory gene products |
GenVec,
Inc. |
10- Nov- 05 |
28- May -14 |
12- Jul- 16 |
US9388234 |
Systems
and methods for identifying Replikin Scaffolds and uses of said Replikin
Scaffolds |
Not
Available |
6- Jun-
03 |
19- Jun -13 |
12- Jul- 16 |
US9388198 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
21- Jan- 14 |
21- Jan -14 |
12- Jul- 16 |
US9388197 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
22- Jan- 13 |
21- Jan -14 |
12- Jul- 16 |
US9387242 |
Chimeric
viruses presenting non-native surface proteins and uses thereof |
Icahn
School of Medicine at Mount Sinai |
2- Dec-
05 |
1- Dec -06 |
12- Jul- 16 |
US9382590 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA
AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) |
25- Mar- 11 |
20- May -15 |
5- Jul- 16 |
US9382545 |
CpG
oligonucleotide analogs containing hydrophobic T analogs with enhanced
immunostimulatory activity |
COLEY
PHARMACEUTICAL GMBH |
27- Sep- 06 |
4- Oct -13 |
5- Jul- 16 |
US9382288 |
Derivatives
of steroid benzylamines, having an antiparasitic antibacterial, antimycotic
and/or antiviral action |
Justus-Liebig-Universitat
Giessen |
6- Oct-
10 |
6- Oct -11 |
5- Jul- 16 |
US9381244 |
VISTA
modulators for diagnosis and treatment of cancer |
KING'S
COLLEGE LONDON |
7- Sep-
12 |
9- Sep -13 |
5- Jul- 16 |
US9381239 |
VLPS
derived from cells that do not express a viral matrix or core protein |
Novavax,
Inc. |
25- May- 07 |
14- Apr -14 |
5- Jul- 16 |
US9381226 |
Methods
and compositions related to inhibition of viral entry |
UNIVERSITY
OF UTAH RESEARCH FOUNDATION |
8- Feb-
07 |
8- Feb -08 |
5- Jul- 16 |
US9381220 |
Sceletium
extract and uses thereof |
H.
L. Hall & Sons Limited |
20- Mar- 09 |
15- Jul- 14 |
5- Jul- 16 |
US9380785 |
Antiviral
resin member |
NBC
MESHTEC, INC. |
6-Jul- 11 |
6- Jul- 12 |
5- Jul- 16 |
US9376486 |
Human
monoclonal antibody with specificity for Dengue virus serotype 1 E protein
and uses thereof |
DSO
National Laboratories |
14- Dec- 10 |
14- Dec -11 |
28- Jun- 16 |
US9376398 |
Carboxylic
acid compounds |
Astrazeneca
Aktiebolag |
18- May- 12 |
17- May -13 |
28- Jun- 16 |
US9375465 |
Conjugates
of GM-CSF and IL-7, compositions and methods related thereto |
Children's
Healthcare of Atlanta, Inc. |
14- Nov- 11 |
13- Nov -12 |
28- Jun- 16 |
US9372156 |
System
for processing contents of a receptacle to detect an optical signal emitted
by the contents |
GEN-PROBE
INCORPORATED |
10- Mar- 05 |
22- Feb -11 |
21- Jun- 16 |
US9371563 |
Nanoreporters
and methods of manufacturing and use thereof |
NanoString
Technologies, Inc. |
23- Dec- 05 |
11- Mar -13 |
21- Jun- 16 |
US9370582 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
11- Jul- 14 |
21- Jun- 16 |
US9370581 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
11- Jul- 14 |
21- Jun- 16 |
US9370570 |
Polychlorinated
biphenyls and squalene-containing adjuvants |
Novartis
AG |
28- Dec- 07 |
10- Dec -13 |
21- Jun- 16 |
US9370531 |
Method of
providing patient specific immune response in amyloidoses and protein
aggregation disorders |
New
York University |
31- Aug- 07 |
1- Sep -08 |
21- Jun- 16 |
US9365577 |
Pyrimidinone
compounds as human neutrophil elastase inhibitors |
Chiesi
Farmaceutici S.p.A. |
18- Dec- 12 |
17- Dec -13 |
14- Jun- 16 |
US9365567 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
30- Sep -14 |
14- Jun- 16 |
US9365523 |
Imidazolyl
amide compounds and uses related thereto |
Children's
Healthcare of Atlanta, Inc. |
31- Mar- 11 |
28- Mar -12 |
14- Jun- 16 |
US9365506 |
Compounds
and compositions as TLR2 agonists |
NOVARTIS
AG |
23- Mar- 10 |
9- Jul- 14 |
14- Jun- 16 |
US9364511 |
Antiviral
preparations obtained from a natural cinnamon extract |
RAMOT
AT TEL-AVIV UNIVERSITY LTD. |
24- Dec- 03 |
22- Jun -06 |
14- Jun- 16 |
US9359360 |
TLR
agonists |
The
Regents of The University of California |
22- Aug- 05 |
20- Nov -12 |
7- Jun-
16 |
US9358280 |
Decreasing
potential iatrogenic risks associated with influenza vaccines |
Novartis
AG |
9- Sep-
04 |
11- Jan -13 |
7- Jun-
16 |
US9353133 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
7- Mar -14 |
31- May -16 |
US9352048 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
4- Dec-
07 |
22- Jul- 14 |
31- May -16 |
US9347055 |
Method
and kit for preparation of sample for use in nucleic acid amplification |
EIKEN
KAGAKU KABUSHIKI KAISHA |
5- Nov-
07 |
5- Nov -08 |
24- May -16 |
US9346866 |
Inhibition
of tace activity with cyclic peptides |
The
Regents of the University of California |
2- Jun-
11 |
19- Sep -14 |
24- May -16 |
US9346794 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
29- Dec -15 |
24- May -16 |
US9346769 |
Tetrazolones
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
23- Aug -13 |
24- May -16 |
US9346753 |
Dithiol
mucolytic agents |
PARION
SCIENCES, INC. |
23- Aug- 13 |
13- Aug -14 |
24- May -16 |
US9345760 |
IPNV-ISAV
bivalent vaccine using a virus-like particle-based platform and methods of
using the same |
Advanced
Bionutrition Corporation |
9- Sep-
11 |
7- Sep -12 |
24- May -16 |
US9340507 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
2- Sep -15 |
17- May -16 |
US9339561 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
5- May -14 |
17- May -16 |
US9339525 |
Inhibition
of biofilm organisms |
Novabiotics
Limited |
31- Mar- 09 |
31- Mar -10 |
17- May -16 |
US9334268 |
4-amino-imidazoquinoline
compounds |
HOFFMAN-LA
ROCHE INC. |
22- Apr- 14 |
22- Apr -15 |
10- May -16 |
US9328110 |
Substituted
imidazo ring systems and methods |
3M
INNOVATIVE PROPERTIES COMPANY |
25- Nov- 03 |
11- Mar -14 |
3- May -16 |
US9328093 |
Selective
inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions
thereof and their therapeutic applications |
HYBRIGENICS
SA |
15- Jan- 10 |
17- Sep -14 |
3- May -16 |
US9326972 |
Use
of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones
for the treatment of autoimmune/inflammatory diseases associated with
toll-like receptor overexpression |
Ohio
University |
16- Mar- 04 |
9- Feb -12 |
3- May -16 |
US9322827 |
B-cell
antigen presenting cell assay |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
8- Apr -11 |
26- Apr- 16 |
US9321999 |
Compositions
for increasing polypeptide stability and activity, and related methods |
SOLIS
BIODYNE OÜ |
19- Nov- 09 |
19- Nov -10 |
26- Apr- 16 |
US9321847 |
Activatable
toxin complexes comprising a cleavable inhibitory peptide |
RAMOT
at Tel Aviv University Ltd. |
20- Sep- 10 |
22- Aug -11 |
26- Apr- 16 |
US9321831 |
RSV-specific
binding molecules and means for producing them |
MedImmune
Limited |
1- Jun-
07 |
13- Sep -13 |
26- Apr- 16 |
US9320784 |
Peptides
shared among lethal cancers and therapeutic compositions comprising said
peptides |
Not
Available |
7- Aug-
09 |
19- Jul- 12 |
26- Apr- 16 |
US9320748 |
Immunologically
useful arginine salts |
Novartis
AG |
7- Mar-
12 |
7- Mar -13 |
26- Apr- 16 |
US9315530 |
Adsorption
of immunopotentiators to insoluble metal salts |
Novartis
AG |
1- Sep-
10 |
1- Sep -11 |
19- Apr- 16 |
US9310375 |
Luminophore-labeled
molecules coupled with particles for microarray-based assays |
CapitalBio
Corporation |
27- Oct- 10 |
27- Oct -10 |
12- Apr- 16 |
US9310088 |
Device
and method for reducing spread of microorganisms and airborne health
hazardous matter and/or for protection from microorganisms and airborne
health hazardous matter |
Technical
University of Denmark |
17- Jul-09 |
14- Jul- 10 |
12- Apr- 16 |
US9309325 |
Antibodies
and methods of use thereof |
The
Regents of the University of California |
7- May-
09 |
4- May -10 |
12- Apr- 16 |
US9303068 |
D-amino
acid derivative-modified peptidoglycan and methods of use thereof |
The
Regents of the University of California |
30- Nov- 12 |
27- Nov -13 |
5- Apr-
16 |
US9303000 |
Olefin
containing nuclear transport modulators and uses thereof |
KARYOPHARM
THERAPEUTICS INC. |
17- Jan- 11 |
16- Jan -12 |
5- Apr-
16 |
US9297010 |
Short
interfering RNA (siRNA) analogues |
Roche
Innovation Center Copenhagen A/S |
21- Mar- 03 |
11- Feb -14 |
29- Mar -16 |
US9295732 |
Conjugated
TLR7 and/or TLR8 and TLR2 polycationic agonists |
INVIVOGEN |
22- Feb- 13 |
22- Feb -13 |
29- Mar -16 |
US9295708 |
Modified
release formulations for oprozomib |
Onyx
Therapeutics, Inc. |
24- Oct- 12 |
24- Oct -13 |
29- Mar -16 |
US9295646 |
Cationic
oil-in-water emulsions |
Novartis
AG |
6-Jul- 10 |
18- Sep -11 |
29- Mar -16 |
US9291628 |
Direct
clone analysis and selection technology |
Dublin
City University |
13- Jul-10 |
13- Jul- 11 |
22- Mar -16 |
US9291597 |
Detecting
targets using mass tags and mass spectrometry |
VENTANA
MEDICAL SYSTEMS, INC. |
2-Jul- 10 |
1- Jul- 11 |
22- Mar -16 |
US9290794 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
12- Nov -12 |
22- Mar -16 |
US9290786 |
Monoclonal
antibody production by EBV transformation of B cells |
Institute
for Research in Biomedicine |
26- Feb- 03 |
25- Apr -13 |
22- Mar -16 |
US9290760 |
Modified
iRNA agents |
ALNYLAM
PHARMACEUTICALS, INC. |
15- Sep- 10 |
14- Sep -11 |
22- Mar -16 |
US9290745 |
Luciferase
biosensor |
PROMEGA
CORPORATION |
10- Oct- 03 |
14- Feb -14 |
22- Mar -16 |
US9290545 |
Compositions
and methods for the treatment of viral infections |
Dana-Farber
Cancer Institute, Inc. |
23- Jan- 08 |
23- Jul- 10 |
22- Mar -16 |
US9290459 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
6- Feb-
13 |
9- Nov -15 |
22- Mar -16 |
US9290457 |
Substituted
dihydropyrimidinones and their use as inhibitors of neutrophil elastase
activity |
Boehringer
Ingelheim International GmbH |
31- Jul-14 |
27- Jul- 15 |
22- Mar -16 |
US9289487 |
II-key/antigenic
epitope hybrid peptide vaccines |
Antigen
Express, Inc. |
14- Sep- 99 |
11- Jan -05 |
22- Mar -16 |
US9284560 |
Application
of highly conserved domain sequences from viral genome as template to design
therapeutic sliRNAs |
Biocross
Institute of Molecular Medicine (Nantong) Co., Ltd. |
19- Sep- 11 |
19- Sep -11 |
15- Mar -16 |
US9278128 |
Vaccines
and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid
molecules encoding the same, and methods for using the same |
The
Trustees of the University of Pennsylvania |
14- Sep- 09 |
6- Jan -14 |
8- Mar -16 |
US9278126 |
Influenza
vaccines with reduced amounts of squalene |
Seqirus
UK Limited |
10- Feb- 09 |
10- Feb -10 |
8- Mar -16 |
US9272024 |
Compositions,
comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics
and methods of using the same |
The
Trustees of the University of Pennsylvania |
12- Dec- 11 |
11- Dec -12 |
1- Mar -16 |
US9271494 |
Shelf
stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial
compositions |
Ecolab
USA, Inc. |
30- Aug- 07 |
30- Aug -07 |
1- Mar -16 |
US9266844 |
Suppression
of SARS replication by SARS helicase inhibitors |
The
Curators of the University of Missouri |
15- Jun- 12 |
17- Jun -13 |
23- Feb -16 |
US9266843 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
9- May -13 |
23- Feb -16 |
US9265876 |
Systems
and methods for pathogen inactivation in blood using UV irradiation while
minimizing heat transfer thereto |
Hemalux
Technologies LLC |
22- Oct- 14 |
22- Oct -14 |
23- Feb -16 |
US9260398 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
PARION
SCIENCES, INC. |
29- May- 12 |
9- Dec -14 |
16- Feb -16 |
US9255144 |
Anti-IL-18
antibodies and their uses |
MedImmune
Limited |
20- Dec- 10 |
20- Dec -11 |
9- Feb -16 |
US9255140 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
NEW
YORK BLOOD CENTER, INC. |
15- Jun- 04 |
23- Mar -09 |
9- Feb -16 |
US9254315 |
Systems
and methods for identifying replikin scaffolds and uses of said replikin
scaffolds |
Not
Available |
28- Apr- 04 |
3- Feb -10 |
9- Feb -16 |
US9254265 |
Small
liposomes for delivery of immunogen encoding RNA |
NOVARTIS
AG |
31- Aug- 10 |
31- Aug -11 |
9- Feb -16 |
US9249427 |
Recombinant
HCMV and RHCMV vectors and uses thereof |
Oregon
Health & Science University |
14- May- 10 |
14- Nov -12 |
2- Feb -16 |
US9249195 |
Reovirus
vaccines and methods of use therefor |
Vanderbilt
University |
7- Apr-
10 |
4- Apr -11 |
2- Feb -16 |
US9248201 |
Mutant
protease biosensors with enhanced detection characteristics |
PROMEGA
CORPORATION |
11- May- 10 |
5- May -14 |
2- Feb -16 |
US9248178 |
Different
serotypes of vesicular stomatitis virus as expression vectors for
immunization regimens |
Not
Available |
8- Jun-
09 |
8- Jun -10 |
2- Feb -16 |
US9242980 |
Lipidated
immune response modifier compound compositions, formulations, and methods |
3M
Innovative Properties Company |
17- Aug- 10 |
16- Aug -11 |
26- Jan- 16 |
US9238809 |
Compositions,
methods, and kits for isolating and analyzing nucleic acids using an anion
exchange material |
QIAGEN
GAITHERSBURG, INC. |
24- Sep- 09 |
5- Aug -10 |
19- Jan- 16 |
US9234175 |
Creating
bioengineered lymph nodes |
H.
Lee Moffitt Cancer Center and Research Institute, Inc. |
17- Nov- 09 |
16- Nov -10 |
12- Jan- 16 |
US9233148 |
Replikin-based
compounds for prevention and treatment of influenza and methods of
differentiating infectivity and lethality in influenza |
Not
Available |
9- Jan- 09 |
16- Oct -09 |
12- Jan- 16 |
US9227977 |
Phosphoinositide
3-kinase inhibitors |
Respivert
Ltd. |
15- Mar- 13 |
14- Mar -14 |
5- Jan-
16 |
US9222075 |
Animal
protein-free media for cultivation of cells |
Baxalta
GmbH |
29- Oct- 04 |
2- May -14 |
29- Dec -15 |
US9221832 |
Heterocyclic
amide derivatives as P2X7 receptor antagonists |
ACTELION
PHARMACEUTICALS LTD. |
22- Jul-11 |
20- Jul- 12 |
29- Dec -15 |
US9221807 |
Substituted
pyridones and pyrazinones and their use as inhibitors of neutrophil elastase
activity |
Boehringer
Ingelheim International GmbH |
21- Feb- 14 |
12- Feb -15 |
29- Dec -15 |
US9220768 |
Decreasing
potential iatrogenic risks associated with influenza vaccines |
Novartis
AG |
9- Sep-
04 |
14- Oct -11 |
29- Dec -15 |
US9217745 |
Arrayed
detector system for measurement of influenza immune response |
University
of Rochester |
2- May-
08 |
11- Jul- 13 |
22- Dec -15 |
US9217157 |
Recombinant
influenza viruses and uses thereof |
Icahn
School of Medicine at Mount Sinai |
27- Jul-09 |
27- Jul- 10 |
22- Dec -15 |
US9216192 |
Toll-like
receptor agonist formulations and their use |
VentiRx
Pharmaceuticals, Inc. |
1- Aug-
08 |
16- Jul- 12 |
22- Dec -15 |
US9213027 |
Lipoparticles
comprising proteins, methods of making, and using the same |
Integral
Molecular, Inc. |
30- Jul-03 |
1- Nov -13 |
15- Dec -15 |
US9212399 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
7- Jan -14 |
15- Dec -15 |
US9212205 |
Nucleic
acid binding compounds and methods of use |
University
of Rochester |
26- Jul-07 |
28- Jul- 08 |
15- Dec -15 |
US9206396 |
Methods
and devices for quantitative viral assays |
Wisconsin
Alumni Research Foundation |
16- Nov- 05 |
16- Nov -06 |
8- Dec -15 |
US9206158 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
10- Jun -15 |
8- Dec -15 |
US9200329 |
Rapid
epidemiologic typing of bacteria |
BioFire
Diagnostics, LLC |
19- May- 08 |
18- May -09 |
1- Dec -15 |
US9200287 |
Phosphate-modified
oligonucleotide analogs with enhanced immunostimulatory activity |
AdiuTide
Pharmaceuticals GmbH |
18- May- 07 |
15- May -08 |
1- Dec -15 |
US9200280 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
9- Jun -14 |
1- Dec -15 |
US9200279 |
Methods
and compositions for the treatment of cancer or other diseases |
CITY
OF HOPE |
26- Jan- 07 |
14- Jan -14 |
1- Dec -15 |
US9200074 |
Antibodies
to IL-1 R1 and methods of making them |
MEDIMMUNE
LIMITED |
7- Nov-
08 |
16- Apr -14 |
1- Dec -15 |
US9199981 |
Compounds
and compositions as C-kit kinase inhibitors |
NOVARTIS
AG |
1- Sep-
11 |
27- Aug -12 |
1- Dec -15 |
US9199897 |
Methods
for preparing squalene |
NOVARTIS
AG |
12- May- 10 |
12- May -11 |
1- Dec -15 |
US9198927 |
Targeting
opposite strand replication intermediates of single- stranded viruses by RNAI |
ALNYLAM
PHARMACEUTICALS, INC. |
24- Sep- 04 |
1- Mar -10 |
1- Dec -15 |
US9193780 |
Amino
acid sequences directed against envelope proteins of a virus and polypeptides
comprising the same for the treatment of viral diseases |
Ablynx
N.V. |
5- Jun- 08 |
5- Jun -09 |
24- Nov -15 |
US9192661 |
Delivery
of self-replicating RNA using biodegradable polymer particles |
Novartis
AG |
6-Jul- 10 |
7- Jun -11 |
24- Nov -15 |
US9187748 |
Compositions
and methods for silencing ebola virus gene expression |
Not
Available |
20- Jul-09 |
28- Mar -14 |
17- Nov -15 |
US9187426 |
Organic
compounds |
Novartis
AG |
27- Jun- 08 |
25- Jun -09 |
17- Nov -15 |
US9186419 |
Directed
evolution and in vitro panning of virus vectors |
The
University of North Carolina at Chapel Hill |
30- Apr- 08 |
17- Jan -14 |
17- Nov -15 |
US9186399 |
Immune
stimulatory oligonucleotide analogs containing modified sugar moieties |
AdiutTide
Pharmaceuticals GmbH |
9- Oct-
07 |
29- Sep -08 |
17- Nov -15 |
US9181303 |
Treatment
of bacterial infections with cyclic antimicrobial peptides |
NovaBiotics
Limited |
22- Dec- 05 |
20- Jun -14 |
10- Nov -15 |
US9181290 |
Inhibition
of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose |
CHANG
GUNG UNIVERSITY |
17- Jun- 11 |
19- Sep -11 |
10- Nov -15 |
US9175047 |
Peptidomimetic
macrocycles |
Aileron
Therapeutics, Inc. |
14- Jan- 09 |
14- Jan -10 |
3- Nov -15 |
US9174925 |
Phorbol
type diterpene compound, pharmaceutical composition for treatment or
prevention of viral infectious diseases including same |
KOREA
RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
26- Oct- 11 |
28- Sep -12 |
3- Nov -15 |
US9169318 |
Neutralizing
molecules to viral antigens |
Sea
Lane Biotechnologies, Inc. |
28- Mar- 08 |
18- Jul- 11 |
27- Oct- 15 |
US9168318 |
Oxidative
reductive potential water solution and methods of using the same |
Oculus
Innovative Sciences, Inc. |
30- Dec- 03 |
11- Aug -04 |
27- Oct- 15 |
US9168299 |
Methods
for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL)
antibodies |
LIPUM
AB |
8- Apr-
09 |
30- Oct -13 |
27- Oct- 15 |
US9168269 |
Inhibitors
of long and very long chain fatty acid metabolism as broad spectrum anti-virals |
THE
TRUSTEES OF PRINCETON UNIVERSITY |
18- Feb- 10 |
18- Feb -11 |
27- Oct- 15 |
US9163222 |
Mutations
in OAS1 genes |
Kineta
Two, LLC |
4- May-
05 |
14- Nov -12 |
20- Oct- 15 |
US9163065 |
Depsipeptide
and uses thereof |
NovoBiotic
Pharmaceuticals, LLC |
3- Dec-
12 |
3- Dec -13 |
20- Oct- 15 |
US9161976 |
Immunotherapy
comprising TLR9 ligand and CD40 ligand |
Trustees
of Dartmouth College |
30- Dec- 02 |
22- Oct -12 |
20- Oct- 15 |
US9156811 |
N-myristoyl
transferase inhibitors |
Univeristy
of Dundee |
2- Sep-
08 |
29- Aug -09 |
13- Oct- 15 |
US9155309 |
Virus
inactivating sheet |
NBC
MESHTEC, INC. |
2- Oct-
09 |
4- Oct -10 |
13- Oct- 15 |
US9149473 |
Targeted
whole genome amplification method for identification of pathogens |
IBIS
BIOSCIENCES, INC. |
14- Sep- 06 |
14- Sep -07 |
6- Oct-
15 |
US9149445 |
Inhibition
of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for
treatment of viral infections |
THE
TRUSTEES OF PRINCETON UNIVERSITY |
27- Jul-09 |
27- Jul- 10 |
6- Oct-
15 |
US9145588 |
Generation
of binding molecules |
MERUS
BIOPHARMACEUTICALS B.V. |
26- Sep- 11 |
26- Sep -12 |
29- Sep -15 |
US9145585 |
Method
for using permuted nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
5- Aug -14 |
29- Sep -15 |
US9145410 |
Pyrazolopyridines
and analogs thereof |
3M
Innovative Properties Company |
3- Oct-
03 |
26- Jan -12 |
29- Sep -15 |
US9144575 |
Anti-viral
azide containing compounds |
LIFE
TECHNOLOGIES CORPORATION |
28- Jul-10 |
28- Jul- 11 |
29- Sep -15 |
US9139833 |
Modified
small interfering RNA molecules and methods of use |
Arrowhead
Research Corporation |
26- Jul-02 |
12- Mar -13 |
22- Sep -15 |
US9139647 |
Diagnosis
and treatment of cancer using anti-TM4SF20 antibody |
FORERUNNER
PHARMA RESEARCH CO., LTD. |
25- Dec- 08 |
25- Dec -09 |
22- Sep -15 |
US9139620 |
Feline
morbillivirus and uses thereof |
THE
GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S
REPUBLIC OF CHINA |
20- Jan- 12 |
22- Jan -13 |
22- Sep -15 |
US9138472 |
CD40L
vaccines, compositions, and methods related thereto |
EMORY
UNIVERSITY |
28- Sep- 10 |
28- Sep -11 |
22- Sep -15 |
US9134247 |
Method
and apparatus for two-step surface-enhanced raman spectroscopy |
REAL-TIME
ANALYZERS, INC. |
16- Dec- 11 |
16- Dec -11 |
15- Sep -15 |
US9133248 |
Methods
of propagating monkey adenoviral vectors |
GenVec,
Inc. |
9- Nov-
09 |
9- Nov -10 |
15- Sep -15 |
US9132423 |
Sample-to-answer
microfluidic cartridge |
Micronics,
Inc. |
29- Jan- 10 |
28- Jan -11 |
15- Sep -15 |
US9132175 |
Bacillus
based delivery system and methods of use |
The
Curators of the University of Missouri |
18- Apr- 11 |
18- Apr -11 |
15- Sep -15 |
US9128101 |
Biomarkers
for theranostics |
Caris
Life Sciences Switzerland Holdings GmbH |
1- Mar-
10 |
1- Mar -11 |
8- Sep -15 |
US9127256 |
Method
for production of reprogrammed cell using chromosomally unintegrated virus
vector |
DNAVEC
CORPORATION |
16- Jul-08 |
16- Jul- 09 |
8- Sep -15 |
US9127251 |
Means and
methods for influencing the stability of antibody producing cells |
ACADEMISCH
MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM |
9- Dec-
05 |
8- Dec -06 |
8- Sep -15 |
US9127028 |
Substrates
for chromogenic detection and methods of use in detection assays and kits |
Ventana
Medical Systems, Inc. |
16- Aug- 10 |
12- Aug -11 |
8- Sep -15 |
US9125952 |
Immunostimulatory
compositions comprising liposome-encapsulated oligonucleotides and epitopes |
Industry
Academic Cooperation Foundation, Hallym University |
17- Jul-09 |
13- Aug -14 |
8- Sep -15 |
US9115093 |
Substituted
bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil
elastase activity |
Boehringer
Ingelheim International GmbH |
4- Mar-
13 |
20- Feb -14 |
25- Aug -15 |
US9115065 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with Arenaviruses |
Kineta,
Inc. |
6- Dec- 04 |
26- Feb -13 |
25- Aug -15 |
US9109199 |
Methods
to produce bunyavirus replicon particles |
STICHTING
DIENST LANDBOUWKUNDIG ONDERZOEK |
20- Sep- 10 |
20- Sep -11 |
18- Aug -15 |
US9107970 |
Method
and a filter for capturing airborne agents |
Not
Available |
15- Jul-08 |
13- Jul- 09 |
18- Aug -15 |
US9107958 |
Hydrazino
1H-imidazoquinolin-4-amines and conjugates made therefrom |
3M
Innovative Properties Company |
3- Jun-
11 |
1- Jun -12 |
18- Aug -15 |
US9107906 |
Compositions
and methods for the treatment of immunodeficiency |
ADMA
BIOLOGICS, INC. |
28- Oct- 14 |
8- Jan -15 |
18- Aug -15 |
US9107904 |
Immunostimulatory
compositions and methods of use thereof |
Massachusetts
Institute of Technology |
5- Apr-
12 |
15- Mar -13 |
18- Aug -15 |
US9102938 |
2′
and 5′ modified monomers and oligonucleotides |
ALNYLAM
PHARMACEUTICALS, INC. |
31- Mar- 11 |
31- Mar -11 |
11- Aug -15 |
US9102911 |
High
density self-contained biological analysis |
BioFire
Diagnostics, LLC |
15- May- 09 |
28- Jan -13 |
11- Aug -15 |
US9102741 |
GAS57
mutant antigens and GAS57 antibodies |
Novartis
AG |
12- Sep- 07 |
13- Oct -14 |
11- Aug -15 |
US9102740 |
Cna-B
domain antigens in vaccines against gram positive bacteria |
NOVARTIS
AG |
12- Jan- 09 |
7- Jun -13 |
11- Aug -15 |
US9102633 |
Arylalkyl-
and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
Parion
Sciences, Inc. |
13- Dec- 13 |
13- Dec -13 |
11- Aug -15 |
US9102624 |
Substituted
4-pyridones and their use as inhibitors of neutrophil elastase activity |
Boehringer
Ingelheim International GmbH |
23- Aug- 12 |
20- Aug -13 |
11- Aug -15 |
US9101597 |
Immunoprotective
primary mesenchymal stem cells and methods |
Autoimmune
Technologies, LLC |
14- Mar- 13 |
14- Mar -13 |
11- Aug -15 |
US9101582 |
Use of a
pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control and Prevention |
31- Jul-08 |
27- Mar -13 |
11- Aug -15 |
US9096585 |
Antiviral
compounds and uses thereof |
Icahn
School of Medicine at Mount Sinai |
28- May- 10 |
31- May -11 |
4- Aug -15 |
US9096543 |
Nuclear
transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
9- May-
12 |
9- May -13 |
4- Aug -15 |
US9090897 |
Production
of IFN-lambda by conventional dendritic cells |
Bavarian
Nordic A/S |
18- Dec- 09 |
17- Dec -10 |
28- Jul- 15 |
US9085641 |
Peptides
regulating the surface expression of the T cell receptor |
Max-Delbruck-Centrum
Fur Molekulare Medizin |
23- Jun- 06 |
23- Jun -07 |
21- Jul- 15 |
US9084808 |
Modified
small interfering RNA molecules and methods of use |
Arrowhead
Research Corporation |
1- Oct-
04 |
9- May -14 |
21- Jul- 15 |
US9084758 |
Antiviral
compositions comprising ethanol extract of Tetracera scandens and use thereof |
The Catholic
University of Korea Industry-Academic Cooperation Foundation |
24- Jul-12 |
25- Aug -14 |
21- Jul- 15 |
US9080209 |
Non-mass
determined base compositions for nucleic acid detection |
IBIS
BIOSCIENCES, INC. |
6- Aug-
09 |
6- Aug -10 |
14- Jul- 15 |
US9080204 |
Compositions
and methods for rapid, real-time detection of influenza a virus (H1N1) Swine
2009 |
Longhorn
Vaccines and Diagnostics, LLC |
12- Sep- 06 |
30- Dec -11 |
14- Jul- 15 |
US9079965 |
Bispecific
antibody |
Wuhan
YZY Biopharma Co., LTD. |
21- Nov- 12 |
13- Mar -14 |
14- Jul- 15 |
US9079943 |
TC-83-derived
alphavirus vectors, particles and methods |
ALPHAVAX,
INC. |
18- May- 04 |
28- Mar -14 |
14- Jul- 15 |
US9079865 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
29- Jul- 12 |
14- Jul- 15 |
US9078885 |
Respiratory
disease treatment |
Pulmagen
Therapeutics (Inflammation) Limited |
7- Aug-
08 |
7- Apr -14 |
14- Jul- 15 |
US9078868 |
Therapeutic
agent for accelerating recovery of animal under medical treatment |
DAIICHI
SANKYO COMPANY, LIMITED |
15- Jan- 10 |
14- Jan -11 |
14- Jul- 15 |
US9073869 |
Method
of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid
(benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
11- Sep -14 |
7- Jul- 15 |
US9072738 |
Chemically
and metabolically stable dipeptide possessing potent sodium channel blocker
activity |
PARION
SCIENCES, INC. |
27- Jun- 11 |
27- Jun -12 |
7- Jul- 15 |
US9072726 |
Methods
of treating or preventing inflammation and hypersensitivity with oxidative
reductive potential water solution |
Oculus
Innovative Sciences, Inc. |
20- Jan- 06 |
21- Dec -09 |
7- Jul- 15 |
US9072702 |
Reverse
genetics using non-endogenous pol I promoters |
Novartis
AG |
21- May- 09 |
21- May -10 |
7- Jul- 15 |
US9067873 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including infections
associated with arenaviruses |
Kineta
Four, LLC |
6- Dec- 04 |
19- Dec -13 |
30- Jun- 15 |
US9066964 |
Use
of tylvalosin as antiviral agent |
Cambridge
University Technical Services |
13- Jul-06 |
13- Jul- 07 |
30- Jun- 15 |
US9063150 |
Method for
detection of antigen-specific antibodies in biological samples |
The United States of America as represented
by the Secretary of the Department of Health and Human Services, Centers for
Disease Control Prevention |
2- Sep-
08 |
25- Aug -09 |
23- Jun- 15 |
US9061001 |
Combination
adjuvant formulation |
Dalhousie
University |
16- Oct- 08 |
15- Oct -09 |
23- Jun- 15 |
US9056900 |
Compositions
and methods for coronavirus inhibition |
Autoimmune
Technologies, LLC. |
4- Nov-
03 |
8- Aug -13 |
16- Jun- 15 |
US9056898 |
Attenuated
RNA virus and applications thereof |
Washington
University |
20- Sep- 07 |
22- Sep -08 |
16- Jun- 15 |
US9056071 |
Compounds
and methods for preventing or treating a viral infection |
CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) |
2- Nov-
07 |
19- Jun -13 |
16- Jun- 15 |
US9051619 |
Methods
and compositions for prostate cancer metastasis |
FLORIDA
AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) |
25- Mar- 11 |
23- Mar -12 |
9- Jun-
15 |
US9051564 |
Compositions
for and methods of identifying antigens |
President
and Fellows of Harvard College |
21- Feb- 06 |
21- Feb -07 |
9- Jun-
15 |
US9051353 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
24- Sep -13 |
9- Jun-
15 |
US9050376 |
Conjugates
of synthetic TLR agonists and uses therefor |
The
Regents of the University of California |
7- Feb-
07 |
19- Jun -14 |
9- Jun-
15 |
US9046523 |
Rapid
bioluminescence detection system |
THE
SECRETARY OF STATE FOR HEALTH |
7- Jan- 09 |
2- Aug -13 |
2- Jun-
15 |
US9045855 |
Anti-viral
member |
NBC
Meshtec, Inc. |
26- Dec- 08 |
28- Dec -09 |
2- Jun-
15 |
US9045727 |
Virus-like
particles, methods of preparation, and immunogenic compositions |
EMORY
UNIVERSITY |
17- May- 02 |
4- Apr -06 |
2- Jun-
15 |
US9045472 |
Imidazoquinoline
compounds |
ASTRAZENECA
AB |
16- Dec- 10 |
16- Dec -11 |
2- Jun-
15 |
US9045470 |
Compounds
and compositions as TLR activity modulators |
IRM
LLC |
2- Sep-
09 |
1- Sep -10 |
2- Jun-
15 |
US9044420 |
Immunogenic
compositions and methods of using the compositions for inducing humoral and
cellular immune responses |
IMMUNE
DESIGN CORP. |
8- Apr-
11 |
6- Apr -12 |
2- Jun-
15 |
US9040310 |
Antibody-nanoparticle
conjugates and methods for making and using such conjugates |
Ventana
Medical Systems, Inc. |
27- Apr- 10 |
27- Apr -11 |
26- May -15 |
US9034646 |
Virally-inactivated
growth factors-containing platelet lysate depleted of PDGF and VEGF and
preparation method thereof |
ZHENG
YANG BIOMEDICAL TECHNOLOGY CO., LTD. |
25- May- 10 |
26- Nov -12 |
19- May -15 |
US9034313 |
Nucleic
acid molecules encoding rantes, and compositions comprising and methods of
using the same |
Inovio
Pharmaceuticals, Inc. |
8- Feb-
10 |
8- Feb -11 |
19- May -15 |
US9029413 |
Treatment
of viral infections by modulation of host cell metabolic pathways |
The
Trustees of Princeton University |
1- Jun-
07 |
3- Apr -12 |
12- May -15 |
US9029382 |
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)
pyrazine-2-carboxamide compounds |
Parion
Sciences, Inc. |
17- Dec- 12 |
13- Dec -13 |
12- May -15 |
US9029315 |
Soluble
PD-1 variants, fusion constructs, and uses thereof |
The
University of Hong Kong |
11- Nov- 10 |
11- Nov -11 |
12- May -15 |
US9028841 |
Synergistic
bacterial compositions and methods of production and use thereof |
Seres
Health, Inc. |
23- Nov- 12 |
20- Mar -14 |
12- May -15 |
US9028837 |
Methods
and compositions for poxvirus A35R protein |
East
Carolina University |
7- Jun-
12 |
20- Dec -12 |
12- May -15 |
US9028823 |
Methods
of inducing or enhancing an immune response in a subject by administering
agonistic GITR binding antibodies |
GITR,
Inc. |
25- Mar- 05 |
1- Mar -13 |
12- May -15 |
US9024001 |
Alphavirus
replicon packaging constructs |
Novartis
Vaccines and Diagnostics, Inc. |
25- May- 04 |
20- May -05 |
5- May -15 |
US9023855 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
14- Sep- 11 |
11- Feb -14 |
5- May -15 |
US9023839 |
Compounds
and compositions as c-kit kinase inhibitors |
IRM
LLC |
1- Sep-
11 |
22- Apr -14 |
5- May -15 |
US9017699 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
New
York Blood Center, Inc. |
15- Jun- 04 |
18- Feb -10 |
28- Apr- 15 |
US9017696 |
Adenovirus
vectors |
Isis
Innovation Limited |
10- Apr- 07 |
10- Apr -08 |
28- Apr- 15 |
US9012622 |
Compositions
and methods using siRNA molecules and siRNA cocktails for the treatment of
breast cancer |
Not
Available |
31- Dec- 08 |
31- Dec -09 |
21- Apr- 15 |
US9011767 |
Transportable
vacuum assisted decontamination unit and decontamination process |
STERIS
Inc. |
1- Apr-
13 |
31- Mar -14 |
21- Apr- 15 |
US9006264 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
9- Sep -13 |
14- Apr- 15 |
US9006194 |
Compositions
and methods for diminishing viral infection and inflammation associated with
viral infection |
Drexel
University |
19- Dec- 08 |
17- Dec -09 |
14- Apr- 15 |
US9005974 |
Means
and methods for influencing the stability of cells |
Academish
Medisch Centrum Bij de Universiteit van Amsterdam |
9- Dec-
05 |
9- Dec -05 |
14- Apr- 15 |
US9005665 |
Compositions
and methods for treating and preventing porcine reproductive and respiratory
syndrome |
Ohio
State Innovation Foundation |
24- Apr- 12 |
24- Apr -13 |
14- Apr- 15 |
US9005599 |
Genetically
modified human umbilical cord perivascular cells for prophylaxis against or
treatment of biological or chemical agents |
Tissue
Regeneration Therapeutics Inc. |
21- Apr- 08 |
20- Apr -09 |
14- Apr- 15 |
US8999996 |
Hydrazide
containing nuclear transport modulators and uses thereof |
Karyopharm
Therapeutics Inc. |
29- Jul-11 |
19- Mar -14 |
7- Apr-
15 |
US8999975 |
Substituted
N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
19- Sep- 11 |
14- Sep -12 |
7- Apr-
15 |
US8999678 |
Method
of increasing the function of an AAV vector |
The
Trustees of the University of Pennsylvania |
7- Apr-
05 |
7- Apr -06 |
7- Apr-
15 |
US8999349 |
HMGB1-derived
peptides enhance immune response to antigens |
The
Regents of the University of California |
27- Jul-10 |
27- Jul- 11 |
7- Apr-
15 |
US8999316 |
Antiviral
compounds |
Long
Island University |
30- May- 07 |
30- May -08 |
7- Apr-
15 |
US8993717 |
Gadd45beta
targeting agents |
Imperial
Innovations Limited |
22- Oct- 09 |
22- Oct -10 |
31- Mar -15 |
US8993581 |
Methods
for treating viral disorders |
Trustees
of Boston University |
24- Sep- 09 |
11- Jun -13 |
31- Mar -15 |
US8993295 |
Methods, compositions,
and kits for the selective activation of protoxins through combinatorial
targeting |
The
General Hospital Corporation |
20- Jul-06 |
20- Jul- 07 |
31- Mar -15 |
US8992939 |
Highly
efficient influenza matrix (M1) proteins |
Novavax,
Inc. |
11- Jul-03 |
24- Oct -11 |
31- Mar -15 |
US8987249 |
Substituted
2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides
inhibitors of Cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
24- Mar -15 |
US8987191 |
Bioactive
peptides and methods of using same |
Compugen
Ltd. |
12- Jul-07 |
21- Jun -13 |
24- Mar -15 |
US8986933 |
Selective
detection of human rhinovirus |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control |
5- Dec-
08 |
5- Dec -08 |
24- Mar -15 |
US8986926 |
Compositions
comprising oriented, immobilized macromolecules and methods for their
preparation |
NanoString
Technologies, Inc. |
23- Dec- 05 |
22- Dec -06 |
24- Mar -15 |
US8986702 |
Antibodies
and processes for preparing the same |
Taiga
Biotechnologies, Inc. |
16- May- 08 |
18- May -09 |
24- Mar -15 |
US8980898 |
Dendrimer
like amino amides possessing sodium channel blocker activity for the
treatment of dry eye and other mucosal diseases |
Parion
Sciences, Inc. |
29- May- 12 |
29- May -13 |
17- Mar -15 |
US8980338 |
Sceletium
extract and uses thereof |
H.L.
Hall & Sons Limited |
20- Mar- 09 |
16- Mar -10 |
17- Mar -15 |
US8980281 |
High-yield
transgenic mammalian expression system for generating virus-like particles |
Academia
Sinica |
5- Sep-
06 |
12- Feb -10 |
17- Mar -15 |
US8975389 |
Nucleic
acid chemical modifications |
Alnylam
Pharmaceuticals, Inc. |
2- Mar-
09 |
2- Mar -10 |
10- Mar -15 |
US8969362 |
9-substituted
8-oxoadenine compound |
AstraZeneca
Aktiebolag |
26- Mar- 04 |
21- Oct -13 |
3- Mar -15 |
US8969350 |
Pharmaceutical
product comprising a p38 kinase inhibitor and a second active ingredient |
Astrazeneca
AB |
18- Dec- 08 |
17- Dec -09 |
3- Mar -15 |
US8962580 |
Chemical
modifications of monomers and oligonucleotides with cycloaddition |
Alnylam
Pharmaceuticals, Inc. |
23- Sep- 08 |
23- Sep -09 |
24- Feb -15 |
US8962332 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
13- Sep -13 |
24- Feb -15 |
US8962330 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
31- Oct -07 |
24- Feb -15 |
US8961983 |
Mucosal
vaccine using cationic nanogel |
National
University Corporation Tokyo Medical and Dental University |
31- Oct- 08 |
5- Sep -14 |
24- Feb -15 |
US8961477 |
Delivery
of immune response modifier compounds |
3M
Innovative Properties Company |
25- Aug- 03 |
25- Aug -04 |
24- Feb -15 |
US8956863 |
Agents
from cells |
The
Brigham and Women's Hospital, Inc. |
15- Oct- 09 |
15- Oct -10 |
17- Feb -15 |
US8956616 |
Constructs
binding to phosphatidylserine and their use in disease treatment |
Board
of Regents, The University of Texas System |
24- Jan- 05 |
24- Jan -06 |
17- Feb -15 |
US8951768 |
Mutations
in OAS1 genes |
Kineta
Two, LLC |
4- May-
05 |
11- Jul- 11 |
10- Feb -15 |
US8951528 |
Immune
response modifier conjugates |
3M
Innovative Properties Company |
22- Feb- 06 |
21- Feb -07 |
10- Feb -15 |
US8945943 |
Personal
glucose meters for detection and quantification of a broad range of analytes |
The
Board of Trustees of the University of Illinois |
26- May- 10 |
26- May -11 |
3- Feb -15 |
US8945904 |
Influenza
virus reassortment |
Novartis
AG |
21- May- 10 |
20- May -11 |
3- Feb -15 |
US8945610 |
Condensation
products based on bicyclic or polycyclic aromatics or heteroaromatics |
BASF
SE |
14- Nov- 07 |
11- Nov -08 |
3- Feb -15 |
US8940864 |
Stabilized
therapeutic small helical antiviral peptides |
New
York Blood Center, Inc. |
5- Oct-
06 |
2- Oct -07 |
27- Jan- 15 |
US8940501 |
Methods
for ligation and uses thereof |
Whitehead
Institute for Biomedical Research |
30- Jan- 09 |
1- Feb -10 |
27- Jan- 15 |
US8937154 |
Stabilized
therapeutic small helical antiviral peptides |
New
York Blood Center, Inc. |
5- Oct-
06 |
2- Feb -12 |
20- Jan- 15 |
US8933210 |
Label-free
functional nucleic acid sensors for detecting target agents |
The
Board of Trustees of the University of Illinois |
6- Oct-
10 |
6- Oct -11 |
13- Jan- 15 |
US8933019 |
Antiviral
cell-penetrating peptides |
New
York Blood Center, Inc. |
6- May-
08 |
31- Oct -12 |
13- Jan- 15 |
US8916552 |
Pharmaceutical
combinations |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
23- Dec -14 |
US8916340 |
Method
for identifying and validating dominant T helper cell epitopes using an
HLA-DM-assisted class II binding assay |
The
John Hopkins University |
6- Jan- 06 |
8- Jan -07 |
23- Dec -14 |
US8906872 |
Antisense
antiviral compound and method for treating ssRNA viral infection |
Sarepta
Therapeutics, Inc. |
16- Sep- 04 |
22- Dec -11 |
9- Dec -14 |
US8906863 |
Proteolysis-resistant
capsid of chimeric hepatitis E virus as an oral delivery vector |
The
Regents of the University of California |
27- Feb- 09 |
1- Sep -11 |
9- Dec -14 |
US8906862 |
Multiple
antigen delivery system using hepatitis E virus-like particle |
National
Institute of Infectious Disease |
27- Feb- 09 |
29- Aug -11 |
9- Dec -14 |
US8901071 |
Compounds
and their use |
Novabiotics
Limited |
31- Mar- 10 |
30- Mar -11 |
2- Dec -14 |
US8900585 |
Influenza
hemagglutinin-specific monoclonal antibodies for preventing and treating
influenza virus infection |
New
York Blood Center, Inc. |
20- Oct- 10 |
20- Oct -11 |
2- Dec -14 |
US8895629 |
Circulation
of components during homogenization of emulsions |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
25- Nov -14 |
US8895577 |
Compounds
and compositions as TLR activity modulators |
Not
Available |
3- Mar-
08 |
22- Apr -13 |
25- Nov -14 |
US8895570 |
Purine
derivatives |
AstraZeneca
AB |
17- Dec- 10 |
14- Dec -11 |
25- Nov -14 |
US8895534 |
Boron
containing small molecules |
Anacor
Pharmaceuticals, Inc. |
20- Jun- 07 |
30- Jul- 10 |
25- Nov -14 |
US8895295 |
High
density self-contained biological analysis |
Biofire
Diagnostics, LLC |
15- Nov- 06 |
14- Nov -07 |
25- Nov -14 |
US8889708 |
Substituted
bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of
cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
18- Nov -14 |
US8889692 |
Pyrazinone
derivatives, pharmaceutically acceptance salts thereof and their uses |
AstraZeneca
AB |
27- Jun- 07 |
14- Sep -12 |
18- Nov -14 |
US8889656 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
30- Apr -13 |
18- Nov -14 |
US8889398 |
Composition
for inactivating an enveloped virus |
Viroblock
SA |
19- May- 06 |
18- May -07 |
18- Nov -14 |
US8889181 |
Immunostimulatory
compositions comprising liposome-encapsulated oligonucleotides and epitopes |
Industry
Academic Cooperation Foundation, Hallym University |
17- Jul-09 |
16- Jun -10 |
18- Nov -14 |
US8889118 |
Anticancer
agent containing dendritic cell having RNA virus transferred thereinto |
DNA
VEC Research Inc. |
24- Jun- 04 |
28- Apr -05 |
18- Nov -14 |
US8889117 |
Modular
nanoparticles for adaptable vaccines |
Yale
University |
15- Feb- 07 |
15- Feb -08 |
18- Nov -14 |
US8884020 |
Indole
compounds |
Ironwood
Pharmaceuticals, Inc. |
7- Aug-
06 |
7- Aug -07 |
11- Nov -14 |
US8883790 |
Pharmaceutical
combinations |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
11- Nov -14 |
US8883500 |
Method of
preparing adenosine-resistant anti-tumor T lymphocytes for adoptive
immunotherapy |
Northeastern
University |
5- Dec-
08 |
7- Dec -09 |
11- Nov -14 |
US8883481 |
Reverse
genetics methods for virus rescue |
Novartis
AG |
20- Oct- 09 |
20- Oct -10 |
11- Nov -14 |
US8883477 |
Oligoadenylate
synthetase (OAS) |
Kineta
Two, LLC |
23- Nov- 05 |
14- Jun -13 |
11- Nov -14 |
US8882484 |
Methods
and compositions for production of recombinant protein in HBX-expressing
mammalian cells |
Bayer
HealthCare LLC |
28- May- 08 |
27- May -09 |
11- Nov -14 |
US8881040 |
System
and method for detecting, collecting, analyzing, and communicating
event-related information |
Georgetown
University |
28- Aug- 08 |
2- Dec -09 |
4- Nov -14 |
US8877775 |
Substituted
2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmbH |
14- Mar- 13 |
12- Mar -14 |
4- Nov -14 |
US8877187 |
Therapeutic
antibodies for treatment and prophylaxis of transmittable viral diseases |
Avianax,
LLC |
25- Jul-05 |
23- Nov -10 |
4- Nov -14 |
US8877060 |
Methods
for removing pathogens from a platelet preparation |
Biovec
Transfusion, LLC |
23- Nov- 10 |
31- Oct -11 |
4- Nov -14 |
US8871816 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
28- Oct- 14 |
US8871790 |
Heterocyclic
modulators of lipid synthesis |
3-V
Biosciences, Inc. |
8- Mar-
11 |
8- Mar -12 |
28- Oct- 14 |
US8871783 |
Substituted
2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides
inhibitors of cathepsin C |
Boehringer
Ingelheim International GmBh |
14- Mar- 13 |
12- Mar -14 |
28- Oct- 14 |
US8871782 |
Alkoxy
substituted imidazoquinolines |
3M
Innovative Properties Company |
3- Oct-
03 |
1- Oct -04 |
28- Oct- 14 |
US8871503 |
Construct |
Isis
Innovation Limited |
28- Mar- 06 |
28- Mar -07 |
28- Oct- 14 |
US8871487 |
Compositions,
methods and uses for inducing viral growth |
Takeda
Vaccines, Inc. |
5- Dec-
08 |
4- Dec -09 |
28- Oct- 14 |
US8871442 |
Enhanced
deposition of chromogens |
Ventana
Medical Systems, Inc. |
30- Dec- 10 |
28- Dec -11 |
28- Oct- 14 |
US8865865 |
N-terminally
modified tetrapeptide derivatives having a C-terminal arginine mimetic |
Philipps-Universitat
Marburg |
29- Oct- 08 |
29- Oct -09 |
21- Oct- 14 |
US8865166 |
Antibodies
to IL-17A and uses thereof |
MedImmune
Limited |
23- Jun- 06 |
22- Jun -07 |
21- Oct- 14 |
US8859568 |
Pyrrolo[3,2-D]pyrimidin-4-one
derivatives and their use in therapy |
Astrazeneca
AB |
6- Dec-
04 |
3- Nov -10 |
14- Oct- 14 |
US8859251 |
Oligoadenylate
synthetase (OAS) |
Kineta
Two, LLC |
23- Nov- 05 |
1- Jul- 13 |
14- Oct- 14 |
US8858958 |
Adjuvant
comprising aluminum, oligonucleotide and polycation |
Novartis
AG |
27- Aug- 09 |
27- Aug -10 |
14- Oct- 14 |
US8858957 |
GAS57
mutant antigens and GAS57 antibodies |
Novartis
AG |
12- Sep- 07 |
14- Mar -13 |
14- Oct- 14 |
US8854617 |
Compounds
and markers for surface-enhanced Raman scattering |
Julius-Maximilians-Universitat
Wurzburg |
24- Sep- 07 |
24- Sep -08 |
7- Oct-
14 |
US8853382 |
Expression
of antibody or a fragment thereof in lactobacillus |
Hera
Pharmaceuticals, Inc. |
5- Aug-
10 |
4- Aug -11 |
7- Oct-
14 |
US8846710 |
Method
of preferentially inducing the biosynthesis of interferon |
3M
Innovative Properties Company |
23- Feb- 05 |
22- Feb -06 |
30- Sep -14 |
US8846697 |
Purine
analogs |
The
Regents of the University of California |
31- May- 06 |
23- Apr -07 |
30- Sep -14 |
US8846643 |
Phosphonates
with reduced toxicity for treatment of viral infections |
The
Regents of the University of California |
14- Apr- 10 |
11- Oct -12 |
30- Sep -14 |
US8846051 |
Modulation
of replicative fitness by deoptimization of synonymous codons |
The United States of America as represented
by the Secretary of the Department of Health and Human Services, Centers for
Disease Control and Prevention |
8- Oct-
04 |
7- Oct -05 |
30- Sep -14 |
US8841100 |
Use
of methylsulfonylmethane (MSM) to modulate microbial activity |
Biogenic
Innovations, LLC |
30- Oct- 09 |
16- Feb -11 |
23- Sep -14 |
US8840899 |
Use
of mTOR inhibitors to enhance T cell immune responses |
Emory
University |
5- Aug-
08 |
5- Aug -09 |
23- Sep -14 |
US8840890 |
Rapid
expression cloning of human monoclonal antibodies from memory B cells |
University
of Maryland, Baltimore |
12- Nov- 08 |
12- Nov -09 |
23- Sep -14 |
US8840873 |
Method of
treating second and third degree burns using oxidative reductive potential
water solution |
Oculus
Innovative Sciences, Inc. |
23- Mar- 05 |
23- Mar -06 |
23- Sep -14 |
US8840774 |
Electrochemistry
and electrogenerated chemiluminescence with a single faradaic electrode |
Board
of Regents of the University of Texas System |
3- Jun-
05 |
28- Oct -13 |
23- Sep -14 |
US8835107 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
Amsterdam
Institute of Viral Genomics B.V. |
18- Aug- 03 |
26- Jul- 10 |
16- Sep -14 |
US8834445 |
Methods
of treating or preventing peritonitis with oxidative reductive potential
water solution |
Oculus
Innovative Sciences, Inc. |
20- Jan- 06 |
30- Mar -12 |
16- Sep -14 |
US8828962 |
SiRNA
compositions and methods for potently inhibiting viral infection |
Xiangxue
Group (Hong Kong) Company Limited |
11- Dec- 08 |
12- Dec -11 |
9- Sep -14 |
US8828956 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
4- Dec -12 |
9- Sep -14 |
US8828940 |
Method of
treating an ischemia-reperfusion injury-related disorder by administering
GPCR ligands |
Compugen
Ltd. |
18- Sep- 06 |
14- Dec -10 |
9- Sep -14 |
US8828929 |
Cytotoxic
T cell epitope peptide for SARS coronavirus, and use thereof |
Japan as
Represented by Director-General of National Institute of Infectious Diseases |
28- Nov- 08 |
27- Nov -09 |
9- Sep -14 |
US8828673 |
Mixed
cell diagnostic systems for detection of respiratory, herpes and enteric
viruses |
Diagnostic
Hybrids Inc |
24- Apr- 98 |
1- Mar -12 |
9- Sep -14 |
US8828659 |
Method
for producing nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
11- Mar -13 |
9- Sep -14 |
US8828407 |
Chimaeric
protein |
The
Pirbright Institute |
7-Jul- 09 |
5- Jul- 10 |
9- Sep -14 |
US8828406 |
Influenza
viruses and uses thereof |
Icahn
School of Medicine at Mount Sinai |
30- Jul-09 |
29- Jul- 10 |
9- Sep -14 |
US8822512 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
20- Sep -11 |
2- Sep -14 |
US8822409 |
Compositions
and uses thereof for the treatment of acute respiratory distress syndrome
(ARDS) and clinical disorders associated with therewith |
Phylogica
Limited |
20- Jun- 07 |
20- Jun -08 |
2- Sep -14 |
US8821897 |
Viral
adjuvants |
The
University of North Carolina at Chapel Hill |
9-Jul- 04 |
24- Nov -10 |
2- Sep -14 |
US8816089 |
Methods
for controlling SR protein phosphorylation, and antiviral agents whose active
ingredients comprise agents that control SR protein activity |
Masatoshi
Hagiwara |
26- Dec- 03 |
19- Nov -12 |
26- Aug -14 |
US8816053 |
Methods
for treating viral infection using IL-28 and IL-29 cysteine mutants |
ZymoGenetics,
Inc. |
2- Apr-
04 |
7- Sep -12 |
26- Aug -14 |
US8815837 |
Respiratory
disease treatment |
Pulmagen
Therapeutics (Inflammation) Limited |
7- Aug-
08 |
29- Jun -12 |
26- Aug -14 |
US8815831 |
Treatment
of Acinetobacter with alginate oligomers and antibiotics |
Algipharma
AS |
3- Jun-
09 |
3- Jun -10 |
26- Aug -14 |
US8815611 |
Surface
for label independent detection and method thereof |
Corning
Incorporated |
10- Apr- 08 |
3- Apr -09 |
26- Aug -14 |
US8815249 |
Ii-key/antigenic
epitope hybrid peptide vaccines |
Antigen
Express, Inc. |
4- Sep-
99 |
26- Jul- 10 |
26- Aug -14 |
US8815244 |
Method
for production of antibody using ostrich |
Japan
Science and Technology Agency |
29- Aug- 05 |
16- Aug -11 |
26- Aug -14 |
US8809377 |
Deubiquitinase
inhibitors and methods for use of the same |
The
Regents of the University of Michigan |
24- Sep- 10 |
23- Sep -11 |
19- Aug -14 |
US8808703 |
Compounds
(cystein based lipopeptides) and compositions as TLR2 agonists used for
treating infections, inflammations, respiratory diseases etc |
Not
Available |
23- Mar- 10 |
23- Mar -11 |
19- Aug -14 |
US8808686 |
Adjuvant-sparing
multi-dose influenza vaccination regimen |
Novartis
AG |
15- Jun- 06 |
19- Sep -11 |
19- Aug -14 |
US8802853 |
Arylalkenyl
and arylalkynyl substituted imidazoquinolines |
3M
Innovative Properties Company |
29- Dec- 03 |
17- Dec -04 |
12- Aug -14 |
US8802647 |
Materials
and methods for prevention and treatment of RNA viral diseases |
University
of South Florida |
30- Apr- 02 |
17- Sep -12 |
12- Aug -14 |
US8802106 |
Peptide
compositions and methods for inhibiting herpesvirus infection |
The
Administrators of the Tulane Educational Fund |
30- Oct- 09 |
29- Oct -10 |
12- Aug -14 |
US8796423 |
Anti-TSG101
antibodies and their uses for treatment of viral infections |
Eli
Lilly and Company |
15- Nov- 06 |
18- Apr -08 |
5- Aug -14 |
US8790655 |
Conjugates
of synthetic TLR agonists and uses therefor |
The
Regents of The University of California |
7- Feb-
07 |
8- Jan -13 |
29- Jul- 14 |
US8785408 |
Compositions
and methods for reducing or protecting against delayed graft function (DGF) |
Quark
Pharmaceuticals, Inc. |
27- Jun- 07 |
26- Jun -08 |
22- Jul- 14 |
US8785375 |
Cyclic
antimicrobial peptides for treating bacterial infections |
Novabiotics
Ltd. |
22- Dec- 05 |
22- Aug -12 |
22- Jul- 14 |
US8784900 |
Antimicrobial
solutions containing dichlorine monoxide and methods of making and using the
same |
Oculus
Innovative Sciences, Inc. |
13- Mar- 07 |
13- Mar -08 |
22- Jul- 14 |
US8779132 |
Pharmaceutical
compounds |
Astex
Therapeutics Limited |
12- Oct- 06 |
12- Oct -07 |
15- Jul- 14 |
US8778963 |
Hydroxylamine
and oxime substituted imidazoquinolines, imidazopyridines, and
imidazonaphthyridines |
3M
Innovative Properties Company |
25- Nov- 03 |
24- Nov -04 |
15- Jul- 14 |
US8778846 |
Composition,
device and associated method |
General
Electric Company |
4- Dec-
06 |
1- Mar -07 |
15- Jul- 14 |
US8778845 |
Composition,
device and associated method |
Genral
Electric Company |
15- Dec- 05 |
1- Mar -07 |
15- Jul- 14 |
US8778358 |
Immunogenic
compositions for gram positive bacteria such as Streptococcus agalactiae |
Novartis
Vaccines and Diagnostics, Inc. |
29- Jul-04 |
18- Oct -10 |
15- Jul- 14 |
US8778275 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
15- Jul- 14 |
US8772471 |
Targeted
delivery of siRNA |
Immune
Disease Institute |
26- Jan- 07 |
25- Jan -08 |
8- Jul- 14 |
US8765939 |
Pyrimidline
derivatives having immune modulating properties that act via TLR7 for the
treatment of viral or allergic diseases and cancers |
AstraZeneca
AB |
22- Nov- 07 |
16- Aug -12 |
1- Jul- 14 |
US8765704 |
Modified
small interfering RNA molecules and methods of use |
Novartis
AG |
28- Feb- 08 |
14- Dec -11 |
1- Jul- 14 |
US8765643 |
Composition,
device and associated method |
General
Electric Company |
4- Dec-
06 |
1- Mar -07 |
1- Jul- 14 |
US8765146 |
Adenoviral
vector-based malaria vaccines |
GenVec,
Inc. |
31- Aug- 05 |
31- Aug -06 |
1- Jul- 14 |
US8765138 |
Antiviral
and antibacterial activity from medicinal mushrooms |
Not
Available |
6- Jan- 04 |
24- Sep -08 |
1- Jul- 14 |
US8765133 |
Method
of producing anti-CD166 antibody in ostrich |
Japan
Science and Technology Agency |
29- Aug- 05 |
16- Aug -11 |
1- Jul- 14 |
US8759307 |
Oligonucleotide
compound and method for treating nidovirus infections |
Sarepta
Therapeutics, Inc. |
24- Dec- 03 |
25- Apr -08 |
24- Jun- 14 |
US8758763 |
Archaeal
polar lipid aggregates for administration to animals |
National
Research Council of Canada |
15- Dec- 06 |
23- Jan -13 |
24- Jun- 14 |
US8758680 |
Method
and device for cleaning air |
Not
Available |
29- Sep- 10 |
27- Sep -11 |
24- Jun- 14 |
US8754071 |
Compounds
and compositions as c-kit kinase inhibitors |
Not
Available |
1- Sep-
11 |
19- Sep -13 |
17- Jun- 14 |
US8754015 |
Modified
phage for displaying post-translationally modified proteins and uses thereof |
University
of Rochester |
21- Nov- 06 |
20- Nov -07 |
17- Jun- 14 |
US8748567 |
Method
for delivery across the blood brain barrier |
Children's
Medical Center Corporation |
22- May- 06 |
22- May -07 |
10- Jun- 14 |
US8748464 |
Use of
SIRT1 activators or inhibitors to modulate an immune response |
The
J. David Gladstone Institutes |
7- Feb-
08 |
16- Jul- 10 |
10- Jun- 14 |
US8748405 |
Methods
and compositions for the treatment of cancer or other diseases |
City
of Hope |
26- Jan- 07 |
9- Sep -11 |
10- Jun- 14 |
US8748156 |
Animal
protein-free media for cultivation of cells |
Baxter
Healthcare SA |
29- Oct- 04 |
16- Apr -13 |
10- Jun- 14 |
US8741813 |
Composition,
device and associated method |
General
Electric Company |
15- Dec- 05 |
28- Feb -07 |
3- Jun-
14 |
US8741653 |
Single
recombination system and methods of use |
Emergent
Product Development GmbH |
22- Dec- 08 |
16- Dec -09 |
3- Jun-
14 |
US8741604 |
Nucleic
acid molecule encoding a specific IL-1R1 antibody |
Medimmune
Limited |
7- Nov-
08 |
14- Sep -12 |
3- Jun-
14 |
US8741564 |
Quantitative
nuclease protection assay (QNPA) and sequencing (QNPS) improvements |
HTG
Molecular Diagnostics, Inc. |
4- May-
11 |
26- Apr -12 |
3- Jun-
14 |
US8741311 |
Methods
and compositions for immunization against virus |
Academia
Sinica |
27- Mar- 09 |
26- Mar -10 |
3- Jun-
14 |
US8735567 |
Multi-targeted
RNAi therapeutics for scarless wound healing of skin |
Not
Available |
6- Nov-
07 |
6- Nov -08 |
27- May -14 |
US8735559 |
Mutant
protease biosensors with enhanced detection characteristics |
Promega
Corporation |
11- May- 10 |
11- May -11 |
27- May -14 |
US8735421 |
Imidazoquinolinyl
sulfonamides |
3M
Innovative Properties Company |
30- Dec- 03 |
23- Dec -04 |
27- May -14 |
US8735410 |
Quinazoline
derivatives as tyrosine kinase inhibitors |
AstraZeneca
AB |
26- Feb- 05 |
24- Feb -06 |
27- May -14 |
US8735348 |
Casein
derived peptides and uses thereof |
Peptera
Ltd. |
1- Mar-
00 |
5- Sep -12 |
27- May -14 |
US8734823 |
Device
including altered microorganisms, and methods and systems of use |
The
Invention Science Fund I, LLC |
14- Dec- 05 |
28- May -10 |
27- May -14 |
US8728793 |
Amphipathic
alpha-helical peptide compositions as antiviral agents |
The Board
of Trustees of the Leland Stanford Junior University |
19- Jul-07 |
14- Jul- 08 |
20- May -14 |
US8722917 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
23- Jan -12 |
13- May -14 |
US8722741 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
AstraZeneca
AB |
24- Aug- 04 |
6- Dec -11 |
13- May -14 |
US8722725 |
Caffeoylquinic
acid derivatives containing nitrogen, and preparation method, pharmaceutical
composition and usage thereof |
Zhejiang
Medicine Co., Ltd. Xinchang Pharmaceutical Factory |
23- Mar- 07 |
21- Mar -08 |
13- May -14 |
US8718948 |
Systems
and methods for distinguishing optical signals of different modulation
frequencies in an optical signal detector |
Gen-Probe
Incorporated |
24- Feb- 11 |
24- Feb -12 |
6- May -14 |
US8716464 |
Compositions
and methods for silencing Ebola virus gene expression |
Not
Available |
20- Jul-09 |
20- Jul- 10 |
6- May -14 |
US8716461 |
Human
parvovirus |
Blood
Systems, Inc. |
24- May- 04 |
24- May -05 |
6- May -14 |
US8710224 |
Heterocyclic
compounds as CCR2B antagonists |
AstraZeneca
AB |
24- Dec- 04 |
13- Sep -13 |
29- Apr- 14 |
US8709730 |
Methods
of preventing and treating viral infections by inhibiting the deISGylation
activity of OTU domain-containing viral proteins |
Icahn
School of Medicine at Mount Sinai |
5- Apr- 07 |
7- Apr -08 |
29- Apr- 14 |
US8709496 |
Use of
deuterium oxide for the treatment of virus-based diseases of the respiratory
tract |
D2
Bioscience Group Ltd. |
6- Jan- 10 |
23- May -12 |
29- Apr- 14 |
US8709447 |
Compositions
and methods for activating innate and allergic immunity |
ID
Biomedical Corporation of Quebec |
22- Oct- 03 |
26- Apr -12 |
29- Apr- 14 |
US8709441 |
TC-83-derived
alphavirus vectors, particles and methods |
Alphavax,
Inc. |
18- May- 04 |
6- Jul- 10 |
29- Apr- 14 |
US8704169 |
Direct
impact ionization (DII) mass spectrometry |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
11- Oct- 11 |
11- Oct -11 |
22- Apr- 14 |
US8703748 |
Cleaning
composition for treating tissue for transplantation derived from human/animal |
CG
BIO Co., Ltd. |
11- Feb- 09 |
10- Feb -10 |
22- Apr- 14 |
US8703467 |
Inactivation
of a pathogen in a sample by a treatment with formalin and UV light |
Baxter
Healthcare SA |
27- May- 04 |
26- May -05 |
22- Apr- 14 |
US8702958 |
Electrochemistry
and electrogenerated chemiluminescence with a single faradaic electrode |
Board
of Regents of the University of Texas System |
3- Jun-
05 |
31- May -12 |
22- Apr- 14 |
US8697873 |
Amide
substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
3M
Innovative Properties Company |
24- Mar- 04 |
24- Mar -05 |
15- Apr- 14 |
US8697853 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
10- Jan -13 |
15- Apr- 14 |
US8697659 |
Analogues
of glycolipids useful as immunoadjuvants |
Luigi
Panza |
12- Oct- 07 |
10- Oct -08 |
15- Apr- 14 |
US8697140 |
Virucidal
disinfectant |
B.
Braun Medical AG |
28- Jan- 05 |
28- May -09 |
15- Apr- 14 |
US8697088 |
VLPs
derived from cells that do not express a viral matrix or core protein |
Novavax,
Inc. |
25- May- 07 |
27- May -08 |
15- Apr- 14 |
US8697087 |
Influenza
vaccines including combinations of particulate adjuvants and
immunopotentiators |
Novartis
AG |
4- Nov-
05 |
6- Nov -06 |
15- Apr- 14 |
US8691837 |
Substituted
imidazo ring systems and methods |
3M
Innovative Properties Company |
25- Nov- 03 |
24- Nov -04 |
8- Apr-
14 |
US8691826 |
Compounds |
Chiesi
Farmaceutici S.p.A. |
14- Sep- 11 |
13- Sep -12 |
8- Apr-
14 |
US8691781 |
Compositions
for treating respiratory viral infections and their use |
Sirnaomics,
Inc. |
5- Nov-
04 |
4- Nov -05 |
8- Apr-
14 |
US8691777 |
Combination
therapy |
Emory
University |
27- Jan- 11 |
25- Jan -12 |
8- Apr-
14 |
US8686152 |
4,4-disubstituted
piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1) |
Janssen
Pharmaceutica NV |
10- Mar- 10 |
9- Mar -11 |
1- Apr-
14 |
US8682619 |
Device
including altered microorganisms, and methods and systems of use |
The
Invention Science Fund I, LLC |
14- Dec- 05 |
28- May -10 |
25- Mar -14 |
US8679839 |
Cell
line from rousettus as host cell for pathogen amplification |
Probiogen
AG |
4- Mar-
08 |
4- Mar -09 |
25- Mar -14 |
US8678184 |
Methods
for producing vaccine adjuvants |
Novartis
AG |
3- Dec-
09 |
3- Dec -10 |
25- Mar -14 |
US8678002 |
Devices
and methods for decreasing human pathogen transmission |
Filligent
Limited |
26- Jun- 07 |
25- Jun -08 |
25- Mar -14 |
US8673983 |
Melanins
synthesized chemically or via enzyme catalysis |
Loyola
University Chicago |
21- Dec- 07 |
22- Dec -08 |
18- Mar -14 |
US8673932 |
Oxime
substituted imidazo-containing compounds |
3M
Innovative Properties Company |
12- Aug- 03 |
12- Aug -04 |
18- Mar -14 |
US8673907 |
Pharmaceutically
acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)
propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their
use in therapy |
AstraZeneca
AB |
17- Dec- 07 |
16- Dec -08 |
18- Mar -14 |
US8673904 |
Epoxide
inhibitors of cysteine proteases |
The Board
of Trustees of the Leland Stanford Junior University |
13- Jun- 06 |
13- Jun -07 |
18- Mar -14 |
US8673558 |
Luciferase
biosensor |
Promega
Corporation |
10- Oct- 03 |
24- Apr -12 |
18- Mar -14 |
US8673331 |
Composition
with sterilizing activity against bacteria, fungus and viruses, application
thereof and method for preparation thereof |
GP&E |
18- Nov- 11 |
18- Nov -11 |
18- Mar -14 |
US8669263 |
Use
of TAM receptor inhibitors as antimicrobials |
Salk
Institute for Biological Studies |
9- Nov-
07 |
8- Mar -13 |
11- Mar -14 |
US8669262 |
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-
pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra
zine-2-carboxamide |
Parion
Sciences, Inc. |
27- Jun- 11 |
26- Jun -12 |
11- Mar -14 |
US8669240 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines & Diagnostics, LLC |
1- Oct-
07 |
19- Mar -13 |
11- Mar -14 |
US8664274 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arena viruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
6- Jul- 11 |
4- Mar -14 |
US8664218 |
Pharmaceutical
compounds |
Astex
Therapeutics Ltd. |
11- Apr- 08 |
30- Jan -13 |
4- Mar -14 |
US8664188 |
siRNA
compositions and methods for potently inhibiting viral infection |
Xiangxue
Group (Hong Kong) Company Limited |
11- Dec- 08 |
11- Dec -09 |
4- Mar -14 |
US8663922 |
Systems
and methods for detecting multiple optical signals |
Gen-Probe
Incorporated |
10- Mar- 05 |
1- Jun -10 |
4- Mar -14 |
US8658767 |
Lipidated
polyepitope vaccines |
National
Health Research Institutes |
15- Nov- 10 |
15- Nov -11 |
25- Feb -14 |
US8658697 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arenaviruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
26- Oct -10 |
25- Feb -14 |
US8658666 |
Substituted
imidazoquinolines and imidazonaphthyridines |
3M
Innovative Properties Company |
11- Feb- 05 |
10- Feb -06 |
25- Feb -14 |
US8658178 |
Carbon
nanotube compositions and methods of use thereof |
Yale
University |
19- Mar- 08 |
19- Mar -09 |
25- Feb -14 |
US8653252 |
Short
interfering RNA (siRNA) analogues |
Santaris
Pharma A/S |
21- Mar- 03 |
22- Mar -04 |
18- Feb -14 |
US8653084 |
Hydrobenzamide
derivatives as inhibitors of Hsp90 |
Astex
Therapeutics Ltd. |
12- Oct- 06 |
12- Oct -07 |
18- Feb -14 |
US8653034 |
Compositions
and methods comprising phosphatidylethanolamine- binding peptide derivatives |
Board
of Regents, The University of Texas System |
15- Jul-02 |
8- May -08 |
18- Feb -14 |
US8652836 |
Defective
ribosomal products in blebs (DRibbles) and methods of use to stimulate an
immune response |
Providence
Health System |
29- Jul-05 |
27- Jul- 06 |
18- Feb -14 |
US8652782 |
Compositions
and methods for detecting, identifying and quantitating
mycobacterial-specific nucleic acids |
Longhorn
Vaccines & Diagnostics, LLC |
12- Sep- 06 |
26- Apr -11 |
18- Feb -14 |
US8652533 |
Durable
biocides and disinfectants |
Mitsui
Norin Co., Ltd. |
7-Jul- 04 |
5- Jul- 05 |
18- Feb -14 |
US8648076 |
Cysteine
protease inhibitors and their therapeutic applications |
Hybrigenics
SA |
5- Aug-
05 |
26- Jul- 06 |
11- Feb -14 |
US8647676 |
Antimicrobial
composition from copepods |
Nofima
Ingrediens |
28- Oct- 08 |
28- Oct -09 |
11- Feb -14 |
US8642596 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arena viruses |
Siga
Technologies, Inc. |
6- Dec- 04 |
6- Dec -05 |
4- Feb -14 |
US8642260 |
Single
quantum-dot based aptameric nanosensors |
The
Research Foundation of the City University of New York |
21- Oct- 08 |
21- Oct -09 |
4- Feb -14 |
US8633322 |
Alkynyl
derivatives useful as DPP-1 inhibitors |
Janssen
Pharmaceutica NV |
29- Oct- 09 |
28- Oct -10 |
21- Jan- 14 |
US8633308 |
Compounds
for preventing or treating viral infections and methods of use thereof |
The
Governors of The University of Alberta |
28- Feb- 07 |
27- Feb -08 |
21- Jan- 14 |
US8632764 |
Directed
evolution and in vivo panning of virus vectors |
University
of North Carolina at Chapel Hill |
30- Apr- 08 |
29- Apr -09 |
21- Jan- 14 |
US8629283 |
Compounds
that modulate negative-sense, single-stranded RNA virus replication and uses
thereof |
Icahn
School of Medicine at Mount Sinai |
6- Mar-
08 |
6- Mar -09 |
14- Jan- 14 |
US8629271 |
Compounds |
AstraZeneca
AB |
6- Feb-
08 |
2- Apr -12 |
14- Jan- 14 |
US8629098 |
Compositions
and methods for adoptive and active immunotherapy |
Yale
University |
15- Jan- 08 |
14- Jan -09 |
14- Jan- 14 |
US8628786 |
Polychlorinated
biphenyls and squalene-containing adjuvants |
Novartis
AG |
28- Dec- 07 |
2- Dec -11 |
14- Jan- 14 |
US8624011 |
Vaccines
and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid
molecules encoding the same, and methods for using the same |
The
Trustees of the University of Pennsylvania |
14- Sep- 09 |
14- Sep -10 |
7- Jan- 14 |
US8623419 |
Technology
for preparation of macromolecular microspheres |
Ansun
Biopharma, Inc. |
24- Jan- 06 |
4- Nov -11 |
7- Jan-
14 |
US8623382 |
Immunogenic
compositions for inducing an immune response to HIV |
Wyeth
LLC |
17- Jun- 04 |
18- Jan -11 |
7- Jan-
14 |
US8623364 |
Antigenic
GM-CSF peptides and antibodies to GM-CSF |
Morphotek,
Inc. |
8- Feb-
06 |
24- Oct -12 |
7- Jan-
14 |
US8617838 |
Fluorescent
proteins and related methods and compounds |
University
of Massachusetts |
20- Sep- 04 |
20- Sep -05 |
31- Dec -13 |
US8615368 |
Method
for determining the amount of an analyte in a sample |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
24- Dec -13 |
US8609370 |
Highly
active glycoproteins-process conditions and an efficient method for their
production |
Glycotope
GmbH |
13- Feb- 04 |
14- Feb -05 |
17- Dec -13 |
US8609101 |
Granulocyte-macrophage
colony-stimulating factor (GM-CSF) neutralizing antibodies |
Theraclone
Sciences, Inc. |
23- Apr- 09 |
23- Apr -10 |
17- Dec -13 |
US8604215 |
Crystalline
tripeptide epoxy ketone protease inhibitors |
Onyx
Therapeutics, Inc. |
20- Mar- 09 |
22- Mar -10 |
10- Dec -13 |
US8603469 |
Methods
of treating cancer with human monoclonal antibodies against interleukin 8 |
Genmab
A/S |
16- Dec- 02 |
27- Dec -11 |
10- Dec -13 |
US8599383 |
Optical
cytometry |
The
Regents of the University of California |
6- May-
09 |
6- May -09 |
3- Dec -13 |
US8598192 |
Hydroxylamine
substituted imidazoquinolines |
3M
Innovative Properties Company |
14- Nov- 03 |
12- Nov -04 |
3- Dec -13 |
US8598134 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
South
Alabama Medical Science Foundation |
22- Oct- 04 |
23- Jul- 10 |
3- Dec -13 |
US8598116 |
Treatment
of influenza virus infection |
Educational
Fund and Autoimmune Technologies, LLC |
4- Nov-
03 |
29- May -12 |
3- Dec -13 |
US8598106 |
Anti-microbial
composition exhibiting residual anti-microbial properties on a surface |
Byotrol
PLC |
17- Sep- 07 |
5- Jul- 11 |
3- Dec -13 |
US8597650 |
Methods
for treating rheumatoid arthritis with anti-bile salt- stimulated lipase
(BSSL) antibodies |
HERNELL
OLLE |
8- Apr-
09 |
6- Apr -10 |
3- Dec -13 |
US8592567 |
Vaccines
and immunotherapeutics using codon-optimized IL-15 and methods for using the
same |
The
Trustees of the University of Pennsylvania |
13- Jan- 06 |
3- May -12 |
26- Nov -13 |
US8592391 |
Method
for therapeutic, clinical and veterinary use poly-ICLC |
SALAZAR
ANDRES |
1-Jul- 03 |
17- Oct -08 |
26- Nov -13 |
US8586770 |
Unsaturated
steroid compounds |
Harbor
Therapeutics, Inc. |
29- Sep- 04 |
18- Feb -11 |
19- Nov -13 |
US8586364 |
Cells and
methodology to generate non-segmented negative-strand RNA viruses |
Institut
Pasteur |
22- Dec- 06 |
21- Dec -07 |
19- Nov -13 |
US8586363 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
10- Dec -10 |
19- Nov -13 |
US8581584 |
Membrane
proteins, mechanisms of action and uses thereof |
Florida
State University Research Foundation |
26- May- 10 |
26- May -11 |
12- Nov -13 |
US8580927 |
Engineered
antibody constant domain molecules |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
31- Jan- 08 |
30- Jan -09 |
12- Nov -13 |
US8580268 |
CpG
oligonucleotide analogs containing hydrophobic T analogs with enhanced
immunostimulatory activity |
Coley
Pharmaceutical GmbH |
27- Sep- 06 |
27- Sep -07 |
12- Nov -13 |
US8569283 |
Compounds
and compositions as c-Kit kinase inhibitors |
LIU
XIAODONG |
1- Sep-
11 |
29- Aug -12 |
29- Oct- 13 |
US8562996 |
RSV-specific
binding molecules and means for producing them |
MedImmune
Limited |
1- Jun-
07 |
30- May -08 |
22- Oct- 13 |
US8562943 |
Quality
control methods for oil-in-water emulsions containing squalene |
Novartis
AG |
8- Nov-
06 |
6- Nov -07 |
22- Oct- 13 |
US8560339 |
System
and method to predict the global spread of infectious agents via commercial
air travel |
Kamran
Khan |
2- Apr-
07 |
2- Apr -08 |
15- Oct- 13 |
US8557767 |
Synthetic
apolipoprotein E mimicking polypeptides and methods of use |
UAB
Research Foundation |
28- Aug- 07 |
27- Aug -08 |
15- Oct- 13 |
US8557248 |
Methods
and compositions for treating malaria |
Cyvax,
Inc. |
9- Aug-
10 |
9- Aug -11 |
15- Oct- 13 |
US8552051 |
Use
of pharmaceutical compositions containing mesembrenone |
H.
L. Hall & Sons Limited |
20- Mar- 09 |
16- Mar -10 |
8- Oct-
13 |
US8552032 |
Bicyclic
derivatives useful as inhibitors of DPP-1 |
Janssen
Pharmaceutica NV |
18- Dec- 09 |
16- Dec -10 |
8- Oct-
13 |
US8551968 |
Methods
for generation of antibodies |
National
Jewish Health |
13- Mar- 07 |
13- Mar -08 |
8- Oct-
13 |
US8551756 |
Avian
influenza chimeric VLPS |
Novavax,
Inc. |
11- Jul-03 |
19- Jan -10 |
8- Oct-
13 |
US8551750 |
Device
including bone cage and method for treatment of disease in a subject |
The
Invention Science Fund I, LLC |
23- Apr- 09 |
28- Jul- 09 |
8- Oct-
13 |
US8551749 |
Device
including bone cage and method for treatment of disease in a subject |
The
Invention Science Fund I, LLC |
23- Apr- 09 |
23- Apr -09 |
8- Oct-
13 |
US8551738 |
Systems
and methods for rapid identification of nucleic acid variants |
Ibis
Biosciences, Inc. |
21- Jul-05 |
11- Nov -09 |
8- Oct-
13 |
US8551469 |
Treatment
of tumors and viral diseases with recombinant interferon alpha |
Superlab
Far East Limited |
28- Feb- 01 |
6- Oct -08 |
8- Oct-
13 |
US8546432 |
Tetrazolones
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
5- May -11 |
1- Oct-
13 |
US8546383 |
Chiral
fused [1,2]imidazo[4,5-c] ring compounds |
3M
Innovative Properties Company |
30- Dec- 04 |
25- May -12 |
1- Oct-
13 |
US8546082 |
Methods
for identification of sepsis-causing bacteria |
Ibis
Biosciences, Inc. |
11- Sep- 03 |
25- May -07 |
1- Oct-
13 |
US8541568 |
Compositions
and methods using siRNA molecules for treatment of gliomas |
BIGNER
DARELL D |
24- May- 08 |
26- May -09 |
24- Sep -13 |
US8541457 |
Aminothiazole
derivatives as human stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
3- Jun-
05 |
5- Jun -06 |
24- Sep -13 |
US8541438 |
Substituted
imidazoquinolines, imidazopyridines, and imidazonaphthyridines |
3M
Innovative Properties Company |
18- Jun- 04 |
21- Dec -10 |
24- Sep -13 |
US8541221 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
1- Jul- 10 |
24- Sep -13 |
US8541003 |
Vectors
expressing SARS immunogens, compositions containing such vectors or expression
products thereof, methods and assays for making and using |
Protein
Sciences Corporation |
20- Jun- 03 |
21- Jun -04 |
24- Sep -13 |
US8529968 |
Decontaminating
composition having simultaneously bactericidal, fungicidal and virocidal properties,
methods for obtaining and using said composition |
Hightech
Bio-Activities Holding GmbH |
29- Mar- 04 |
29- Mar -05 |
10- Sep -13 |
US8524715 |
Phenoxyacetic
acid derivatives useful for treating respiratory diseases |
Astrazeneca
AB |
23- Nov- 04 |
22- Nov -05 |
3- Sep -13 |
US8524488 |
Methods
and devices for determining a cell characteristic, and applications employing
the same |
The
Regents of the University of California |
10- Sep- 02 |
9- Mar -05 |
3- Sep -13 |
US8524241 |
Fusion
proteins comprising a fragment of Vibrio cholerae exotoxin A |
The
General Hospital Corporation |
20- Jul-07 |
18- Jul- 08 |
3- Sep -13 |
US8519106 |
Monoclonal
human tumor-specific antibody |
University
of Zurich |
13- Mar- 07 |
13- Mar -08 |
27- Aug -13 |
US8507545 |
Cytotoxic
T cell activator comprising EP4 agonist |
National
University Corporation, Hamamatsu University School of Medicine |
8- May-
07 |
7- May -08 |
13- Aug -13 |
US8507544 |
Bi-aryl
amide compounds as CRTh2 receptor modulators |
Astrazeneca
AB |
5-Jul- 07 |
3- Jul- 08 |
13- Aug -13 |
US8507455 |
Folate
conjugates |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
4- Dec -08 |
13- Aug -13 |
US8506968 |
SARS
vaccine compositions and methods of making and using them |
Eli
Lilly and Company |
29- Jun- 00 |
28- Dec -09 |
13- Aug -13 |
US8506966 |
Adjuvanted
influenza vaccines for pediatric use |
Novartis
AG |
22- Feb- 08 |
20- Feb -09 |
13- Aug -13 |
US8501746 |
Organic
compounds |
Novartis
AG |
5- Jun-
06 |
4- Jun -07 |
6- Aug -13 |
US8501699 |
Bicyclic
nucleosides and nucleotides as therapeutic agents |
Biota
Scientific Management Pty Ltd |
3-Jul- 08 |
7- Sep -12 |
6- Aug -13 |
US8501461 |
System
for performing multi-formatted assays |
Gen-Probe
Incorporated |
10- Mar- 05 |
3- Dec -09 |
6- Aug -13 |
US8497405 |
Process
for dispersing vaporous hydrogen peroxide |
STERIS
Inc. |
6- Mar-
07 |
28- Feb -13 |
30- Jul- 13 |
US8497112 |
Method
for producing viral vaccines |
Baxter
Healthcare SA |
28- Aug- 07 |
28- Aug -08 |
30- Jul- 13 |
US8494781 |
Systems
and methods for identifying replikin scaffolds and uses of said replikin
scaffolds |
BOGOCH
ELENORE S |
6- Jun-
03 |
10- Dec -10 |
23- Jul- 13 |
US8492329 |
Bioactive
peptides and methods of using same |
Compugen
Ltd. |
12- Jul-07 |
11- Jul- 08 |
23- Jul- 13 |
US8486959 |
Dibenzo[f,h]isoquinoline
derivatives |
National
Health Research Institutes |
14- Jan- 10 |
14- Jan -11 |
16- Jul- 13 |
US8486678 |
Pharmaceutical
compositions for the treatment of virus infection |
Kineta
Two, LLC |
23- Nov- 05 |
1- Feb -12 |
16- Jul- 13 |
US8486619 |
Arrayed
imaging reflectometry (air) sensor chip comprising influenza hemagglutinin
(HA) polypeptides suitable for the detection of antiviral immune responses |
University
of Rochester |
2- May- 08 |
1- May -09 |
16- Jul- 13 |
US8486420 |
Live
virus vaccines |
Children's
Hospital, Inc. |
15- Feb- 05 |
15- Feb -06 |
16- Jul- 13 |
US8481547 |
Substituted
benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 |
Janssen
Pharmaceutica NV |
18- Dec- 09 |
16- Dec -10 |
9- Jul- 13 |
US8481270 |
Method
for chromogenic detection of two or more target molecules in a single sample |
Ventana
Medical Systems, Inc. |
22- Aug- 08 |
21- Aug -09 |
9- Jul- 13 |
US8481255 |
Scytovirin
domain 1 related polypeptides |
The
United States of America, as represented by the Secretary, Department of
Health and Human Services |
25- May- 05 |
30- Sep -11 |
9- Jul- 13 |
US8476292 |
Amide
and carbamate derivatives of N-{2-[4-amino-2-
(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- dimethylethyl}methanesulfonamide
and methods |
3M
Innovative Properties Company |
9- Sep- 05 |
8- Sep -06 |
2- Jul- 13 |
US8476288 |
Salts
756 |
AstraZeneca
AB |
21- May- 09 |
20- May -10 |
2- Jul- 13 |
US8476265 |
Compounds-801 |
AstraZeneca
AB |
30- Jul-10 |
14- Sep -12 |
2- Jul- 13 |
US8470771 |
Method
and medicament for inhibiting the infection of influenza virus |
Institute
of Microbiology, Chinese Academy of Sciences |
14- Nov- 07 |
18- Dec -07 |
25- Jun- 13 |
US8470769 |
Method of
treatment of bacterial infection by administration of poly- lysine |
Novabiotics,
Ltd. |
18- Aug- 04 |
30- Nov -11 |
25- Jun- 13 |
US8470346 |
Anti-viral
pharmaceutical compositions |
Mast
Therapeutics, Inc. |
10- Dec- 03 |
19- May -11 |
25- Jun- 13 |
US8470335 |
Recombinant
SARS-CoV nsp12 and the use of thereof and the method for producing it |
Industry-Academic
Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation
Foundation |
13- Jun- 08 |
13- Jun -08 |
25- Jun- 13 |
US8466284 |
Some
2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
Astra
Zeneca AB |
6- Nov-
07 |
5- Nov -08 |
18- Jun- 13 |
US8466167 |
Compounds
and compositions as TLR activity modulators |
IRM
LLC |
3- Mar-
08 |
27- Feb -09 |
18- Jun- 13 |
US8466124 |
RNA
sequence motifs in the context of defined internucleotide linkages inducing
specific immune modulatory profiles |
Coley
Pharmaceutical GmbH |
13- Aug- 07 |
12- Jun -12 |
18- Jun- 13 |
US8465751 |
Cna—B
domain antigens in vaccines against gram positive bacteria |
Novartis
AG |
12- Jan- 09 |
12- Jan -10 |
18- Jun- 13 |
US8461125 |
Compositions
and methods to treat asthma |
The
Children's Hospital of Philadelphia |
14- Feb- 08 |
13- Aug -10 |
11- Jun- 13 |
US8460914 |
Decreasing
potential iatrogenic risks associated with vaccines and vaccine antigens |
Novartis
AG |
9- Sep-
04 |
10- Jan -13 |
11- Jun- 13 |
US8460605 |
Decontaminant
dispenser suitable for use as a projectile |
STERIS
Inc. |
6- Mar-
07 |
20- Feb -08 |
11- Jun- 13 |
US8455483 |
Compounds—801 |
AstraZeneca
AB |
31- Jul-09 |
30- Jul- 10 |
4- Jun-
13 |
US8450471 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
28- May -13 |
US8450467 |
Carbohydrate
conjugates as delivery agents for oligonucleotides |
Alnylam
Pharmaceuticals, Inc. |
4- Dec-
07 |
14- Dec -11 |
28- May -13 |
US8450350 |
Triazoles
as inhibitors of fatty acid synthase |
Infinity
Pharmaceuticals, Inc. |
5- May-
10 |
5- May -11 |
28- May -13 |
US8450284 |
Coiled-coil
lipopeptide helical bundles and synthetic virus-like particles |
Universitaet
Zuerich |
9- Dec-
06 |
6- Dec -07 |
28- May -13 |
US8450055 |
Malaria
antigen screening method |
The
United States of America as Represented by the Secretary of the Navy |
31- Aug- 05 |
25- Aug -06 |
28- May -13 |
US8445650 |
Mutant
botulinum neurotoxin serotype A polypeptide and uses thereof |
Thomas
Jefferson University |
25- Sep- 07 |
25- Sep -08 |
21- May -13 |
US8445447 |
B7-DC
variants immunogenic compositions and methods of use thereof |
The
Johns Hopkins University |
13- Jul-07 |
7- Mar -12 |
21- May -13 |
US8444961 |
RNA virus
infection inhibitor, method for inhibition of infection by RNA virus, RNA
virus infection-inhibiting product, and use as RNA virus infection inhibitor |
Sekisui
Chemical Co., Ltd. |
16- Jun- 09 |
16- Jun -10 |
21- May -13 |
US8440704 |
Quercetin-containing
compositions |
Quercegen
Pharmaceuticals LLC |
17- Jul-06 |
16- Dec -09 |
14- May -13 |
US8440649 |
Phenanthroindolizidine
analogues |
National
Health Research Institutes |
24- Feb- 09 |
11- Feb -10 |
14- May -13 |
US8440642 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
1- Sep -11 |
14- May -13 |
US8440432 |
Tal
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
14- May -13 |
US8440431 |
TAL
effector-mediated DNA modification |
Iowa
State University Research Foundation, Inc. |
10- Dec- 09 |
22- Mar -12 |
14- May -13 |
US8440408 |
Animal
protein-free media for cultivation of cells |
Baxter
Healthcare S.A. |
29- Oct- 04 |
10- Dec -10 |
14- May -13 |
US8436178 |
Imidazoquinolines
with immuno-modulating properties |
AstraZeneca
AB |
8- May-
07 |
6- May -08 |
7- May -13 |
US8436024 |
2-pyridone
compounds |
Astrazeneca
AB |
2- Oct-
09 |
1- Oct -10 |
7- May -13 |
US8431160 |
Microparticles
containing biodegradable polymer and cationic polysaccharide for use in
immunogenic compositions |
Novartis
AG |
24- Feb- 06 |
24- Feb -07 |
30- Apr- 13 |
US8431134 |
Use of a
pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a
pathogen |
The
United States of America as represented by the Secretary of the Department of
Health and Human Services,
Centers for Disease Control and Prevention |
31- Jul-08 |
31- Jul- 09 |
30- Apr- 13 |
US8426565 |
Dendritic
cell marker and uses thereof |
Walter
and Eliza Hall Institute of Medical Research |
30- Aug- 07 |
29- Aug -08 |
23- Apr- 13 |
US8420798 |
Method
for producing nucleic acid probes |
Ventana
Medical Systems, Inc. |
1- Sep-
06 |
31- Aug -07 |
16- Apr- 13 |
US8420784 |
Interleukin
10 receptor, (IL-10R) antibodies |
Kyowa
Hakko Kirin Co., Ltd. |
27- May- 08 |
27- May -09 |
16- Apr- 13 |
US8420096 |
Cell-penetrating
SOCS polypeptides that inhibit cytokine-induced signaling |
Vanderbilt
University |
4- Mar-
04 |
4- Mar -05 |
16- Apr- 13 |
US8420094 |
Fusion
proteins comprising a fragment of Vibrio cholerae exotoxin A |
The
General Hospital Corporation |
20- Jul-07 |
18- Jul- 08 |
16- Apr- 13 |
US8415394 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
Astrazeneca
AB |
6- Oct-
05 |
21- Dec -11 |
9- Apr-
13 |
US8415361 |
Use
of TAM receptor inhibitors as antimicrobials |
The
Salk Institute for Biological Studies |
9- Nov- 07 |
7- Nov -08 |
9- Apr-
13 |
US8415330 |
Biological
specimen collection and transport system and method of use |
Longhorn
Vaccines & Diagnostics, LLC |
1- Oct-
07 |
1- Oct -12 |
9- Apr-
13 |
US8415309 |
Bicyclic
nucleosides and nucleotides as therapeutic agents |
Biota
Scientific Managment Pty Ltd |
1-Jul- 09 |
11- Jan -12 |
9- Apr-
13 |
US8415118 |
Porcine
DC-SIGN, ICAM-3 and LSECtin and uses thereof |
Virginia
Tech Intellectual Properties, Inc. |
29- Oct- 07 |
29- Oct -08 |
9- Apr-
13 |
US8415102 |
Methods
and computer systems for identifying target-specific sequences for use in
nanoreporters |
NanoString
Technologies, Inc. |
10- Apr- 07 |
10- Apr -08 |
9- Apr-
13 |
US8410149 |
Sulfonyl
semicarbazides, semicarbazides and ureas, pharmaceutical compositions
thereof, and methods for treating hemorrhagic fever viruses, including
infections associated with arenaviruses |
Siga
Technologies Inc. |
6- Dec- 04 |
28- Oct -10 |
2- Apr- 13 |
US8410114 |
2-pyrazinone
derivatives for the treatment of disease or condition in which inhibition of
neutrophil elastase activity is beneficial |
AstraZeneca
AB |
8- May-
06 |
6- Jan -12 |
2- Apr-
13 |
US8409589 |
Mutant
forms of streptolysin O |
Novartis
AG |
21- Dec- 07 |
14- Sep -11 |
2- Apr-
13 |
US8399651 |
Nucleic
acids encoding GAS57 mutant antigens |
Novartis
AG |
12- Sep- 07 |
10- Sep -12 |
19- Mar -13 |
US8398992 |
Methods
and compositions for polytopic vaccination |
Polytopos
LLC |
29- Apr- 05 |
22- Dec -11 |
19- Mar -13 |
US8394986 |
Phenoxiacetic
acid derivatives |
AstraZeneca
AB |
21- Aug- 03 |
26- Jul- 11 |
12- Mar -13 |
US8394945 |
Compositions
for use in identification of bacteria |
Ibis
Biosciences, Inc. |
11- Sep- 03 |
7- Mar -07 |
12- Mar -13 |
US8394386 |
Sequential
delivery of immunogenic molecules via adenovirus and adeno-associated
virus-mediated administrations |
The
Trustees of the University of Pennsylvania |
28- Apr- 04 |
27- Apr -05 |
12- Mar -13 |
US7829712 |
Pyridazine
derivatives for inhibiting human stearoyl-CoA-desaturase |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
9- Nov -10 |
US7829707 |
Pyrrolo
[3,2-d]pyrimidin-4-one derivatives and their use in therapy |
AstraZeneca
AB |
6- Dec-
04 |
5- Dec -05 |
9- Nov -10 |
US7829302 |
Method
for detecting the specificity of activated lymphocyte |
HU
JUN |
8- Dec-
03 |
7- Dec -04 |
9- Nov -10 |
US7820210 |
Methods
and apparatus to prevent, treat, and cure the symptoms of nausea caused by
chemotherapy treatments of human cancers |
Inhalation,
Inc. |
3- Apr- 00 |
18- Mar -08 |
26- Oct- 10 |
US7812135 |
GITR-binding
antibodies |
TOLERRX,
Inc. |
25- Mar- 05 |
27- Mar -06 |
12- Oct- 10 |
US7803918 |
Coronavirus,
nucleic acid, protein, and methods for the generation of vaccine, medicaments
and diagnostics |
Amsterdam
Institute of Viral Genomics B.V. |
18- Aug- 03 |
18- Aug -04 |
28- Sep -10 |
US7803796 |
Homopiperazine
compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot
structure of SARS coronavirus |
Sungkyunkwan
University Foundation For Corporate Collaboration |
22- Dec- 06 |
20- Dec -07 |
28- Sep -10 |
US7803765 |
Methods
of constructing biodiverse gene fragment libraries and biological modulators
isolated therefrom |
Phylogica
Limited |
20- Feb- 04 |
20- Feb -04 |
28- Sep -10 |
US7799800 |
Lipid-modified
immune response modifiers |
3M
Innovative Properties Company |
30- Oct- 03 |
12- Aug -04 |
21- Sep -10 |
US7794998 |
Primate
T-lymphotropic viruses |
Johns
Hopkins University |
21- Feb- 05 |
24- Feb -07 |
14- Sep -10 |
US7794659 |
Signal
measuring system having a movable signal measuring device |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
14- Sep -10 |
US7790878 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
Alnylam
Pharmaceuticals, Inc. |
22- Oct- 04 |
25- Jun -09 |
7- Sep -10 |
US7790449 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing the same, and uses
therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
6- Sep -07 |
7- Sep -10 |
US7790159 |
Methods, combinations
and kits for treating viral infections using immunoconjugates and antibodies
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
7- Sep -10 |
US7786290 |
Double-stranded
ribonucleic acid with increased effectiveness in an organism |
Alnylam
Pharmaceuticals, Inc. |
13- Jun- 03 |
14- Jun -04 |
31- Aug -10 |
US7785775 |
Human
virus causing severe acute respiratory syndrome (SARS) and uses thereof |
Versitech
Limited |
24- Mar- 03 |
8- Jun -07 |
31- Aug -10 |
US7785612 |
Polyamino
acid for use as adjuvant |
Masanori
Baba |
20- Apr- 05 |
19- Apr -06 |
31- Aug -10 |
US7781226 |
Particle
on membrane assay system |
The
Board of Regents of the University of Texas System |
27- Feb- 04 |
22- Dec -04 |
24- Aug -10 |
US7781203 |
Supports
for assaying analytes and methods of making and using thereof |
Corning
Incorporated |
29- Dec- 05 |
7- Jun -06 |
24- Aug -10 |
US7777036 |
Heterocyclic
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
17- Aug -10 |
US7777022 |
Bioinformatically
detectable group of novel regulatory viral and viral associated
oligonucleotides and uses thereof |
Rosetta
Genomics, Ltd. |
26- Nov- 02 |
26- May -04 |
17- Aug -10 |
US7776521 |
Coronavirus
isolated from humans |
The
United States of America as represented by the Secretary of the Department of Health and
Human Services, Centers for Disease Control and Prevention |
25- Apr- 03 |
14- May -07 |
17- Aug -10 |
US7767817 |
Water
soluble boronic acid fluorescent reporter compounds and methods of use
thereof |
FANG
HAO |
5- Sep-
03 |
7- Sep -04 |
3- Aug -10 |
US7767677 |
Heterocyclic
derivatives and their use as stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
3- Aug -10 |
US7767658 |
Vaccine
composition |
Aventis
Pasteur SA |
17- Nov- 03 |
9- Jan -08 |
3- Aug -10 |
US7767657 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
16- Aug -06 |
3- Aug -10 |
US7767210 |
RNA
virus vaccines and methods |
The
Board of Regents of the University of Oklahoma |
14- Dec- 05 |
14- Dec -06 |
3- Aug -10 |
US7763618 |
Pyridyl
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
29- Jul-03 |
29- Jul- 04 |
27- Jul- 10 |
US7758868 |
Modified
polymerases and attenuated viruses and methods of use thereof |
The
Penn State Research Foundation |
22- Dec- 06 |
24- Dec -07 |
20- Jul- 10 |
US7754711 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
9- Feb -05 |
13- Jul- 10 |
US7750123 |
Antibodies
against SARS-CoV and methods of use thereof |
Dana
Farber Cancer Institute, Inc. |
25- Nov- 03 |
24- Nov -04 |
6- Jul- 10 |
US7749445 |
Method
and apparatus for analyzing bioprocess fluids |
BioScale,
Inc. |
2- May-
05 |
19- Dec -06 |
6- Jul- 10 |
US7745486 |
Quercetin-containing
compositions |
Quercegen
Pharma LLC |
17- Jul-06 |
16- Jul- 07 |
29- Jun- 10 |
US7745442 |
Methods
of reducing risk of infection from pathogens |
Parion
Sciences, Inc. |
20- Aug- 03 |
18- Aug -04 |
29- Jun- 10 |
US7745147 |
Methods
and uses of antibodies in the purification of interferon |
ViraNative
AB |
12- Feb- 05 |
13- Feb -06 |
29- Jun- 10 |
US7745119 |
System
for detecting polynucleotides |
Investigen,
Inc. |
20- May- 03 |
21- Nov -05 |
29- Jun- 10 |
US7745118 |
Comparative
genomic resequencing |
Roche
Nimblegen, Inc. |
8- Apr-
04 |
8- Apr -05 |
29- Jun- 10 |
US7741450 |
Antibodies
to GM-CSF |
Morphotek
Inc. |
8- Feb-
06 |
8- Feb -07 |
22- Jun- 10 |
US7741360 |
Bi-aryl
or aryl-heteroaryl substituted indoles |
AstraZeneca
AB |
26- May- 06 |
25- May -07 |
22- Jun- 10 |
US7740858 |
SARS-CoV-specific
B-cell epitope and applications thereof |
National
Taiwan University |
21- Sep- 04 |
21- Sep -04 |
22- Jun- 10 |
US7737135 |
Biphenyloxyacetic
acid derivatives for the treatment of respiratory disease |
AstraZeneca
AB |
24- Aug- 04 |
22- Aug -05 |
15- Jun- 10 |
US7736850 |
Strain
of SARS-associated coronavirus and applications thereof |
Centre
National de la Recherche Scientifique |
2- Dec-
03 |
2- Dec -04 |
15- Jun- 10 |
US7732177 |
Oligoadenylate
Synthetase (OAS) |
Illumigen
Biosciences, Inc. |
23- Nov- 05 |
17- Nov -06 |
8- Jun-
10 |
US7731978 |
Mutant
forms of streptolysin O |
Novartis
AG |
21- Dec- 07 |
19- Dec -08 |
8- Jun-
10 |
US7728110 |
Antibodies
to SARS coronavirus |
Amgen,
Inc. |
19- May- 06 |
21- May -07 |
1- Jun-
10 |
US7725565 |
System
and method for detecting, collecting, analyzing, and communicating event
related information |
Georgetown
University |
25- Feb- 08 |
19- Nov -08 |
25- May -10 |
US7723570 |
Edible
vaccines expressed in soybeans |
SoyMeds,
Inc. |
12- Oct- 04 |
12- Oct -05 |
25- May -10 |
US7723041 |
Assay for
SARS coronavirus by amplification and detection of the replicase sequence |
Becton,
Dickinson and Company |
12- Sep- 03 |
3- Feb -09 |
25- May -10 |
US7722886 |
Compositions
and methods for treatment of severe acute respiratory syndrome (SARS) |
Wyeth |
20- May- 04 |
20- May -04 |
25- May -10 |
US7714109 |
Combinations
and kits for cancer treatment using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
11- May -10 |
US7713515 |
Methods
and compositions for use in diagnosing and characterizing diseases involving
abnormal apoptosis |
R.E.D.
Laboratories N.V. |
27- May- 03 |
26- May -04 |
11- May -10 |
US7709521 |
Substituted
indole derivatives for pharmaceutical compositions for treating respiratory
diseases |
AstraZeneca
AB |
18- Aug- 03 |
16- Aug -04 |
4- May -10 |
US7709511 |
Benzothiazolone
derivatives |
AstraZeneca
AB |
9- Aug-
05 |
3- Aug -06 |
4- May -10 |
US7709188 |
Multi-allelic
detection of SARS-associated coronavirus |
Birch
Biomedical Research LLC |
22- Aug- 03 |
13- Aug -04 |
4- May -10 |
US7700782 |
Compounds
569 |
AstraZeneca
AB |
19- Dec- 07 |
19- Dec -07 |
20- Apr- 10 |
US7700728 |
Use of
chimeric receptors in a screening assay for identifying agonists and
antagonists of cell receptors |
Schering
Corporation |
24- Mar- 05 |
24- Mar -06 |
20- Apr- 10 |
US7700727 |
Compositions
and kits for detecting pathogen infection |
Biokit,
S.A. |
23- Dec- 03 |
27- Apr -05 |
20- Apr- 10 |
US7700273 |
Peptidomimetics
that mimic a conformational-dependent neutralizing epitope of the human
immunodeficiency virus (HIV) CCR5 coreceptor |
The
United States of America as represented by the Department of Health and Human
Services |
9- Apr- 04 |
11- Apr -05 |
20- Apr- 10 |
US7700120 |
Adjuvancy
and immune potentiating properties of natural products of Onchocerca volvulus |
New
York Blood Center |
15- Jun- 04 |
15- Jun -05 |
20- Apr- 10 |
US7696406 |
Expression
of a recombinant transgene |
Board
of Trustees Operating Michigan State University |
3-Jul- 03 |
2- Jul- 04 |
13- Apr- 10 |
US7696330 |
Binding
molecules against SARS-coronavirus and uses thereof |
Crucell
Holland B.V. |
22- Jul-03 |
20- Jan -06 |
13- Apr- 10 |
US7691877 |
Pharmaceuticals |
Pfizer
Inc. |
17- Feb- 06 |
16- Feb -07 |
6- Apr-
10 |
US7691646 |
Hazardous
substance removing method, hazardous substance removing material used therein
such as air filter, mask, wipe sheet, and the like, and storage method
thereof |
Daikin
Industries, Ltd. |
28- Mar- 03 |
21- Nov -08 |
6- Apr- 10 |
US7691599 |
Mammalian
genes involved in viral infection and tumor suppression |
Zirus,
Inc. |
2- May-
02 |
2- May -03 |
6- Apr-
10 |
US7691390 |
Viral
protein |
CHANG
MING-FU |
2- Mar-
04 |
19- Sep -07 |
6- Apr-
10 |
US7687535 |
Substituted
3-sulfur indoles |
AstraZeneca
AB |
27- May- 03 |
25- May -04 |
30- Mar -10 |
US7687475 |
RNA
interference in respiratory epithelial cells |
University
of Iowa Research Foundation |
9-Jul- 04 |
16- Oct -07 |
30- Mar -10 |
US7682688 |
Microporous
materials, methods, and articles for localizing and quantifying analytes |
University
of Utah Research Foundation |
26- Nov- 02 |
20- Nov -03 |
23- Mar -10 |
US7678774 |
Treating
severe acute respiratory syndrome |
Hemispherx
Biopharma |
16- May- 03 |
26- Jan -07 |
16- Mar -10 |
US7678386 |
Liposomes
coated with selected antibodies that bind to aminophospholipids |
Board
of Regents the University of Texas |
15- Jul-02 |
15- Aug -03 |
16- Mar -10 |
US7674795 |
Fluorene
derivatives, composition containing said derivatives and the use thereof |
Aventis
Pharma SA |
19- May- 05 |
14- Nov -07 |
9- Mar -10 |
US7670807 |
RNA-dependent
DNA polymerase from Geobacillus stearothermophilus |
East
Tennessee State Univ. Research Foundation |
10- Mar- 04 |
10- Mar -04 |
2- Mar -10 |
US7670565 |
Building
decontamination with vaporous hydrogen peroxide |
Steris
Inc |
31- Jan- 03 |
3- Mar -08 |
2- Mar -10 |
US7666996 |
Casein
derived peptides and uses thereof |
Peptera
Pharmaceuticals Ltd |
1- Mar-
00 |
1- Mar -04 |
23- Feb -10 |
US7666592 |
Methods
for concurrent identification and quantification of an unknown bioagent |
Ibis
Biosciences, Inc. |
18- Feb- 04 |
17- Feb -05 |
23- Feb -10 |
US7662860 |
3D-structure
model of SARS coronavirus 3CL protease and anti- SARS drugs |
Shanghai
Institute of Materia Medica, Chinese Academy of Sciences |
4- Jun-
03 |
2- Dec -05 |
16- Feb -10 |
US7648997 |
Hydroxylamine
substituted imidazoquinolines |
Coley
Pharmaceutical Group, Inc. |
12- Aug- 03 |
12- Aug -04 |
19- Jan- 10 |
US7648844 |
Method
and apparatus for detection of analyte using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
19- Jan- 10 |
US7645881 |
Methods
for treating hepatitis C |
PTC
Therapeutics, Inc. |
22- Jul-04 |
14- Jul- 05 |
12- Jan- 10 |
US7642350 |
Purine
derivatives |
Pfizer
Limited |
4- May-
05 |
3- May -06 |
5- Jan-
10 |
US7636637 |
Variable
length probe selection |
Roche
NimbleGen, Inc. |
18- Jun- 04 |
20- Jun -05 |
22- Dec -09 |
US7635557 |
Enzymatic
diagnostic test for SARS and other viral diseases |
MND
Diagnostic Ltd. |
23- Jun- 03 |
23- Jun -04 |
22- Dec -09 |
US7635485 |
Method
of accelerated vaccination against Ebola viruses |
The
United States of America as represented by the Department of Health and Human
Services |
1- Aug-
03 |
17- Jan -06 |
22- Dec -09 |
US7632638 |
Methods
and apparatus for detecting viruses using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
15- Dec -09 |
US7629443 |
Neutralizing
monoclonal antibodies against severe acute respiratory syndrome-associated
coronavirus |
New
York Blood Center, Inc. |
2- Jun-
04 |
8- Feb -06 |
8- Dec -09 |
US7629385 |
Sphingolipid-derived
pharmaceutical compositions |
Jado
Technologies GmbH |
29- Jun- 04 |
29- Jun -05 |
8- Dec -09 |
US7629137 |
Methods
and apparatus for detecting bacteria using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
8- Dec -09 |
US7629114 |
Method of
collecting nasopharyngeal cells and secretions for diagnosis of viral upper
respiratory infections and screening for nasopharyngeal cancer |
World
Sense Technology Limited |
26- Aug- 03 |
20- Aug -04 |
8- Dec -09 |
US7625563 |
Cancer
treatment methods using selected immunoconjugates for binding to
aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
1- Dec -09 |
US7625492 |
Charge-based
water filtration systems |
The
University of Wyoming Research Corporation |
28- Jan- 03 |
28- Jan -04 |
1- Dec -09 |
US7625428 |
Bioagent
air filtration systems |
The
University of Wyoming Research Corporation |
28- Jan- 03 |
28- Jan -04 |
1- Dec -09 |
US7623997 |
Computer-implemented
biological sequence identifier system and method |
The
United States of America as represented by the Secretary of the Navy |
2-Jul- 04 |
6- Jun -06 |
24- Nov -09 |
US7622559 |
Human
monoclonal antibodies against interleukin 8 (IL-8) |
Genmab
A/S |
16- Dec- 02 |
27- Jun -07 |
24- Nov -09 |
US7622125 |
Polycistronic
HIV vector constructs |
Novartis
Vaccines and Diagnostics, Inc. |
5- May-
04 |
5- May -05 |
24- Nov -09 |
US7622118 |
Cancer
treatment methods using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
24- Nov -09 |
US7622112 |
Anti-SARS
monoclonal antibodies |
Not
Available |
5- Dec-
03 |
6- Dec -04 |
24- Nov -09 |
US7619067 |
Evolved
interferon-alpha polypeptides |
Maxygen,
Inc. |
18- May- 05 |
17- May -06 |
17- Nov -09 |
US7618802 |
Compositions
of coronaviruses with a recombination-resistant genome |
The
University of North Carolina at Chapel Hill |
21- Jul-03 |
19- Jan -06 |
17- Nov -09 |
US7618788 |
Proteome
epitope tags and methods of use thereof in protein modification analysis |
Millipore
Corporation |
10- May- 02 |
5- Feb -04 |
17- Nov -09 |
US7618635 |
Super-antigen
fusion proteins and the use thereof |
Healthbanks
Biotech Co., Ltd. |
21- Jul-04 |
19- Jul- 05 |
17- Nov -09 |
US7615381 |
Method
and apparatus for detecting estradiol and metabolites thereof using an
acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
10- Nov -09 |
US7615223 |
Selected
immunoconjugates for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
10- Nov -09 |
US7611908 |
Method
and apparatus for therapeutic drug monitoring using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
3- Nov -09 |
US7611704 |
Compositions
and methods for treating viral infections using antibodies and immunoconjugates
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
3- Nov -09 |
US7605161 |
Pyridyl
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
20- Oct- 09 |
US7605135 |
Baicalin
as a treatment for SARS infection |
The
University of Hong Kong |
10- Nov- 03 |
8- Nov -04 |
20- Oct- 09 |
US7604960 |
Transient
protein expression methods |
Crucell
Holland B.V. |
15- Apr- 99 |
1- Jun -07 |
20- Oct- 09 |
US7604801 |
Methods
for detecting parvovirus infections |
The
Research Foundation of State University of New York |
5- May-
03 |
16- Oct -08 |
20- Oct- 09 |
US7598382 |
Aryl
substituted imidazoquinolines |
Coley
Pharmaceutical Group, Inc. |
20- Dec- 02 |
13- Jan -06 |
6- Oct-
09 |
US7598094 |
Methods
and apparatus for detecting cardiac injury markers using an acoustic device |
BioScale,
Inc. |
2- May-
05 |
2- May -06 |
6- Oct-
09 |
US7598072 |
Assay
to detect viral uncoating |
Wisconsin
Alumni Research Foundation |
9- Dec-
03 |
8- Dec -04 |
6- Oct-
09 |
US7597936 |
Method
of producing a pigmented composite microporous material |
University
of Utah Research Foundation |
26- Nov- 02 |
26- May -04 |
6- Oct-
09 |
US7595381 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
10- Jun -08 |
29- Sep -09 |
US7595163 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
10- Jun -08 |
29- Sep -09 |
US7592343 |
Pyridazine-piperazine
compounds and their use as stearoyl-CoA desaturase inhibitors |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
22- Sep -09 |
US7592322 |
RNAi
modulation of RSV, PIV and other respiratory viruses and uses thereof |
Alnylam
Pharmaceuticals, Inc. |
22- Oct- 04 |
14- Jun -05 |
22- Sep -09 |
US7592008 |
Membrane
scaffold proteins |
The Board
of Trustees of the University of Illinois, a body corporate and politic of
the State of Illinois |
20- Nov- 00 |
11- Jan -05 |
22- Sep -09 |
US7589092 |
Prodrugs
of heteroaryl compounds |
Koronis
Pharmaceuticals, Incorporated |
20- Jun- 03 |
27- Dec -06 |
15- Sep -09 |
US7585647 |
Nucleic
acid encoding recombinant interferon |
WEI
GUANGWEN |
28- Aug- 03 |
26- Aug -04 |
8- Sep -09 |
US7582740 |
Methods
and kits for detecting SARS-associated coronavirus |
The
Trustees of Columbia University In the City of New York |
17- Apr- 03 |
23- Jan -04 |
1- Sep -09 |
US7582621 |
Boron-containing
small molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
16- Feb -06 |
1- Sep -09 |
US7579396 |
Polymer
composite |
Eastman
Kodak Company |
31- Jan- 07 |
31- Jan -07 |
25- Aug -09 |
US7579359 |
1-alkoxy
1H-imidazo ring systems and methods |
3M
Innovative Properties Company |
2- Sep-
04 |
1- Sep -05 |
25- Aug -09 |
US7572621 |
Detection,
characterization and treatment of viral infection and methods thereof |
Canadian
Blood Services |
9- Apr-
03 |
11- Oct -05 |
11- Aug -09 |
US7572448 |
Combined
cancer treatment methods using selected antibodies to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
11- Aug -09 |
US7572442 |
Selected
antibody compositions for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Jul- 03 |
11- Aug -09 |
US7569536 |
Method
for controlling SR protein phosphorylation, and antiviral agents whose active
ingredients comprise agents that control SR protein activity |
Masatoshi
Hagiwara |
26- Dec- 03 |
24- Dec -04 |
4- Aug -09 |
US7569384 |
Albumin
fusion proteins |
Human
Genome Sciences, Inc. |
9- Feb-
04 |
8- Aug -06 |
4- Aug -09 |
US7550140 |
Antibody
to the human OX40 receptor |
Crucell
Holland B.V. |
13- Jun- 02 |
13- Jun -03 |
23- Jun- 09 |
US7547698 |
Bicyclic
heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase
(SCD) |
Xenon
Pharmaceuticals Inc. |
20- Sep- 04 |
20- Sep -05 |
16- Jun- 09 |
US7547516 |
Method
for reducing the presence of amplification inhibitors in a reaction
receptacle |
Gen-Probe
Incorporated |
10- Mar- 05 |
10- Mar -06 |
16- Jun- 09 |
US7547512 |
High-throughput
diagnostic assay for the human virus causing severe acute respiratory
syndrome (SARS) |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
16- Jun- 09 |
US7544697 |
Pyrazolopyridines
and analogs thereof |
Coley
Pharmaceutical Group, Inc. |
3- Oct-
03 |
1- Apr -05 |
9- Jun-
09 |
US7541436 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
4- May -07 |
2- Jun-
09 |
US7541163 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
14- Aug -07 |
2- Jun-
09 |
US7531630 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
13- Sep -06 |
12- May -09 |
US7531324 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
13- Sep -06 |
12- May -09 |
US7521424 |
Albumin
fusion proteins |
Human
Genome Sciences, Inc. |
22- Jan- 03 |
7- Jul- 05 |
21- Apr- 09 |
US7521185 |
Assay for
SARS coronavirus by amplification and detection of the replicase sequence |
Becton,
Dickinson and Company |
12- Sep- 03 |
13- Sep -04 |
21- Apr- 09 |
US7514436 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
7- Apr-
09 |
US7511124 |
Compositions
comprising phosphatidylethanolamine-binding peptides linked to anti-viral
agents |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
31- Mar -09 |
US7504384 |
Use
of lipid conjugates in the treatment of infection |
Yissum
Research Development Company of the Hebrew University of Jerusalem |
10- Jan- 00 |
8- Sep -05 |
17- Mar -09 |
US7504382 |
Protease
inhibitors for coronaviruses and SARS-CoV and the use thereof |
Cytovia,
Inc. |
6- May-
03 |
6- May -04 |
17- Mar -09 |
US7504205 |
Uncharacterized
ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for
SARS therapy |
The
Burnham Institute |
17- May- 04 |
17- May -05 |
17- Mar -09 |
US7504097 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
17- Mar -09 |
US7498409 |
Screening
assay for TLR7, TLR8 and TLR9 agonists and antagonists |
Schering
Corporation |
24- Mar- 05 |
23- Mar -06 |
3- Mar -09 |
US7498152 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
3- Mar -09 |
US7495011 |
Anti-coronavirus
drug |
aRigen
Pharmaceuticals, Inc. |
15- Jul-03 |
14- Jul- 04 |
24- Feb -09 |
US7491793 |
Influenza
virus inhibiting peptides |
The
Administrators of the Tulane Educational Fund |
4- Nov-
03 |
3- Nov -04 |
17- Feb -09 |
US7491706 |
Artificial
cpg single-stranded oligodeoxynucleotide and antiviral use thereof |
Changchun
Huapu Biotechnology Co., Ltd. |
25- Jul-03 |
26- Jul- 04 |
17- Feb -09 |
US7491508 |
Methods
of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
The
Trustees of the University of Pennsylvania |
20- Jun- 03 |
15- Jun -04 |
17- Feb -09 |
US7491489 |
Synthetic
peptide targeting critical sites on the SARS-associated coronavirus spike
protein responsible for viral infection and method of use thereof |
The
University of Hong Knog |
22- Nov- 04 |
28- Oct -05 |
17- Feb -09 |
US7491397 |
Receptor
binding polypeptides |
National
Health Research Institutes |
9- Jan- 04 |
10- Jan -05 |
17- Feb -09 |
US7488801 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7488589 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7488473 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
30- Oct -06 |
10- Feb -09 |
US7485432 |
Selective
modulation of TLR-mediated biological activity |
3M
Innovative Properties Company |
27- Feb- 03 |
27- Feb -04 |
3- Feb -09 |
US7482334 |
Therapeutic
treatment methods |
Hollis-Eden
Pharmaceuticals, Inc. |
28- Aug- 02 |
12- Feb -07 |
27- Jan- 09 |
US7482149 |
Inhibition
of SARS coronavirus infection with clinically approved antiviral drugs |
Genome
Institute of Singapore |
9- Jun-
03 |
9- Jun -04 |
27- Jan- 09 |
US7479484 |
Peptides
and peptidomimetics having immune-modulating, anti- inflammatory, and
anti-viral activity |
Takeda
Pharmaceutical Company Limited |
25- Jun- 03 |
25- Jun -04 |
20- Jan- 09 |
US7470666 |
Use of
Ulinastatin and its pharmaceutical composition for treating severe acute
respiratory syndrome |
Guangdong
Techpool Biochem. Pharma. Co., Ltd. |
26- May- 03 |
25- May -04 |
30- Dec -08 |
US7470548 |
Hazardous
substance removing method, hazardous substance removing material used therein
such as air filter, mask, wipe sheet, and the like, and storage method
thereof |
Daikin
Industries, Ltd. |
28- Mar- 03 |
26- Mar -04 |
30- Dec -08 |
US7468418 |
Compositions
for enhancing transport of molecules into cells |
AVI
BioPharma., Inc. |
29- Apr- 03 |
29- Apr -04 |
23- Dec -08 |
US7465836 |
Hydrolytically-resistant
boron-containing therapeutics and methods of use |
Anacor
Pharmaceuticals, Inc. |
16- Jun- 03 |
15- Jun -04 |
16- Dec -08 |
US7462615 |
Inhibitors
of cysteine proteases, the pharmaceutical compositions thereof and their
therapeutic applications |
Hybrigenics
SA |
8- Dec-
05 |
8- Dec -05 |
9- Dec -08 |
US7460960 |
Proteome
epitope tags and methods of use thereof in protein modification analysis |
Epitome
Biosystems, Inc. |
10- May- 02 |
13- Nov -03 |
2- Dec -08 |
US7456180 |
Piperazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
25- Nov -08 |
US7455833 |
Methods
and compositions for treating viral infections using antibodies and immunoconjugates
to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
25- Nov -08 |
US7452542 |
Live
attenuated coronavirus vaccines |
Vanderbilt
University |
21- May- 04 |
23- May -05 |
18- Nov -08 |
US7445889 |
Methods
for detecting parvovirus infections |
The
Research Foundation of State University of New York |
5- May-
03 |
5- May -04 |
4- Nov -08 |
US7442761 |
Replikin
peptides and uses thereof |
BOGOCH
ELENORE S |
6- Jun-
03 |
4- Jun -04 |
28- Oct- 08 |
US7442508 |
Methods
for detection and production of influenza viruses |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
28- Apr -06 |
28- Oct- 08 |
US7439349 |
Method
for preparation of large volume batches of poly-ICLC with increased
biological potency; therapeutic, clinical and veterinary uses thereof |
Not
Available |
3-Jul- 02 |
1- Jul- 03 |
21- Oct- 08 |
US7439052 |
Method
of making modified immunodeficiency virus particles |
Lipid
Sciences |
29- Jun- 00 |
10- Apr -06 |
21- Oct- 08 |
US7435588 |
Systems
for detection and production of respiratory, herpes and enteric viruses |
Diagnostic
Hybrids, Inc. |
20- Sep- 05 |
28- Apr -06 |
14- Oct- 08 |
US7435538 |
High
throughput screening method of drug for physiologically active protein |
CellFree
Sciences Co., Ltd. |
8- Sep-
03 |
8- Sep -04 |
14- Oct- 08 |
US7432045 |
Method
of inhibiting influenza infection with antiviral peptides |
Wisconsin
Alumni Research Foundation |
1- Dec-
03 |
1- Dec -04 |
7- Oct-
08 |
US7429656 |
Inhibition
of SARS-associated coronavirus (SCoV) infection and replication by RNA
interference |
The
University of Hong Kong |
19- May- 03 |
14- Jun -06 |
30- Sep -08 |
US7427479 |
Methods
and kits for identifying target nucleotides in mixed populations |
Applera
Corporation |
30- Apr- 04 |
29- Apr -05 |
23- Sep -08 |
US7424370 |
Computational
method for identifying adhesin and adhesin-like proteins of therapeutic
potential |
Council
of Scientific and Industrial Research |
20- Jul-04 |
7- Feb -05 |
9- Sep -08 |
US7407663 |
Modified
immunodeficiency virus particles |
Lipid
Sciences, Inc. |
29- Jun- 00 |
20- Jun -03 |
5- Aug -08 |
US7407662 |
Modified
viral particles with immunogenic properties and reduced lipid content |
Lipid
Sciences, Inc. |
29- Jun- 00 |
21- Jun -04 |
5- Aug -08 |
US7405207 |
Nebulizer
formulations of dehydroepiandrosterone and methods of treating asthma or
chronic obstructive pulmonary disease using compositions thereof |
Epigenesis
Pharmaceuticals, Inc. |
17- Jun- 02 |
17- Jun -03 |
29- Jul- 08 |
US7405046 |
Compositions
and methods for treatment of rhinovirus |
The
Quigley Corporation |
6- Aug-
01 |
27- Oct -06 |
29- Jul- 08 |
US7399588 |
Method
for detecting SARS coronavirus |
Eiken
Kagaku Kabushiki Kaisha |
27- Jun- 03 |
15- Jun -04 |
15- Jul- 08 |
US7396914 |
SARS
nucleic acids, proteins, antibodies, and uses thereof |
University
of Massachusetts |
4- Aug-
03 |
4- Aug -04 |
8- Jul- 08 |
US7393856 |
Anti-viral
uses of borinic acid complexes |
Anacor
Pharmaceuticals, Inc. |
14- Jun- 04 |
14- Jun -05 |
1- Jul- 08 |
US7393638 |
Assay
system and methods for detecting SARS-CV |
AsiaGEN
Corporation |
1-Jul- 03 |
1- Jul- 03 |
1- Jul- 08 |
US7387271 |
Immunostimulatory
combinations |
3M
Innovative Properties Company |
30- Dec- 02 |
30- Dec -03 |
17- Jun- 08 |
US7384909 |
Anti-viral
treatment methods using phosphatidylethanolamine- binding peptides linked to
anti-viral agents |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
10- Jun- 08 |
US7378386 |
Anti-viral
treatment methods using phosphatidylethanolamine- binding peptide derivatives |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
27- May -08 |
US7375210 |
PCR
primer set for detecting severe acute respiratory syndrome
(SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the
same |
Samsung
Electronics Co., Ltd. |
12- Dec- 03 |
24- Nov -04 |
20- May -08 |
US7375202 |
Human
virus causing severe acute respiratory syndrome (SARS) and uses thereof |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
20- May -08 |
US7375180 |
Methods
and compositions related to IRM compounds and Toll-like receptor 8 |
3M
Innovative Properties Company |
13- Feb- 03 |
12- Feb -04 |
20- May -08 |
US7374883 |
Method
and kit for the detection of a novel coronoavirus associated with the severe
acute respiratory syndrome (SARS) |
QIAGEN
Diagnostics GmbH |
30- Apr- 03 |
30- Apr -04 |
20- May -08 |
US7371850 |
Method
and composition for reducing expression of ROCK-II |
Myriad
Genetics, Inc. |
20- Aug- 03 |
20- Aug -04 |
13- May -08 |
US7371837 |
Human
virus causing respiratory tract infection and uses thereof |
The
University of Hong Kong |
21- Jul-04 |
16- May -05 |
13- May -08 |
US7371525 |
Compositions
and methods for diagnosing and treating severe acute respiratory syndrome
(SARS) |
The
Chinese University of Hong Kong |
29- Jul-03 |
28- Jul- 04 |
13- May -08 |
US7361747 |
Isolation
and characterization of the precursor virus of human SARS virus:
SARS-associated corona virus-like virus |
The
University of Hong Kong |
22- May- 03 |
24- May -04 |
22- Apr- 08 |
US7361304 |
Building
decontamination with vaporous hydrogen peroxide |
Steris
Inc. |
31- Jan- 03 |
29- Jan -04 |
22- Apr- 08 |
US7358068 |
Antiviral
oligonucleotides |
Replicor,
Inc. |
13- Sep- 02 |
12- Sep -03 |
15- Apr- 08 |
US7354908 |
Materials
and methods for prevention and treatment of RNA viral diseases |
University
of South Florida |
30- Apr- 02 |
30- Apr -03 |
8- Apr-
08 |
US7354551 |
Room
decontamination with hydrogen peroxide vapor |
Steris
Inc |
8-Jul- 04 |
8- Jul- 04 |
8- Apr-
08 |
US7344740 |
Methods
and apparatus to prevent, treat, and cure the symptoms of nausea caused by
chemotherapy treatments of human cancers |
Inhalation,
Inc. |
3- Apr- 00 |
27- Nov -04 |
18- Mar -08 |
US7344720 |
Vaccine
composition |
Sanofi
Pasteur SA |
17- Nov- 03 |
15- Nov -04 |
18- Mar -08 |
US7339051 |
Compositions
and methods for the treatment of severe acute respiratory syndrome (SARS) |
Isis
Pharmaceuticals, Inc. |
28- Apr- 03 |
26- Apr -04 |
4- Mar -08 |
US7335658 |
Pyridazine
derivatives and their use as therapeutic agents |
Xenon
Pharmaceuticals Inc. |
30- Jul-03 |
29- Jul- 04 |
26- Feb -08 |
US7332475 |
Preventive
or therapeutic composition for viral infectious disease |
Kyowa
Hakko Kogyo Co., Ltd. |
22- Jul-03 |
22- Jul- 04 |
19- Feb -08 |
US7332294 |
CXCL10-based
diagnosis and treatment of respiratory illnesses |
University
Health Network |
17- Aug- 04 |
17- Aug -04 |
19- Feb -08 |
US7320857 |
Characterization
of the earliest stages of the severe acute respiratory syndrome (SARS) virus
and uses thereof |
Chinese
National Human Genome Center at Shanghai |
9-Jul- 04 |
9- Jul- 04 |
22- Jan- 08 |
US7318918 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
19- May- 04 |
18- May -05 |
15- Jan- 08 |
US7314613 |
Interferon-alpha
polypeptides and conjugates |
Maxygen,
Inc. |
18- Nov- 02 |
19- May -04 |
1- Jan-
08 |
US7312036 |
Compositions
for use in identification of viral hemorrhagic fever viruses |
ISIS
Pharmaceuticals, Inc. |
22- Mar- 04 |
21- Mar -05 |
25- Dec -07 |
US7297786 |
RNA
interference in respiratory epitheial cells |
University
of Iowa Research Foundation |
9-Jul- 04 |
11- Jul- 05 |
20- Nov -07 |
US7291498 |
Methods
of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
The
Trustees of the University of Pennsylvania |
20- Jun- 03 |
20- Jun -03 |
6- Nov -07 |
US7282568 |
Human
monoclonal antibodies against interleukin 8 (IL-8) |
Genmab
A/S |
16- Dec- 02 |
16- Dec -03 |
16- Oct- 07 |
US7282199 |
Adeno-associated
virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
25- Apr -03 |
16- Oct- 07 |
US7267942 |
Diagnostic
assay for the human virus causing severe acute respiratory syndrome (SARS) |
The
University of Hong Kong |
24- Mar- 03 |
24- Mar -04 |
11- Sep -07 |
US7261867 |
Production
of silver sulfate grains using organo-sulfate or organo- sulfonate additives |
Eastman
Kodak Company |
7- Apr-
06 |
7- Apr -06 |
28- Aug -07 |
US7247303 |
Selected
antibody CDRs for binding to aminophospholipids |
Board
of Regents, The University of Texas System |
15- Jul-02 |
15- Aug -03 |
24- Jul- 07 |
US7244732 |
Prodrugs
of heteroaryl compounds |
Koronis
Pharmaceuticals, Incorporated |
20- Jun- 03 |
31- Mar -04 |
17- Jul- 07 |
US7223787 |
Prenylation
inhibitors reduce host cell permissiveness to viral replication |
Board
of Regents, The University of Texas System |
21- Oct- 03 |
21- Oct -03 |
29- May -07 |
US7220852 |
Coronavirus
isolated from humans |
The
United States of America as represented by the Secretary of the Department of Health and
Human Services, Centers for Disease Control and Prevention |
25- Apr- 03 |
12- Apr -04 |
22- May -07 |
US7183300 |
Inhibitors
of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and
analogues thereof |
AGARWAL
ATUL |
11- Nov- 04 |
10- Nov -05 |
27- Feb -07 |
US7166435 |
Compositions
and methods for reducing the transmissivity of illnesses |
The
Quigley Corporation |
6- Aug-
01 |
14- Dec -04 |
23- Jan- 07 |
US7163947 |
1-Amino
1H-imidazoquinolines |
3M
Innovative Properties Company |
7- Mar-
03 |
3- Sep -04 |
16- Jan- 07 |
US7151163 |
Antiviral
agents for the treatment, control and prevention of infections by
coronaviruses |
Sequoia
Pharmaceuticals, Inc. |
28- Apr- 03 |
28- Apr -04 |
19- Dec -06 |
US7151091 |
Compositions
and methods for preventing infection |
La
Jolla Biosciences LLC |
20- Sep- 02 |
22- Sep -03 |
19- Dec -06 |
US7148248 |
Method of
treating or inhibiting the development of brain inflammation and sepsis |
NOZAKI
MASAKO |
29- Nov- 02 |
26- Nov -03 |
12- Dec -06 |
US7129223 |
Inhibition
of SARS-associated coronavirus (SCoV) infection and replication by RNA
interference |
The
University of HongKong |
19- May- 03 |
19- May -04 |
31- Oct- 06 |
US7129042 |
Compositions
and methods for detecting severe acute respiratory syndrome coronavirus |
Diagnostic
Hybrids, Inc. |
3- Nov-
03 |
3- Nov -03 |
31- Oct- 06 |
US7115563 |
Composition
and its therapeutic use |
Insignion
Holding Limited |
29- May- 02 |
29- May -03 |
3- Oct-
06 |
US7091214 |
Aryl
substituted Imidazoquinolines |
3M
Innovative Properties Co. |
20- Dec- 02 |
18- Dec -03 |
15- Aug -06 |
US7048953 |
Methods
and apparatus to prevent, treat and cure infections of the human respiratory
system by pathogens causing severe acute respiratory syndrome (SARS) |
Inhalation,
Inc. |
3- Apr- 00 |
2- May -03 |
23- May -06 |
US7023593 |
Apparatus
for forming nano-grating device |
Industrial
Technology Research Institute |
28- Nov- 03 |
17- Mar -04 |
4- Apr-
06 |
US6946291 |
Mixed
cell diagnostic systems |
Diagnostic
Hybrids, Inc. |
24- Apr- 98 |
30- Mar -04 |
20- Sep -05 |
US20200176
079 |
METHODS
AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES |
Not
Available |
19- Jul-17 |
18- Jul- 18 |
4- Jun-
20 |
US20200173
925 |
MICROSCOPIC
BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC
BODY DETECTION DEVICE |
JAPAN
SCIENCE AND TECHNOLOGY AGENCY |
29- Mar- 17 |
28- Mar -18 |
4- Jun- 20 |
US20200172
883 |
COMPOSITIONS
FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS |
Not
Available |
19- Nov- 09 |
13- Sep -19 |
4- Jun-
20 |
US20200172
879 |
DHFR
TUNABLE PROTEIN REGULATION |
Not
Available |
3- Mar-
17 |
2- Sep -19 |
4- Jun-
20 |
US20200172
600 |
RSV
F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
15- Jul-09 |
16- Aug -17 |
4- Jun-
20 |
US20200172
513 |
DIHYDROPYRIMIDINYL
BENZAZEPINE CARBOXAMIDE COMPOUNDS |
Hoffmann-La
Roche Inc. |
12- Jun- 16 |
5- Feb -20 |
4- Jun-
20 |
US20200172
480 |
CONJUGATES
OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Jul-12 |
5- Feb -20 |
4- Jun-
20 |
US20200171
085 |
Method
of Treating Respiratory Tract Infection |
Not
Available |
19- May- 17 |
18- May -18 |
4- Jun-
20 |
US20200171
060 |
FLEX-NUCLEOSIDE
ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES |
Not
Available |
31- Jul-17 |
26- Jan -18 |
4- Jun-
20 |
US20200166
505 |
METHOD
AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID
SAMPLE BY USING NEODYMIUM MAGNETS |
The
U.S.A., as represented by the Secretary, Department of Health and Human
Services |
1- Sep- 15 |
30- Jan -20 |
28- May -20 |
US20200165
632 |
ENHANCING
AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION |
Spark
Therapeutics, Inc. |
7- Jun-
17 |
6- Jun -18 |
28- May -20 |
US20200165
630 |
COMPOSITIONS
FOR THE TREATMENT OF DISEASE |
Not
Available |
29- Apr- 16 |
28- Apr -17 |
28- May -20 |
US20200165
613 |
VIRUS
LIKE PARTICLE |
The
University of Leeds |
1- Jun-
17 |
31- May -18 |
28- May -20 |
US20200165
594 |
CRISPR
SYSTEM BASED ANTIVIRAL THERAPY |
MASSACHUSETTS
INSTITUTE OF TECHNOLOGY |
7-Jul- 17 |
6- Jul- 18 |
28- May -20 |
US20200165
585 |
NEW
CHIMERIC ENZYMES AND THEIR APPLICATIONS |
Not
Available |
27- Jul-17 |
27- Jul- 18 |
28- May -20 |
US20200165
357 |
CARBONIC
ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF |
Not
Available |
2- Dec-
05 |
21- Oct -19 |
28- May -20 |
US20200164
334 |
MICROSPOTTING
DEVICE |
Not
Available |
18- Apr- 12 |
11- Oct -19 |
28- May -20 |
US20200164
067 |
Methods
and Compositions for Inhibiting Akt3 |
Not
Available |
15- Jan- 16 |
5- Feb -20 |
28- May -20 |
US20200164
058 |
TRIMERIC
S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY
SYNDROME-CORONAVIRUS |
King
Abdulaziz University |
27- Nov- 18 |
27- Nov -18 |
28- May -20 |
US20200164
020 |
PUM
1 PROTEIN AS TARGET FOR VIRUS INHIBITION |
Not
Available |
12- Apr- 17 |
12- Apr -17 |
28- May -20 |
US20200163
878 |
LIPID
NANOPARTICLE MRNA VACCINES |
Not
Available |
26- Oct- 16 |
26- Oct -17 |
28- May -20 |
US20200157
600 |
METHODS
AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION |
Not
Available |
19- Nov- 18 |
19- Nov -18 |
21- May -20 |
US20200157
222 |
ANTI-PD-L1
ANTIBODIES AND USES THEREOF |
Not
Available |
29- Mar- 18 |
29- Mar -19 |
21- May -20 |
US20200157
221 |
ONCOLYTIC
VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES |
Not
Available |
30- Jun- 16 |
28- Jan -20 |
21- May -20 |
US20200155
704 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
30- Jan -20 |
21- May -20 |
US20200155
699 |
MODIFIED
VIRUS-LIKE PARTICLES OF CMV |
Not
Available |
22- Oct- 14 |
26- Nov -19 |
21- May -20 |
US20200155
667 |
VACCINE
COMPOSITIONS |
Not
Available |
27- Jul-17 |
24- Jan -20 |
21- May -20 |
US20200155
664 |
INFLUENZA
VACCINES WITH REDUCED AMOUNTS OF SQUALENE |
Not
Available |
10- Feb- 09 |
26- Jun -19 |
21- May -20 |
US20200155
662 |
COMBINATION
IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS |
Not
Available |
26- May- 17 |
25- May -18 |
21- May -20 |
US20200155
660 |
COMPOSITIONS
AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY |
Not
Available |
23- Sep- 15 |
22- Nov -19 |
21- May -20 |
US20200155
646 |
EV576 For
Use in the Treatment of Viral Infections of the Respiratory Tract |
Volution
Immuno Pharmaceuticals SA |
8- Jan- 10 |
7- Jun -19 |
21- May -20 |
US20200149
062 |
ENGINEERED
TSC2 |
Not
Available |
14- Jul-17 |
13- Jul- 18 |
14- May -20 |
US20200149
048 |
Transbiotic
Regulation of Bacterial Gene Expression |
Not
Available |
22- May- 17 |
22- May -18 |
14- May -20 |
US20200148
749 |
ANTIBODIES
AND PROCESSES FOR PREPARING THE SAME |
Not
Available |
16- May- 08 |
10- Oct -19 |
14- May -20 |
US20200147
203 |
VACCINATION
OF IMMUNOCOMPROMISED SUBJECTS |
Not
Available |
26- Sep- 14 |
10- Jan -20 |
14- May -20 |
US20200147
193 |
COMPOSITIONS
AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS |
Not
Available |
2- Jun- 17 |
2- Jun -18 |
14- May -20 |
US20200147
171 |
COMPOSITIONS
OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST
CANCERS, INFECTIONS DISEASES AND DISORDERS |
Not
Available |
18- Sep- 18 |
18- Sep -19 |
14- May -20 |
US20200140
547 |
MULTIFUNCTIONAL
ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE |
Not
Available |
26- May- 17 |
25- May -18 |
7- May -20 |
US20200140
493 |
Engineering
Virus-like Nanocarriers for Biomolecule Delivery |
Not
Available |
26- Oct- 18 |
25- Oct -19 |
7- May -20 |
US20200140
398 |
HUMAN
HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS |
AZIENDA
OSPEDALIERA UNIVERSITARIA SENESE |
13- Feb- 15 |
6- Jan -20 |
7- May -20 |
US20200138
937 |
Genetically
Attenuated Nucleic Acid Vaccine |
Not
Available |
2- Jun-
17 |
1- Jun -18 |
7- May -20 |
US20200138
936 |
Phenotypically
Wild-Type and Genetically Attenuated Viruses |
Not
Available |
2- Jun-
17 |
1- Jun -18 |
7- May -20 |
US20200138
818 |
METHODS
OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB |
Not
Available |
7- Nov-
18 |
6- Nov -19 |
7- May -20 |
US20200138
780 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
19- Dec -19 |
7- May -20 |
US20200131
518 |
CONTROL
OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE |
Not
Available |
14- Mar- 17 |
14- Mar -18 |
30- Apr- 20 |
US20200129
487 |
CHEMOTHERAPY
FOR CANCER USING AZABICYCLO COMPOUND |
TAIHO
PHARMACEUTICAL CO., LTD. |
30- Jun- 17 |
29- Jun -18 |
30- Apr- 20 |
US20200127
954 |
RNA
TARGETING METHODS AND COMPOSITIONS |
Salk
Institute for Biological Studies |
22- Aug- 17 |
31- Dec -18 |
23- Apr- 20 |
US20200124
599 |
ACCURATE,
RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING
SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL |
CELLEMEDY
CO., LTD |
13- Apr- 17 |
13- Apr -18 |
23- Apr- 20 |
US20200123
233 |
AMINO
ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
Ablynx
N.V. |
5- Jun- 08 |
1- Aug -19 |
23- Apr- 20 |
US20200123
205 |
Inhibition
Of TCR Signaling With Peptide Variants |
Not
Available |
22- Oct- 18 |
18- Dec -19 |
23- Apr- 20 |
US20200123
203 |
COMPOSITIONS
COMPRISING CURONS AND USES THEREOF |
FLAGSHIP
PIONEERING INNOVATIONS V, INC. |
13- Jun- 17 |
13- Jun -18 |
23- Apr- 20 |
US20200115
448 |
CELLS
EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS
AND USES THEREOF |
Not
Available |
26- Apr- 17 |
22- Oct -19 |
16- Apr- 20 |
US20200115
434 |
ANTIBODY/T-CELL
RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF |
Not
Available |
23- Oct- 15 |
29- Oct -19 |
16- Apr- 20 |
US20200113
996 |
CHIMERIC
VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF
IMMUNE RESPONSES |
Not
Available |
23- Jun- 17 |
21- Jun -18 |
16- Apr- 20 |
US20200113
967 |
PEPTIDES
AND USES THEREFOR AS ANTIVIRAL AGENTS |
Not
Available |
26- May- 17 |
26- May -17 |
16- Apr- 20 |
US20200113
831 |
LIPOSOMES
HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 11 |
16- Dec -19 |
16- Apr- 20 |
US20200113
830 |
PEGYLATED
LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA |
GLAXOSMITHKLINE
BIOLOGICALS S.A. |
31- Aug- 11 |
16- Dec -19 |
16- Apr- 20 |
US20200109
403 |
IN
VIVO DELIVERY OF OLIGONUCLEOTIDES |
Not
Available |
12- Dec- 11 |
18- Dec -19 |
9- Apr-
20 |
US20200108
136 |
METHODS
AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES |
Not
Available |
6- Apr-
07 |
22- Nov -19 |
9- Apr-
20 |
US20200102
558 |
TRANSKINGDOM
PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY |
Not
Available |
3- Apr-
17 |
3- Oct -19 |
2- Apr-
20 |
US20200102
550 |
TAL
EFFECTOR-MEDIATED DNA MODIFICATION |
Not
Available |
10- Dec- 09 |
28- Aug -19 |
2- Apr-
20 |
US20200102
544 |
POXVIRUS-PLASMODIUM
RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND
METHODS OF MAKING AND USING THE SAME |
Not
Available |
30- Dec- 13 |
11- Sep -19 |
2- Apr- 20 |
US20200102
362 |
TUMOR
NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING
AND BIOACTIVITY |
Not
Available |
6- Apr-
17 |
5- Apr -18 |
2- Apr-
20 |
US20200102
292 |
SUBSTITUTED
BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF |
Not
Available |
3-Jul- 13 |
10- Jul- 19 |
2- Apr-
20 |
US20200101
158 |
ANTI-TIGIT
ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF |
Not
Available |
1- Oct-
15 |
22- Oct -19 |
2- Apr-
20 |
US20200101
153 |
MVA-BN
AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN |
Not
Available |
6- Apr-
17 |
6- Apr -18 |
2- Apr-
20 |
US20200101
142 |
PDE5
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY |
Not
Available |
12- Jun- 17 |
12- Jun -18 |
2- Apr-
20 |
US20200101
119 |
METHODS
OF TREATMENT OF INFECTIONS USING BACTERIA |
Not
Available |
27- Sep- 18 |
26- Sep -19 |
2- Apr-
20 |
US20200101
087 |
PHARMACEUTICAL
COMPOSITIONS AND METHODS |
Not
Available |
3- Aug-
15 |
21- Nov -19 |
2- Apr-
20 |
US20200100
480 |
TRAIT
SELECTION IN AVIANS |
Not
Available |
31- May- 17 |
31- May -18 |
2- Apr-
20 |
US20200095
324 |
ANTI-TIGIT
ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF |
Not
Available |
30- Mar- 17 |
30- Mar -18 |
26- Mar -20 |
US20200093
919 |
MODIFIED
PEDV SPIKE PROTEIN |
Not
Available |
20- Sep- 18 |
18- Sep -19 |
26- Mar -20 |
US20200093
909 |
PLASMODIUM
SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND
ANTIBODIES BINDING TO |
Not
Available |
19- Apr- 17 |
19- Apr -18 |
26- Mar -20 |
US20200093
855 |
ENHANCED
IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE |
Not
Available |
11- Sep- 17 |
3- Jun -19 |
26- Mar -20 |
US20200093
841 |
Broad
Spectrum Antiviral and Methods of Use |
Not
Available |
17- Apr- 06 |
30- Apr -19 |
26- Mar -20 |
US20200087
655 |
PURIFICATION
OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES |
Not
Available |
14- Jul-15 |
22- Nov -19 |
19- Mar -20 |
US20200087
646 |
OPTIMIZED
HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE |
Not
Available |
31- May- 17 |
31- May -18 |
19- Mar -20 |
US20200087
630 |
INFLUENZA
VIRUS AND TYPE 1 DIABETES |
Istituto
Zooprofilattico Sperimentale delle Venezie |
10- Oct- 12 |
25- Jul- 19 |
19- Mar -20 |
US20200087
359 |
GRIFFITHSIN
MUTANTS |
The
United States of America,as represented by the Secretary,Department of Health
and Human Services |
10- Feb- 15 |
27- Nov -19 |
19- Mar -20 |
US20200087
313 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
29- Jul-11 |
25- Apr -19 |
19- Mar -20 |
US20200087
298 |
Imidazo[4,5-c]
Ring Compounds Containing Guanidine Substituted Benzamide Groups |
Not
Available |
1- Mar-
17 |
27- Feb -18 |
19- Mar -20 |
US20200087
280 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
25- Nov -19 |
19- Mar -20 |
US20200086
324 |
DEVICES
AND METHODS FOR NUCLEIC ACID EXTRACTION |
Not
Available |
30- Jun- 16 |
27- Dec -18 |
19- Mar -20 |
US20200085
984 |
APPARATUS,
METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS |
THE
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
7- Mar-
11 |
25- Nov -19 |
19- Mar -20 |
US20200085
947 |
VISTA
MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER |
Not
Available |
7- Sep-
12 |
14- May -19 |
19- Mar -20 |
US20200085
943 |
PHARMACEUTICAL
COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE
PROTEIN OR PEPTIDE ANTIGEN |
CureVac
AG |
31- Jan- 12 |
29- Aug -19 |
19- Mar -20 |
US20200085
872 |
IMMUNE
CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS |
Not
Available |
19- Apr- 17 |
19- Apr -18 |
19- Mar -20 |
US20200085
852 |
EPIDERMAL
MRNA VACCINE |
Not
Available |
5- Aug-
15 |
5- Aug -16 |
19- Mar -20 |
US20200085
756 |
NANOPARTICLE
VACCINE ADJUVANT AND METHODS OF USE THEREOF |
Not
Available |
14- Sep- 18 |
12- Jul- 19 |
19- Mar -20 |
US20200080
141 |
METHODS
AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS |
Not
Available |
11- Dec- 13 |
19- Nov -19 |
12- Mar -20 |
US20200080
111 |
Methods
for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome
Editing and Compositions Thereof |
Not
Available |
18- Sep- 15 |
19- Sep -16 |
12- Mar -20 |
US20200079
820 |
DERIVATIVES
OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE |
Hangzhou
DAC Biotech Co., Ltd. |
20- Apr- 16 |
20- Apr -16 |
12- Mar -20 |
US20200079
781 |
Substituted
2,4 diamino-quinoline as new medicament for fibrosis, autophagy and
cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases |
Not
Available |
5- Sep- 18 |
1- Aug -19 |
12- Mar -20 |
US20200078
335 |
COMPOSITIONS
AND METHODS TO REDUCE PATHOGENESIS |
Not
Available |
1- May-
17 |
1- May -18 |
12- Mar -20 |
US20200072
836 |
MEDIA
ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF |
Not
Available |
5- May-
14 |
2- Apr -19 |
5- Mar -20 |
US20200071
723 |
RNA-BASED
DELIVERY SYSTEMS WITH LEVELS OF CONTROL |
Not
Available |
30- Aug- 18 |
29- Aug -19 |
5- Mar -20 |
US20200071
421 |
BISPECIFIC
ANTIBODY |
Not
Available |
20- Nov- 13 |
8- Apr -19 |
5- Mar -20 |
US20200069
814 |
CONJUGATION
OF A CYTOTOXIC DRUG WITH BIS-LINKAGE |
Hangzhou
DAC Biotech Co., Ltd. |
6- Apr-
17 |
6- Apr -17 |
5- Mar -20 |
US20200062
764 |
ALKYL
PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME |
Not
Available |
17- Nov- 16 |
17- Nov -17 |
27- Feb -20 |
US20200061
187 |
METHODS
FOR PREPARING SQUALENE |
Not
Available |
12- May- 10 |
4- Nov -19 |
27- Feb -20 |
US20200061
185 |
PREFUSION
CORONAVIRUS SPIKE PROTEINS AND THEIR USE |
The
Scripps Research Institute |
25- Oct- 16 |
25- Oct -17 |
27- Feb -20 |
US20200060
981 |
CATIONIC
NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES |
Not
Available |
9- Dec-
16 |
11- Dec -17 |
27- Feb -20 |
US20200056
221 |
METHODS
FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA |
Not
Available |
8- Nov-
13 |
25- Oct -19 |
20- Feb -20 |
US20200056
159 |
NOVEL
ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR |
Not
Available |
28- Feb- 17 |
27- Feb -18 |
20- Feb -20 |
US20200055
927 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
25- Oct -19 |
20- Feb -20 |
US20200055
926 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
25- Oct -19 |
20- Feb -20 |
US20200054
731 |
IMMUNOMODULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
7- Jan- 14 |
15- Jul- 19 |
20- Feb -20 |
US20200054
660 |
DNA
METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY |
St.
Jude Children's Research Hospital |
9- Dec-
16 |
7- Dec -17 |
20- Feb -20 |
US20200054
259 |
HIGH
DENSITY ANALOG MULTIPEXING |
EnLiSense,
LLC |
17- Aug- 18 |
16- Aug -19 |
20- Feb -20 |
US20200048
722 |
METHODS
FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL,
VIRAL, AND PROTOZOAN NUCLEIC ACIDS |
Not
Available |
8- May- 15 |
24- Aug -19 |
13- Feb -20 |
US20200048
649 |
VIRUS-LIKE
PARTICLES AND USES THEREOF |
Not
Available |
13- Mar- 17 |
13- Mar -18 |
13- Feb -20 |
US20200048
636 |
IMMUNISATION
OF LARGE MAMMALS WITH LOW DOSES OF RNA |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 10 |
18- Oct -19 |
13- Feb -20 |
US20200046
865 |
DECONTAMINATION
DEVICE AND METHOD USING ULTRASONIC CAVITATION |
Not
Available |
29- Dec- 17 |
22- Aug -19 |
13- Feb -20 |
US20200046
826 |
METHODS
AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS |
Academia
Sinica |
27- Mar- 09 |
4- Jun -19 |
13- Feb -20 |
US20200046
692 |
SPECIFIC
AKT3 INHIBITOR AND USES THEREOF |
Not
Available |
15- Jan- 16 |
2- Oct -19 |
13- Feb -20 |
US20200040
408 |
HANDHELD
NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION |
Not
Available |
8- Feb-
16 |
6- May -19 |
6- Feb -20 |
US20200040
042 |
CHIMERIC
MOLECULES AND USES THEREOF |
Not
Available |
30- Mar- 17 |
29- Mar -18 |
6- Feb -20 |
US20200038
871 |
DEVICES,
PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE,
EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE,
LIGASE, POLYMERASE, AND SEQUENCING REACTIONS |
Not
Available |
29- Mar- 17 |
29- Mar -18 |
6- Feb -20 |
US20200038
373 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
9- May-
12 |
16- May -19 |
6- Feb -20 |
US20200033
343 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
14- Oct -19 |
30- Jan- 20 |
US20200032
255 |
METHODS
AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES |
Not
Available |
26- Jan- 07 |
6- Mar -19 |
30- Jan- 20 |
US20200031
871 |
NOVEL
DEPSIPEPTIDES AND USES THEREOF |
Not
Available |
4- Apr-
17 |
30- Mar -18 |
30- Jan- 20 |
US20200031
819 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
26- Jun -19 |
30- Jan- 20 |
US20200030
441 |
Lipidated
Immune Response Modifier Compound Compositions, Formulations, and Methods |
Not
Available |
17- Aug- 10 |
8- Jul- 19 |
30- Jan- 20 |
US20200030
432 |
ZOONOTIC
DISEASE RNA VACCINES |
ModernaTX,
Inc. |
17- Mar- 17 |
16- Mar -18 |
30- Jan- 20 |
US20200030
422 |
COMBINATION
OF VACCINATION AND OX40 AGONISTS |
CureVac
AG |
9- Sep-
16 |
15- Apr -19 |
30- Jan- 20 |
US20200024
616 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC
TROPISM |
Not
Available |
30- Mar- 18 |
29- Mar -19 |
23- Jan- 20 |
US20200024
310 |
NOVEL
DEPSIPEPTIDE AND USES THEREOF |
Not
Available |
3- Dec-
12 |
1- Aug -19 |
23- Jan- 20 |
US20200020
420 |
Method
for Establishing Machine Learning Model for Predicting Toxicity of siRNA to
Certain Type of Cells and Application Thereof |
Not
Available |
8- Dec- 16 |
7- Dec -17 |
16- Jan- 20 |
US20200017
926 |
CELL-FREE
NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF |
Not
Available |
7- Nov-
13 |
28- Aug -19 |
16- Jan- 20 |
US20200017
832 |
COMPOSITIONS
FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS,
METHODS AND USES THEREOF |
Not
Available |
5- Apr- 17 |
5- Apr -18 |
16- Jan- 20 |
US20200017
588 |
MODULAR
TETRAVALENT BISPECIFIC ANTIBODY PLATFORM |
Not
Available |
14- Oct- 16 |
16- Oct -17 |
16- Jan- 20 |
US20200017
554 |
SELF-ASSEMBLING
PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS |
Not
Available |
23- Mar- 17 |
22- Mar -18 |
16- Jan- 20 |
US20200017
514 |
ADAMANTANE
DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION |
Not
Available |
12- Jul-18 |
12- Jul- 18 |
16- Jan- 20 |
US20200017
455 |
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS |
Not
Available |
24- Jan- 14 |
19- Mar -19 |
16- Jan- 20 |
US20200016
589 |
LOADING
VIALS |
Not
Available |
10- Nov- 11 |
24- Sep -19 |
16- Jan- 20 |
US20200016
286 |
Production
of Immune-Response-Stimulating Aerosols By Non- Thermal Plasma Treatment Of
Airborne Pathogens |
Not
Available |
13- Jul-18 |
12- Jul- 19 |
16- Jan- 20 |
US20200016
280 |
Compositions
For Enhancing Transport Of Molecules Into Cells |
Not
Available |
29- Apr- 03 |
9- Apr -19 |
16- Jan- 20 |
US20200016
161 |
METHODS
FOR TREATING VIRAL DISORDERS |
TRUSTEES
OF BOSTON UNIVERSITY |
24- Sep- 09 |
22- Jul- 19 |
16- Jan- 20 |
US20200010
883 |
METHODS
AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS |
Not
Available |
9- Oct-
15 |
7- Jun -19 |
9- Jan-
20 |
US20200010
519 |
NUCLEASE
FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE
INTEGRATION |
Not
Available |
10- Mar- 17 |
9- Mar -18 |
9- Jan-
20 |
US20200009
244 |
NANOPARTICLE
VACCINES WITH NOVEL STRUCTURAL COMPONENTS |
Not
Available |
13- Jun- 18 |
13- Jun -19 |
9- Jan-
20 |
US20200002
674 |
ERYTHROID
CELLS COMPRISING PHENYLALANINE HYDROXYLASE |
Not
Available |
18- Nov- 13 |
16- Sep -19 |
2- Jan-
20 |
US20200000
931 |
SYNTHETIC
NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS |
Not
Available |
15- Jul-16 |
10- Apr -19 |
2- Jan-
20 |
US20190391
150 |
COMPOSITIONS
AND METHODS FOR CAPTURING EXOSOMES |
Not
Available |
1- May-
15 |
10- Sep -19 |
26- Dec -19 |
US20190390
249 |
BIOLOGICAL
SPECIMEN COLLECTION AND TRANSPORT SYSTEM |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
19- Jun -17 |
26- Dec -19 |
US20190390
229 |
GENE
EDITING REAGENTS WITH REDUCED TOXICITY |
Not
Available |
21- Apr- 16 |
20- Apr -17 |
26- Dec -19 |
US20190390
179 |
SYNTHETIC
REVERSE TRANSCRIPTASES AND USES THEREOF |
Not
Available |
12- Apr- 16 |
12- Apr -17 |
26- Dec -19 |
US20190390
176 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL
MUSCLE TROPISM |
Not
Available |
2- Dec- 15 |
3- Jul- 19 |
26- Dec -19 |
US20190389
816 |
ANTIVIRAL
COMPOUNDS AND METHODS |
Biotron
Limited |
26- Jun- 03 |
29- Aug -19 |
26- Dec -19 |
US20190388
473 |
METHODS
AND COMPOSITIONS FOR IMMUNOMODULATION |
Not
Available |
1- Apr-
14 |
30- Aug -19 |
26- Dec -19 |
US20190382
799 |
VIRAL
METHODS OF MAKING GENETICALLY MODIFIED CELLS |
Not
Available |
27- Oct- 16 |
19- Apr -19 |
19- Dec -19 |
US20190382
433 |
GLYCOLIPIDS
AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY |
THE
UNIVERSITY OF NOTTINGHAM |
4- Apr-
14 |
25- Jul- 19 |
19- Dec -19 |
US20190381
180 |
HYBRID
CARRIERS FOR NUCLEIC ACID CARGO |
Not
Available |
9- Jun-
16 |
9- Jun -17 |
19- Dec -19 |
US20190381
162 |
PAN
FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING |
Not
Available |
28- Mar- 16 |
27- Mar -17 |
19- Dec -19 |
US20190381
155 |
COMBINATION
OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY |
CureVac
AG |
22- Feb- 13 |
29- Aug -19 |
19- Dec -19 |
US20190380
995 |
PREVENTION
AND TREATMENT OF VIRAL INFECTIONS |
Not
Available |
2- Jun-
16 |
3- Jul- 19 |
19- Dec -19 |
US20190380
891 |
MOBILE
CLINICS |
Baylor
College of Medicine |
12- Nov- 14 |
28- Aug -19 |
19- Dec -19 |
US20190376
151 |
MODIFIED
OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING
NUCLEIC ACIDS |
Not
Available |
4- Apr- 12 |
8- Feb -19 |
12- Dec -19 |
US20190376
034 |
PLATELETS
COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF |
Not
Available |
18- Nov- 13 |
23- Aug -19 |
12- Dec -19 |
US20190375
801 |
HSP
FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS
DISEASE |
Not
Available |
9- Sep-
16 |
8- Sep -17 |
12- Dec -19 |
US20190374
650 |
COMPOSITIONS
AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE CONJUGATES |
Not
Available |
22- Feb- 17 |
21- Feb -18 |
12- Dec -19 |
US20190374
610 |
MEDICAL
USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS |
Not
Available |
20- Dec- 16 |
20- Dec -17 |
12- Dec -19 |
US20190374
576 |
VIRAL
METHODS OF T CELL THERAPY |
Not
Available |
27- Oct- 16 |
19- Apr -19 |
12- Dec -19 |
US20190370
834 |
SYSTEM
FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENS |
Not
Available |
1- Jun-
18 |
1- Jun -18 |
5- Dec -19 |
US20190367
553 |
COMPOSITIONS
AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN
KINASE 1 |
Not
Available |
27- Oct- 17 |
26- Apr -19 |
5- Dec -19 |
US20190367
525 |
PYRROLO
AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
19- Jul- 19 |
5- Dec -19 |
US20190367
453 |
CONJUGATES
OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Jul-12 |
13- Aug -19 |
5- Dec -19 |
US20190365
925 |
AAV
VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM |
Not
Available |
21- Nov- 14 |
13- Jun -19 |
5- Dec -19 |
US20190365
756 |
PYRIMIDINE
COMPOUNDS CONTAINING ACIDIC GROUPS |
Not
Available |
4- Jun-
18 |
3- Jun -19 |
5- Dec -19 |
US20190359
990 |
VIRAL
SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF |
Not
Available |
25- Jan- 17 |
25- Jan -18 |
28- Nov -19 |
US20190359
635 |
ISOTHIAZOLOPYRIMIDINONES,
PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb- 15 |
18- Jul- 19 |
28- Nov -19 |
US20190359
629 |
THIENOPYRIMIDINONES
AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
18- Jul- 19 |
28- Nov -19 |
US20190358
335 |
STOMACH ACID-STABLE
AND MUCIN-BINDING PROTEIN-POLYMER CONJUGATES |
Not
Available |
12- Jan- 17 |
12- Jan -18 |
28- Nov -19 |
US20190358
312 |
ANTIGEN-ADJUVANT
COUPLING REAGENTS AND METHODS OF USE |
Not
Available |
19- Dec- 17 |
19- Dec -18 |
28- Nov -19 |
US20190358
304 |
ORAL
DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR
ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY
HYPERTESNIONS, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND
EXPOERIMENTALLY INDUCED OCULAR DISORDERS |
Not
Available |
18- Oct- 13 |
29- May -19 |
28- Nov -19 |
US20190358
170 |
Lipids
and Lipid Compositions for the Delivery of Active Agents |
Not
Available |
19- Dec- 13 |
12- Aug -19 |
28- Nov -19 |
US20190352
639 |
GENOME
EDITING REAGENTS AND THEIR USE |
Not
Available |
10- Feb- 17 |
12- Feb -18 |
21- Nov -19 |
US20190352
615 |
METHOD
FOR PURIFYING VIRUS |
Not
Available |
22- Dec- 16 |
21- Dec -17 |
21- Nov -19 |
US20190352
608 |
CD137
ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION |
Not
Available |
16- Sep- 13 |
30- Jan -19 |
21- Nov -19 |
US20190352
357 |
HELIX-GRAFTED
PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS |
Colorado
State University Research Foundation |
7- Nov-
14 |
7- Aug -19 |
21- Nov -19 |
US20190346
443 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
28- Jun -19 |
14- Nov -19 |
US20190345
504 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
CureVac
AG |
30- Dec- 14 |
26- Jul- 19 |
14- Nov -19 |
US20190345
503 |
CIRCULAR
RNAS AND THEIR USE IN IMMUNOMODULATION |
Not
Available |
20- Jun- 16 |
15- Jun -17 |
14- Nov -19 |
US20190345
481 |
PURIFICATION
OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDES |
Not
Available |
14- Jul-15 |
5- Jul- 19 |
14- Nov -19 |
US20190345
221 |
BROAD
SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOF |
Tianjin
Dongya Biological Technology Co., Ltd. |
9- May-
18 |
9- May -18 |
14- Nov -19 |
US20190345
166 |
COMPOUNDS
AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS |
Not
Available |
1- May-
14 |
24- Jul- 19 |
14- Nov -19 |
US20190343
862 |
DELIVERY
OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
6-Jul- 10 |
16- Jul- 19 |
14- Nov -19 |
US20190337
990 |
POLYPEPTIDES
FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY |
Not
Available |
13- Feb- 15 |
5- Jun -19 |
7- Nov -19 |
US20190336
969 |
PARALLELIZED
SAMPLE HANDLING |
Not
Available |
19- Apr- 13 |
27- Mar -19 |
7- Nov -19 |
US20190336
611 |
HYBRID
CARRIERS FOR NUCLEIC ACID CARGO |
CureVac
AG |
9- Jun-
16 |
9- Jun -17 |
7- Nov -19 |
US20190336
608 |
CATIONIC
CARRIERS FOR NUCLEIC ACID DELIVERY |
CureVac
AG |
9- Jun-
16 |
9- Jun -17 |
7- Nov -19 |
US20190336
597 |
METHODS
OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES |
Not
Available |
8- Jan- 13 |
17- May -19 |
7- Nov -19 |
US20190336
456 |
USE OF
XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS |
ABIOGEN
PHARMA S.P.A. |
15- Jul-16 |
13- Jul- 17 |
7- Nov -19 |
US20190330
618 |
ENZYMATIC
ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES |
Not
Available |
1- Dec-
05 |
22- Jan -19 |
31- Oct- 19 |
US20190330
572 |
CLEANING
COMPOSITION, METHOD OF MAKING AND USE THEREOF |
Not
Available |
8- Sep-
16 |
21- Jun -19 |
31- Oct- 19 |
US20190330
245 |
Boron-Containing
Small Molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
12- Jul- 19 |
31- Oct- 19 |
US20190330
187 |
Chemical
Compounds |
Not
Available |
18- Mar- 14 |
10- May -19 |
31- Oct- 19 |
US20190330
164 |
HYDRAZIDE
CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
29- Jul-11 |
28- Nov -18 |
31- Oct- 19 |
US20190330
149 |
CONJUGATES
OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Jul-12 |
9- May -19 |
31- Oct- 19 |
US20190328
869 |
IMMUNOTHERAPEUTIC
PRODUCT AND MDSC MODULATOR COMBINATION THERAPY |
Transgene
SA |
10- Oct- 16 |
10- Oct -17 |
31- Oct- 19 |
US20190328
865 |
IMMUNOGENIC
COMPOSITION FOR MERS CORONAVIRUS INFECTION |
Not
Available |
28- Jul-14 |
17- Nov -17 |
31- Oct- 19 |
US20190328
804 |
AAV
Vectors Targeted to Oligodendrocytes |
Not
Available |
28- Sep- 12 |
15- Jul- 19 |
31- Oct- 19 |
US20190323
068 |
PCR Ready
Compositions and Methods for Screening Biological Samples |
Longhorn
Vaccines and Diagnostics, LLC |
12- Sep- 06 |
28- Jun -19 |
24- Oct- 19 |
US20190322
989 |
PRODUCTION
OF VIRUSES IN CELL CULTURE |
Not
Available |
24- Nov- 15 |
25- Jan -19 |
24- Oct- 19 |
US20190322
725 |
COMPOSITIONS
COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF |
Not
Available |
13- May- 14 |
2- Jul- 19 |
24- Oct- 19 |
US20190321
481 |
IMMUNOMODULATORY
COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING
CYTOKINE STORMS |
NantBio,
Inc. |
11- Nov- 16 |
9- Nov -17 |
24- Oct- 19 |
US20190321
403 |
ENGINEERED
B CELLS AND RELATED COMPOSITIONS AND METHODS |
Juno
Therapeutics, Inc. |
2- Dec-
16 |
30- Nov -17 |
24- Oct- 19 |
US20190316
109 |
COMPOSITION
COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE SENESCENT
CELLS |
Not
Available |
17- Apr- 12 |
10- Jun -19 |
17- Oct- 19 |
US20190316
091 |
ERYTHROID
CELLS COMPRISING ARGINASE |
Not
Available |
18- Nov- 13 |
30- May -19 |
17- Oct- 19 |
US20190316
090 |
ERYTHROID
CELLS COMPRISING ARGININE DEIMINASE |
RUBIUS
THERAPEUTICS, INC. |
18- Nov- 13 |
30- May -19 |
17- Oct- 19 |
US20190316
089 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
10- May -19 |
17- Oct- 19 |
US20190315
840 |
ANTI-DENGUE
VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF
USE |
Not
Available |
16- Sep- 16 |
10- Jun -19 |
17- Oct- 19 |
US20190315
807 |
VIRUS-LIKE
PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIES |
Not
Available |
27- Jul-16 |
26- Jul- 17 |
17- Oct- 19 |
US20190314
496 |
POLYMERIC
CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT |
CureVac
AG |
1- Apr-
14 |
18- Jun -19 |
17- Oct- 19 |
US20190314
483 |
Vaccines
Including Antigen From Four Strains of Influenza Virus |
Not
Available |
6- Dec-
06 |
30- Nov -18 |
17- Oct- 19 |
US20190314
482 |
VACCINES
AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES |
Medigen,
Inc. |
28- Nov- 16 |
21- Nov -17 |
17- Oct- 19 |
US20190314
480 |
IMMUNOGENIC
COMPOSITIONS AND USES THEREOF |
Not
Available |
25- Mar- 15 |
23- Apr -19 |
17- Oct- 19 |
US20190314
471 |
MOLECULAR
VACCINES FOR INFECTIOUS DISEASE |
Not
Available |
2- Oct-
08 |
27- Jun -19 |
17- Oct- 19 |
US20190314
455 |
CYTOKINE CONJUGATES
FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
Not
Available |
3- Aug-
17 |
7- Jun -19 |
17- Oct- 19 |
US20190314
372 |
PYRIMIDINE
COMPOUNDS CONTAINING ACIDIC GROUPS |
Not
Available |
5- Dec-
16 |
25- Mar -19 |
17- Oct- 19 |
US20190310
168 |
AIRBORNE
AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS |
Not
Available |
22- Jul-14 |
4- Mar -19 |
10- Oct- 19 |
US20190309
357 |
CRISPR
EFFECTOR SYSTEM BASED DIAGNOSTICS |
MASSACHUSETTS
INSTITUTE OF TECHNOLOGY |
9- Dec-
16 |
25- Feb -19 |
10- Oct- 19 |
US20190309
262 |
ERYTHROID
CELLS COMPRISING SERINE DEHYDRATASE |
Not
Available |
18- Nov- 13 |
4- Jun -19 |
10- Oct- 19 |
US20190309
261 |
ERYTHROID
CELLS COMPRISING LYSINE OXIDASE |
Not
Available |
18- Nov- 13 |
4- Jun -19 |
10- Oct- 19 |
US20190309
048 |
Optimized
Human Clotting Factor VIII Gene Expression Cassettes and Their Use |
Not
Available |
6- Feb-
15 |
20- May -19 |
10- Oct- 19 |
US20190309
039 |
CRYPTIC
POLYPEPTIDES AND USES THEREOF |
Not
Available |
29- Jan- 15 |
22- Apr -19 |
10- Oct- 19 |
US20190308
980 |
PYRROLOTRIAZINONES
AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
24- Jun -19 |
10- Oct- 19 |
US20190308
969 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
Not
Available |
11- Nov- 16 |
13- Nov -17 |
10- Oct- 19 |
US20190308
943 |
3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2- CARBOXAMIDE COMPOUNDS |
Parion
Sciences, Inc. |
17- Dec- 12 |
13- Mar -19 |
10- Oct- 19 |
US20190307
878 |
IMMUNE
COMPLEX |
The
Rockefeller University |
20- Mar- 15 |
10- May -19 |
10- Oct- 19 |
US20190307
722 |
ANTIVIRAL
COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES |
Not
Available |
21- Oct- 16 |
20- Oct -17 |
10- Oct- 19 |
US20190298
824 |
ALBUMIN-BINDING
IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF |
THE
UNITED STATES OF AMERICA, as represented by the Secretary, Department of
Health and Human Serv |
4- May-
16 |
4- May -17 |
3- Oct-
19 |
US20190298
752 |
METHODS
FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) |
Invirsa,
Inc. |
27- Mar- 18 |
26- Mar -19 |
3- Oct-
19 |
US20190298
750 |
Nucleotide
and Nucleoside Therapeutic Compositions and Uses Related Thereto |
Not
Available |
11- Sep- 13 |
21- Nov -18 |
3- Oct-
19 |
US20190293
656 |
NON-RADIOACTIVE
CYTOTOXICITY ASSAYS |
Not
Available |
19- Sep- 16 |
19- Sep -17 |
26- Sep -19 |
US20190292
580 |
DNA
LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR BIOCHEMICAL SENSING |
Rutgers,
The State University of New Jersey |
23- Mar- 18 |
22- Mar -19 |
26- Sep -19 |
US20190292
563 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
The
Trustees of the University of Pennsylvania |
17- Dec- 01 |
8- Apr -19 |
26- Sep -19 |
US20190292
561 |
SCALABLE
METHODS FOR PRODUCING RECOMBINANT ADENO- ASSOCIATED VIRAL (AAV) VECTOR IN
SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE |
SPARK
THERAPEUTICS, INC. |
1- Dec- 15 |
1- Dec -16 |
26- Sep -19 |
US20190292
236 |
MODULATION
OF IFI16 AND STING ACTIVITY |
Not
Available |
9- Aug-
16 |
9- Aug -17 |
26- Sep -19 |
US20190292
216 |
Cyclic
Di-Nucleotide Induction of Type I Interferon |
Not
Available |
3- May-
13 |
19- Feb -19 |
26- Sep -19 |
US20190292
178 |
HOST
TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES |
Dana-Farber
Cancer Institute, Inc. |
11- Apr- 12 |
26- Jan -18 |
26- Sep -19 |
US20190290
674 |
Composition
for Promoting Production of Immunostimulatory Factor |
Kyoto
University |
2- Aug-
16 |
31- Jul- 17 |
26- Sep -19 |
US20190285
632 |
METABALOMICS
AND VIRAL DIAGNOSTICS SUITE |
Excision
Biotherapeutics, Inc. |
24- May- 16 |
24- May -17 |
19- Sep -19 |
US20190284
575 |
REVERSE
GENETICS USING NON-ENDOGENOUS POL I PROMOTERS |
Not
Available |
21- May- 09 |
30- Jan -19 |
19- Sep -19 |
US20190284
531 |
DETECTION
OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOF |
Not
Available |
15- May- 15 |
24- May -19 |
19- Sep -19 |
US20190284
230 |
ASSEMBLED
GLYCOPROTEINS |
Not
Available |
29- Sep- 16 |
22- Sep -17 |
19- Sep -19 |
US20190282
694 |
IMMUNOPROTECTIVE
PRIMARY MESENCHYMAL STEM CELLS AND METHODS |
AUTOIMMUNE
TECHNOLOGIES, LLC |
14- Mar- 13 |
30- May -19 |
19- Sep -19 |
US20190282
608 |
Method
Of Treating Inflammation |
Not
Available |
1- Apr-
10 |
29- May -19 |
19- Sep -19 |
US20190276
523 |
COMPOSITION
AND METHODS OF TREATING B CELL DISORDERS |
Not
Available |
2- Sep-
16 |
5- Sep -17 |
12- Sep -19 |
US20190275
519 |
SYSTEM
FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS |
Not
Available |
8- Nov-
16 |
8- Nov -17 |
12- Sep -19 |
US20190275
101 |
STRUCTURE
OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROAD- SPECTRUM PROTEASE INHIBITORS |
Not
Available |
5- Oct-
16 |
5- Oct -17 |
12- Sep -19 |
US20190269
694 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
Not
Available |
8- Mar-
11 |
11- Oct -18 |
5- Sep -19 |
US20190269
672 |
Specific
Akt3 Inhibitor and Uses Thereof |
Not
Available |
15- Jan- 16 |
20- May -19 |
5- Sep -19 |
US20190264
267 |
PHASING |
Wave
Life Sciences Ltd. |
25- Jul-16 |
24- Jul- 17 |
29- Aug -19 |
US20190264
177 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
10- May -19 |
29- Aug -19 |
US20190263
934 |
FC
VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFE |
Not
Available |
26- Jan- 18 |
25- Jan -19 |
29- Aug -19 |
US20190262
448 |
Cationic
Oil-In-Water Emulsions |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
18- Sep- 11 |
7- Mar -19 |
29- Aug -19 |
US20190262
371 |
METHODS
AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS |
Not
Available |
20- Oct- 16 |
20- Oct -17 |
29- Aug -19 |
US20190256
585 |
ANTIBODY
SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT
BINDING TO THE PEPTIDE |
Not
Available |
10- Jun- 15 |
10- Jun -16 |
22- Aug -19 |
US20190256
579 |
MIDDLE
EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE |
The
U.S.A., as represented by the Secretary, Department of Health and Human
Services |
24- Feb- 15 |
3- May -19 |
22- Aug -19 |
US20190255
085 |
METHODS
FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS |
Not
Available |
16- Sep- 15 |
1- Feb -19 |
22- Aug -19 |
US20190254
968 |
OIL-IN-WATER
EMULSIONS THAT CONTAIN NUCLEIC ACIDS |
GLAXOSMITHKLINE
BIOLOGICALS S.A. |
6-Jul- 11 |
2- May -19 |
22- Aug -19 |
US20190250
153 |
MULTI-CONFIGURABLE
SENSING ARRAY AND METHODS OF USING SAME |
Board
of Regents, The University of Texas System |
20- Oct- 16 |
19- Oct -17 |
15- Aug -19 |
US20190248
883 |
HUMAN
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) |
Not
Available |
16- Dec- 02 |
20- Feb -19 |
15- Aug -19 |
US20190248
866 |
POLYPEPTIDES
AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION |
Not
Available |
30- Jun- 11 |
30- Apr -18 |
15- Aug -19 |
US20190248
865 |
ANTIBODY/T-CELL
RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF |
Not
Available |
23- Oct- 15 |
21- Oct -16 |
15- Aug -19 |
US20190247
529 |
METHOD
AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES |
Not
Available |
29- Dec- 17 |
23- Apr -19 |
15- Aug -19 |
US20190247
489 |
ADJUVANTED
INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING |
Not
Available |
20- Oct- 11 |
16- Nov -18 |
15- Aug -19 |
US20190247
485 |
Dimethyl
Fumarate and Vaccination Regimens |
Biogen
MA Inc. |
14- Mar- 14 |
23- Apr -19 |
15- Aug -19 |
US20190247
440 |
METHODS
AND COMPOSITIONS FOR IMMUNOMODULATION |
Not
Available |
1- Apr-
14 |
12- Apr -19 |
15- Aug -19 |
US20190247
367 |
TREATMENT
OF INFECTIOUS DISEASES |
CHILDREN'S
MEDICAL CENTER CORPORATION |
26- Jan- 15 |
23- Apr -19 |
15- Aug -19 |
US20190241
646 |
ANTI-PNEUMOCOCCAL
HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL
INFECTION |
Not
Available |
15- Mar- 17 |
15- Apr -19 |
8- Aug -19 |
US20190241
618 |
INHIBITION
OF TCR SIGNALING WITH PEPTIDE VARIANTS |
Not
Available |
30- Sep- 09 |
22- Oct -18 |
8- Aug -19 |
US20190240
317 |
HPIV3
RNA VACCINES |
ModernaTX,
Inc. |
22- Oct- 15 |
28- Mar -19 |
8- Aug -19 |
US20190233
447 |
PROTEIN
PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED
HAPTENS |
Not
Available |
28- Aug- 15 |
25- Feb -19 |
1- Aug -19 |
US20190232
282 |
METHODS
AND COMPOSITIONS FOR DETECTING ANALYTES |
Not
Available |
23- Sep- 16 |
20- Sep -17 |
1- Aug -19 |
c |
MASK |
NBC
MESHTEC INC. |
17- Oct- 16 |
13- Oct -17 |
1- Aug -19 |
US20190225
986 |
GENE
TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR
PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN |
Not
Available |
28- Oct- 05 |
30- Nov -18 |
25- Jul- 19 |
US20190225
971 |
METHOD OF
INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE |
Not
Available |
10- Aug- 15 |
4- Aug -16 |
25- Jul- 19 |
US20190224
339 |
COMPOSITIONS
FOR THE TREATMENT OF DISEASE |
Not
Available |
29- Apr- 16 |
28- Apr -17 |
25- Jul- 19 |
US20190223
445 |
ANTIMICROBIAL
GEOPOLYMER COMPOSITIONS |
Not
Available |
14- Jul-16 |
13- Jul- 17 |
25- Jul- 19 |
US20190220
524 |
DETERMINING
EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHS |
Not
Available |
16- Jan- 18 |
29- Mar -18 |
18- Jul- 19 |
US20190219
563 |
Assay
for Detecting TH1 and TH2 Cell Populations |
Not
Available |
16- May- 14 |
17- Dec -18 |
18- Jul- 19 |
US20190218
574 |
METHOD
OF INCREASING THE FUNCTION OF AN AAV VECTOR |
The
Trustees of the University of Pennsylvania |
2- Oct-
07 |
28- Mar -19 |
18- Jul- 19 |
US20190218
277 |
ANTI-DENGUE
VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF
USE |
Not
Available |
16- Sep- 16 |
15- Sep -17 |
18- Jul- 19 |
US20190218
207 |
3-(Pyridin-3-yl)-Acrylamide
and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators |
Not
Available |
17- Aug- 15 |
17- Aug -16 |
18- Jul- 19 |
US20190216
951 |
METHOD
FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS |
CureVac
AG |
21- Aug- 13 |
1- Apr -19 |
18- Jul- 19 |
US20190216
917 |
HMPV
RNA VACCINES |
ModernaTX,
Inc. |
22- Oct- 15 |
28- Mar -19 |
18- Jul- 19 |
US20190216
915 |
TRANSGENIC
VERO-CD4/CCR5 CELL LINE |
Not
Available |
2- Oct-
15 |
15- Feb -19 |
18- Jul- 19 |
US20190216
841 |
Regimens
and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens |
Not
Available |
20- Apr- 11 |
20- Mar -19 |
18- Jul- 19 |
US20190211
361 |
COMPOSITIONS
COMPRISING CURONS AND USES THEREOF |
Not
Available |
13- Jun- 17 |
27- Mar -19 |
11- Jul- 19 |
US20190211
355 |
DNA
MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED
RNA VIRUSES AND USES THERE OF |
Not
Available |
5- Jan- 15 |
4- Jan -16 |
11- Jul- 19 |
US20190211
024 |
SMALL
MOLECULES HAVING ANTIVIRAL PROPERTIES |
General
Research Laboratory |
19- Aug- 16 |
19- Aug -17 |
11- Jul- 19 |
US20190209
678 |
MANUFACTURE
OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY |
Not
Available |
2- Dec-
14 |
12- Mar -19 |
11- Jul- 19 |
US20190209
604 |
OLIGONUCLEOTIDES,
COMPOSITIONS AND METHODS THEREOF |
WAVE
LIFE SCIENCES LTD. |
3- Jun-
16 |
2- Jun -17 |
11- Jul- 19 |
US20190207
890 |
RNA
TARGETING METHODS AND COMPOSITIONS |
Salk
Institute for Biological Studies |
22- Aug- 17 |
31- Dec -18 |
4- Jul- 19 |
US20190204
330 |
APPLICATION
OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS |
Not
Available |
28- Jun- 16 |
19- Dec -18 |
4- Jul- 19 |
US20190203
268 |
LOOP-MEDIATED
ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROBES |
Not
Available |
2- Jan- 18 |
31- Dec -18 |
4- Jul- 19 |
US20190203
186 |
PRODUCTION
OF VIRUSES IN AVIAN EGGS |
Not
Available |
24- Nov- 15 |
25- Jan -19 |
4- Jul- 19 |
US20190203
170 |
Avian
Cells for Improved Virus Production |
Not
Available |
5- Jun-
13 |
21- Dec -18 |
4- Jul- 19 |
US20190202
929 |
COMPOSITIONS
AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML
USING USP10 BIOMARKERS AND MODULATORS |
Not
Available |
20- Sep- 16 |
20- Sep -17 |
4- Jul- 19 |
US20190202
868 |
CORONAVIRUS
PROTEINS AND ANTIGENS |
Phibro
Animal Health Corporation |
7- Feb-
14 |
15- Mar -19 |
4- Jul- 19 |
US20190202
854 |
ENANTIOMERS
OF THE 1',6'-ISOMER OF NEPLANOCIN A |
Not
Available |
4- Aug-
14 |
8- Mar -19 |
4- Jul- 19 |
US20190201
565 |
DECONTAMINATION
DEVICE AND METHOD USING ULTRASONIC CAVITATION |
Not
Available |
29- Dec- 17 |
11- Sep -18 |
4- Jul- 19 |
US20190201
564 |
DECONTAMINATION
DEVICE AND METHOD USING ULTRASONIC CAVITATION |
Not
Available |
29- Dec- 17 |
29- Dec -17 |
4- Jul- 19 |
US20190201
552 |
Aptamer
Compositions and Methods of Use Thereof |
Not
Available |
28- Dec- 17 |
28- Dec -18 |
4- Jul- 19 |
US20190201
433 |
2'-SUBSTITUTED-N6-SUBSTITUTED
PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT |
Atea
Pharmaceuticals, Inc. |
7- Sep-
16 |
5- Mar -19 |
4- Jul- 19 |
US20190201
352 |
DESIGN,
SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS
ACTIVITY |
Not
Available |
30- Jan- 15 |
12- Mar -19 |
4- Jul- 19 |
US20190201
337 |
HYDROPHILIC
FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS |
Not
Available |
3- Dec-
09 |
3- Jan -19 |
4- Jul- 19 |
US20190194
728 |
Systemic
inflammatory and pathogen biomarkers and uses therefor |
Not
Available |
24- Aug- 16 |
24- Aug -17 |
27- Jun- 19 |
US20190194
717 |
METHOD
AND KIT FOR DETECTING PATHOGENIC MICROORGANISM |
JAPAN
SCIENCE AND TECHNOLOGY AGENCY |
5- Sep-
16 |
4- Sep -17 |
27- Jun- 19 |
US20190194
628 |
METHODS
FOR PRODUCING VIRUS FOR VACCINE PRODUCTION |
Takeda
Pharmaceutical Company Limited |
1- Sep-
16 |
1- Sep -17 |
27- Jun- 19 |
US20190194
322 |
IDENTIFICATION
OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY |
BIO-TECHNE
CORPORATION |
3- Aug-
16 |
3- Aug -17 |
27- Jun- 19 |
US20190194
299 |
MIDDLE
EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF
USE THEREOF |
Not
Available |
25- Apr- 14 |
19- Nov -18 |
27- Jun- 19 |
US20190194
226 |
FUSED [1,2]IMIDAZO[4,5-C]
RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS |
Not
Available |
26- Aug- 16 |
1- Aug -17 |
27- Jun- 19 |
US20190194
150 |
COMPOUNDS
AND METHODS FOR MODULATING RNA FUNCTION |
Arrakis
Therapeutics, Inc. |
1-Jul- 16 |
30- Jun -17 |
27- Jun- 19 |
US20190192
691 |
REGULATED
BIOCIRCUIT SYSTEMS |
Not
Available |
11- Apr- 16 |
11- Apr -17 |
27- Jun- 19 |
US20190192
581 |
Methods
of Populating a Gastrointestinal Tract |
Not
Available |
4- Feb-
13 |
1- Aug -18 |
27- Jun- 19 |
US20190187
151 |
ASSAY FOR
QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPE STANDARDS |
UVic
Industry Partnerships Inc. |
6- Jun-
16 |
7- Apr -17 |
20- Jun- 19 |
US20190187
130 |
COLORS
FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI- DYE QUINONE METHIDE AND
TYRAMIDE CONJUGATES |
Not
Available |
28- Jun- 16 |
19- Dec -18 |
20- Jun- 19 |
US20190185
922 |
LUMINOPHORE-LABELED
MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS |
CapitalBio
Corporation |
5- Dec-
13 |
20- Nov -18 |
20- Jun- 19 |
US20190185
832 |
DIET CONTROLLED
EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOF |
Not
Available |
3- Jun-
16 |
2- Jun -17 |
20- Jun- 19 |
US20190184
067 |
MODIFIED
ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS |
Not
Available |
1- Nov-
15 |
28- Feb -19 |
20- Jun- 19 |
US20190184
018 |
CARBOHYDRATE
CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES |
Not
Available |
4- Dec-
07 |
20- Nov -18 |
20- Jun- 19 |
US20190183
968 |
METHODS
AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO
CXCR4 CELLS |
Not
Available |
13- Jan- 11 |
27- Feb -19 |
20- Jun- 19 |
US20190183
918 |
SYSTEMIC
IN VIVO DELIVERY OF OLIGONUCLEOTIDES |
Not
Available |
12- Jun- 13 |
29- Oct -18 |
20- Jun- 19 |
US20190177
739 |
RECOMBINANT
INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS |
Not
Available |
21- Jan- 08 |
13- Dec -18 |
13- Jun- 19 |
US20190175
716 |
Adenoviral
Vector |
Not
Available |
23- Jun- 16 |
23- Jun -17 |
13- Jun- 19 |
US20190175
528 |
INHIBITION
OF BIOFILM ORGANISMS |
Not
Available |
31- Mar- 09 |
13- Feb -19 |
13- Jun- 19 |
US20190169
677 |
PORTABLE
MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSES |
Click
Diagnostics, Inc. |
9- Nov-
17 |
9- Nov -18 |
6- Jun-
19 |
US20190169
639 |
CRISPR-RELATED
METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
EDITAS
MEDICINE, INC. |
7- Nov-
13 |
24- Jan -19 |
6- Jun-
19 |
US20190169
595 |
RNA
TARGETING METHODS AND COMPOSITIONS |
Salk
Institute for Biological Studies |
22- Aug- 17 |
25- Jan -19 |
6- Jun-
19 |
US20190167
787 |
Methods
and Compositions for Inhibiting Akt3 |
Not
Available |
15- Jan- 16 |
6- Feb -19 |
6- Jun-
19 |
US20190167
786 |
EMULSIONS
WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES |
Not
Available |
4- Nov-
05 |
9- Jul- 18 |
6- Jun-
19 |
US20190167
636 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED
2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES
INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
8- Feb -19 |
6- Jun- 19 |
US20190166
866 |
METHOD
FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCH |
Not
Available |
4- Dec-
17 |
30- Nov -18 |
6- Jun-
19 |
US20190160
129 |
Novel
Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating
Agents |
Not
Available |
1- Oct-
15 |
1- Feb -19 |
30- May -19 |
US20190160
063 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
31- Dec- 15 |
30- Dec -16 |
30- May -19 |
US20190154
687 |
DETECTION
DEVICE AND DETECTION METHOD |
Kabushiki
Kaisha Toshiba |
17- Nov- 17 |
7- Mar -18 |
23- May -19 |
US20190154
550 |
BIOAEROSOL
DETECTION SYSTEMS AND METHODS OF USE |
Not
Available |
6- Apr-
16 |
6- Apr -17 |
23- May -19 |
US20190153
471 |
COMPOSITIONS
FOR THE TREATMENT OF DISEASE |
Not
Available |
29- Apr- 16 |
28- Apr -17 |
23- May -19 |
US20190153
086 |
Heterodimeric
Immunoglobulins |
Not
Available |
21- Nov- 12 |
5- Feb -19 |
23- May -19 |
US20190151
844 |
DEVICES
AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL |
Click
Diagnostics, Inc. |
29- Jun- 16 |
21- Dec -18 |
23- May -19 |
US20190151
474 |
RNA-BASED
LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES |
Kyoto
University |
8- Sep-
14 |
8- Sep -15 |
23- May -19 |
US20190144
930 |
ENHANCED
METHODS OF RIBONUCLEIC ACID HYBRIDIZATION |
Not
Available |
6- Dec-
13 |
9- Jan -19 |
16- May -19 |
US20190144
929 |
DEVICES
FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS |
Not
Available |
15- Mar- 17 |
15- Mar -18 |
16- May -19 |
US20190144
827 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
RUBIUS
THERAPEUTICS, INC. |
18- Nov- 13 |
19- Nov -18 |
16- May -19 |
US20190144
556 |
ANTAGONISTIC
ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES |
Not
Available |
13- May- 16 |
12- May -17 |
16- May -19 |
US20190144
484 |
ALKYNE
CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES
RELATED THERETO |
Not
Available |
28- Apr- 16 |
28- Apr -17 |
16- May -19 |
US20190142
929 |
INFLUENZA
VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINS |
Not
Available |
10- Feb- 09 |
15- Oct -18 |
16- May -19 |
US20190142
927 |
LOW-ADDITIVE
INFLUENZA VACCINES |
Not
Available |
27- Jun- 07 |
26- Jun -18 |
16- May -19 |
US20190136
226 |
DEVICES
AND METHODS FOR NUCLEIC ACID EXTRACTION |
Not
Available |
11- May- 16 |
9- Nov -18 |
9- May -19 |
US20190136
215 |
Replication
Conditional Virus that Specifically Kills Senescent Cells |
Not
Available |
17- Apr- 12 |
6- Jul- 18 |
9- May -19 |
US20190135
875 |
TRI-SEGMENTED
PICHINDE VIRUSES AS VACCINE VECTORS |
Not
Available |
18- May- 16 |
17- May -17 |
9- May -19 |
US20190135
873 |
COMPOSITIONS
AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE |
Not
Available |
19- Dec- 16 |
19- Dec -18 |
9- May -19 |
US20190135
788 |
DIHYDROPYRIMIDINYL
BENZAZEPINE CARBOXAMIDE COMPOUNDS |
Hoffmann-La
Roche Inc. |
12- Jun- 16 |
7- Dec -18 |
9- May -19 |
US20190134
214 |
GLP-1
Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof |
Not
Available |
6- May-
16 |
4- May -17 |
9- May -19 |
US20190134
193 |
USE OF
TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS
IMMUNOSUPPRESSORS |
SALK
INSTITUTE FOR BIOLOGICAL STUDIES |
9- Nov-
07 |
9- Aug -18 |
9- May -19 |
US20190134
186 |
INFLUENZA
VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT |
Not
Available |
4- Nov-
05 |
10- Jul- 18 |
9- May -19 |
US20190134
062 |
PHARMACEUTICAL
COMPOSITIONS AND METHODS |
Not
Available |
3- Aug-
15 |
8- Jan -19 |
9- May -19 |
US20190128
893 |
QUINONE
METHIDE ANALOG SIGNAL AMPLIFICATION |
Not
Available |
24- Feb- 14 |
7- Nov -18 |
2- May -19 |
US20190128
810 |
SYSTEM
FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCE |
Not
Available |
31- Dec- 15 |
13- Dec -18 |
2- May -19 |
US20190127
441 |
METHODS
AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY |
University
of Vermont and State Agricultural College |
13- Apr- 16 |
13- Apr -17 |
2- May -19 |
US20190127
405 |
QUINONE
METHIDE ANALOG SIGNAL AMPLIFICATION |
Not
Available |
24- Feb- 14 |
7- Nov -18 |
2- May -19 |
US20190127
401 |
CHARGED
LINKERS AND THEIR USES FOR CONJUGATION |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Aug- 16 |
20- Dec -18 |
2- May -19 |
US20190127
400 |
CHARGED
LINKERS AND THEIR USES FOR CONJUGATION |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Aug- 16 |
20- Dec -18 |
2- May -19 |
US20190127
399 |
CHARGED
LINKERS AND THEIR USES FOR CONJUGATION |
HANGZHOU
DAC BIOTECH CO., LTD. |
12- Aug- 16 |
20- Dec -18 |
2- May -19 |
US20190125
858 |
COLD
ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE FOR MUCOSAL
DELIVERY |
Not
Available |
18- Apr- 16 |
18- Apr -17 |
2- May -19 |
US20190125
806 |
Antimicrobial
and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for
Producing Antimicrobial and Antiviral Agent |
Murata
Manufacturing Co., Ltd. |
13- Jun- 16 |
13- Dec -18 |
2- May -19 |
US20190125
724 |
PREVENTION
AND TREATMENT OF VIRAL INFECTIONS |
Not
Available |
2- Jun-
16 |
27- Nov -18 |
2- May -19 |
US20190119
744 |
CAPTURE
PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC
TESTS |
Not
Available |
31- Jul-09 |
5- Nov -18 |
25- Apr- 19 |
US20190119
743 |
COMPOSITIONS
AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS |
Not
Available |
15- Aug- 16 |
26- Oct -18 |
25- Apr- 19 |
US20190119
701 |
METHODS
FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF |
Not
Available |
8- Sep-
17 |
7- Sep -18 |
25- Apr- 19 |
US20190119
266 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
24- Oct -18 |
25- Apr- 19 |
US20190119
220 |
CARBOXYLIC
ACID COMPOUNDS |
Sumitomo
Dainippon Pharma Co., Ltd. |
18- May- 12 |
23- Oct -18 |
25- Apr- 19 |
US20190117
793 |
MODULAR
NANODEVICES FOR SMART ADAPTABLE VACCINES |
Not
Available |
15- Feb- 07 |
1- Oct -18 |
25- Apr- 19 |
US20190117
702 |
USE
OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS |
Indiana
University Research and Technology Corporation |
6- May-
14 |
31- Oct -18 |
25- Apr- 19 |
US20190112
596 |
TAL-EFFECTOR
ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS |
Not
Available |
4- Apr-
12 |
12- Apr -18 |
18- Apr- 19 |
US20190112
394 |
USING
SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION |
Whitehead
Institute for Biomedical Research |
28- Jun- 11 |
24- Sep -18 |
18- Apr- 19 |
US20190111
141 |
A
PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE |
Ewha
University - Industry Collaboration Foundation |
6- Apr-
16 |
6- Apr -17 |
18- Apr- 19 |
US20190105
653 |
PORTABLE
PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENS |
Not
Available |
5- Oct-
17 |
5- Oct -18 |
11- Apr- 19 |
US20190105
381 |
METHOD
FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID
PARTICLES FOR TREATING CANCER |
Not
Available |
16- Mar- 16 |
16- Mar -16 |
11- Apr- 19 |
US20190105
334 |
Anti-Viral
Azide Containing Compounds |
Not
Available |
28- Jul-10 |
3- Dec -18 |
11- Apr- 19 |
US20190100
586 |
Humanized
Anti-Claudin-1 Antibodies and Uses Thereof |
Chu
Strasbourg, Les Hôpitaux Universitaires de Strasbourg |
22- Mar- 16 |
21- Mar -17 |
4- Apr-
19 |
US20190099
493 |
Targeting
Lipids |
Arbutus
Biopharma Corporation |
4- Dec-
07 |
10- Oct -17 |
4- Apr-
19 |
US20190099
479 |
RECOMBINANT
HCMV AND RHCMV VECTORS AND USES THEREOF |
Not
Available |
14- May- 10 |
27- Apr -18 |
4- Apr-
19 |
US20190094
224 |
METHODS
AND COMPOSITIONS FOR DETECTING SINGLE T CELL RECEPTOR AFFINITY AND SEQUENCE |
Not
Available |
11- Apr- 16 |
6- Apr -17 |
28- Mar -19 |
US20190091
329 |
CATIONIC
OIL-IN-WATER EMULSIONS |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
6-Jul- 11 |
6- Dec -18 |
28- Mar -19 |
US20190091
221 |
METHODS
AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS |
TRUSTEES
OF BOSTON UNIVERSITY |
11- Mar- 10 |
23- Apr -18 |
28- Mar -19 |
US20190085
057 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
15- Nov -18 |
21- Mar -19 |
US20190085
024 |
Alpha-Ketoamide
Inhibitors Of Cysteine Proteases |
Not
Available |
15- Sep- 17 |
17- Sep -18 |
21- Mar -19 |
US20190085
013 |
NUCLEOTIDE
AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO |
Not
Available |
7- Mar-
16 |
7- Mar -17 |
21- Mar -19 |
US20190084
943 |
CHLORO-PYRAZINE
CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY |
Parion
Sciences, Inc. |
17- Dec- 12 |
23- Aug -18 |
21- Mar -19 |
US20190083
602 |
METHOD
FOR PRODUCING RNA MOLECULE COMPOSITIONS |
Not
Available |
22- Dec- 15 |
22- Dec -16 |
21- Mar -19 |
US20190083
592 |
IMMUNOSTIMULATORY
COMBINATIONS |
Not
Available |
30- Dec- 02 |
22- Oct -18 |
21- Mar -19 |
US20190083
569 |
MICROBICIDAL
COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS |
Not
Available |
11- Jun- 15 |
24- Jul- 18 |
21- Mar -19 |
US20190083
525 |
COMPOSITIONS
COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL
INFECTIONS |
Not
Available |
11- Jul-17 |
10- Jul- 18 |
21- Mar -19 |
US20190083
520 |
N4-Hydroxycytidine
and Derivatives and Anti-Viral Uses Related Thereto |
Not
Available |
10- Mar- 16 |
10- Mar -17 |
21- Mar -19 |
US20190083
408 |
CONTROLLED-RELEASE
PEPTIDE COMPOSITIONS AND USES THEREOF |
Not
Available |
2- Dec-
11 |
4- Dec -18 |
21- Mar -19 |
US20190083
397 |
OIL-IN-WATER
EMULSIONS INCLUDING RETINOIC ACID |
NOVARTIS
AG |
23- Dec- 15 |
21- Dec -16 |
21- Mar -19 |
US20190078
060 |
DECREASING
POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES |
Novartis
AG |
9- Sep-
04 |
8- Nov -18 |
14- Mar -19 |
US20190078
051 |
Animal
Protein-Free Media for Cultivation of Cells |
Baxalta
GmbH |
29- Oct- 04 |
29- Oct -18 |
14- Mar -19 |
US20190077
847 |
AMINO
ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
Ablynx
N.V. |
5- Jun- 08 |
17- Oct -17 |
14- Mar -19 |
US20190077
764 |
BENZAZEPINE
DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION |
Hoffmann-La
Roche Inc. |
23- May- 16 |
13- Nov -18 |
14- Mar -19 |
US20190077
763 |
BENZAZEPINE
DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION |
Hoffmann-La
Roche Inc. |
23- May- 16 |
13- Nov -18 |
14- Mar -19 |
US20190076
520 |
VACCINES
AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING |
Not
Available |
4- Apr-
08 |
11- Sep -18 |
14- Mar -19 |
US20190076
468 |
ENHANCED
IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE |
Not
Available |
11- Sep- 17 |
11- Sep -17 |
14- Mar -19 |
US20190071
423 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190071
422 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190071
421 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190071
420 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190071
419 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190071
418 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
2- Nov -18 |
7- Mar -19 |
US20190062
785 |
MULTIVALENT
VACCINES FOR RABIES VIRUS AND CORONOVIRUSES |
Not
Available |
4- Apr-
16 |
31- Mar -17 |
28- Feb -19 |
US20190062
724 |
RNA
TARGETING METHODS AND COMPOSITIONS |
Salk
Institute for Biological Studies |
22- Aug- 17 |
27- Mar -18 |
28- Feb -19 |
US20190062
713 |
HIGHLY
EFFICIENT INFLUENZA MATRIX (M1) PROTEINS |
Not
Available |
11- Jul-03 |
22- Mar -18 |
28- Feb -19 |
US20190062
408 |
CONSERVED
HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE |
Not
Available |
25- Aug- 08 |
20- Jun -18 |
28- Feb -19 |
US20190062
380 |
FUSION
PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND
METHODS OF MAKING AND USE THEREOF |
Not
Available |
7- Sep- 12 |
28- Aug -18 |
28- Feb -19 |
US20190062
326 |
2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE
DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF
SLEEP-RELATED BREATHING DISORDERS |
BAYER
PHARMA AKTIENGESELLSCHAFT |
10- Dec- 15 |
7- Dec -16 |
28- Feb -19 |
US20190062
323 |
PI-Kinase
Inhibitors with Anti-Infective Activity |
Not
Available |
26- Feb- 16 |
24- Feb -17 |
28- Feb -19 |
US20190060
435 |
PEPTIDE
VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE |
The
United States of America, as represented by the Secretary, Dept of Health and
Human Service |
27- Feb- 16 |
27- Feb -17 |
28- Feb -19 |
US20190060
364 |
INTRACELLULAR
GENOMIC TRANSPLANT AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
6- Nov -18 |
28- Feb -19 |
US20190060
363 |
INTRACELLULAR
GENOMIC TRANSPLANT AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
6- Nov -18 |
28- Feb -19 |
US20190060
262 |
ENHANCED
EXPRESSION OF RNA VECTORS |
UNIVERSITY
COURT OF THE UNIVERSITY OF EDINBURGH |
25- Mar- 13 |
5- Sep -18 |
28- Feb -19 |
US20190060
239 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
17- Oct -18 |
28- Feb -19 |
US20190056
122 |
Clean
Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use Thereof |
Synexis
LLC |
20- Apr- 15 |
20- Apr -16 |
21- Feb -19 |
US20190055
256 |
ANTI-VIRAL
DRUG |
DORING
INTERNATIONAL GMBH |
24- Feb- 16 |
24- Feb -17 |
21- Feb -19 |
US20190055
241 |
GUANIDINE
SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS |
Not
Available |
31- Aug- 15 |
22- Oct -18 |
21- Feb -19 |
US20190055
234 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
24- Oct -18 |
21- Feb -19 |
US20190054
188 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
2- Oct -18 |
21- Feb -19 |
US20190054
127 |
ANTIVIRAL
AGENT AND ANTIVIRAL FOOD |
EDUCATIONAL
CORPORATION MUKOGAWA GAKUIN |
4- Mar-
16 |
22- Nov -16 |
21- Feb -19 |
US20190054
122 |
INTRACELLULAR
GENOMIC TRANSPLANT AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
5- Nov -18 |
21- Feb -19 |
US20190049
378 |
CONTINUOUS
PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS |
Not
Available |
10- Mar- 05 |
21- Jun -18 |
14- Feb -19 |
US20190048
344 |
CHEMICAL
MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION |
Not
Available |
23- Sep- 08 |
16- Aug -18 |
14- Feb -19 |
US20190048
082 |
PSEUDOTYPED
ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES |
Not
Available |
30- Jun- 16 |
25- Oct -18 |
14- Feb -19 |
US20190048
049 |
CARGOMERS |
CERENIS
THERAPEUTICS HOLDING SA |
10- Aug- 17 |
10- Aug -18 |
14- Feb -19 |
US20190048
026 |
Boron-Containing
Small Molecules |
Anacor
Pharmaceuticals, Inc. |
16- Feb- 05 |
18- Oct -18 |
14- Feb -19 |
US20190046
690 |
MATERIALS
WITH IMPROVED PROPERTIES |
Not
Available |
1- Nov-
15 |
2- Nov -16 |
14- Feb -19 |
US20190046
654 |
ALBUMIN
BINDING PEPTIDE CONJUGATES AND METHODS THEREOF |
Not
Available |
9- Aug-
17 |
9- Aug -18 |
14- Feb -19 |
US20190046
635 |
COMPOSITION
FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITION |
NITTO
DENKO CORPORATION |
2- Feb-
16 |
1- Feb -17 |
14- Feb -19 |
US20190040
451 |
FULLY
INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCES |
Not
Available |
8- Jan- 16 |
9- Jan -17 |
7- Feb -19 |
US20190040
378 |
NOVEL
NUCLEIC ACID MOLECULES |
Not
Available |
4-Jul- 17 |
3- Jul- 18 |
7- Feb -19 |
US20190040
370 |
TRACKING
AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 |
Not
Available |
23- Nov- 15 |
3- Aug -18 |
7- Feb -19 |
US20190040
105 |
Method
for Preventing and Treating Hyperpermeability |
Not
Available |
5- Mar-
09 |
19- Oct -18 |
7- Feb -19 |
US20190038
742 |
MESENCHYMAL
STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME |
Longeveron
LLC |
4- Feb-
16 |
2- Feb -17 |
7- Feb -19 |
US20190032
077 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
CureVac
AG |
30- Dec- 13 |
9- Jul- 18 |
31- Jan- 19 |
US20190032
041 |
COMPOSITIONS
FOR AND METHODS OF IDENTIFYING ANTIGENS |
Not
Available |
21- Feb- 06 |
12- Feb -18 |
31- Jan- 19 |
US20190031
740 |
COMPOSITIONS
COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF |
Not
Available |
13- May- 14 |
15- Oct -18 |
31- Jan- 19 |
US20190031
679 |
NOVEL
MONOTHIOL MUCOLYTIC AGENTS |
Not
Available |
30- Jan- 15 |
5- Sep -18 |
31- Jan- 19 |
US20190031
605 |
TETRAHYDRONAPHTHALENE
DERIVATIVE |
ONO
PHARMACEUTICAL CO., LTD. |
29- Jan- 16 |
27- Jan -17 |
31- Jan- 19 |
US20190030
187 |
sirna/Nanoparticle
Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral
Infection |
Sirnaomics,
Inc. |
8- Sep-
15 |
7- Sep -16 |
31- Jan- 19 |
US20190030
094 |
BACTERIAL
STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY DISORDERS |
Not
Available |
27- Jan- 16 |
27- Jan -17 |
31- Jan- 19 |
US20190025
292 |
ANTIGEN
PRESENTING CELL ASSAY |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
25- Sep -18 |
24- Jan- 19 |
US20190024
096 |
PROCESS
FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL |
Not
Available |
7- Aug-
15 |
7- Aug -15 |
24- Jan- 19 |
US20190023
799 |
GITR
Antibodies And Methods Of Inducing Or Enhancing An Immune Response |
Not
Available |
25- Mar- 05 |
28- Jun -18 |
24- Jan- 19 |
US20190023
779 |
METHOD OF
PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY |
Not
Available |
28- Dec- 11 |
5- Oct -18 |
24- Jan- 19 |
US20190023
769 |
COMPOSITIONS
AND METHODS FOR INHIBITING PATHOGEN INFECTION |
Not
Available |
29- Oct- 12 |
21- Sep -18 |
24- Jan- 19 |
US20190022
249 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
2- Oct -18 |
24- Jan- 19 |
US20190022
216 |
ANTIBODY/T-CELL
RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF |
Not
Available |
23- Oct- 15 |
4- Sep -18 |
24- Jan- 19 |
US20190022
214 |
Attenuated
Infectious Bronchitis Virus |
Not
Available |
27- Jan- 16 |
26- Jan -17 |
24- Jan- 19 |
US20190022
213 |
MERS-CoV
Vaccine |
Not
Available |
29- Nov- 13 |
29- Jun -18 |
24- Jan- 19 |
US20190022
116 |
N4-Hydroxycytidine
and Derivatives and Anti-Viral Uses Related Thereto |
Not
Available |
26- Dec- 14 |
16- Dec -15 |
24- Jan- 19 |
US20190017
112 |
METHOD OF
DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTION |
HTG
Molecular Diagnostics, Inc. |
11- Feb- 16 |
10- Feb -17 |
17- Jan- 19 |
US20190017
068 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
17- Dec- 01 |
26- Sep -18 |
17- Jan- 19 |
US20190017
000 |
CLEANING
COMPOSITION, METHOD OF MAKING AND USE THEREOF |
Not
Available |
8- Sep-
16 |
19- Sep -18 |
17- Jan- 19 |
US20190016
785 |
ANTIBODIES
THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF |
Not
Available |
7- Oct-
15 |
7- Oct -16 |
17- Jan- 19 |
US20190016
772 |
GM-CSF
and IL-4 Conjugates, Compositions, and Methods Related Thereto |
Not
Available |
23- Oct- 12 |
2- Oct -18 |
17- Jan- 19 |
US20190016
710 |
MULTICYCLIC
COMPOUNDS AND USES THEREOF |
Not
Available |
31- Dec- 15 |
29- Dec -16 |
17- Jan- 19 |
US20190016
690 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
31- Dec- 15 |
30- Dec -16 |
17- Jan- 19 |
US20190015
527 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
25- Jul- 18 |
17- Jan- 19 |
US20190015
522 |
IMMUNOSTIMULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
5- Apr-
12 |
19- Jul- 18 |
17- Jan- 19 |
US20190015
501 |
NUCLEIC
ACID VACCINES |
ModernaTX,
Inc. |
23- Apr- 14 |
27- Sep -18 |
17- Jan- 19 |
US20190015
432 |
Lipid
Disulfide Prodrugs and Uses Related Thereto |
Not
Available |
13- Jul-17 |
13- Jul- 18 |
17- Jan- 19 |
US20190010
469 |
ATTENUATED
VIRUSES USEFUL FOR VACCINES |
Not
Available |
30- Mar- 07 |
16- Jul- 18 |
10- Jan- 19 |
US20190010
240 |
COMPOSITION
COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND |
Not
Available |
15- Mar- 13 |
2- Aug -18 |
10- Jan- 19 |
US20190010
132 |
ARYLALKYL-AND
ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS |
Parion
Sciences, Inc. |
13- Dec- 13 |
4- Apr -18 |
10- Jan- 19 |
US20190008
954 |
NEGATIVELY
CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION |
CureVac
AG |
31- Jan- 12 |
11- Jun -18 |
10- Jan- 19 |
US20190008
948 |
NUCLEIC
ACID VACCINES |
ModernaTX,
Inc. |
23- Apr- 14 |
16- Jul- 18 |
10- Jan- 19 |
US20190008
833 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
9- May-
12 |
17- Jul- 18 |
10- Jan- 19 |
US20190004
061 |
DETECTING
TARGETS USING MASS TAGS AND MASS SPECTROMETRY |
Not
Available |
2-Jul- 10 |
4- Aug -18 |
3- Jan-
19 |
US20190002
477 |
ANTI-VIRAL
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF |
Kineta,
Inc. |
9- May-
14 |
31- Jan -18 |
3- Jan-
19 |
US20190002
448 |
SUBSTITUTED
BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF |
Not
Available |
31- Dec- 15 |
29- Dec -16 |
3- Jan-
19 |
US20190002
393 |
Lipids
and Lipid Compositions for the Delivery of Active Agents |
Not
Available |
5- Sep-
14 |
19- Sep -18 |
3- Jan-
19 |
US20190001
010 |
ADDITIVE
COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF |
Not
Available |
8- Dec-
14 |
13- Jul- 18 |
3- Jan-
19 |
US20190000
959 |
NUCLEIC
ACID VACCINES |
ModernaTX,
Inc. |
23- Apr- 14 |
27- Jul- 18 |
3- Jan-
19 |
US20190000
745 |
POLYMER-BASED
ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF |
eXion
labs Inc. |
28- Jul-16 |
4- Sep -18 |
3- Jan-
19 |
US20180372
747 |
METHODS
OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUE |
Not
Available |
22- Nov- 15 |
21- May -18 |
27- Dec -18 |
US20180372
733 |
ANTIBODY-NANOPARTICLE
CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES |
Not
Available |
27- Apr- 10 |
21- Jun -18 |
27- Dec -18 |
US20180371
536 |
METHODS
FOR RNA QUANTIFICATION |
Not
Available |
1- Jun-
15 |
26- May -16 |
27- Dec -18 |
US20180371
461 |
APTAMERS,
NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS
FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTION |
Not
Available |
10- Dec- 15 |
1- Dec -16 |
27- Dec -18 |
US20180371
410 |
MEANS
AND METHODS FOR INFLUENCING THE STABILITY OF CELLS |
Not
Available |
4- Dec-
09 |
28- Aug -18 |
27- Dec -18 |
US20180369
386 |
LIPIDS
AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS |
Not
Available |
8- Mar-
13 |
29- Aug -18 |
27- Dec -18 |
US20180369
364 |
RECOMBINANT
VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEIN |
Not
Available |
2-Jul- 15 |
1- Jul- 16 |
27- Dec -18 |
US20180368
417 |
ANTIMICROBIAL
COMPOSITIONS AND METHODS |
Not
Available |
23- Sep- 14 |
19- Jun -18 |
27- Dec -18 |
US20180365
375 |
METHODS
AND SYSTEMS FOR MULTIPLE TAXONOMIC CLASSIFICATION |
Not
Available |
24- Apr- 15 |
4- Oct -17 |
20- Dec -18 |
US20180363
027 |
STABILIZING
COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID |
Not
Available |
6- Oct-
06 |
15- May -18 |
20- Dec -18 |
US20180362
625 |
REGULATION
OF CYTOKINE PRODUCTION |
Not
Available |
4- Dec-
15 |
2- Dec -16 |
20- Dec -18 |
US20180360
877 |
METHODS
FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURE |
Not
Available |
8- Dec- 15 |
8- Dec -16 |
20- Dec -18 |
US20180360
736 |
FILM
DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES |
Intelgenx
Corp. |
2- Dec-
13 |
23- Aug -18 |
20- Dec -18 |
US20180355
017 |
COMPOSITIONS
AND METHODS FOR INTERNALIZING ENZYMES |
Not
Available |
7- Jun-
17 |
6- Jun -18 |
13- Dec -18 |
US20180353
594 |
METHOD
FOR INACTIVATING VIRUSES USING ELECTRON BEAMS |
Not
Available |
26- Jul-13 |
21- Aug -18 |
13- Dec -18 |
US20180346
574 |
ANTI-PD-L1
ANTIBODIES AND USES THEREOF |
Not
Available |
13- Jun- 16 |
9- Aug -18 |
6- Dec -18 |
US20180346
573 |
ANTI-PD-L1
ANTIBODIES AND USES THEREOF |
Not
Available |
13- Jun- 16 |
9- Aug -18 |
6- Dec -18 |
US20180346
522 |
HUMAN
RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND
VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME |
Not
Available |
10- Apr- 12 |
6- Aug -18 |
6- Dec -18 |
US20180346
516 |
PEPTIDES
AND USES THEREFOR AS ANTIVIRAL AGENTS |
Not
Available |
27- Nov- 15 |
28- Nov -16 |
6- Dec -18 |
US20180346
485 |
ISOTHIAZOLOPYRIMIDINONES,
PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb- 15 |
27- Feb -18 |
6- Dec -18 |
US20180346
480 |
THIENOPYRIMIDINONES
AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
1- Mar -18 |
6- Dec -18 |
US20180344
877 |
RECOMBINANT
PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF |
Children's
Healthcare of Atlanta, Inc. |
16- Apr- 15 |
8- Aug -18 |
6- Dec -18 |
US20180344
832 |
METHODS
AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY |
Not
Available |
20- Apr- 15 |
20- Apr -16 |
6- Dec -18 |
US20180344
751 |
Broad
Spectrum Antiviral and Methods of Use |
Not
Available |
17- Apr- 06 |
26- Dec -17 |
6- Dec -18 |
US20180340
219 |
CRISPR
EFFECTOR SYSTEM BASED DIAGNOSTICS |
MASSACHUSETTS
INSTITUTE OF TECHNOLOGY |
9- Dec-
16 |
9- Mar -18 |
29- Nov -18 |
US20180340
218 |
CRISPR
EFFECTOR SYSTEM BASED DIAGNOSTICS |
MASSACHUSETTS
INSTITUTE OF TECHNOLOGY |
9- Dec-
16 |
9- Mar -18 |
29- Nov -18 |
US20180340
215 |
SAMPLE
ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCE |
Not
Available |
28- Aug- 15 |
26- Aug -16 |
29- Nov -18 |
US20180340
154 |
PRODUCTION
OF VIRUSES IN AVIAN EGGS |
Not
Available |
24- Nov- 15 |
23- Nov -16 |
29- Nov -18 |
US20180340
153 |
PRODUCTION
OF VIRUSES IN CELL CULTURE |
Not
Available |
24- Nov- 15 |
23- Nov -16 |
29- Nov -18 |
US20180339
991 |
PYRROLOTRIAZINONES
AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
24- May -18 |
29- Nov -18 |
US20180339
988 |
PYRROLO
AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
18- Jan -18 |
29- Nov -18 |
US20180339
014 |
PEPTIDOMIMETIC
MACROCYCLES |
Not
Available |
14- Jan- 09 |
7- Jun -18 |
29- Nov -18 |
US20180334
480 |
CORONAVIRUSES
EPITOPE-BASED VACCINES |
RAMOT
AT TEL-AVIV UNIVERSITY LTD. |
17- Sep- 15 |
15- Sep -16 |
22- Nov -18 |
US20180333
485 |
Compositions,
Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics
And Methods Of Using The Same |
Not
Available |
12- Dec- 11 |
9- May -18 |
22- Nov -18 |
US20180327
800 |
MONOCLONAL
ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS |
Not
Available |
26- Feb- 03 |
21- May -18 |
15- Nov -18 |
US20180327
738 |
STABILIZED
REAGENTS FOR GENOME MODIFICATION |
Not
Available |
20- Nov- 15 |
18- Nov -16 |
15- Nov -18 |
US20180327
697 |
CLEANING
COMPOSITION, METHOD OF MAKING AND USE THEREOF |
Not
Available |
8- Sep-
16 |
12- Jun -18 |
15- Nov -18 |
US20180327
484 |
RSV-SPECIFIC
BINDING MOLECULES AND MEANS FOR PRODUCING THEM |
Not
Available |
1- Jun-
07 |
23- Jul- 18 |
15- Nov -18 |
US20180326
070 |
CARBOHYDRATE
CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES |
Not
Available |
4- Dec-
07 |
20- Nov -17 |
15- Nov -18 |
US20180326
051 |
LIPIDATED
IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS |
Not
Available |
17- Aug- 10 |
24- Jul- 18 |
15- Nov -18 |
US20180326
045 |
COMBINATION
PIV3/HMPV RNA VACCINES |
ModernaTX,
Inc. |
22- Oct- 15 |
20- Jul- 18 |
15- Nov -18 |
US20180326
044 |
NSP10 SELF-ASSEMBLING
FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER
NANOMATERIAL APPLICATIONS |
Not
Available |
13- Oct- 15 |
13- Oct -16 |
15- Nov -18 |
US20180326
039 |
VACCINE
COMPOSITIONS |
Not
Available |
16- Sep- 15 |
16- Sep -16 |
15- Nov -18 |
US20180325
076 |
ANTIMICROBIAL
COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM |
OXISCIENCE,
LLC |
28- Aug- 14 |
24- Jul- 18 |
15- Nov -18 |
US20180321
242 |
VIRAL
BIOMARKERS AND USES THEREFOR |
Not
Available |
6- Nov-
15 |
4- Nov -16 |
8- Nov -18 |
US20180319
811 |
DERIVATIVES
OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL
INFECTIONS |
Not
Available |
30- Oct- 15 |
28- Oct -16 |
8- Nov -18 |
US20180319
779 |
SUBSTITUTED
BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF |
Not
Available |
3-Jul- 13 |
4- Dec -17 |
8- Nov -18 |
US20180318
447 |
COMPOSITIONS
AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY |
Not
Available |
3- Dec-
15 |
30- Nov -16 |
8- Nov -18 |
US20180318
366 |
METHOD
OF TREATMENT USING ONCOLYTIC VIRUSES |
Not
Available |
15- Jun- 15 |
15- Jun -16 |
8- Nov -18 |
US20180318
350 |
Immune
Cells with DNMT3A Gene Modifications and Methods Related Thereto |
Not
Available |
4- Nov-
15 |
4- Nov -16 |
8- Nov -18 |
US20180312
575 |
ANTIBODIES
AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF |
Not
Available |
6- Dec-
07 |
20- Mar -18 |
1- Nov -18 |
US20180312
545 |
OPTIMIZED
NUCLEIC ACID MOLECULES |
Not
Available |
9- Nov-
15 |
9- Nov -16 |
1- Nov -18 |
US20180312
544 |
RECOMBINANT
HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3
F PROTEIN AND USES THEREOF |
The
United States of America, as represented by the Secretary, Dept. of Health
and Human Services |
20- Jan- 15 |
20- Jan -16 |
1- Nov -18 |
US20180311
338 |
MICRONEEDLE
COMPOSITIONS AND METHODS OF USING SAME |
Not
Available |
11- Jan- 16 |
11- Jul- 18 |
1- Nov -18 |
US20180311
273 |
Method
of Treating Inflammation |
Not
Available |
1- Apr-
10 |
26- Jun -18 |
1- Nov -18 |
US20180305
773 |
CRISPR
EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTION |
Not
Available |
12- Apr- 17 |
12- Apr -18 |
25- Oct- 18 |
US20180305
760 |
Pathogen
biomarkers and uses therefor |
Not
Available |
30- Sep- 15 |
30- Sep -16 |
25- Oct- 18 |
US20180305
451 |
HIDE1
COMPOSITIONS AND METHODS |
Not
Available |
13- Jul-15 |
13- Jul- 16 |
25- Oct- 18 |
US20180305
412 |
COMPOSITIONS
AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE |
Not
Available |
19- Dec- 16 |
9- Jul- 18 |
25- Oct- 18 |
US20180305
357 |
IMMUNE
RESPONSE MODIFIER COMPOSITIONS AND METHDOS |
Not
Available |
22- Dec- 06 |
25- Jun -18 |
25- Oct- 18 |
US20180305
356 |
NOVEL
KINASE INHIBITORS |
Not
Available |
19- Oct- 12 |
18- May -18 |
25- Oct- 18 |
US20180303
874 |
Compositions
and Methods for the Prevention of Microbial Infections |
Not
Available |
10- Nov- 11 |
30- Nov -17 |
25- Oct- 18 |
US20180303
768 |
DESIGN,
SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING
ANTI-CORONAVIRUS ACTIVITY |
Not
Available |
30- Jan- 15 |
2- Jul- 18 |
25- Oct- 18 |
US20180303
090 |
TREATMENT
COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT |
Not
Available |
30- Oct- 15 |
17- Oct -16 |
25- Oct- 18 |
US20180267
031 |
METHOD
AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID
SAMPLE BY USING NEODYMIUM MAGNETS |
The
U.S.A., as represented by the Secretary, Department of Health and Human
Services |
1- Sep- 15 |
8- Aug -16 |
20- Sep -18 |
US20180265
847 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
29- Mar -18 |
20- Sep -18 |
US20180265
822 |
LIQUID
LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF |
Not
Available |
8- Sep-
16 |
21- May -18 |
20- Sep -18 |
US20180265
574 |
Anti-pneumococcal
hyperimmune globulin for the treatment and prevention of pneumococcal
infection |
Not
Available |
15- Mar- 17 |
15- Mar -17 |
20- Sep -18 |
US20180265
507 |
HOST
TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES |
Dana-Farber
Cancer Institute, Inc. |
11- Apr- 12 |
26- Jan -18 |
20- Sep -18 |
US20180264
098 |
MODULATION
OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS |
The
Government of the USA as represented by the Secretary of the Dept. of Health
and Human Service |
8- Oct-
04 |
31- May -18 |
20- Sep -18 |
US20180258
162 |
Methods
Of Treating Inflammation Associated Airway Diseases And Viral Infections |
Not
Available |
2- Jan- 15 |
22- May -18 |
13- Sep -18 |
US20180258
160 |
Optimized
Crosslinkers for Trapping a Target on a Substrate |
Not
Available |
13- Nov- 15 |
11- May -18 |
13- Sep -18 |
US20180258
159 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY |
Not
Available |
28- Oct- 14 |
14- May -18 |
13- Sep -18 |
US20180258
151 |
RECOMBINANT
SUPER-COMPOUND INTERFERON AND USES THEREOF |
Not
Available |
28- Feb- 01 |
2- Mar -18 |
13- Sep -18 |
US20180251
737 |
COMPOSITIONS,
METHODS AND USES FOR INDUCING VIRAL GROWTH |
Not
Available |
5- Dec-
08 |
28- Dec -17 |
6- Sep -18 |
US20180251
540 |
HUMAN
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) |
Not
Available |
16- Dec- 02 |
30- Apr -18 |
6- Sep -18 |
US20180251
436 |
CERTAIN
(2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS
DIPEPTIDYL PEPTIDASE 1 INHIBITORS |
Not
Available |
24- Jan- 14 |
19- Sep -17 |
6- Sep -18 |
US20180250
602 |
PAPAYA
MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE
IMMUNE RESPONSE |
Not
Available |
11- Feb- 14 |
1- May -18 |
6- Sep -18 |
US20180250
381 |
SOLUBLE
NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES |
Not
Available |
20- Aug- 10 |
12- Oct -17 |
6- Sep -18 |
US20180245
056 |
COMPOSITIONS
FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS |
Not
Available |
19- Nov- 09 |
9- Oct -17 |
30- Aug -18 |
US20180245
053 |
VIRAL
VACCINES AND METHODS OF FORMING THE SAME |
Not
Available |
27- Feb- 17 |
27- Feb -18 |
30- Aug -18 |
US20180244
759 |
NOVEL
METHODS OF GENERATING ANTIBODIES |
Rutgers,
The State University of New Jersey |
19- Aug- 15 |
18- Aug -16 |
30- Aug -18 |
US20180244
756 |
MIDDLE
EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE |
The
United States of America, as Represented by the Secretary, Dept. of Health
and Human Services |
24- Feb- 15 |
24- Feb -16 |
30- Aug -18 |
US20180244
669 |
IMIDAZO[4,5-c]
RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS |
Not
Available |
31- Aug- 15 |
26- Aug -16 |
30- Aug -18 |
US20180244
660 |
CYCLOPROPYLDERIVATIVES
AND THEIR USE AS KINASE INHIBITORS |
Not
Available |
17- Aug- 15 |
17- Aug -16 |
30- Aug -18 |
US20180243
347 |
IMMUNOMODULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
25- Aug- 15 |
22- Aug -16 |
30- Aug -18 |
US20180237
835 |
METHODS
OF ANALYZING VIRUS-DERIVED THERAPEUTICS |
American
International Biotechnology, LLC |
31- Jul-15 |
29- Jul- 16 |
23- Aug -18 |
US20180237
788 |
IMPROVEMENTS
IN OR RELATING TO DNA RECOMBINATION |
The
Regents of the University of California |
8- Aug-
15 |
5- Aug -16 |
23- Aug -18 |
US20180237
786 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
CUREVAC
AG |
28- Aug- 15 |
22- Aug -16 |
23- Aug -18 |
US20180237
502 |
PAN-EBOLA
AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILS |
Integrated
BioTherapeutics, Inc. |
11- Mar- 15 |
11- Mar -16 |
23- Aug -18 |
US20180237
435 |
GUANIDINE
SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS |
Not
Available |
31- Aug- 15 |
26- Aug -16 |
23- Aug -18 |
US20180236
058 |
REVERSE
GENETICS SYSTEMS |
Not
Available |
31- Jul-09 |
16- Oct -17 |
23- Aug -18 |
US20180236
054 |
Tetanus
Toxoid and CCL3 Improve DC Vaccines |
Duke
University |
14- Nov- 13 |
19- Apr -18 |
23- Aug -18 |
US20180235
948 |
(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-
METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4-
FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCER |
Not
Available |
18- Aug- 15 |
18- Aug -16 |
23- Aug -18 |
US20180230
521 |
BIOAGENT
DETECTION OLIGONUCLEOTIDES |
Not
Available |
27- Dec- 11 |
13- Apr -18 |
16- Aug -18 |
US20180230
447 |
ACTIVE
LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) |
Northwestern
University |
24- Jan- 17 |
24- Jan -18 |
16- Aug -18 |
US20180228
695 |
DEVICES,
SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY
ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS |
Not
Available |
11- Aug- 15 |
11- Aug -16 |
16- Aug -18 |
US20180223
290 |
METHOD
FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS |
GenVec,
Inc. |
10- Nov- 05 |
7- Sep -17 |
9- Aug -18 |
US20180222
906 |
SUBSTITUTED
IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES |
3M
Innovative Properties Company |
18- Jun- 04 |
9- Apr -18 |
9- Aug -18 |
US20180221
464 |
IMMUNOGENIC
COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE
RESPONSES |
Not
Available |
3- Aug-
15 |
3- Aug -16 |
9- Aug -18 |
US20180216
164 |
HIGH
DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS |
Not
Available |
15- Nov- 06 |
19- Mar -18 |
2- Aug -18 |
US20180216
067 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
29- Mar -18 |
2- Aug -18 |
US20180215
831 |
Antibody
Derivatives with Conditionally Enabled Effector Function |
Not
Available |
27- Jul-15 |
27- Jul- 16 |
2- Aug -18 |
US20180215
801 |
CRYPTIC
POLYPEPTIDES AND USES THEREOF |
Not
Available |
29- Jan- 15 |
29- Jan -16 |
2- Aug -18 |
US20180215
794 |
TREATING
CANCER WITH VIRAL NUCLEIC ACID |
Mayo
Foundation for Medical Education and Research |
20- Feb- 07 |
27- Mar -18 |
2- Aug -18 |
US20180214
430 |
Selective
Inhibitors Of i-NOS For Use Against Viral Infection |
UCL
Business PLC |
17- Jul-15 |
15- Jul- 16 |
2- Aug -18 |
US20180209
960 |
Method of
Determining, Identifying or Isolating Cell-Penetrating Peptides |
Not
Available |
23- May- 11 |
11- Dec -17 |
26- Jul- 18 |
US20180208
897 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
19- Mar -18 |
26- Jul- 18 |
US20180208
659 |
ANTI-PD-L1
ANTIBODIES AND USES THEREOF |
Not
Available |
13- Jun- 16 |
13- Jun -17 |
26- Jul- 18 |
US20180208
653 |
METHODS
FOR ENHANCING AN IMMUNE RESPONSE |
Not
Available |
20- Jan- 17 |
19- Jan -18 |
26- Jul- 18 |
US20180207
258 |
ADJUVANTED
INFLUENZA VACCINES FOR PEDIATRIC USE |
Not
Available |
22- Feb- 08 |
5- Mar -18 |
26- Jul- 18 |
US20180207
145 |
PHARMACEUTICAL
COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES |
GlaxoSmithKline
Intellectual Property (No. 2) Limited |
12- May- 14 |
19- Mar -18 |
26- Jul- 18 |
US20180201
998 |
COMPOSITIONS
AND METHODS FOR DETECTION OF GENETIC DEAFNESS GENE MUTATION |
CapitalBio
Corporation |
14- Jul-15 |
14- Jul- 15 |
19- Jul- 18 |
US20180201
907 |
METHODS
FOR INCREASING THE INFECTIVITY OF VIRUSES |
Not
Available |
26- Jan- 12 |
13- Mar -18 |
19- Jul- 18 |
US20180201
687 |
ANTIBODIES
HAVING SPECIFICITY TO MYOSIN 18A AND USES THEREOF |
Not
Available |
7-Jul- 15 |
7- Jul- 16 |
19- Jul- 18 |
US20180200
365 |
Methods
and Compositions for Inhibiting Akt3 |
Not
Available |
17- Jan- 17 |
20- Feb -18 |
19- Jul- 18 |
US20180200
364 |
LIPIDATED
IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS |
3M
Innovative Properties Company |
17- Aug- 10 |
27- Nov -17 |
19- Jul- 18 |
US20180200
224 |
Antiviral
Activity from Medicinal Mushrooms and Their Active Constituents |
Not
Available |
31- Mar- 15 |
12- Mar -18 |
19- Jul- 18 |
US20180200
196 |
Modular
Particulars for Immunotherapy |
Not
Available |
1- Nov-
13 |
3- Jan -18 |
19- Jul- 18 |
US20180196
061 |
INFLUENZA
POTENCY ASSAYS |
Not
Available |
7-Jul- 15 |
7- Jul- 16 |
12- Jul- 18 |
US20180195
048 |
METHODS
FOR PRODUCING VIRUS FOR VACCINE PRODUCTION |
Takeda
Vaccines, Inc. |
13- Feb- 15 |
12- Feb -16 |
12- Jul- 18 |
US20180194
850 |
ANTAGONISTIC
ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES |
Not
Available |
15- May- 15 |
13- May -16 |
12- Jul- 18 |
US20180194
829 |
POLYPEPTIDES
AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED
DISORDERS AND CANCER |
Not
Available |
15- Apr- 11 |
13- Nov -17 |
12- Jul- 18 |
US20180194
735 |
Sulfinylphenyl
or Sulfonimidoylphenyl Benzazepines |
Hoffmann
La-Roche Inc. |
17- Sep- 15 |
8- Mar -18 |
12- Jul- 18 |
US20180193
477 |
DRUG-CONJUGATED
BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS |
Not
Available |
15- Jul-15 |
15- Jul- 16 |
12- Jul- 18 |
US20180187
213 |
Variant
AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and
Tissues |
The
Children's Hospital of Philadelphia |
22- Jul-13 |
6- Dec -17 |
5- Jul- 18 |
US20180187
211 |
METHODS
AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY |
Not
Available |
9- Jan- 15 |
7- Jan -16 |
5- Jul- 18 |
US20180187
165 |
HAND,
FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF |
Takeda
Vaccines, Inc. |
7- Nov-
14 |
27- Oct -17 |
5- Jul- 18 |
US20180187
154 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
20- Feb -18 |
5- Jul- 18 |
US20180187
153 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
20- Feb -18 |
5- Jul- 18 |
US20180187
131 |
DISINFECTING
AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOF |
COMMISSARIAT
A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
16- Jun- 15 |
15- Jun -16 |
5- Jul- 18 |
US20180186
897 |
NOVEL
VACCINES IN PREVENTION AND TREATMENT OF MALARIA |
Not
Available |
26- Jun- 15 |
24- Jun -16 |
5- Jul- 18 |
US20180186
821 |
PROTEIN
PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED
HAPTENS |
Not
Available |
28- Aug- 15 |
28- Feb -18 |
5- Jul- 18 |
US20180186
802 |
COMPOUNDS
AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS |
Not
Available |
1- May-
14 |
27- Feb -18 |
5- Jul- 18 |
US20180186
792 |
HETEROBIFUNCTIONAL
LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER
CONJUGATES MADE THEREFROM |
3M
Innovative Properties Company |
3- Jun- 11 |
26- Feb -18 |
5- Jul- 18 |
US20180186
534 |
Powdered
Pouch And Method Of Making Same |
MONOSOL,
LLC |
16- Apr- 12 |
29- Dec -17 |
5- Jul- 18 |
US20180185
469 |
COMPOSITIONS
AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY
SYNDROME |
Not
Available |
24- Apr- 12 |
14- Dec -17 |
5- Jul- 18 |
US20180185
392 |
Pharmaceutical
Compositions and Methods |
Not
Available |
3- Aug-
15 |
29- Nov -17 |
5- Jul- 18 |
US20180185
345 |
METHODS
AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS |
Not
Available |
19- Jun- 15 |
17- Jun -16 |
5- Jul- 18 |
US20180180
544 |
USE OF A
FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A
FLUOROMETER |
Not
Available |
14- Jun- 12 |
22- Feb -18 |
28- Jun- 18 |
US20180179
300 |
GENERATION
OF BINDING MOLECULES |
Merus
N.V. |
26- Sep- 11 |
22- Nov -17 |
28- Jun- 18 |
US20180179
274 |
PROTEINS
COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES THEREOF |
Not
Available |
26- Jun- 15 |
24- Jun -16 |
28- Jun- 18 |
US20180177
863 |
METHODS
OF MAKING AND USING LIVE ATTENUATED VIRUSES |
Not
Available |
23- Sep- 15 |
31- Oct -17 |
28- Jun- 18 |
US20180177
862 |
ANTIGENICALLY
MATCHED INFLUENZA VACCINES |
Not
Available |
26- Jun- 15 |
24- Jun -16 |
28- Jun- 18 |
US20180177
860 |
VACCINE
CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD
THEREFOR |
Not
Available |
11- Jun- 15 |
7- Jun -16 |
28- Jun- 18 |
US20180163
182 |
PROCESSES
FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS |
Human
Services |
10- Jun- 15 |
10- Jun -16 |
14- Jun- 18 |
US20180162
838 |
Chemical
Compounds |
Not
Available |
18- Mar- 14 |
13- Dec -17 |
14- Jun- 18 |
US20180162
835 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
11- Dec -17 |
14- Jun- 18 |
US20180161
425 |
NOVEL
PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATION |
Not
Available |
10- Dec- 14 |
10- Dec -15 |
14- Jun- 18 |
US20180161
422 |
NUCLEIC
ACID COMPRISING OR CODING FOR A HISTONE STEM- LOOP AND A POLY(A) SEQUENCE OR
A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED
PATHOGENIC ANTIGEN |
CureVac
AG |
15- Feb- 12 |
8- Feb -18 |
14- Jun- 18 |
US20180161
279 |
GASTRO-RETENTIVE
MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF |
Not
Available |
14- Dec- 16 |
13- Dec -17 |
14- Jun- 18 |
US20180160
662 |
Transgenic
Immunodeficient Mouse Expressing Human SIRP-alpha |
Institut
Pasteur |
26- Mar- 12 |
25- Jan -18 |
14- Jun- 18 |
US20180149
659 |
DIAGNOSIS
AND TREATMENT OF MERS-RELATED RENAL DISEASE |
Not
Available |
4- Jun-
15 |
3- Jun -16 |
31- May -18 |
US20180148
727 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
Not
Available |
30- Dec- 14 |
29- Dec -15 |
31- May -18 |
US20180142
239 |
METHODS
AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES |
Not
Available |
26- Jan- 07 |
14- Jun -17 |
24- May -18 |
US20180142
198 |
DELIVERY
OF BIOMOLECULES TO IMMUNE CELLS |
Not
Available |
31- Oct- 14 |
30- Oct -15 |
24- May -18 |
US20180142
006 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
12- Jan -18 |
24- May -18 |
US20180142
005 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
12- Jan -18 |
24- May -18 |
US20180142
004 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
11- Jan -18 |
24- May -18 |
US20180142
003 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
9- Jan -18 |
24- May -18 |
US20180142
002 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
5- Jan -18 |
24- May -18 |
US20180140
659 |
ANALOGS
OF C5a AND METHODS OF USING SAME |
Not
Available |
29- Jun- 10 |
12- Jan -18 |
24- May -18 |
US20180140
625 |
PRODUCTION
OF STABLE NON-POLYADENYLATED RNAS |
Massachusetts
Institute of Technology |
16- Oct- 12 |
31- Jul- 17 |
24- May -18 |
US20180140
580 |
METHOD OF
TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS |
Not
Available |
29- Nov- 02 |
23- Oct -17 |
24- May -18 |
US20180135
099 |
NANOREPORTERS
AND METHODS OF MANUFACTURING AND USE THEREOF |
Not
Available |
23- Dec- 05 |
2- Jan -18 |
17- May -18 |
US20180135
012 |
MEMBRANE-RECEIVER
COMPLEX THERAPEUTICS |
Not
Available |
13- May- 15 |
13- May -16 |
17- May -18 |
US20180134
783 |
HUMAN
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) |
Not
Available |
16- Dec- 02 |
26- Apr -16 |
17- May -18 |
US20180134
770 |
ANTIBODY
PRODUCING NON-HUMAN ANIMALS |
Merus
N.V. |
27- Jun- 08 |
12- Jan -18 |
17- May -18 |
US20180133
246 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
7- Mar-
12 |
1- Nov -17 |
17- May -18 |
US20180127
836 |
IMPROVED COMPOSITIONS
AND METHODS FOR DETECTION OF VIRUSES |
Not
Available |
7- May-
15 |
6- May -16 |
10- May -18 |
US20180127
783 |
CRISPR-RELATED
METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
EDITAS
MEDICINE, INC. |
7- Nov-
13 |
29- Nov -17 |
10- May -18 |
US20180127
384 |
HYDRAZIDE
CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
29- Jul-11 |
21- Jun -17 |
10- May -18 |
US20180125
965 |
HAND,
FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF |
Takeda
Vaccines, Inc. |
7- Nov-
14 |
6- Nov -15 |
10- May -18 |
US20180125
952 |
PRIME-BOOST
REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT |
Not
Available |
15- May- 15 |
13- May -16 |
10- May -18 |
US20180125
883 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
7- Mar-
12 |
20- Sep -17 |
10- May -18 |
US20180112
270 |
C-CBL
MUTATIONS AND USES THEREOF |
Not
Available |
4- Jun-
10 |
22- Mar -16 |
26- Apr- 18 |
US20180111
991 |
MODULATORS
OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR
HELPER CELLS |
Not
Available |
2- Dec- 14 |
2- Jun -17 |
26- Apr- 18 |
US20180111
907 |
DENDRIMER
LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE
TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES |
Not
Available |
29- May- 12 |
20- Dec -17 |
26- Apr- 18 |
US20180110
845 |
METHOD
OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN
AGGREGATION DISORDERS |
Not
Available |
31- Aug- 07 |
18- Dec -17 |
26- Apr- 18 |
US20180105
815 |
Bivalent
siRNA Chimeras and Methods of Use Thereof |
Not
Available |
18- Oct- 16 |
6- Oct -17 |
19- Apr- 18 |
US20180105
596 |
ANTI-TYRO3
ANTIBODIES AND USES THEREOF |
Not
Available |
17- Apr- 15 |
15- Apr -16 |
19- Apr- 18 |
US20180105
514 |
HETEROCYCLIC
AMIDES USEFUL AS PROTEIN MODULATORS |
Not
Available |
7- Apr-
16 |
3- Jan -18 |
19- Apr- 18 |
US20180104
241 |
CHEMICALLY
AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER
ACTIVITY |
PARION
SCIENCES, INC. |
27- Jun- 11 |
15- Dec -17 |
19- Apr- 18 |
US20180100
181 |
METHODS
FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME |
Not
Available |
17- Apr- 15 |
15- Apr -16 |
12- Apr- 18 |
US20180099
999 |
FUSION
PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA |
Not
Available |
17- Sep- 14 |
14- Dec -17 |
12- Apr- 18 |
US20180098
972 |
TREATMENT
OF INFECTIOUS DISEASES |
CHILDREN'S
MEDICAL CENTER CORPORATION |
26- Jan- 15 |
26- Jan -16 |
12- Apr- 18 |
US20180092
932 |
Anti-Viral
Azide Containing Compounds |
Not
Available |
28- Jul-10 |
7- Dec -17 |
5- Apr-
18 |
US20180087
049 |
MAXIMIZING
DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBES |
Not
Available |
27- Sep- 16 |
7- Sep -17 |
29- Mar -18 |
US20180086
818 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY |
Not
Available |
28- Oct- 14 |
13- Nov -17 |
29- Mar -18 |
US20180085
457 |
ANTIBODY/T-CELL
RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF |
Not
Available |
23- Oct- 15 |
1- Dec -17 |
29- Mar -18 |
US20180085
432 |
STING
(Stimulator of Interferon Genes), A Regulator of Innate Immune Responses |
Not
Available |
4- Aug-
08 |
15- Sep -17 |
29- Mar -18 |
US20180085
388 |
DELIVERY
OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
6-Jul- 10 |
5- Oct -17 |
29- Mar -18 |
US20180079
746 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
Not
Available |
19- Mar- 15 |
15- Mar -16 |
22- Mar -18 |
US20180078
625 |
COMPOSITIONS
AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS |
Not
Available |
25- Mar- 15 |
25- Mar -16 |
22- Mar -18 |
US20180078
532 |
IMMEDIATE
RELEASE FORMULATIONS FOR OPROZOMIB |
AMGEN
INC. |
21- Sep- 16 |
18- Sep -17 |
22- Mar -18 |
US20180078
507 |
BIODEGRADABLE
POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL
COMPOSITIONS AND USES THEREOF |
Not
Available |
16- Sep- 16 |
15- Sep -17 |
22- Mar -18 |
US20180073
073 |
METHODS
AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASING |
Not
Available |
18- Mar- 15 |
16- Mar -16 |
15- Mar -18 |
US20180072
813 |
CARBONIC
ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF |
Not
Available |
2- Dec-
05 |
9- May -17 |
15- Mar -18 |
US20180072
796 |
MAST CELL
STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION |
Not
Available |
8- Sep-
16 |
17- Nov -17 |
15- Mar -18 |
US20180072
752 |
COUMARIN
DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS
PREPARATION AND USE |
Not
Available |
30- Mar- 15 |
2- Feb -16 |
15- Mar -18 |
US20180071
219 |
Technology
for Preparation of Macromolecular Microspheres |
Not
Available |
24- Jan- 06 |
25- Sep -17 |
15- Mar -18 |
US20180067
299 |
ENDOSCOPIC
APPARATUS FOR THERMAL DISTRIBUTION MONITORING |
ELECTRONICS
AND TELECOMMUNICATIONS RESEARCH INSTITUTE |
7- Sep-
16 |
31- May -17 |
8- Mar -18 |
US20180066
228 |
Detection
of T Cell Exhaustion or Lack of T Cell Costimulation and Uses Thereof |
Not
Available |
15- May- 15 |
15- Nov -17 |
8- Mar -18 |
US20180066
216 |
CLEANING
COMPOSITION, METHOD OF MAKING AND USE THEREOF |
Not
Available |
8- Sep-
16 |
6- Sep -17 |
8- Mar -18 |
US20180065
981 |
HETEROCYCLYLMETHYL-THIENOURACILE
AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR |
Not
Available |
26- Mar- 15 |
21- Mar -16 |
8- Mar -18 |
US20180064
790 |
Composition
for Treatment or Prevention of Infectious Inflammatory Diseases, or
Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase
as an Active Ingredient |
Not
Available |
26- Feb- 15 |
25- Aug -17 |
8- Mar -18 |
US20180064
752 |
ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED
POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND
TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS
(HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A
(IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED
POLYALLYLAMINE DERIVATIVE |
Not
Available |
29- Jul-14 |
25- Oct -17 |
8- Mar -18 |
US20180058
988 |
SAMPLE
FIXATION AND STABILISATION |
Not
Available |
1- Mar-
13 |
14- Aug -17 |
1- Mar -18 |
US20180057
871 |
COMPOSITIONS
AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS |
Not
Available |
15- Aug- 16 |
1- Nov -17 |
1- Mar -18 |
US20180057
841 |
METHOD
OF INCREASING THE FUNCTION OF AN AAV VECTOR |
Not
Available |
7- Apr-
05 |
27- Oct -17 |
1- Mar -18 |
US20180057
817 |
Particle-Nucleic
Acid Conjugates and Therapeutic Uses Related Thereto |
Not
Available |
25- Jun- 12 |
9- Oct -17 |
1- Mar -18 |
US20180057
594 |
PSEUDOTYPED
ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES |
Not
Available |
30- Jun- 16 |
29- Sep -17 |
1- Mar -18 |
US20180057
509 |
ALKYLOXY
SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES |
Not
Available |
9- Feb-
05 |
2- Nov -17 |
1- Mar -18 |
US20180057
488 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
7- Nov -17 |
1- Mar -18 |
US20180055
925 |
DISPLAY
PLATFORM FROM BACTERIAL SPORE COAT PROTEINS |
The
United States of America, as represented by the Secretary, Department of
Health and Human Serv |
3- Mar-
15 |
7- Aug -15 |
1- Mar -18 |
US20180055
769 |
CIRCULATION
OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS |
Not
Available |
3- Dec-
09 |
26- Jun -17 |
1- Mar -18 |
US20180051
267 |
TAL
EFFECTOR-MEDIATED DNA MODIFICATION |
Not
Available |
10- Dec- 09 |
5- Oct -17 |
22- Feb -18 |
US20180051
266 |
TAL
EFFECTOR-MEDIATED DNA MODIFICATION |
Not
Available |
10- Dec- 09 |
21- Aug -17 |
22- Feb -18 |
US20180050
059 |
DELIVERY
OF RNA TO DIFFERENT CELL TYPES |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
6-Jul- 10 |
30- Aug -17 |
22- Feb -18 |
US20180044
687 |
ARTIFICIAL
NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION |
Not
Available |
12- Dec- 14 |
11- Dec -15 |
15- Feb -18 |
US20180044
328 |
PEPTIDYL
NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS |
Prozymex
A/S |
5- Mar-
15 |
4- Mar -16 |
15- Feb -18 |
US20180043
007 |
INFLUENZA
VIRUS VECTORS AND USES THEREFOR |
Not
Available |
17- Mar- 14 |
21- Aug -17 |
15- Feb -18 |
US20180037
952 |
SYSTEM
AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
21- Aug -17 |
8- Feb -18 |
US20180037
942 |
ENZYME-INDEPENDENT
MOLECULAR INDEXING |
Not
Available |
3- Aug-
16 |
1- Aug -17 |
8- Feb -18 |
US20180037
871 |
CANCER
INITIATING CELL AND USE THEREOF |
Not
Available |
8- Aug-
16 |
8- Aug -16 |
8- Feb -18 |
US20180037
636 |
STRUCTURED
VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE |
DANA-FARBER
CANCER INSTITUTE, INC. |
18- Jun- 09 |
21- Sep -17 |
8- Feb -18 |
US20180037
634 |
ENGINEERED
POLYPEPTIDES AND USES THEREOF |
Not
Available |
2- Aug-
16 |
2- Aug -17 |
8- Feb -18 |
US20180037
617 |
METHODS
AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER
ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF
PROTEINS |
Institute
of Biophysics, Chinese Academy of Sciences |
22- Aug- 14 |
21- Aug -15 |
8- Feb -18 |
US20180036
398 |
FLAVIVIRUS
REPLICONS |
Not
Available |
27- Feb- 15 |
25- Feb -16 |
8- Feb -18 |
US20180036
237 |
OIL/SURFACTANT
MIXTURES FOR SELF-EMULSIFICATION |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
23- Feb- 15 |
23- Feb -16 |
8- Feb -18 |
US20180031
555 |
METHOD
FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF
ANTIBODIES |
Merus
N.V. |
27- Jun- 08 |
18- Jul- 17 |
1- Feb -18 |
US20180030
429 |
Polypeptide
Assemblies and Methods for the Production Thereof |
Not
Available |
27- Feb- 15 |
29- Feb -16 |
1- Feb -18 |
US20180030
411 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
13- Oct -17 |
1- Feb -18 |
US20180028
677 |
Peptides
for Assisting Delivery Across the Blood Brain Barrier |
Children's
Medical Center Corporation |
22- May- 06 |
30- Jun -17 |
1- Feb -18 |
US20180028
626 |
IMMUNOTHERAPEUTIC
VACCINE AND ANTIBODY COMBINATION THERAPY |
Transgene
SA |
13- Feb- 15 |
12- Feb -16 |
1- Feb -18 |
US20180028
562 |
METHODS
OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE
REDUCTIVE POTENTIAL WATER SOLUTION |
SONOMA
PHARMACEUTICALS, INC. |
20- Jan- 06 |
10- Oct -17 |
1- Feb -18 |
US20180028
449 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
27- Jun -17 |
1- Feb -18 |
US20180028
431 |
POLYMER-BASED
ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF |
eXion
labs Inc. |
28- Jul-16 |
27- Jul- 17 |
1- Feb -18 |
US20180023
048 |
ANIMAL
PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS |
Not
Available |
29- Oct- 04 |
22- Sep -17 |
25- Jan- 18 |
US20180022
781 |
POLYPEPTIDES
FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY |
CENTRE
NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) |
13- Feb- 15 |
12- Feb -16 |
25- Jan- 18 |
US20180021
448 |
Conjugates
of Cell Binding Molecules with Cytotoxic Agents |
Hangzhou
DAC Biotech Co., Ltd. |
12- Jul-12 |
16- Apr -14 |
25- Jan- 18 |
US20180016
307 |
GRIFFITHSIN
MUTANTS |
The
United States of America, as represented by the Secretary, Department of
Health and Human Serv |
10- Feb- 15 |
10- Feb -16 |
18- Jan- 18 |
US20180016
285 |
Boron-Containing
Small Molecules |
Not
Available |
20- Jun- 07 |
28- Sep -17 |
18- Jan- 18 |
US20180016
243 |
HUMAN
HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS |
Not
Available |
13- Feb- 15 |
12- Feb -16 |
18- Jan- 18 |
US20180015
174 |
SYNTHETIC
NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS |
Not
Available |
15- Jul-16 |
14- Jul- 17 |
18- Jan- 18 |
US20180015
052 |
DESIGN,
SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING
ANTI-CORONAVIRUS ACTIVITY |
Not
Available |
30- Jan- 15 |
28- Jan -16 |
18- Jan- 18 |
US20180010
167 |
ORGANISM
IDENTIFICATION PANEL |
Not
Available |
2- Apr-
07 |
26- Jul- 17 |
11- Jan- 18 |
US20180010
125 |
DOUBLE-STRANDED
OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF |
Quark
Pharmaceuticals Inc. |
12- Sep- 12 |
15- Feb -17 |
11- Jan- 18 |
US20180009
787 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
31- May- 16 |
22- Sep -17 |
11- Jan- 18 |
US20180008
689 |
RNA VIRUS
ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE SPACE |
Not
Available |
28- Jan- 15 |
28- Jan -16 |
11- Jan- 18 |
US20180002
743 |
FLUOROGENIC
PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF TARGET RNA SEQUENCES |
Not
Available |
18- Jun- 16 |
16- Jun -17 |
4- Jan-
18 |
US20180002
406 |
NEUTRALIZING
GP41 ANTIBODIES AND THEIR USE |
The
United States of America, as represented by the Secretary, Department of
Health and Human |
7- Nov-
11 |
8- Sep -17 |
4- Jan-
18 |
US20180000
929 |
D-AMINO
ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF |
Not
Available |
30- Nov- 12 |
14- Sep -17 |
4- Jan-
18 |
US20180000
926 |
METHODS
OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS |
Not
Available |
15- Jan- 15 |
15- Jan -16 |
4- Jan-
18 |
US20180000
868 |
Induced
Hepatocytes and Uses Thereof |
Not
Available |
26- Nov- 14 |
15- Sep -17 |
4- Jan-
18 |
US20180000
724 |
METHODS
FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION
OF A VACCINE |
Not
Available |
26- Jul-10 |
10- May -17 |
4- Jan- 18 |
US20170369
843 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
29- Mar -17 |
28- Dec -17 |
US20170369
470 |
Cyclic
Compounds and Uses Thereof |
Not
Available |
16- Dec- 14 |
16- Dec -15 |
28- Dec -17 |
US20170368
203 |
Compositions
For Enhancing Transport Of Molecules Into Cells |
Not
Available |
29- Apr- 03 |
10- Jan -17 |
28- Dec -17 |
US20170368
201 |
SCALABLE
MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE
SUSPENSION CELL CULTURE SYSTEM |
The
Children's Hospital of Philadelphia |
15- Mar- 13 |
8- Sep -17 |
28- Dec -17 |
US20170368
167 |
COMPOSITIONS
AND METHODS RELATED TO NEUROLOGICAL DISORDERS |
Not
Available |
21- Aug- 12 |
6- Jun -16 |
28- Dec -17 |
US20170362
300 |
OLIGOPEPTIDE-FREE
CELL CULTURE MEDIA |
Not
Available |
4- Jan- 06 |
7- Aug -17 |
21- Dec -17 |
US20170362
297 |
CHIMERIC
ANTIGEN RECEPTORS AND METHODS OF USE THEREOF |
Not
Available |
19- Dec- 14 |
21- Dec -15 |
21- Dec -17 |
US20170362
187 |
3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2- CARBOXAMIDE COMPOUNDS |
Parion
Sciences, Inc. |
17- Dec- 12 |
29- Jun -17 |
21- Dec -17 |
US20170362
170 |
HEPATITIS
C ANTIVIRAL COMPOSITIONS AND METHODS |
Not
Available |
3- Aug-
07 |
29- Jun -17 |
21- Dec -17 |
US20170360
962 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN
NEUTRALIZING ANTIBODIES |
Not
Available |
16- Feb- 16 |
18- Aug -17 |
21- Dec -17 |
US20170360
960 |
AAV
Vectors Targeted to the Central Nervous System |
Not
Available |
21- Nov- 14 |
20- Nov -15 |
21- Dec -17 |
US20170360
908 |
VACCINE
PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING
BISPHOSPHONATES |
NITTO
DENKO CORPORATION |
3- Sep- 14 |
2- Sep -15 |
21- Dec -17 |
US20170360
881 |
PEPTIDOMIMETIC
MACROCYCLES AND USES THEREOF |
Not
Available |
17- Jun- 16 |
16- Jun -17 |
21- Dec -17 |
US20170360
875 |
METHODS
FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS |
MIDDLE
TENNESSEE STATE UNIVERSITY |
22- Dec- 14 |
22- Dec -15 |
21- Dec -17 |
US20170358
082 |
STAIN-FREE
HISTOPATHOLOGY BY CHEMICAL IMAGING |
Not
Available |
15- Mar- 13 |
2- Aug -17 |
14- Dec -17 |
US20170354
727 |
MODULATION
OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS |
Not
Available |
8- Oct-
04 |
23- Aug -17 |
14- Dec -17 |
US20170348
433 |
NOVEL
RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN
NEUTRALIZING ANTIBODIES |
The
Board of Trustees of the Leland Stanford Junior University |
16- Feb- 16 |
16- Feb -17 |
7- Dec -17 |
US20170348
402 |
SYSTEM
AND METHOD FOR DELIVERING GENETIC MATERIAL OR PROTEIN TO CELLS |
Not
Available |
30- Jul-14 |
30- Jul- 15 |
7- Dec -17 |
US20170348
369 |
Plant
Extract and Its Therapeutic Use |
Not
Available |
16- May- 08 |
18- Jul- 17 |
7- Dec -17 |
US20170342
442 |
RECOMBINANT
SELF-REPLICATING POLYCISTRONIC RNA MOLECULES |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
11- Oct- 11 |
15- Aug -17 |
30- Nov -17 |
US20170342
405 |
MOLECULAR
INDEXING OF INTERNAL SEQUENCES |
Not
Available |
31- May- 16 |
16- May -17 |
30- Nov -17 |
US20170342
056 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
31- May- 16 |
26- May -17 |
30- Nov -17 |
US20170340
735 |
Anti-TIGIT
Antigen-Binding Proteins and Methods of Use Thereof |
Not
Available |
1- Oct-
15 |
19- Jun -17 |
30- Nov -17 |
US20170340
725 |
COMBINATION
PIV3/HMPV RNA VACCINES |
ModernaTX,
Inc. |
22- Oct- 15 |
11- Aug -17 |
30- Nov -17 |
US20170340
721 |
METHODS
AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES |
Not
Available |
3- Sep-
14 |
3- Sep -15 |
30- Nov -17 |
US20170340
611 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
31- May- 16 |
26- May -17 |
30- Nov -17 |
US20170337
459 |
SPATIALLY
ADDRESSABLE MOLECULAR BARCODING |
Not
Available |
27- Feb- 15 |
2- Aug -17 |
23- Nov -17 |
US20170336
412 |
Multiplex
Immuno Screening Assay |
Institut
Pasteur |
4- May-
12 |
19- Jul- 17 |
23- Nov -17 |
US20170336
411 |
B-CELL
ANTIGEN PRESENTING CELL ASSAY |
The
University of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
9- Aug -17 |
23- Nov -17 |
US20170335
408 |
Methods
and Systems of Multi-Assay Processing and Analysis |
Not
Available |
15- Mar- 16 |
15- Mar -17 |
23- Nov -17 |
US20170335
374 |
METHODS
AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A
SAMPLE |
Not
Available |
6- Mar- 12 |
6- Jul- 17 |
23- Nov -17 |
US20170334
984 |
HUMAN
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) |
Not
Available |
16- Dec- 02 |
26- Apr -16 |
23- Nov -17 |
US20170334
973 |
NON-HUMAN
PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED
AGAINST ENVELOPE GLYCOPROTEINS |
Not
Available |
28- Oct- 14 |
27- Oct -15 |
23- Nov -17 |
US20170334
941 |
2',2'-DIHALO
NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND
CANCER |
Not
Available |
31- Oct- 14 |
30- Oct -15 |
23- Nov -17 |
US20170334
919 |
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET
HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES
AND THEIR USE AS PHOSPHOINOSITIDE
3-KINASE INHIBITORS |
RESPIVERT
LTD. |
15- Mar- 13 |
27- Jul- 17 |
23- Nov -17 |
US20170334
864 |
3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-
PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)
CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE |
Parion
Sciences, Inc. |
27- Jun- 11 |
1- Mar -17 |
23- Nov -17 |
US20170333
586 |
ADDITIVE
COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF |
Not
Available |
8- Dec-
14 |
23- May -15 |
23- Nov -17 |
US20170333
553 |
LIPIDATED
IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS |
Not
Available |
21- May- 13 |
1- Aug -17 |
23- Nov -17 |
US20170333
494 |
PROBIOTIC
THERAPEUTIC APPLICATIONS |
Not
Available |
10- Nov- 14 |
9- Nov -15 |
23- Nov -17 |
US20170333
457 |
Anti-Viral
Azide Containing Compounds |
Not
Available |
28- Jul-10 |
8- Aug -17 |
23- Nov -17 |
US20170333
267 |
MOBILE
CLINICS |
Baylor
College of Medicine |
12- Nov- 14 |
11- Nov -15 |
23- Nov -17 |
US20170328
819 |
SAMPLE
FIXATION AND STABILISATION |
Not
Available |
1- Mar-
13 |
30- May -17 |
16- Nov -17 |
US20170327
543 |
POLYIONIC
PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES |
Not
Available |
8- Sep-
10 |
31- Jan -17 |
16- Nov -17 |
US20170327
472 |
CHLORO-PYRAZINE
CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY |
Parion
Sciences, Inc. |
17- Dec- 12 |
7- Mar -17 |
16- Nov -17 |
US20170327
439 |
DIHYDRONAPHTHALENE
DERIVATIVE |
ONO
PHARMACEUTICAL CO., LTD. |
3- Dec-
14 |
3- Dec -14 |
16- Nov -17 |
US20170326
256 |
RECOMBINANT
PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF |
Children's
Healthcare of Atlanta, Inc. |
16- Apr- 15 |
15- Apr -16 |
16- Nov -17 |
US20170326
123 |
Throat
solution for treatment of cold, flu and sore throat |
Not
Available |
12- May- 16 |
12- May -16 |
16- Nov -17 |
US20170322
682 |
SYSTEM
AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING
EVENT-RELATED INFORMATION |
Georgetown
University |
25- Feb- 08 |
27- Jul- 17 |
9- Nov -17 |
US20170322
201 |
ANTIGEN
PRESENTING CELL ASSAY |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
20- Jul- 17 |
9- Nov -17 |
US20170321
192 |
Recombinant
RNA Viruses and Uses Thereof |
Icahn
School of Medicine at Mount Sinai |
6- Jun-
10 |
6- Apr -17 |
9- Nov -17 |
US20170319
712 |
METHODS
AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE |
3M
INNOVATIVE PROPERTIES COMPANY |
10- Apr- 03 |
27- Jul- 17 |
9- Nov -17 |
US20170319
673 |
TRI-SEGMENTED
ARENAVIRUSES AS VACCINE VECTORS |
Not
Available |
13- Nov- 14 |
12- Nov -15 |
9- Nov -17 |
US20170319
551 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
9- May-
12 |
24- Jan -17 |
9- Nov -17 |
US20170313
765 |
DIRECT
EXPRESSION OF ANTIBODIES |
Not
Available |
29- Oct- 14 |
28- Oct -15 |
2- Nov -17 |
US20170313
685 |
BROAD-SPECTRUM
NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS |
Purdue
Research Foundation |
28- Apr- 16 |
28- Apr -17 |
2- Nov -17 |
US20170312
371 |
MODIFIED
VIRUS-LIKE PARTICLES OF CMV |
SAIBA
GMBH |
22- Oct- 14 |
20- Oct -15 |
2- Nov -17 |
US20170312
357 |
MANUFACTURE
OF SURFACTANT-CONTAINING COMPOSITIONS |
Not
Available |
2- Dec-
14 |
2- Dec -15 |
2- Nov -17 |
US20170308
679 |
BIOSECURITY
SCREENING SYSTEM AND METHOD |
Not
Available |
16- Oct- 14 |
12- Oct -15 |
26- Oct- 17 |
US20170307
562 |
CHEMICALLY
DIFFERENTIATED SENSOR ARRAY |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
8- May -17 |
26- Oct- 17 |
US20170306
354 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
17- Dec- 01 |
1- May -17 |
26- Oct- 17 |
US20170306
293 |
MEANS AND
METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS |
Not
Available |
9- Dec-
05 |
2- Jun -17 |
26- Oct- 17 |
US20170306
001 |
CHIMERIZATION
AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING
ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADES |
NATIONAL
UNIVERSITY OF SINGAPORE |
27- Mar- 14 |
27- Mar -15 |
26- Oct- 17 |
US20170305
868 |
ARYLALKYL-AND
ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS |
Parion
Sciences, Inc. |
13- Dec- 13 |
1- Mar -17 |
26- Oct- 17 |
US20170304
829 |
PRINTED
CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULE |
Click
Diagnostics, Inc. |
22- Apr- 16 |
21- Apr -17 |
26- Oct- 17 |
US20170304
466 |
AAV-Based
Gene Therapy |
Not
Available |
6- Oct-
14 |
6- Oct -15 |
26- Oct- 17 |
US20170304
459 |
METHODS
AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE |
Not
Available |
10- Oct- 14 |
7- Oct -15 |
26- Oct- 17 |
US20170304
429 |
VACCINATION
OF IMMUNOCOMPROMISED SUBJECTS |
Not
Available |
26- Sep- 14 |
25- Sep -15 |
26- Oct- 17 |
US20170304
420 |
POLYMER
ADJUVANT |
Oxford
University Innovation Limited |
10- Oct- 14 |
9- Oct -15 |
26- Oct- 17 |
US20170304
354 |
TREATMENT
OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS |
Marine
Polymer Technologies, Inc. |
15- Apr- 11 |
13- Mar -17 |
26- Oct- 17 |
US20170299
591 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
13- Dec -16 |
19- Oct- 17 |
US20170298
100 |
ANTI-VIRAL
PEPTIDES |
Not
Available |
1- Oct-
14 |
30- Sep -15 |
19- Oct- 17 |
US20170296
663 |
Conjugates
of Cell Binding Molecules with Cytotoxic Agents |
Hangzhou
DAC Biotech Co., Ltd. |
16- Apr- 14 |
16- Apr -14 |
19- Oct- 17 |
US20170296
574 |
Method
of Treating Inflammation |
Not
Available |
1- Apr-
10 |
28- Jun -17 |
19- Oct- 17 |
US20170292
132 |
TISSUE
PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME,
AND USES THEREOF |
Not
Available |
29- Apr- 13 |
20- Jun -17 |
12- Oct- 17 |
US20170290
909 |
METHODS
AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING
FLAGELLIN |
Bavarian
Nordic A/S |
26- Sep- 14 |
25- Sep -15 |
12- Oct- 17 |
US20170281
966 |
Device
to Kill Micro-Organisms Inside the Respiratory Tract |
Not
Available |
1- Apr-
16 |
28- Mar -17 |
5- Oct-
17 |
US20170281
759 |
BISPHOSPHONATE-CONTAINING
VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITY |
NITTO
DENKO CORPORATION |
3- Sep-
14 |
2- Sep -15 |
5- Oct-
17 |
US20170275
621 |
CHIRAL
CONTROL |
Not
Available |
13- Jul-12 |
17- Mar -17 |
28- Sep -17 |
US20170275
592 |
CULTURE
MEDIUM |
Koninklijke
Nederlandse Akademie Van Wetenschappen |
27- Nov- 14 |
27- Nov -15 |
28- Sep -17 |
US20170275
323 |
GLYCOLIPIDS
AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY |
THE
UNIVERSITY OF NOTTINGHAM |
4- Apr-
14 |
7- Apr -15 |
28- Sep -17 |
US20170275
253 |
BENZAZEPINE
SULFONAMIDE COMPOUNDS |
Hoffmann-La
Roche Inc. |
18- Dec- 14 |
14- Jun -17 |
28- Sep -17 |
US20170275
243 |
Lipids
and Lipid Compositions for the Delivery of Active Agents |
Novartis
AG |
5- Sep-
14 |
4- Sep -15 |
28- Sep -17 |
US20170274
064 |
MODIFIED
BAT INFLUENZA VIRUSES AND THEIR USES |
Not
Available |
5- Sep-
14 |
4- Sep -15 |
28- Sep -17 |
US20170274
024 |
AAV
Vectors Targeted to Oligodendrocytes |
Not
Available |
28- Sep- 12 |
17- Apr -17 |
28- Sep -17 |
US20170267
969 |
Animal
Protein-Free Media for Cultivation of Cells |
Baxalta
GmbH |
29- Oct- 04 |
18- May -17 |
21- Sep -17 |
US20170267
722 |
INHIBITORY
PEPTIDES OF VIRAL INFECTION |
Not
Available |
17- Jul-14 |
25- May -17 |
21- Sep -17 |
US20170267
649 |
STABLE
SODIUM CHANNEL BLOCKERS |
PARION
SCIENCES, INC. |
30- Jun- 14 |
30- Jan -17 |
21- Sep -17 |
US20170266
272 |
TRANSGENIC
VERO-CD4/CCR5 CELL LINE |
Not
Available |
2- Oct-
15 |
6- Apr -17 |
21- Sep -17 |
US20170266
190 |
DRUG
COMBINATION |
Not
Available |
15- Mar- 13 |
5- Jun -17 |
21- Sep -17 |
US20170266
160 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED
2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES
INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
6- Jun -17 |
21- Sep -17 |
US20170261
431 |
CONTINUOUS
PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS |
Not
Available |
10- Mar- 05 |
19- May -17 |
14- Sep -17 |
US20170260
223 |
ENANTIOMERS
OF THE 1',6'-ISOMER OF NEPLANOCIN A |
Not
Available |
4- Aug-
14 |
17- May -17 |
14- Sep -17 |
US20170260
147 |
ANTIVIRAL
COMPOUNDS AND METHODS |
Biotron
Limited |
26- Jun- 03 |
23- May -17 |
14- Sep -17 |
US20170259
976 |
DEGRADABLE
MATERIALS AND PACKAGING MADE FROM SAME |
MONOSOL,
LLC |
3- Oct-
14 |
2- Oct -15 |
14- Sep -17 |
US20170258
904 |
Antagonism
of the VIP Signaling Pathway |
Not
Available |
2- Feb-
11 |
22- May -17 |
14- Sep -17 |
US20170258
893 |
MERS-CoV
Vaccine |
Not
Available |
29- Nov- 13 |
26- Nov -14 |
14- Sep -17 |
US20170253
861 |
HIGHLY
EFFICIENT INFLUENZA MATRIX (M1) PROTEINS |
Not
Available |
11- Jul-03 |
6- Oct -16 |
7- Sep -17 |
US20170252
430 |
POLYMERIC
CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT |
Not
Available |
1- Apr-
14 |
1- Apr -15 |
7- Sep -17 |
US20170252
417 |
PROTEIN-CHAPERONED
T-CELL VACCINES |
Not
Available |
7- Mar-
16 |
7- Mar -17 |
7- Sep -17 |
US20170247
688 |
ENZYMATIC
ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES |
NUEVOLUTION
A/S |
1- Dec-
05 |
12- Dec -16 |
31- Aug -17 |
US20170247
453 |
SOLUBLE
ENGINEERED MONOMERIC FC |
The
United States of America, as represented by the Secretary, Department of
Health and Human Serv |
16- Mar- 12 |
9- May -17 |
31- Aug -17 |
US20170247
423 |
STAPLED
INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION |
Not
Available |
29- Feb- 16 |
28- Feb -17 |
31- Aug -17 |
US20170246
347 |
MATERIALS
WITH IMPROVED PROPERTIES |
Not
Available |
1- Nov-
15 |
5- May -17 |
31- Aug -17 |
US20170241
998 |
METHOD
FOR THE IMMOBILIZATION OF BIOMOLECULES |
Not
Available |
22- Feb- 16 |
17- Feb -17 |
24- Aug -17 |
US20170240
639 |
ACTRII
ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY |
Not
Available |
22- Feb- 16 |
22- Feb -17 |
24- Aug -17 |
US20170239
397 |
MODIFIED
ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS |
Not
Available |
1- Nov-
15 |
5- May -17 |
24- Aug -17 |
US20170239
364 |
METHODS
AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY |
Not
Available |
28- Mar- 11 |
2- Mar -17 |
24- Aug -17 |
US20170239
349 |
COMPOSITIONS
AND METHODS RELATED TO NEUROLOGICAL DISORDERS |
Not
Available |
20- Feb- 15 |
6- Jun -16 |
24- Aug -17 |
US20170239
291 |
METHOD OF
PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER
SOLUTION |
SONOMA
PHARMACEUTICALS, INC. |
30- Dec- 03 |
9- May -17 |
24- Aug -17 |
US20170234
781 |
MEMBRANE-ASSISTED
PURIFICATION |
Accelerate
Diagnostics, Inc. |
7- Mar-
11 |
3- May -17 |
17- Aug -17 |
US20170226
593 |
HANDHELD
NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION |
Not
Available |
8- Feb-
16 |
8- Feb -16 |
10- Aug -17 |
US20170226
511 |
APTAMERS
FOR BINDING FLAVIVIRUS PROTEINS |
National
University of Singapore |
13- Nov- 13 |
13- Nov -14 |
10- Aug -17 |
US20170226
232 |
MODIFIED
ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS |
Not
Available |
1- Nov-
15 |
2- Nov -16 |
10- Aug -17 |
US20170226
222 |
BISPECIFIC
ANTIBODY |
Not
Available |
20- Nov- 13 |
18- Jan -17 |
10- Aug -17 |
US20170226
173 |
GM-CSF
and IL-4 Conjugates, Compositions, and Methods Related Thereto |
Not
Available |
23- Oct- 12 |
19- Apr -17 |
10- Aug -17 |
US20170224
813 |
VACCINE
PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING
SUPPRESSION OF INDUCTION OF CTL |
NITTO
DENKO CORPORATION |
4- Aug- 14 |
4- Aug -15 |
10- Aug -17 |
US20170224
812 |
LIQUID
IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL
COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG |
NITTO
DENKO CORPORATION |
4- Aug- 14 |
4- Aug -15 |
10- Aug -17 |
US20170224
616 |
OIL-IN-WATER
EMULSIONS THAT CONTAIN NUCLEIC ACIDS |
GLAXOSMITHKLINE
BIOLOGICALS SA |
6-Jul- 11 |
24- Apr -17 |
10- Aug -17 |
US20170219
560 |
MALARIA
ANTIGEN SCREENING METHOD |
United
States of America as Represented by the Secretary of the Navy |
31- Aug- 05 |
10- Apr -17 |
3- Aug -17 |
US20170216
431 |
VACCINE
PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION |
NITTO
DENKO CORPORATION |
2- Oct-
14 |
1- Oct -15 |
3- Aug -17 |
US20170216
430 |
IMMUNE-INDUCTION-PROMOTING
COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL
COMPOSITION |
NITTO
DENKO CORPORATION |
4- Aug- 14 |
4- Aug -15 |
3- Aug -17 |
US20170216
429 |
COMPOSITION
FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL
COMPOSITION |
NITTO
DENKO CORPORATION |
4- Aug- 14 |
4- Aug -15 |
3- Aug -17 |
US20170216
427 |
Coronavirus |
Not
Available |
23- Jul-14 |
23- Jul- 15 |
3- Aug -17 |
US20170216
348 |
METAL
NANOCLUSTERS AND USES THEREOF |
Not
Available |
7- Aug-
14 |
7- Aug -15 |
3- Aug -17 |
US20170216
347 |
ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED
POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND
TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS
(HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A
(IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED
POLYALLYLAMINE DERIVATIVE |
UNIWERSYTET
JAGIELLONSKI |
29- Jul-14 |
29- Jul- 15 |
3- Aug -17 |
US20170212
116 |
BIOSENSORS
FOR THE DETECTION OF INFECTION AND ASSOCIATED MALADIES |
ULISSE
BIOMED SRL |
31- Jan- 14 |
26- Jan -15 |
27- Jul- 17 |
US20170212
019 |
POLYMER
STABILIZATION OF CHROMOGEN SOLUTIONS |
Not
Available |
23- Jan- 12 |
10- Apr -17 |
27- Jul- 17 |
US20170211
096 |
LCMV-GP-VSV-Pseudotyped
Vectors and Tumor-Infiltrating Virus- Producing Cells for the Therapy of
Tumors |
Not
Available |
29- Jun- 11 |
7- Apr -17 |
27- Jul- 17 |
US20170211
069 |
USE
OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE
AND PROMOTING AUTHOPHAGY |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
7- Mar- 12 |
27- Jan -17 |
27- Jul- 17 |
US20170211
058 |
METHOD
AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLES |
Not
Available |
6- Aug-
14 |
5- Aug -15 |
27- Jul- 17 |
US20170209
844 |
MICROSPOTTING
DEVICE |
Not
Available |
18- Apr- 12 |
5- Jan -17 |
27- Jul- 17 |
US20170209
595 |
DISULFUR
BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE |
Suzhou
M-Conj Biotech Co., Ltd. |
15- Jul-15 |
5- Apr -17 |
27- Jul- 17 |
US20170209
590 |
METHODS
AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO
CXCR4 CELLS |
Not
Available |
13- Jan- 11 |
10- Jan -17 |
27- Jul- 17 |
US20170209
570 |
Carbon
Nanotube Compositions and Methods of Use Thereof |
Not
Available |
19- Mar- 08 |
17- Mar -17 |
27- Jul- 17 |
US20170209
376 |
COMPOSITIONS
WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE
FOR PREVENTION AND TREATMENT OF VIRAL DISEASES |
Not
Available |
14- Apr- 04 |
10- Mar -17 |
27- Jul- 17 |
US20170205
399 |
POLYMERS
AND CONJUGATES COMPRISING THE SAME |
Not
Available |
2- Oct-
14 |
31- Mar -17 |
20- Jul- 17 |
US20170204
143 |
Constrained
proteins and uses therefor |
Not
Available |
21- Jul-14 |
21- Jul- 15 |
20- Jul- 17 |
US20170204
083 |
THERAPEUTIC
HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES |
RUTGERS,
THE STATE UNIVERSITY OF NEW JERSEY |
11- Sep- 12 |
13- Jan -17 |
20- Jul- 17 |
US20170202
975 |
DISULFUR
BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE |
Suzhou
M-Conj Biotech Co., Ltd. |
15- Jul-15 |
5- Apr -17 |
20- Jul- 17 |
US20170202
960 |
CATIONIC
OIL-IN-WATER EMULSIONS |
GLAXOSMITHKLINE
BIOLOGICALS, SA |
6-Jul- 11 |
23- Mar -17 |
20- Jul- 17 |
US20170202
959 |
ADJUVANT
COMPOSITIONS AND RELATED METHODS |
Not
Available |
24- Mar- 15 |
23- Mar -17 |
20- Jul- 17 |
US20170202
956 |
Methods
and Compositions for Inhibiting Akt3 |
Not
Available |
15- Jan- 16 |
17- Jan -17 |
20- Jul- 17 |
US20170202
955 |
Adjuvanted
Influenza Vaccines for Pediatric Use |
Not
Available |
22- Feb- 08 |
30- Dec -16 |
20- Jul- 17 |
US20170202
949 |
DEFECTIVE
RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN
IMMUNE RESPONSE |
Providence
Health & Services - Oregon |
29- Jul-05 |
29- Dec -16 |
20- Jul- 17 |
US20170202
829 |
Specific
Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications |
Not
Available |
15- Jan- 16 |
17- Jan -17 |
20- Jul- 17 |
US20170196
979 |
LIPIDS
AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS |
Novartis
AG |
8- Mar-
13 |
27- Sep -16 |
13- Jul- 17 |
US20170196
954 |
PRIME-BOOST
REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR |
Not
Available |
15- Jul-14 |
14- Jul- 15 |
13- Jul- 17 |
US20170191
933 |
Systems
and Methods for Analyzing a Sample and for Monitoring the Performance of an
Optical Signal Detector |
Not
Available |
31- Dec- 15 |
23- Dec -16 |
6- Jul- 17 |
US20170191
079 |
METHOD
OF INCREASING THE FUNCTION OF AN AAV VECTOR |
Not
Available |
7- Apr-
05 |
18- Jan -17 |
6- Jul- 17 |
US20170190
770 |
HUMAN
MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) |
CORMORANT
PHARMACEUTICALS AB |
16- Dec- 02 |
26- Apr -16 |
6- Jul- 17 |
US20170189
521 |
LIPIDATED
IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS |
3M
Innovative Properties Company |
17- Aug- 10 |
19- Aug -16 |
6- Jul- 17 |
US20170175
140 |
METHODS
FOR USING A 5'-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN EUKARYOTIC
CELLS |
Not
Available |
16- Dec- 15 |
14- Dec -16 |
22- Jun- 17 |
US20170173
585 |
POINT OF
CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION |
Not
Available |
11- Jul-14 |
10- Jul- 15 |
22- Jun- 17 |
US20170173
176 |
ACETYLENEDICARBOXYL
LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
3- Mar -17 |
22- Jun- 17 |
US20170173
168 |
ACETYLENEDICARBOXYL
LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
3- Mar -17 |
22- Jun- 17 |
US20170173
164 |
HYDRAZINO
1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM |
Not
Available |
3- Jun-
11 |
6- Mar -17 |
22- Jun- 17 |
US20170168
052 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
13- Dec -16 |
15- Jun- 17 |
US20170168
044 |
QUANTITATIVE
ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING |
XIAMEN
UNIVERSITY |
9- Jun-
14 |
24- Sep -14 |
15- Jun- 17 |
US20170166
574 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
14- Dec- 15 |
12- Dec -16 |
15- Jun- 17 |
US20170165
366 |
Anti-TIGIT
Antigen-Binding Proteins and Methods of Use Thereof |
Not
Available |
1- Oct-
15 |
13- Feb -17 |
15- Jun- 17 |
US20170165
359 |
IMMUNOSTIMULATORY
COMBINATIONS OF TLR LIGANDS AND METHODS OF USE |
Not
Available |
11- Aug- 10 |
23- Aug -16 |
15- Jun- 17 |
US20170165
341 |
REPLICATION
DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION |
Not
Available |
24- Aug- 12 |
15- Feb -17 |
15- Jun- 17 |
US20170165
230 |
USE
OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO
MODULATE T CELL IMMUNITY |
Not
Available |
9- Apr- 14 |
9- Apr -15 |
15- Jun- 17 |
US20170160
218 |
APPARATUS
AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONS |
Not
Available |
31- Jul-12 |
23- Feb -17 |
8- Jun-
17 |
US20170159
027 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
15- Feb -17 |
8- Jun- 17 |
US20170159
026 |
Novel
Recombinant Adeno-Associated Virus Capsids with Enhanced Human Skeletal
Muscle Tropism |
Not
Available |
2- Dec-
15 |
2- Dec -16 |
8- Jun-
17 |
US20170158
752 |
MIDDLE
EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF
USE THEREOF |
Not
Available |
25- Apr- 14 |
27- Apr -15 |
8- Jun- 17 |
US20170157
262 |
CONJUGATES
OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS |
Not
Available |
12- Jul-12 |
12- Jul- 12 |
8- Jun-
17 |
US20170157
151 |
Broad
Spectrum Antiviral and Methods of Use |
Not
Available |
17- Apr- 06 |
16- Feb -17 |
8- Jun-
17 |
US20170152
274 |
CHARGED
LINKERS AND THEIR USES FOR CONJUGATION |
Hangzhou
DAC Biotech Co., Ltd. |
28- Feb- 14 |
28- Feb -14 |
1- Jun-
17 |
US20170152
271 |
GAK
MODULATORS AS ANTIVIRALS |
Katholieke
Universiteit Leuven |
23- Jul-14 |
23- Jul- 15 |
1- Jun-
17 |
US20170151
346 |
DISULFUR
BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE |
SUZHOU
M-CONJ BIOTECH CO., LTD. |
15- Jul-15 |
13- Feb -17 |
1- Jun-
17 |
US20170151
291 |
SYNERGISTIC
BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF |
Not
Available |
25- Nov- 13 |
25- Nov -14 |
1- Jun-
17 |
US20170145
394 |
TRACKING
AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 |
Not
Available |
23- Nov- 15 |
22- Nov -16 |
25- May -17 |
US20170144
984 |
MODULATORS
OF THE RELAXIN RECEPTOR 1 |
Not
Available |
4- May-
12 |
25- Aug -16 |
25- May -17 |
US20170143
845 |
ACETYLENEDICARBOXYL
LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE |
SUZHOU
M-CONJ BIOTECH CO., LTD |
15- Jul-15 |
3- Feb -17 |
25- May -17 |
US20170143
820 |
IMMUNOGENIC
COMBINATIONS |
GLAXOSMITHKLINE
SA |
13- Jun- 14 |
12- Jun -15 |
25- May -17 |
US20170143
758 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Advanced
Inhalation Therapies (AIT) Ltd. |
11- Sep- 13 |
4- Jan -17 |
25- May -17 |
US20170143
749 |
SUBSTITUTED
NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF |
Not
Available |
24- Jun- 14 |
2- Feb -17 |
25- May -17 |
US20170137
527 |
GITR
ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSE |
Not
Available |
25- Mar- 05 |
7- Nov -16 |
18- May -17 |
US20170137
430 |
Nuclear
Transport Modulators And Uses Thereof |
Not
Available |
29- Jul-11 |
22- Jul- 16 |
18- May -17 |
US20170136
118 |
NEUTRALIZING
MOLECULES TO VIRAL ANTIGENS |
Not
Available |
28- Mar- 08 |
8- Jun -16 |
18- May -17 |
US20170136
043 |
THERAPEUTIC
USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE
ACTIVITY |
The
University of North Carolina at Chapel Hill |
11- Apr- 14 |
30- Jan -17 |
18- May -17 |
US20170131
271 |
ANTIBODY-NANOPARTICLE
CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES |
Not
Available |
27- Apr- 10 |
12- Sep -16 |
11- May -17 |
US20170130
200 |
INTRACELLULAR
GENOMIC TRANSPLANT AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
29- Jul- 16 |
11- May -17 |
US20170129
947 |
REGULATING
THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED
PHOSPHATIDYL SERINE |
Kolltan
Pharmaceuticals, Inc. |
25- Jul-12 |
20- Sep -16 |
11- May -17 |
US20170129
891 |
SUBSTITUTED
IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES |
Not
Available |
18- Jun- 04 |
23- Jan -17 |
11- May -17 |
US20170128
465 |
Pharmaceutical
Compositions and Methods |
Not
Available |
3- Aug-
15 |
6- Dec -16 |
11- May -17 |
US20170122
853 |
PHOTO-CONTROLLED
REMOVAL OF TARGETS IN VITRO AND IN VIVO |
THE
UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF
HEALTH AND HUMAN SERV |
8- Aug-
14 |
7- Aug -15 |
4- May -17 |
US20170121
372 |
NOVEL
DEPSIPEPTIDE AND USES THEREOF |
Not
Available |
3- Dec-
12 |
15- Jun -16 |
4- May -17 |
US20170119
872 |
SOLUBLE
NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES |
Not
Available |
20- Aug- 10 |
11- Oct -16 |
4- May -17 |
US20170119
871 |
LOW-ADDITIVE
INFLUENZA VACCINES |
Not
Available |
27- Jun- 07 |
24- Jun -16 |
4- May -17 |
US20170119
820 |
MODIFIED
CELLS AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
29- Jul- 16 |
4- May -17 |
US20170119
786 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
Not
Available |
8- Mar-
11 |
11- Nov -16 |
4- May -17 |
US20170119
734 |
TETRAZOLONES
AS INHIBITORS OF FATTY ACID SYNTHASE |
Not
Available |
5- May-
10 |
22- Apr -16 |
4- May -17 |
US20170118
995 |
MINERAL
FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING
UNICELLULAR ORGANISMS AND/OR VIRUSES |
Riken
Techno System Co., Ltd. |
17- Sep- 14 |
6- Dec -16 |
4- May -17 |
US20170114
053 |
HETEROCYCLIC
COMPOUNDS AND METHODS OF USE THEREOF |
The
United States of America, as represented by the Secretary, Department of
Health and Human Serv |
12- Jun- 14 |
12- Jun -15 |
27- Apr- 17 |
US20170112
929 |
VISTA
MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER |
Not
Available |
7- Sep-
12 |
6- Jun -16 |
27- Apr- 17 |
US20170107
254 |
Modified
Antimicrobial Peptides |
Not
Available |
2- Apr-
14 |
2- Apr -15 |
20- Apr- 17 |
US20170107
195 |
Chemical
Compounds |
AstraZeneca
AB |
18- Mar- 14 |
17- Mar -15 |
20- Apr- 17 |
US20170106
077 |
INFLUENZA
VIRUS VECTORS AND USES THEREFOR |
Not
Available |
17- Mar- 14 |
13- Mar -15 |
20- Apr- 17 |
US20170101
459 |
CLEAVAGE
AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING
AZOBENZENE-CONTAINING PEPTIDES |
Not
Available |
6- Jun- 14 |
5- Jun -15 |
13- Apr- 17 |
US20170101
413 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.p.A. |
12- Jun- 14 |
12- Jun -14 |
13- Apr- 17 |
US20170100
474 |
METHODS
AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES |
Not
Available |
6- Apr-
07 |
22- Jul- 16 |
13- Apr- 17 |
US20170100
385 |
PHARMACEUTICAL
COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES |
GLAXOSMITHKLINE
INTELLECTUAL PROPERTY (NO. 2) LIMITED |
12- May- 14 |
8- May -15 |
13- Apr- 17 |
US20170096
646 |
Modified
Adenovirus Hexon Protein and Uses Thereof |
Not
Available |
28- Apr- 06 |
20- Dec -16 |
6- Apr-
17 |
US20170096
455 |
METHODS
AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS |
The
University of North Carolina at Chapel Hill |
20- Mar- 14 |
20- Mar -15 |
6- Apr-
17 |
US20170096
441 |
PHOSPHONATES
WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS |
Not
Available |
14- Apr- 10 |
9- Sep -16 |
6- Apr-
17 |
US20170096
417 |
Multicyclic
Compounds And Methods Of Using Same |
Karyopharm
Therapeutics Inc. |
20- Sep- 13 |
19- Sep -14 |
6- Apr-
17 |
US20170095
818 |
INTEGRATED
MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION AND MICROARRAY DETECTION |
CapitalBio
Corporation |
31- Mar- 14 |
31- Mar -15 |
6- Apr-
17 |
US20170095
521 |
Novel
Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating
Agents |
Not
Available |
1- Oct-
15 |
30- Sep -16 |
6- Apr-
17 |
US20170089
911 |
QUINONE
METHIDE ANALOG SIGNAL AMPLIFICATION |
Not
Available |
24- Feb- 14 |
24- Aug -16 |
30- Mar -17 |
US20170088
858 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
17- Dec- 01 |
20- Oct -16 |
30- Mar -17 |
US20170088
848 |
Recombinant
Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants
Expressing Hemagglutinin |
Medicago
Inc. |
21- Jan- 08 |
2- Sep -16 |
30- Mar -17 |
US20170088
559 |
ALKYLOXY
SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES |
Not
Available |
9- Feb-
05 |
12- Dec -16 |
30- Mar -17 |
US20170086
463 |
ANTIVIRAL
AGENT |
Not
Available |
3- Sep-
08 |
12- Dec -16 |
30- Mar -17 |
US20170082
608 |
Assay
for Detecting TH1 and TH2 Cell Populations |
Not
Available |
16- May- 14 |
15- May -15 |
23- Mar -17 |
US20170082
607 |
MALARIA
ANTIGEN SCREENING METHOD |
Not
Available |
31- Aug- 05 |
19- Apr -13 |
23- Mar -17 |
US20170081
655 |
PURIFICATION
OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES |
Not
Available |
14- Jul-15 |
13- Jul- 16 |
23- Mar -17 |
US20170081
393 |
ENGINEERED
ANTIBODY CONSTANT DOMAIN MOLECULES |
The
U.S.A., as represented by the Secretary, Department of Health and Human
Services |
31- Jan- 08 |
2- Dec -16 |
23- Mar -17 |
US20170081
392 |
COMPOSITIONS
COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF |
Not
Available |
13- May- 14 |
13- May -15 |
23- Mar -17 |
US20170080
084 |
OIL/SURFACTANT
MIXTURES FOR SELF-EMULSIFICATION |
Not
Available |
17- Mar- 14 |
17- Mar -15 |
23- Mar -17 |
US20170080
079 |
METHODS
OF MAKING AND USING LIVE ATTENUATED VIRUSES |
Not
Available |
23- Sep- 15 |
23- Sep -16 |
23- Mar -17 |
US20170080
078 |
COMPOSITIONS
AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY
SYNDROME |
Not
Available |
24- Apr- 12 |
3- Oct -16 |
23- Mar -17 |
US20170079
920 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
5- Dec -16 |
23- Mar -17 |
US20170079
916 |
COMPOSITIONS
AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY |
Not
Available |
23- Sep- 15 |
23- Sep -16 |
23- Mar -17 |
US20170079
253 |
TRANSGENIC
MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE,
EXPERIMENTAL USES AND APPLICATIONS |
INSTITUT
PASTEUR |
30- Jul-03 |
17- Jul- 12 |
23- Mar -17 |
US20170073
738 |
Compositions
and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood Samples |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
25- Nov -16 |
16- Mar -17 |
US20170073
730 |
METHODS
AND COMPOSITIONS FOR LIBRARY NORMALIZATION |
Not
Available |
11- Sep- 15 |
8- Sep -16 |
16- Mar -17 |
US20170073
727 |
METHODS
FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA |
Not
Available |
8- Nov-
13 |
2- Nov -16 |
16- Mar -17 |
US20170073
390 |
Method
for Identifying and Validating Dominant T Helper Cell Epitopes Using an
HLA-DM-Assisted Class II Binding Assay |
Not
Available |
6- Jan- 06 |
5- Dec -14 |
16- Mar -17 |
US20170073
352 |
NOVEL
SUBSTITUTED SPIROCYCLES |
Not
Available |
12- Sep- 14 |
29- Nov -16 |
16- Mar -17 |
US20170072
053 |
METHODS
FOR PREPARING SQUALENE |
Not
Available |
12- May- 10 |
22- Nov -16 |
16- Mar -17 |
US20170071
980 |
METHOD OF
USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL APPLICATIONS |
OCULUS
INNOVATIVE SCIENCES, INC. |
2- May-
05 |
22- Nov -16 |
16- Mar -17 |
US20170071
964 |
METHODS
FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS |
Not
Available |
16- Sep- 15 |
16- Sep -16 |
16- Mar -17 |
US20170071
867 |
NOVEL
NANOPARTICLE COMPOSITIONS |
Not
Available |
3- Apr-
13 |
28- Nov -16 |
16- Mar -17 |
US20170067
030 |
ATTENUATED
VIRUSES USEFUL FOR VACCINES |
Not
Available |
30- Mar- 07 |
7- Sep -16 |
9- Mar -17 |
US20170067
021 |
MODIFIED
CELLS AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
2- Sep -16 |
9- Mar -17 |
US20170066
788 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
18- Nov -16 |
9- Mar -17 |
US20170066
787 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
18- Nov -16 |
9- Mar -17 |
US20170066
731 |
SMALL
MOLECULE FATTY ACID SYNTHASE INHIBITORS |
Not
Available |
7- Mar-
14 |
5- Mar -15 |
9- Mar -17 |
US20170065
706 |
METHODS
AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE
VACCINATIONS |
Not
Available |
2-Jul- 07 |
14- Sep -16 |
9- Mar -17 |
US20170065
693 |
Sequential
administration of a replication defective adenovirus vector in vaccination
protocols |
Not
Available |
2-Jul- 07 |
14- Sep -16 |
9- Mar -17 |
US20170065
677 |
EV576 FOR
USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT |
Volution
Immuno Pharmaceuticals SA |
8- Jan- 10 |
22- Jul- 16 |
9- Mar -17 |
US20170065
636 |
MODIFIED
CELLS AND METHODS OF THERAPY |
Not
Available |
31- Jul-15 |
29- Aug -16 |
9- Mar -17 |
US20170058
430 |
BACTERIAL
IDENTIFICATION IN CLINICAL INFECTIONS |
Not
Available |
18- Feb- 14 |
18- Feb -15 |
2- Mar -17 |
US20170058
365 |
SYSTEMS
AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS |
Not
Available |
1- Sep-
15 |
3- Feb -16 |
2- Mar -17 |
US20170057
978 |
ANTI-VIRAL
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF |
Kineta,
Inc. |
9- May-
14 |
8- May -15 |
2- Mar -17 |
US20170057
968 |
COMPOUNDS
AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS |
NOVARTIS
AG |
1- May-
14 |
29- Apr -15 |
2- Mar -17 |
US20170057
938 |
CERTAIN
(2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS
DIPEPTIDYL PEPTIDASE 1 INHIBITORS |
Not
Available |
24- Jan- 14 |
8- Nov -16 |
2- Mar -1 |
US20170052
190 |
Covalently
Linked Thermostable Kinase for Decontamination Process Validation |
Not
Available |
20- Feb- 08 |
8- Jul- 16 |
23- Feb -17 |
US20170051
053 |
METHOD OF
PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY |
Not
Available |
28- Dec- 11 |
7- Sep -16 |
23- Feb -17 |
US20170051
046 |
H1N1
FLU VIRUS NEUTRALIZING ANTIBODIES |
MEDIGEN
BIOTECHNOLOGY CORPORATION |
20- Aug- 15 |
20- Aug -15 |
23- Feb -17 |
US20170051
022 |
ADENOVIRUS
COMPRISING AN ALBUMIN-BINDING MOIETY |
Not
Available |
30- Apr- 14 |
30- Apr -15 |
23- Feb -17 |
US20170051
007 |
PHARMACEUTICAL
COMPOSITIONS AND METHODS |
Not
Available |
3- Aug-
15 |
28- Jul- 16 |
23- Feb -17 |
US20170049
813 |
ANTIMICROBIAL
SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE
SAME |
OCULUS
INNOVATIVE SCIENCES, INC. |
13- Mar- 07 |
8- Nov -16 |
23- Feb -17 |
US20170044
603 |
CAPTURE
PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC
TESTS |
Not
Available |
31- Jul-09 |
15- Aug -16 |
16- Feb -17 |
US20170044
595 |
PCR Ready
Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences |
Longhorn
Vaccines and Diagnostics, LLC |
24- Aug- 07 |
26- Oct -16 |
16- Feb -17 |
US20170044
237 |
ANTIBODIES
AND PROCESSES FOR PREPARING THE SAME |
Not
Available |
16- May- 08 |
23- Aug -16 |
16- Feb -17 |
US20170044
168 |
COMPOUNDS
AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS |
NOVARTIS
AG |
1- May-
14 |
29- Apr -15 |
16- Feb -17 |
US20170042
994 |
COMPOSITIONS
HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS |
ASSISTANCE
PUBLIQUE - HOPITAUX DE PARIS |
22- Jul-11 |
29- Jul- 16 |
16- Feb -17 |
US20170042
898 |
METHODS
AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS |
HEMAQUEST
PHARMACEUTICALS, INC. |
11- Mar- 10 |
27- Oct -16 |
16- Feb -17 |
US20170039
316 |
Compositions,
processes and algorithms for microbial detection |
Not
Available |
12- Nov- 03 |
25- Oct -04 |
9- Feb -17 |
US20170039
314 |
BIOINFORMATIC
PROCESSES FOR DETERMINATION OF PEPTIDE BINDING |
IOGENETICS,
LLC |
23- Mar- 10 |
13- Sep -12 |
9- Feb -17 |
US20170038
085 |
AIR
CURTAIN DEVICE |
Not
Available |
7- Aug-
15 |
19- Nov -15 |
9- Feb -17 |
US20170037
457 |
NUCLEIC
ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND
DEVICE FOR SAME |
Not
Available |
5- Feb- 14 |
29- Jan -15 |
9- Feb -17 |
US20170037
379 |
CHIMERIC VIRUSES
PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOF |
Icahn
School of Medicine at Mount Sinai |
2- Dec-
05 |
3- Mar -16 |
9- Feb -17 |
US20170037
376 |
METHOD
FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND
USES THEREOF |
GUANGZHOU
INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES |
15- Nov- 13 |
12- Nov -14 |
9- Feb -17 |
US20170037
090 |
RECOMBINANT
EXPRESSION OF MULTIPROTEIN COMPLEXES USING POLYGENES |
Not
Available |
8- Nov-
05 |
26- Oct -16 |
9- Feb -17 |
US20170037
045 |
HETEROBIFUNCTIONAL
LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER
CONJUGATES MADE THEREFROM |
3M
Innovative Properties Company |
3- Jun- 11 |
24- Oct -16 |
9- Feb -17 |
US20170035
878 |
Multi-Functional
Mucosal Vaccine Platform |
Not
Available |
11- Feb- 14 |
11- Feb -15 |
9- Feb -17 |
US20170035
845 |
Compositions
and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression |
Not
Available |
7- Aug-
15 |
5- Aug -16 |
9- Feb -17 |
US20170029
877 |
POLYTAG
PROBES |
Not
Available |
26- Feb- 10 |
31- Mar -16 |
2- Feb -17 |
US20170029
847 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
CureVac
AG |
30- Dec- 13 |
28- Jun -16 |
2- Feb -17 |
US20170029
489 |
HUMAN
MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN
AND USES THEREOF |
Not
Available |
14- Dec- 10 |
1- Jun -16 |
2- Feb -17 |
US20170028
082 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
3- Aug -16 |
2- Feb -17 |
US20170028
054 |
VACCINE
COMPOSITION |
NITTO
DENKO CORPORATION |
4- Apr-
12 |
11- Oct -16 |
2- Feb -17 |
US20170027
975 |
Methods
of Treating Coronavirus Infection |
United
States Government as represented by the Secretary, Department of Health and
Human Services |
7- Apr-
14 |
7- Apr -15 |
2- Feb -17 |
US20170027
944 |
METHODS
FOR TREATING VIRAL DISORDERS |
Not
Available |
24- Sep- 09 |
18- Feb -15 |
2- Feb -17 |
US20170022
577 |
METHODS
OF TESTING FOR INTRACELLULAR PATHOGENS |
Novartis
AG |
8- Mar-
10 |
23- Sep -16 |
26- Jan- 17 |
US20170022
242 |
NOVEL
ANTIVIRAL AND ANTITUMORAL COMPOUNDS |
KATHOLIEKE
UNIVERSITEIT LEUVEN, KU LEUVEN R&D |
17- Apr- 14 |
17- Apr -15 |
26- Jan- 17 |
US20170021
013 |
D-AMINO
ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF |
Not
Available |
30- Nov- 12 |
31- Mar -16 |
26- Jan- 17 |
US20170020
926 |
METHODS
AND COMPOSITIONS FOR IMMUNOMODULATION |
Not
Available |
1- Apr-
14 |
13- Mar -15 |
26- Jan- 17 |
US20170016
048 |
COMPOSITIONS
AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDS |
Not
Available |
18- May- 15 |
17- May -16 |
19- Jan- 17 |
US20170015
716 |
STABILIZED
ANTI-MICROBIAL PEPTIDES |
Not
Available |
2-Jul- 15 |
1- Jul- 16 |
19- Jan- 17 |
US20170014
496 |
COMBINATION
OF VACCINATION AND OX40 AGONISTS |
Not
Available |
12- Mar- 14 |
12- Mar -14 |
19- Jan- 17 |
US20170014
423 |
Benzazepine
Dicarboxamide Compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
28- Sep -16 |
19- Jan- 17 |
US20170011
131 |
SYSTEM
AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT
RELATED INFORMATION |
Georgetown
University |
25- Feb- 08 |
23- Sep -16 |
12- Jan- 17 |
US20170010
264 |
EXOSOME-MEDIATED
DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES |
Not
Available |
6- Oct-
08 |
20- Sep -16 |
12- Jan- 17 |
US20170009
237 |
Short
Interfering RNA (siRNA) Analogues |
Not
Available |
21- Mar- 03 |
28- Mar -16 |
12- Jan- 17 |
US20170007
577 |
METHOD OF
TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS |
Not
Available |
29- Nov- 02 |
19- Sep -16 |
12- Jan- 17 |
US20170002
042 |
PEPTIDOMIMETIC
MACROCYCLES |
Not
Available |
1-Jul- 15 |
1- Jul- 16 |
5- Jan-
17 |
US20170000
878 |
CONSTRAINED
IMMUNOGENIC COMPOSITIONS AND USES THEREFOR |
Not
Available |
23- Jun- 10 |
9- Aug -16 |
5- Jan-
17 |
US20170000
873 |
Dimethyl
Fumarate and Vaccination Regimens |
Not
Available |
14- Mar- 14 |
13- Mar -15 |
5- Jan-
17 |
US20160376
596 |
COMPOSITIONS
AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS |
Bavarian
Nordic A/S |
28- Nov- 13 |
25- Nov -14 |
29- Dec -16 |
US20160376
321 |
A
NOVEL SARS IMMUNOGENIC COMPOSITION |
BAYLOR
COLLEGE OF MEDICINE |
26- Nov- 13 |
21- Nov -14 |
29- Dec -16 |
US20160375
137 |
TARGETING
LIPIDS |
Tekmira
Pharmaceuticals Corporation |
4- Dec-
07 |
22- Oct -13 |
29- Dec -16 |
US20160375
132 |
HOMOGENOUS
SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF |
Not
Available |
15- Dec- 09 |
5- Jul- 16 |
29- Dec -16 |
US20160369
268 |
TRANSCRIPTION
ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USE |
The
Board of Regents of the University of Texas System |
1-Jul- 13 |
25- Jun -14 |
22- Dec -16 |
US20160368
956 |
METHOD OF
PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A
RESPIRATORY VIRUS |
Not
Available |
9- May-
13 |
23- Aug -16 |
22- Dec -16 |
US20160368
904 |
SUBSTITUTED
BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF |
Not
Available |
3-Jul- 13 |
3- Jul- 14 |
22- Dec -16 |
US20160367
587 |
Systemic
In Vivo Delivery of Oligonucleotides |
OncoImmunin,
Inc. |
12- Jun- 13 |
12- Jun -14 |
22- Dec -16 |
US20160367
188 |
ORAL
SENSOR ALERTING AND COMMUNICATION SYSTEM AND DEVELOPERS' TOOL KIT |
Not
Available |
17- Jun- 15 |
10- Sep -15 |
22- Dec -16 |
US20160363
557 |
AMPEROMETRIC
GAS SENSOR |
Not
Available |
25- Jun- 12 |
25- Aug -16 |
15- Dec -16 |
US20160362
730 |
PHOTO-SELECTIVE
METHOD FOR BIOLOGICAL SAMPLE ANALYSIS |
Not
Available |
26- Feb- 14 |
26- Aug -16 |
15- Dec -16 |
US20160362
454 |
Identification
and Attenuation of the Immunosuppressive Domains in Fusion Proteins of
Enveloped RNA Viruses |
Not
Available |
7- Oct-
11 |
10- Jun -16 |
15- Dec -16 |
US20160361
382 |
MICROBICIDAL
COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS |
Not
Available |
11- Jun- 15 |
13- Jun -16 |
15- Dec -16 |
US20160361
259 |
Methods
for the Preparation of Liposomes |
Not
Available |
23- Sep- 09 |
2- Aug -16 |
15- Dec -16 |
US20160354
451 |
METHOD
OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN
AGGREGATION DISORDERS |
Not
Available |
31- Aug- 07 |
9- Jun -16 |
8- Dec -16 |
US20160354
428 |
METHODS
AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY |
Not
Available |
8- Feb-
07 |
2- Jun -16 |
8- Dec -16 |
US20160354
347 |
Nuclear
Transport Modulators and Uses Thereof |
Not
Available |
9- May-
12 |
6- Jan -16 |
8- Dec -16 |
US20160348
153 |
EXTRACTION
AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS |
THE
UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health
and Human Serv |
29- May- 15 |
31- May -16 |
1- Dec -16 |
US20160348
132 |
TC-83-DERIVED
ALPHAVIRUS VECTORS, PARTICLES AND METHODS |
Not
Available |
18- May- 04 |
11- Aug -16 |
1- Dec -16 |
US20160348
115 |
CpG
Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced
Immunostimulatory Activity |
Not
Available |
27- Sep- 06 |
26- May -16 |
1- Dec -16 |
US20160348
110 |
NUCLEIC
ACID CHEMICAL MODIFICATIONS |
Not
Available |
2- Mar-
09 |
11- Aug -16 |
1- Dec -16 |
US20160347
816 |
POLYPEPTIDES
AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED
DISORDERS AND CANCER |
Not
Available |
15- Apr- 11 |
29- Feb -16 |
1- Dec -16 |
US20160347
814 |
VSTM5
POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS
DISEASES AND IMMUNE RELATED DISEASES |
Not
Available |
11- Sep- 13 |
10- Mar -16 |
1- Dec -16 |
US20160347
784 |
NOVEL
NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF |
Not
Available |
6-Jul- 09 |
27- May -16 |
1- Dec -16 |
US20160346
309 |
TREATMENT
OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS |
Not
Available |
1- Jun-
07 |
21- Dec -15 |
1- Dec -16 |
US20160340
713 |
STABILIZING
COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID |
Not
Available |
6- Oct-
06 |
20- May -16 |
24- Nov -16 |
US20160340
319 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
6- Feb- 13 |
5- Aug -16 |
24- Nov -16 |
US20160339
097 |
CORONAVIRUS
PROTEINS AND ANTIGENS |
MJ
Biologics, Inc. |
7- Feb-
14 |
4- Aug -16 |
24- Nov -16 |
US20160338
998 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF |
3-V
Biosciences, Inc. |
20- Dec- 13 |
19- Dec -14 |
24- Nov -16 |
US20160333
356 |
OLIGONUCLEOTIDE
MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY |
Not
Available |
3- Mar-
11 |
28- Jul- 16 |
17- Nov -16 |
US20160333
089 |
Antigenic
GM-CSF Peptides and Antibodies to GM-CSF |
Not
Available |
8- Feb-
06 |
18- Jul- 16 |
17- Nov -16 |
US20160333
076 |
NEUTRALIZING
GP41 ANTIBODIES AND THEIR USE |
The
United States of America, as represented by the Secretary, Department of
Health and Human Serv |
7- Nov-
11 |
2- Aug -16 |
17- Nov -16 |
US20160331
828 |
NUCLEIC
ACID VACCINES |
Moderna
Therapeutics, Inc. |
23- Apr- 14 |
5- Apr -16 |
17- Nov -16 |
US20160331
816 |
ORAL DELIVERY
OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)
BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC
DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR
DISORDERS |
Not
Available |
18- Oct- 13 |
18- Apr -16 |
17- Nov -16 |
US20160331
758 |
TOLL-LIKE
RECEPTOR AGONIST FORMULATIONS AND THEIR USE |
Not
Available |
1- Aug-
08 |
21- Dec -15 |
17- Nov -16 |
US20160327
506 |
CAPACITIVE
LIQUID CRYSTAL BIOSENSORS |
Not
Available |
6- May-
15 |
5- May -16 |
10- Nov -16 |
US20160327
484 |
A
METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST
HYDROLYSATE AND ITS USE |
Not
Available |
30- Dec- 13 |
18- Dec -14 |
10- Nov -16 |
US20160326
598 |
METHODS
AND COMPOSITIONS FOR PROSTATE CANCER METASTASIS |
Not
Available |
25- Mar- 11 |
27- May -16 |
10- Nov -16 |
US20160326
325 |
POWDERED
POUCH AND METHOD OF MAKING SAME |
Not
Available |
16- Apr- 12 |
19- Jul- 16 |
10- Nov -16 |
US20160326
233 |
NEUTRALIZING
HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN |
Not
Available |
16- Jan- 14 |
15- Jan -15 |
10- Nov -16 |
US20160326
141 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS |
Not
Available |
7- Jan- 14 |
7- Jan -15 |
10- Nov -16 |
US20160325
283 |
BIOAGENT
DETECTION SYSTEMS, DEVICES, AND METHODS |
Not
Available |
30- Mar- 09 |
18- Jul- 16 |
10- Nov -16 |
US20160324
834 |
Use
of mTOR Inhibitors to Enhance T Cell Immune Responses |
Not
Available |
5- Aug-
08 |
16- May -16 |
10- Nov -16 |
US20160320
390 |
COMPOSITIONS
AND METHODS FOR CAPTURING EXOSOMES |
Not
Available |
1- May-
15 |
1- May -15 |
3- Nov -16 |
US20160318
985 |
Chimeric
Virus-Like Particles Incorporating Fusion GPI Anchored GM-CSF and IL-4
Conjugates |
Not
Available |
29- Apr- 15 |
29- Apr -16 |
3- Nov -16 |
US20160318
861 |
NOVEL
PRODRUGS OF DITHIOL MUCOLYTIC AGENTS |
PARION
SCIENCES, INC. |
30- Apr- 15 |
2- May -16 |
3- Nov -16 |
US20160317
647 |
NUCLEIC
ACID VACCINES |
Moderna
Therapeutics, Inc. |
23- Apr- 14 |
1- Apr -16 |
3- Nov -16 |
US20160317
637 |
IMMUNOMODULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
7- Jan- 14 |
7- Jan -15 |
3- Nov -16 |
US20160317
496 |
METHODS
OF TREATING CANCER AND OTHER DISORDERS |
Not
Available |
12- Nov- 10 |
27- Jun -16 |
3- Nov -16 |
US20160317
458 |
Lipids
and Lipid Compositions for the Delivery of Active Agents |
Not
Available |
19- Dec- 13 |
17- Dec -14 |
3- Nov -16 |
US20160312
276 |
METHODS
AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION |
Not
Available |
23- Apr- 15 |
21- Apr -16 |
27- Oct- 16 |
US20160311
886 |
Constructs
Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging |
Not
Available |
24- Jan- 05 |
12- Jul- 16 |
27- Oct- 16 |
US20160311
835 |
NOVEL
ANTIBIOTICS |
Not
Available |
26- May- 11 |
30- Nov -15 |
27- Oct- 16 |
US20160311
816 |
COMPOSITIONS
AND METHODS FOR INHIBITING KINASES |
Not
Available |
23- Apr- 15 |
22- Apr -16 |
27- Oct- 16 |
US20160311
759 |
Lipids
and Lipid Compositions for the Delivery of Active Agents |
Not
Available |
19- Dec- 13 |
17- Dec -14 |
27- Oct- 16 |
US20160310
511 |
Myxovirus
Therapeutics, Compounds, and Uses Related Thereto |
Not
Available |
24- Oct- 11 |
7- Jul- 16 |
27- Oct- 16 |
US20160305
936 |
DIRECT
CLONE ANALYSIS AND SELECTION TECHNOLOGY |
Not
Available |
13- Jul-10 |
18- Feb -16 |
20- Oct- 16 |
US20160304
954 |
COMPOSITIONS
AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS |
Not
Available |
11- Dec- 13 |
11- Dec -14 |
20- Oct- 16 |
US20160304
942 |
Enhanced
Methods of Ribonucleic Acid Hybridization |
Not
Available |
6- Dec-
13 |
5- Dec -14 |
20- Oct- 16 |
US20160304
904 |
Directed
Evolution and In Vivo Panning of Virus Vectors |
Not
Available |
30- Apr- 08 |
28- Jun -16 |
20- Oct- 16 |
US20160304
883 |
ARTIFICIAL
NUCLEIC ACID MOLECULES |
CureVac
AG |
30- Dec- 13 |
28- Jun -16 |
20- Oct- 16 |
US20160304
882 |
METHOD
FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS |
GenVec,
Inc. |
10- Nov- 05 |
27- Jun -16 |
20- Oct- 16 |
US20160304
586 |
PROCESS
FOR PREPARING INFLUENZA VACCINES |
Crucell
Holland B.V. |
5- Dec-
13 |
4- Dec -14 |
20- Oct- 16 |
US20160304
579 |
POLYPEPTIDES
AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION |
Not
Available |
30- Jun- 11 |
29- Feb -16 |
20- Oct- 16 |
US20160304
472 |
Hydrazide
Containing Nuclear Transport Modulators and Uses Thereof |
Not
Available |
29- Jul-11 |
13- Nov -15 |
20- Oct- 16 |
US20160303
194 |
Compositions
And Method For Treatment Of Inflammatory Bowel Disease |
Not
Available |
2- Jun-
11 |
21- Apr -16 |
20- Oct- 16 |
US20160303
052 |
MODULAR
PARTICLES FOR IMMUNOTHERAPY |
Not
Available |
1- Nov-
13 |
31- Oct -14 |
20- Oct- 16 |
US20160299
141 |
NAD
ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF
PROTEINS WITH PARP MUTANTS |
Biolog
Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH |
8- Apr- 15 |
1- Apr -16 |
13- Oct- 16 |
US20160298
179 |
LUMINOPHORE-LABELED
MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS |
CapitalBio
Corporation |
5- Dec-
13 |
2- Dec -14 |
13- Oct- 16 |
US20160296
617 |
Immunogenic
Composition for MERS Coronavirus Infection |
Not
Available |
1- Mar-
13 |
28- Feb -14 |
13- Oct- 16 |
US20160296
616 |
IMMUNOGENIC
COMPOSITIONS AND USES THEREOF |
Not
Available |
25- Mar- 15 |
25- Mar -16 |
13- Oct- 16 |
US20160295
844 |
GENETICALLY
MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF |
Not
Available |
13- Apr- 15 |
12- Apr -16 |
13- Oct- 16 |
US20160292
393 |
SYSTEMS
AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF |
Not
Available |
24- Oct- 13 |
13- Apr -16 |
6- Oct-
16 |
US20160289
740 |
METHODS
AND COMPOSITIONS FOR COMBINATORIAL BARCODING |
Not
Available |
30- Mar- 15 |
29- Mar -16 |
6- Oct-
16 |
US20160289
191 |
ORGANIC
COMPOUNDS |
NOVARTIS
AG |
27- Jun- 08 |
9- Oct -15 |
6- Oct-
16 |
US20160288
121 |
Slip
Chip Device and Methods |
Not
Available |
24- Mar- 09 |
25- May -16 |
6- Oct-
16 |
US20160287
697 |
INJECTABLE
VACCINE COMPOSITION |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
6- Oct-
16 |
US20160287
622 |
COMPOSITIONS
AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING
PROTEIN-RNA INTERACTION |
Massachusetts
Institute of Technology |
18- Nov- 13 |
7- Nov -14 |
6- Oct- 16 |
US20160281
109 |
GENE
TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR
PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN |
Not
Available |
28- Oct- 05 |
10- Jun -16 |
29- Sep -16 |
US20160280
707 |
ALKOXY
SUBSTITUTED IMIDAZOQUINOLINES |
Not
Available |
3- Oct-
03 |
13- Jun -16 |
29- Sep -16 |
US20160279
237 |
ADJUVANT
COMPOSITIONS AND RELATED METHODS |
Not
Available |
24- Mar- 15 |
24- Mar -16 |
29- Sep -16 |
US20160279
193 |
IMMUNOSUPPRESSIVE
AGENTS AND THEIR USE IN THERAPY |
Not
Available |
6- Nov-
13 |
6- Nov -14 |
29- Sep -16 |
US20160279
165 |
PULSE
INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
24- Mar- 15 |
24- Mar -16 |
29- Sep -16 |
US20160279
163 |
Method
of Treating Inflammation |
Not
Available |
1- Apr-
10 |
3- Jun -16 |
29- Sep -16 |
US20160278
349 |
Immunocompromised
Ungulates |
Not
Available |
27- Oct- 08 |
23- Mar -15 |
29- Sep -16 |
US20160272
707 |
VSTM5
ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND
IMMUNE RELATED DISEASES |
Not
Available |
11- Sep- 13 |
11- Sep -14 |
22- Sep -16 |
US20160271
241 |
BUNYAVIRUSES
WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING THESE
VIRUSES |
Stichting
Dienst Landbouwkundig Onderzoek |
21- May- 13 |
21- May -14 |
22- Sep -16 |
US20160271
240 |
Tetanus
Toxoid and CCL3 Improve DC Vaccines |
Duke
University |
14- Nov- 13 |
14- Nov -15 |
22- Sep -16 |
US20160271
137 |
INHIBITORS
OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM
ANTI-VIRALS |
Not
Available |
18- Feb- 10 |
27- Oct -15 |
22- Sep -16 |
US20160267
244 |
METHODS
OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS |
Not
Available |
8- Aug-
08 |
19- May -16 |
15- Sep -16 |
US20160265
025 |
NANOREPORTERS
AND METHODS OF MANUFACTURING AND USE THEREOF |
Not
Available |
23- Dec- 05 |
20- May -16 |
15- Sep -16 |
US20160264
971 |
COMPOSITIONS
AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION |
Not
Available |
20- Jul-09 |
9- Oct -15 |
15- Sep -16 |
US20160264
962 |
TAL-EFFECTOR
ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS |
Not
Available |
4- Apr-
12 |
28- Jul- 15 |
15- Sep -16 |
US20160263
156 |
RED BLOOD
CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG
DISEASE |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
7- Nov-
13 |
6- Nov -14 |
15- Sep -16 |
US20160258
949 |
CHIPS,
DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGY |
Not
Available |
9- Oct-
13 |
9- Oct -14 |
8- Sep -16 |
US20160257
932 |
GENETICALLY
ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA
LYASE RECEIVER POLYPEPTIDE |
Not
Available |
18- Nov- 13 |
17- May -16 |
8- Sep -16 |
US20160257
653 |
Benzazepine
Dicarboxamide Compounds |
Hoffmann-La
Roche Inc. |
6- Mar-
15 |
4- Mar -16 |
8- Sep -16 |
US20160256
870 |
Slip
Chip Device and Methods |
Not
Available |
24- Mar- 09 |
25- May -16 |
8- Sep -16 |
US20160256
541 |
Cationic
Oil-In-Water Emulsions |
Not
Available |
6-Jul- 10 |
11- Mar -16 |
8- Sep -16 |
US20160253
584 |
SPATIALLY
ADDRESSABLE MOLECULAR BARCODING |
Not
Available |
27- Feb- 15 |
26- Feb -16 |
1- Sep -16 |
US20160251
637 |
COMPOSITIONS
FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS |
Not
Available |
19- Nov- 09 |
11- Mar -16 |
1- Sep -16 |
US20160251
631 |
DECREASING
POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES |
Novartis
AG |
9- Sep-
04 |
9- May -16 |
1- Sep -16 |
US20160251
399 |
PEPTIDOMIMETIC
MACROCYCLES |
Not
Available |
14- Jan- 09 |
7- Apr -16 |
1- Sep -16 |
US20160251
362 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
18- Dec- 12 |
10- May -16 |
1- Sep -16 |
US20160251
319 |
CARBOXYLIC
ACID COMPOUNDS |
Astrazeneca
Aktiebolag |
18- May- 12 |
11- May -16 |
1- Sep -16 |
US20160250
326 |
Conjugates
of GM-CSF and IL-7, and Compositions Thereof |
Not
Available |
14- Nov- 11 |
18- May -16 |
1- Sep -16 |
US20160250
278 |
PEPTIDOMIMETIC
MACROCYCLES |
Not
Available |
14- Jan- 09 |
7- Apr -16 |
1- Sep -16 |
US20160250
168 |
ESTERS OF
SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS |
Not
Available |
3- Oct-
12 |
3- Mar -16 |
1- Sep -16 |
US20160238
601 |
METHODS
AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS |
Not
Available |
14- Oct- 13 |
14- Oct -14 |
18- Aug -16 |
US20160238
600 |
METHOD
FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF
ANTIBODIES |
Merus
B.V. |
30- May- 03 |
27- Apr -16 |
18- Aug -16 |
US20160237
455 |
CRISPR-RELATED
METHODS AND COMPOSITIONS |
Editas
Medicine, Inc. |
27- Sep- 13 |
26- Sep -14 |
18- Aug -16 |
US20160237
123 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
Not
Available |
23- Jan- 08 |
4- May -16 |
18- Aug -16 |
US20160237
082 |
DEUBIQUITINASE
INHIBITORS AND METHODS FOR USE OF THE SAME |
Not
Available |
10- Oct- 13 |
10- Oct -14 |
18- Aug -16 |
US20160235
840 |
Compositions,
Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics
And Methods Of Using The Same |
Not
Available |
12- Dec- 11 |
26- Feb -16 |
18- Aug -16 |
US20160235
837 |
THERAPIES,
VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS
(MERS CoV) |
Not
Available |
16- Oct- 13 |
16- Oct -14 |
18- Aug -16 |
US20160235
835 |
INFLUENZA
VACCINES WITH REDUCED AMOUNTS OF SQUALENE |
Seqirus
UK Limited |
10- Feb- 09 |
27- Jan -16 |
18- Aug -16 |
US20160235
675 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
24- Mar -16 |
18- Aug -16 |
US20160230
190 |
Lentiviral
Vectors Having a Mutated Integrase Protein and uses Thereof |
Not
Available |
17- Sep- 13 |
17- Sep -14 |
11- Aug -16 |
US20160229
904 |
Optimized
Human Clotting Factor VIII Gene Expression Cassettes and Their Use |
Not
Available |
6- Feb-
15 |
5- Feb -16 |
11- Aug -16 |
US20160229
872 |
ISOTHIAZOLOPYRIMIDINONES,
PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC
PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb- 15 |
4- Feb -16 |
11- Aug -16 |
US20160229
864 |
THIENOPYRIMIDINONES
AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
4- Feb -16 |
11- Aug -16 |
US20160229
833 |
QUINAZOLINONES
AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
5- Feb-
15 |
4- Feb -16 |
11- Aug -16 |
US20160228
540 |
NASAL
MUCOSAL VACCINE COMPOSITION |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
11- Aug -16 |
US20160228
533 |
Use of
EGFR Pathway Inhibitors to Increase Immune Responses to Antigens |
Emory
University |
23- Sep- 13 |
23- Sep -14 |
11- Aug -16 |
US20160228
532 |
METHOD OF
OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONS |
Merck
Sharp & Dohme Corp. |
16- Oct- 13 |
13- Oct -14 |
11- Aug -16 |
US20160228
463 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
20- Apr -16 |
11- Aug -16 |
US20160222
414 |
CONSTRUCTS
AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE IMMUNE
RESPONSES |
Not
Available |
14- Mar- 13 |
15- Apr -16 |
4- Aug -16 |
US20160222
072 |
Universal
Protein Tag for Double Stranded Nucleic Acid Delivery |
Not
Available |
23- Oct- 13 |
22- Oct -14 |
4- Aug -16 |
US20160222
023 |
NOVEL
MONOTHIOL MUCOLYTIC AGENTS |
PARION
SCIENCES, INC. |
30- Jan- 15 |
29- Jan -16 |
4- Aug -16 |
US20160222
010 |
4-AMINO-IMIDAZOQUINOLINE
COMPOUNDS |
Hoffmann-La
Roche Inc. |
22- Apr- 14 |
7- Apr -16 |
4- Aug -16 |
US20160221
994 |
Substituted
2,3-Dihydrobenzofuranyl Compounds And Uses Thereof |
Not
Available |
29- Nov- 12 |
27- Nov -13 |
4- Aug -16 |
US20160220
664 |
ANTIGEN
AND METHOD FOR PRODUCTION THEREOF |
Not
Available |
13- Sep- 13 |
12- Sep -14 |
4- Aug -16 |
US20160220
595 |
NUCLEOTIDE
AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO |
Not
Available |
11- Sep- 13 |
10- Sep -14 |
4- Aug -16 |
US20160220
536 |
USE OF
PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES
FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-
LIKE RECEPTOR OVEREXPRESSION |
Not
Available |
16- Mar- 04 |
19- Feb -16 |
4- Aug -16 |
US20160215
282 |
SYNTHETIC
ANTISERUM FOR RAPID-TURNAROUND THERAPIES |
Not
Available |
28- Jan- 15 |
20- Jan -16 |
28- Jul- 16 |
US20160215
262 |
CD137
ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION |
Not
Available |
16- Sep- 13 |
16- Sep -14 |
28- Jul- 16 |
US20160213
776 |
ADSORPTION
OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS |
GlaxoSmithKline
Biologicals SA |
1- Sep-
10 |
7- Apr -16 |
28- Jul- 16 |
US20160213
773 |
MUCOSAL
VACCINE COMPOSITION |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
28- Jul- 16 |
US20160213
761 |
CARBON
NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
19- Mar- 08 |
5- Apr -16 |
28- Jul- 16 |
US20160213
647 |
COMPOSITIONS
AND METHODS FOR INHIBITING VIRAL INFECTION |
Not
Available |
28- Jan- 15 |
27- Jan -16 |
28- Jul- 16 |
US20160213
610 |
MODIFIED
RELEASE FORMULATIONS FOR OPROZOMIB |
Not
Available |
24- Oct- 12 |
28- Jan -16 |
28- Jul- 16 |
US20160207
980 |
FC-CONTAINING
MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM
PROFILES |
AMGEN
INC. |
5- Sep-
13 |
5- Sep -14 |
21- Jul- 16 |
US20160207
949 |
NOVEL
CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE |
Hangzhou
DAC Biotech Co., Ltd |
2- Sep-
13 |
2- Sep -13 |
21- Jul- 16 |
US20160207
900 |
PEPTIDYL
NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS |
PROZYMEX
A/S |
9- Sep-
13 |
8- Sep -14 |
21- Jul- 16 |
US20160206
729 |
IMMUNOGENIC
MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND
METHODS |
Not
Available |
19- Sep- 13 |
19- Sep -14 |
21- Jul- 16 |
US20160206
719 |
COMBINATION
OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY |
CureVac
AG |
22- Feb- 13 |
5- Apr -16 |
21- Jul- 16 |
US20160206
638 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
5- Apr -16 |
21- Jul- 16 |
US20160206
575 |
Inhibition
of Biofilm Organisms |
NOVABIOTICS
LIMITED |
31- Mar- 09 |
28- Mar -16 |
21- Jul- 16 |
US20160202
258 |
B-CELL
ANTIGEN PRESENTING CELL ASSAY |
University
of Pittsburgh - Of the Commonwealth System of Higher Education |
8- Apr-
10 |
21- Mar -16 |
14- Jul- 16 |
US20160201
110 |
DIAGNOSIS
AND TREATMENT OF INCIPIENT DIABETES |
Not
Available |
9- Jan- 15 |
17- Nov -15 |
14- Jul- 16 |
US20160201
088 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
17- Dec- 01 |
30- Mar -16 |
14- Jul- 16 |
US20160199
486 |
ARRANGING
INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION |
Not
Available |
3- Dec-
09 |
22- Mar -16 |
14- Jul- 16 |
US20160199
449 |
METHOD OF
REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING
ALPHA INTERFERON |
Hemispherx
Biopharma, Inc. |
21- Aug- 13 |
21- Aug -14 |
14- Jul- 16 |
US20160199
416 |
Induced
Hepatocytes and Uses Thereof |
Not
Available |
26- Nov- 14 |
25- Nov -15 |
14- Jul- 16 |
US20160199
407 |
HALIDES
IN THE TREATMENT OF PATHOGENIC INFECTION |
THE
UNIVERSITY OF IOWA RESEARCH FOUNDATION |
25- Jan- 08 |
17- Dec -15 |
14- Jul- 16 |
US20160194
387 |
Methods
Of Treating Inflammation Associated Airway Diseases And Viral Infections |
Not
Available |
2- Jan- 15 |
31- Dec -15 |
7- Jul- 16 |
US20160194
322 |
SUBSTITUTED
IMIDAZO RING SYSTEMS AND METHODS |
Not
Available |
25- Nov- 03 |
14- Mar -16 |
7- Jul- 16 |
US20160194
278 |
DITHIOL
MUCOLYTIC AGENTS |
PARION
SCIENCES, INC. |
23- Aug- 13 |
11- Mar -16 |
7- Jul- 16 |
US20160193
603 |
SAMPLE-TO-ANSWER
MICROFLUIDIC CARTRIDGE |
Not
Available |
29- Jan- 10 |
5- Aug -15 |
7- Jul- 16 |
US20160193
327 |
MUCOSAL
VACCINE COMPOSITION |
NITTO
DENKO CORPORATION |
3- Oct-
13 |
2- Oct -14 |
7- Jul- 16 |
US20160193
321 |
MAKING
INFLUENZA VIRUS VACCINES WITHOUT USING EGGS |
Novartis
AG |
11- Sep- 06 |
5- Nov -15 |
7- Jul- 16 |
US20160193
315 |
PEPTIDES
SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID
PEPTIDES |
Not
Available |
7- Aug- 09 |
17- Mar -16 |
7- Jul- 16 |
US20160192
658 |
HYDROGEN-CONTAINING
ANTIMICROBIAL AGENT |
Not
Available |
13- Aug- 13 |
5- Aug -14 |
7- Jul- 16 |
US20160185
786 |
PYRROLOTRIAZINONES
AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
29- Dec -15 |
30- Jun- 16 |
US20160185
785 |
PYRROLO
AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
Not
Available |
30- Dec- 14 |
29- Dec -15 |
30- Jun- 16 |
US20160184
424 |
INTRANASAL
VACCINATION DOSAGE REGIMEN |
Not
Available |
17- Dec- 12 |
17- Dec -13 |
30- Jun- 16 |
US20160184
334 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
11- Mar -16 |
30- Jun- 16 |
US20160177
337 |
METHOD
FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS
VECTOR |
Not
Available |
16- Jul-08 |
8- Mar -16 |
23- Jun- 16 |
US20160177
336 |
Expression
Tools for Multiprotein Applications |
Not
Available |
9- Mar-
04 |
11- Dec -15 |
23- Jun- 16 |
US20160175
433 |
LIPIDATED
IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS |
Not
Available |
17- Aug- 10 |
15- Dec -15 |
23- Jun- 16 |
US20160175
394 |
Compositions
and Uses of Lectins |
Emory
University |
12- Feb- 10 |
11- Dec -15 |
23- Jun- 16 |
US20160175
387 |
Use
of Immune Suppressive Domains as Medicaments |
Not
Available |
10- Apr- 13 |
10- Apr -14 |
23- Jun- 16 |
US20160174
631 |
PROTECTIVE
MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH
EACH OTHER, FORMULATIONS FORMING THE SAME, AND METHOD OF PRODUCING THEREOF |
Not
Available |
23- Dec- 14 |
10- Dec -15 |
23- Jun- 16 |
US20160168
203 |
Cyclic
Antimicrobial Peptides |
NOVABIOTICS
LIMITED |
24- Feb- 06 |
9- Nov -15 |
16- Jun- 16 |
US20160168
101 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.p.A. |
15- Dec- 14 |
27- Nov -15 |
16- Jun- 16 |
US20160166
710 |
METHOD
FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS |
CureVac
AG |
21- Aug- 13 |
19- Feb -16 |
16- Jun- 16 |
US20160166
676 |
Use
of Immune Suppressive Peptides as Adjuvants |
Not
Available |
10- Apr- 13 |
10- Apr -14 |
16- Jun- 16 |
US20160160
258 |
MONOCLONAL
ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS |
Not
Available |
26- Feb- 03 |
8- Feb -16 |
9- Jun-
16 |
US20160160
178 |
IMMUNOTHERAPY
USING STEM CELLS |
Not
Available |
9- Dec-
14 |
2- Dec -15 |
9- Jun-
16 |
US20160159
927 |
IDENTIFICATION
OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V- R) AND USE THEREOF TO PRODUCE
VISTA/VSIG8 AGONISTS AND ANTAGONISTS |
Not
Available |
5- Dec- 14 |
7- Dec -15 |
9- Jun- 16 |
US20160158
341 |
PREPARATION
OF INFLUENZA VIRUS VACCINE ANTIGENS |
Novartis
AG |
18- Mar- 08 |
7- Dec -15 |
9- Jun-
16 |
US20160158
340 |
INFLUENZA
VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS |
Not
Available |
27- Jan- 06 |
4- Dec -15 |
9- Jun-
16 |
US20160158
339 |
METHOD
FOR INACTIVATING VIRUSES USING ELECTRON BEAMS |
Not
Available |
26- Jul-13 |
24- Jul- 14 |
9- Jun-
16 |
US20160158
308 |
TREATMENT
OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY
FORMULATED GLUTATHIONE |
CHILDREN'S
HEALTHCARE OF ATLANTA, INC. |
12- Nov- 13 |
14- Aug -14 |
9- Jun- 16 |
US20160158
294 |
Methods
of Populating a Gastrointestinal Tract |
Not
Available |
4- Feb-
13 |
4- Feb -14 |
9- Jun-
16 |
US20160158
154 |
PROTEIN
VESICLES AND METHODS OF MAKING AND USING THEREOF |
Not
Available |
5- Dec-
14 |
7- Dec -15 |
9- Jun-
16 |
US20160153
034 |
Rapid
Epidemiologic Typing of Bacteria |
Not
Available |
19- May- 08 |
11- Nov -15 |
2- Jun-
16 |
US20160152
693 |
AMINO
ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND
POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
Ablynx
N.V. |
5- Jun- 08 |
29- Oct -15 |
2- Jun- 16 |
US20160152
676 |
HELIX-GRAFTED
PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS |
COLORADO
STATE UNIVERSITY RESEARCH FOUNDATION |
7- Nov-
14 |
9- Nov -15 |
2- Jun-
16 |
US20160152
667 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
Not
Available |
23- Jan- 08 |
9- Feb -16 |
2- Jun-
16 |
US20160152
596 |
Nuclear
Transport Modulators and Uses Thereof |
Karyopharm
Therapeutics Inc. |
21- Jun- 13 |
20- Jun -14 |
2- Jun-
16 |
US20160151
399 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
17- Feb -16 |
2- Jun-
16 |
US20160146
806 |
RECEPTORS
FOR B7-H4 |
Not
Available |
17- May- 13 |
19- May -14 |
26- May -16 |
US20160146
786 |
Method
of monitoring cellular trafficking of peptides |
Not
Available |
26- Jun- 13 |
26- Jun -14 |
26- May -16 |
US20160145
246 |
NUCLEAR
TRANSPORT MODULATORS AND USES THEREOF |
Not
Available |
9- May-
12 |
23- Jun -15 |
26- May -16 |
US20160144
061 |
Compositions
and Imaging Methods Comprising Detectably Labeled
Phosphatidylethanolamine-Binding Peptides |
Not
Available |
15- Jul-02 |
4- Feb -16 |
26- May -16 |
US20160139
143 |
DETECTING
TARGETS USING MASS TAGS AND MASS SPECTROMETRY |
Not
Available |
2-Jul- 10 |
28- Dec -15 |
19- May -16 |
US20160137
702 |
GAS57
MUTANT ANTIGENS AND GAS57 ANTIBODIES |
Not
Available |
12- Sep- 07 |
7- Aug -15 |
19- May -16 |
US20160137
649 |
PYRROLO-PYRROLE
CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
MEDICAL USES THEREOF |
Not
Available |
3-Jul- 13 |
1- Jul- 14 |
19- May -16 |
US20160135
453 |
SHELF
STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL
COMPOSITIONS |
Not
Available |
30- Aug- 07 |
20- Jan -16 |
19- May -16 |
US20160130
367 |
GENERATION
OF BINDING MOLECULES |
Merus
B.V. |
26- Sep- 11 |
16- Sep -15 |
12- May -16 |
US20160130
345 |
COMBINATION
OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY |
Not
Available |
22- Feb- 13 |
21- Feb -14 |
12- May -16 |
US20160130
265 |
SUBSTITUTED
4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY |
Not
Available |
23- Aug- 12 |
29- Dec -15 |
12- May -16 |
US20160129
110 |
IMMUNOPROTECTIVE
PRIMARY MESENCHYMAL STEM CELLS AND METHODS |
AUTOIMMUNE
TECHNOLOGIES, LLC |
14- Mar- 13 |
17- Jul- 15 |
12- May -16 |
US20160129
104 |
HAND,
FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF |
Not
Available |
7- Nov-
14 |
6- Nov -15 |
12- May -16 |
US20160129
095 |
Immunostimulatory
Combinations |
Not
Available |
30- Dec- 02 |
10- Sep -15 |
12- May -16 |
US20160128
937 |
CIRCULATION
OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS |
Novartis
AG |
3- Dec-
09 |
5- Sep -14 |
12- May -16 |
US20160122
412 |
COMPOSITION
COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND |
Not
Available |
15- Mar- 13 |
16- Mar -14 |
5- May -16 |
US20160122
397 |
REPLIKIN-BASED
COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING
INFECTIVITY AND LETHALITY IN INFLUENZA |
Not
Available |
23- Apr- 09 |
2- Dec -15 |
5- May -16 |
US20160122
312 |
ANTI-VIRAL
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
16- Jul-13 |
16- Jul- 14 |
5- May -16 |
US20160122
306 |
DENDRIMER
LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE
TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES |
PARION
SCIENCES, INC. |
29- May- 12 |
5- Jan -16 |
5- May -16 |
US20160116
462 |
ANTIBODY-NANOPARTICLE
CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES |
Not
Available |
27- Apr- 10 |
21- Apr -15 |
28- Apr- 16 |
US20160115
522 |
MUTANT
PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS |
Not
Available |
11- May- 10 |
7- Jan -16 |
28- Apr- 16 |
US20160115
221 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY |
Not
Available |
28- Oct- 14 |
2- Jul- 15 |
28- Apr- 16 |
US20160114
322 |
PARALLELIZED
SAMPLE HANDLING |
Not
Available |
19- Apr- 13 |
18- Apr -14 |
28- Apr- 16 |
US20160114
037 |
COMPOSITIONS
AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY |
Not
Available |
28- Oct- 14 |
8- Jan -15 |
28- Apr- 16 |
US20160114
027 |
RECOMBINANT
HCMV AND RHCMV VECTORS AND USES THEREOF |
Not
Available |
14- May- 10 |
1- Oct -15 |
28- Apr- 16 |
US20160114
022 |
THERAPIES,
VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING EBOLAVIRUS AND
MARBURG VIRUS |
Not
Available |
11- Oct- 14 |
10- Oct -15 |
28- Apr- 16 |
US20160113
929 |
METHODS
AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS |
Not
Available |
11- Mar- 10 |
2- Jun -15 |
28- Apr- 16 |
US20160113
920 |
COMPOSITIONS
AND METHODS FOR INHIBITING BACTERIAL AND VIRAL PATHOGENS |
Not
Available |
24- Oct- 14 |
23- Oct -15 |
28- Apr- 16 |
US20160113
881 |
NOVEL
NANOPARTICLE COMPOSITIONS |
Not
Available |
3- Apr-
13 |
3- Apr -14 |
28- Apr- 16 |
US20160113
870 |
CIRCULATION
OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS |
Novartis
AG |
3- Dec-
09 |
5- Sep -14 |
28- Apr- 16 |
US20160108
463 |
Biological
Specimen Collection and Transport System |
Longhorn
Vaccines and Diagnostics, LLC |
1- Oct-
07 |
15- Dec -15 |
21- Apr- 16 |
US20160108
461 |
TARGETED
WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS |
Not
Available |
14- Sep- 06 |
5- Oct -15 |
21- Apr- 16 |
US20160108
359 |
AVIAN
CELLS FOR IMPROVED VIRUS PRODUCTION |
Not
Available |
5- Jun-
13 |
3- Jun -14 |
21- Apr- 16 |
US20160108
097 |
MONOMERIC
GRIFFITHSIN TANDEMERS |
The
United States of America, as represented by the Secretary, Department of Health
and Human Serv |
5- Jun-
13 |
5- Jun -14 |
21- Apr- 16 |
US20160108
096 |
FUSION
PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA |
Not
Available |
17- Sep- 14 |
17- Sep -15 |
21- Apr- 16 |
US20160108
063 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
21- Dec -15 |
21- Apr- 16 |
US20160106
842 |
LIPIDS
AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS |
Not
Available |
8- Mar-
13 |
6- Mar -14 |
21- Apr- 16 |
US20160102
295 |
MODIFIED
ADENOVIRUS HEXON PROTEIN AND USES THEREOF |
Not
Available |
28- Apr- 06 |
22- May -15 |
14- Apr- 16 |
US20160102
091 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
3-V
BIOSCIENCES, INC. |
8- Mar-
11 |
5- Oct -15 |
14- Apr- 16 |
US20160101
145 |
PEPTIDOMIMETIC
MACROCYCLES AND FORMULATIONS THEREOF |
Not
Available |
24- Sep- 14 |
24- Sep -15 |
14- Apr- 16 |
US20160096
899 |
METHODS
FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE SALT-STIMULATED LIPASE (BSSL)
ANTIBODIES |
Not
Available |
8- Apr-
09 |
28- Sep -15 |
7- Apr-
16 |
US20160096
895 |
BINDING
MEMBERS-513 |
Not
Available |
7- Nov-
08 |
23- Oct -15 |
7- Apr-
16 |
US20160095
936 |
IMMUNOSTIMULATORY
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
5- Apr-
12 |
2- Jul- 15 |
7- Apr-
16 |
US20160090
589 |
COMPOSITIONS
FOR AND METHODS OF IDENTIFYING ANTIGENS |
Not
Available |
21- Feb- 06 |
6- May -15 |
31- Mar -16 |
US20160090
389 |
Phosphoinositide
3-Kinase Inhibitors |
Respivert
Ltd. |
15- Mar- 13 |
4- Dec -15 |
31- Mar -16 |
US20160084
835 |
METHODS
FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA |
EXTHERA
MEDICAL CORPORATION |
8- Nov-
13 |
16- Oct -15 |
24- Mar -16 |
US20160083
748 |
TISSUE
PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME,
AND USES THEREOF |
Not
Available |
29- Apr- 13 |
29- Apr -14 |
24- Mar -16 |
US20160083
689 |
ANIMAL
PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS |
Not
Available |
29- Oct- 04 |
30- Nov -15 |
24- Mar -16 |
US20160082
074 |
COMPOSITIONS
AND METHODS FOR TREATING CORONAVIRUS INFECTION |
LUDWIG-MAXIMILIANS-UNIVERSITAET
MUENCHEN |
11- Mar- 14 |
8- May -15 |
24- Mar -16 |
US20160081
982 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED
2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES
INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
1- Dec -15 |
24- Mar -16 |
US20160081
346 |
ANTIMICROBIAL
COMPOSITIONS AND METHODS |
Not
Available |
23- Sep- 14 |
22- Sep -15 |
24- Mar -16 |
US20160077
094 |
Media
Elaborated with Newly Synthesized Antibodies (MENSA) and Uses Thereof |
Not
Available |
5- May-
14 |
5- May -15 |
17- Mar -16 |
US20160076
094 |
Efficient
Deep Sequencing and Rapid Genomic Speciation of RNA Viruses (vRNAseq) |
Not
Available |
8- Sep-
14 |
1- Sep -15 |
17- Mar -16 |
US20160076
053 |
REPLICATION
DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION |
Not
Available |
24- Aug- 12 |
15- Mar -13 |
17- Mar -16 |
US20160075
704 |
NOVEL
SUBSTITUTED SPIROCYCLES |
Not
Available |
12- Sep- 14 |
10- Sep -15 |
17- Mar -16 |
US20160074
507 |
METHOD
FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID
PARTICLES FOR INDUCING IMMUNE RESPONSE |
Not
Available |
16- Sep- 14 |
16- Sep -15 |
17- Mar -16 |
US20160074
506 |
DELIVERY
OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES |
Not
Available |
6-Jul- 10 |
23- Nov -15 |
17- Mar -16 |
US20160074
481 |
Clottable
Concentrate Of Platelet Growth Factors And Preparation Method Thereof |
Zheng
Yang Biomedical Technology Co., LTD. |
7- Jan- 08 |
30- Nov -15 |
17- Mar -16 |
US20160068
843 |
Compositions
and Methods for "Resistance-Proof" SiRNA Therapeutics for Influenza |
Sirnaomics,
Inc. |
8-Jul- 12 |
7- Jul- 13 |
10- Mar -16 |
US20160068
587 |
OLIGOPEPTIDE-FREE
CELL CULTURE MEDIA |
Not
Available |
3- Jan- 07 |
16- Nov -15 |
10- Mar -16 |
US20160068
573 |
PEPTIDOMIMETIC
MACROCYCLES |
Not
Available |
14- Jan- 09 |
14- Sep -15 |
10- Mar -16 |
US20160067
333 |
GENERATING
PEPTOID VACCINES |
The
Board of Regents of the University of Texas System |
3- May-
13 |
2- May -14 |
10- Mar -16 |
US20160060
598 |
MEANS AND
METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS |
Not
Available |
9- Dec-
05 |
26- Aug -15 |
3- Mar -16 |
US20160060
231 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
6- Feb- 13 |
9- Nov -15 |
3- Mar -16 |
US20160060
230 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
6- Feb- 13 |
9- Nov -15 |
3- Mar -16 |
US20160060
224 |
N-MYRISTOYL
TRANSFERASE INHIBITORS |
UNIVERSITY
OF DUNDEE |
2- Sep-
08 |
31- Aug -15 |
3- Mar -16 |
US20160058
814 |
PLANT
EXTRACTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS |
Not
Available |
26- Aug- 14 |
26- Aug -14 |
3- Mar -16 |
US20160058
012 |
WEAR
RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE |
Not
Available |
14- Dec- 10 |
24- Sep -15 |
3- Mar -16 |
US20160058
008 |
ANTIMICROBIAL
COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM |
Not
Available |
28- Aug- 14 |
28- Aug -15 |
3- Mar -16 |
US20160054
312 |
CHEMICALLY
DIFFERENTIATED SENSOR ARRAY |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
15- Oct -15 |
25- Feb -16 |
US20160053
308 |
PROBE KIT
FOR DETECTING A SINGLE STRAND TARGET NUCLEOTIDE SEQUENCE |
Fondzione
Istituto Italiano Di Tecnolgia |
27- Dec- 12 |
27- Dec -13 |
25- Feb -16 |
US20160053
222 |
BACILLUS
BASED DELIVERY SYSTEM AND METHODS OF USE |
Not
Available |
18- Apr- 11 |
9- Sep -15 |
25- Feb -16 |
US20160052
959 |
RADIOLABELED
CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC METHODS |
BRIGHAM
YOUNG UNIVERSITY |
22- Aug- 14 |
19- Aug -15 |
25- Feb -16 |
US20160051
691 |
CARBOHYDRATE
CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES |
Not
Available |
4- Dec-
07 |
25- Aug -15 |
25- Feb -16 |
US20160051
670 |
METHODS
FOR PREPARING SQUALENE |
Not
Available |
12- May- 10 |
23- Oct -15 |
25- Feb -16 |
US20160051
669 |
COMPOSITIONS
AND METHODS FOR SELECTIVELY MODULATING TREGS |
Not
Available |
21- Aug- 14 |
21- Aug -15 |
25- Feb -16 |
US20160046
705 |
HETERODIMERIC
IMMUNOGLOBULINS |
Not
Available |
21- Nov- 12 |
21- Nov -13 |
18- Feb -16 |
US20160046
687 |
GM-CSF
AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS RELATED THERETO |
Not
Available |
23- Oct- 12 |
23- Oct -13 |
18- Feb -16 |
US20160045
547 |
METHOD OF
PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER
SOLUTION |
OCULUS
INNOVATIVE SCIENCES, INC. |
30- Dec- 03 |
27- Oct -15 |
18- Feb -16 |
US20160041
168 |
ARRAYED
DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE |
Not
Available |
2- May-
08 |
23- Oct -15 |
11- Feb -16 |
US20160040
161 |
In
Vivo Delivery of Oligonucleotides |
OncoImmunin
Inc. |
12- Dec- 11 |
12- Dec -12 |
11- Feb -16 |
US20160039
867 |
SINGLE-CHAIN
ANTIPARALLEL COILED COIL PROTEINS |
Complix
NV |
8- Dec-
08 |
21- Aug -15 |
11- Feb -16 |
US20160039
860 |
ENANTIOMERS
OF THE 1',6'-ISOMER OF NEPLANOCIN A |
Not
Available |
4- Aug-
14 |
4- Aug -15 |
11- Feb -16 |
US20160039
826 |
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2- (TRIFLUOROMETHYL)BENZYL)
QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE
INHIBITORS |
Not
Available |
15- Mar- 13 |
14- Mar -14 |
11- Feb -16 |
US20160039
812 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
31- Jul-14 |
27- Jul- 15 |
11- Feb -16 |
US20160032
319 |
VECTORS
COMPRISING STUFFER/FILLER POLYNUCLEOTIDE SEQUENCES AND METHODS OF USE |
THE
CHILDREN'S HOSPITAL OF PHILADELPHIA |
15- Mar- 13 |
14- Mar -14 |
4- Feb -16 |
US20160031
861 |
SUBSTITUTED
OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C |
Not
Available |
1- Aug-
14 |
31- Jul- 15 |
4- Feb -16 |
US20160031
831 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
31- Jul-14 |
27- Jul- 15 |
4- Feb -16 |
US20160031
830 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
31- Jul-14 |
27- Jul- 15 |
4- Feb -16 |
US20160031
829 |
SUBSTITUTED
BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL
ELASTASE ACTIVITY |
Not
Available |
31- Jul-14 |
27- Jul- 15 |
4- Feb -16 |
US20160031
825 |
SUBSTITUTED
DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE
ACTIVITY |
Not
Available |
31- Jul-14 |
27- Jul- 15 |
4- Feb -16 |
US20160030
443 |
METHODS
AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION |
Not
Available |
14- Mar- 13 |
14- Mar -14 |
4- Feb -16 |
US20160025
675 |
METHOD
FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
1- Oct -15 |
28- Jan- 16 |
US20160025
603 |
AIRBORNE
AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS |
Not
Available |
22- Jul-14 |
21- Jul- 15 |
28- Jan- 16 |
US20160024
525 |
REVERSE
GENETICS USING NON-ENDOGENOUS POL I PROMOTERS |
NOVARTIS
AG |
21- May- 09 |
7- May -15 |
28- Jan- 16 |
US20160024
158 |
Inhibitory
Polypeptides Specific to WNT Inhibitors |
Not
Available |
15- Mar- 13 |
14- Mar -14 |
28- Jan- 16 |
US20160022
801 |
RODENT
HEPADNAVIRUS CORES WITH REDUCED CARRIER- SPECIFIC ANTIGENICITY |
Not
Available |
15- Mar- 13 |
14- Mar -14 |
28- Jan- 16 |
US20160016
999 |
INHIBITORY
PEPTIDES OF VIRAL INFECTION |
Not
Available |
17- Jul-14 |
16- Jul- 15 |
21- Jan- 16 |
US20160016
986 |
STABILIZED
NUCLEOTIDES FOR MEDICAL TREATMENT |
Not
Available |
21- Jul-14 |
21- Jul- 15 |
21- Jan- 16 |
US20160016
916 |
Exo
Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
Not
Available |
15- Mar- 13 |
14- Mar -14 |
21- Jan- 16 |
US20160015
826 |
Constructs
Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging |
Not
Available |
24- Jan- 05 |
2- Feb -15 |
21- Jan- 16 |
US20160015
803 |
IMMUNOSTIMULATORY
COMBINATIONS AND USE THEREOF |
Not
Available |
18- Jul-14 |
17- Jul- 15 |
21- Jan- 16 |
US20160011
183 |
MULTIANALYTE
ASSAY |
Not
Available |
30- Apr- 07 |
15- Jun -15 |
14- Jan- 16 |
US20160008
809 |
METHODS
AND COMPOSITIONS FOR PAPER-BASED AND HYBRID MICROFLUIDIC DEVICES INTEGRATED
WITH NUCLEIC ACID AMPLIFICATION FOR DISEASE DIAGNOSIS |
University
of Texas at El Paso |
10- Jul-14 |
10- Jul- 15 |
14- Jan- 16 |
US20160008
461 |
METHODS
OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES |
Not
Available |
8- Jan- 13 |
2- Aug -14 |
14- Jan- 16 |
US20160008
451 |
NANOPARTICLE-BASED
COMPOSITIONS |
Not
Available |
14- Mar- 13 |
14- Mar -14 |
14- Jan- 16 |
US20160008
397 |
IMMUNOMODULATION
BY CONTROLLING EXPRESSION LEVELS OF MICRORNAS IN DENDRITIC CELLS |
Not
Available |
14- Jul-14 |
10- Jul- 15 |
14- Jan- 16 |
US20160008
363 |
DRUG
COMBINATION |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
14- Jan- 16 |
US20160003
747 |
Apparatus
for two-step surface-enhanced raman spectroscopy |
REAL-TIME
ANALYZERS, INC |
16- Dec- 11 |
11- Sep -15 |
7- Jan-
16 |
US20160002
608 |
METHODS
TO PRODUCE BUNYAVIRUS REPLICON PARTICLES |
Not
Available |
20- Sep- 10 |
10- Jul- 15 |
7- Jan-
16 |
US20160000
905 |
Nanoparticle
Delivery of TLR Agonists and Antigens |
Not
Available |
25- Feb- 13 |
24- Feb -14 |
7- Jan-
16 |
US20160000
790 |
DRUG
COMBINATION |
VERONA
PHARMA PLC |
15- Mar- 13 |
17- Mar -14 |
7- Jan-
16 |
US20160000
754 |
Antiviral
Activity from Medicinal Mushrooms and their Active Constituents |
Not
Available |
6- Jan- 04 |
14- Sep -15 |
7- Jan-
16 |
US20150377
887 |
IN
SITU AFFINITY MATURATION OF ANTIBODIES |
Not
Available |
27- Feb- 13 |
27- Feb -14 |
31- Dec -15 |
US20150376
621 |
MODIFIED
SMALL INTERFERING RNA MOLECULES AND METHODS OF USE |
ARROWHEAD
RESEARCH CORPORATION |
28- Feb- 08 |
14- May -15 |
31- Dec -15 |
US20150376
584 |
METHODS
OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA,
EBOLA, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS,
ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND POXVIRUS IN
MAMMALIAN PATIENTS |
TAMIR
BIOTECHNOLOGY, INC. |
28- Mar- 14 |
10- Jun -15 |
31- Dec -15 |
US20150376
145 |
STABLE
SODIUM CHANNEL BLOCKERS |
PARION
SCIENCES, INC. |
30- Jun- 14 |
30- Jun -15 |
31- Dec -15 |
US20150376
131 |
SUBSTITUTED
4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY |
Not
Available |
23- Aug- 12 |
2- Sep -15 |
31- Dec -15 |
US20150374
723 |
Anti-Viral
Azide Containing Compounds |
Not
Available |
28- Jul-10 |
20- Aug -15 |
31- Dec -15 |
US20150374
626 |
TREATMENT
OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE
WITH LIPOSOMALLY FORMULATED GLUTATHIONE |
YOUR
ENERGY SYSTEMS, LLC |
15- Feb- 13 |
15- Mar -13 |
31- Dec -15 |
US20150369
806 |
DETECTION
OF VIRAL DISEASES USING A BIOCHIP THAT CONTAINS GOLD NANOPARTICLES |
Not
Available |
19- Jun- 14 |
17- Jun -15 |
24- Dec -15 |
US20150368
661 |
METHODS
FOR PRODUCING ANTIBODIES |
Not
Available |
11- Feb- 13 |
11- Feb -14 |
24- Dec -15 |
US20150368
294 |
GADD45BETA
TARGETING AGENTS |
Not
Available |
22- Oct- 09 |
10- Feb -15 |
24- Dec -15 |
US20150366
888 |
SUBSTITUTED
NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF |
Not
Available |
24- Jun- 14 |
22- Jun -15 |
24- Dec -15 |
US20150366
796 |
INTRADERMAL
DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS |
Not
Available |
1- Feb- 13 |
30- Jan -14 |
24- Dec -15 |
US20150361
432 |
MODIFIED
SMALL INTERFERING RNA MOLECULES AND METHODS OF USE |
Not
Available |
26- Jul-02 |
6- Aug -15 |
17- Dec -15 |
US20150361
097 |
HETEROCYCLIC
AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS |
Not
Available |
22- Jan- 13 |
21- Jan -14 |
17- Dec -15 |
US20150361
096 |
HETEROCYCLIC
AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS |
Not
Available |
22- Jan- 13 |
21- Jan -14 |
17- Dec -15 |
US20150359
871 |
IMMUNOGENIC
COMPOSITIONS COMPRISING SILICIFIED VIRUS AND METHODS OF USE |
PORTLAND
STATE UNIVERSITY |
31- Jan- 13 |
31- Jan -14 |
17- Dec -15 |
US20150359
746 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
17- Jun -15 |
17- Dec -15 |
US20150355
172 |
ADP-RIBOSE
DETECTION REAGENTS |
The
Board of Regents of the University of Texas System |
10- Jun- 14 |
9- Jun -15 |
10- Dec -15 |
US20150353
905 |
CAS9-NUCLEIC
ACID COMPLEXES AND USES RELATED THERETO |
Not
Available |
16- Jan- 13 |
15- Jan -14 |
10- Dec -15 |
US20150353
596 |
17-Substituted
Steroid Compounds |
Not
Available |
28- Aug- 02 |
24- Aug -15 |
10- Dec -15 |
US20150353
561 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.P.A. |
9- Jun-
14 |
5- Jun -15 |
10- Dec -15 |
US20150352
218 |
HYDRAZINO
1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM |
3M
INNOVATIVE PROPERTIES COMPANY |
3- Jun-
11 |
14- Aug -15 |
10- Dec -15 |
US20150344
425 |
INDOLE
CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS |
ACTELION
PHARMACEUTICALS LTD |
18- Dec- 12 |
17- Dec -13 |
3- Dec -15 |
US20150343
028 |
METHODS
OF MODULATING IMMUNE RESPONSES BY MODIFYING AKT3 BIOACTIVITY |
Not
Available |
17- Apr- 14 |
17- Apr -15 |
3- Dec -15 |
US20150337
369 |
SINGLE
CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT MULTIPLEX AMPLIFICATION AND
DEEP SEQUENCING |
Not
Available |
7- May-
14 |
30- Apr -15 |
26- Nov -15 |
US20150337
334 |
METHOD
FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS
VECTOR |
Not
Available |
16- Jul-08 |
29- Jul- 15 |
26- Nov -15 |
US20150337
015 |
ANTIVIRAL
RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE |
The
United States of America, as represented by the Secretary of the Army, on
behalf of the United |
6- Dec-
12 |
4- Jun -15 |
26- Nov -15 |
US20150335
733 |
Immunogenic
Composition and Methods of Using the Compositions for Inducing Humoral and
Cellular Immune Responses |
Not
Available |
8- Apr-
11 |
27- Apr -15 |
26- Nov -15 |
US20150335
728 |
METHODS
AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS |
Academia
Sinica |
27- Mar- 09 |
18- Feb -14 |
26- Nov -15 |
US20150335
657 |
Methods
for Modulating Sirtuin Enzymes |
Not
Available |
5- May-
14 |
4- May -15 |
26- Nov -15 |
US20150329
866 |
NOVEL
siRNAS AND METHODS OF USE THEREOF |
Not
Available |
25- Oct- 06 |
8- Jan -15 |
19- Nov -15 |
US20150329
834 |
METHODS
OF PROPAGATING MONKEY ADENOVIRAL VECTORS |
GenVec,
Inc. |
9- Nov-
09 |
4- Aug -15 |
19- Nov -15 |
US20150328
282 |
METHODS
FOR TREATING VIRAL DISORDERS |
Not
Available |
24- Sep- 09 |
5- Aug -15 |
19- Nov -15 |
US20150322
491 |
High
density self-contained biological analysis |
Not
Available |
15- Nov- 06 |
16- Jul- 15 |
12- Nov -15 |
US20150322
155 |
ACETYLENEDICARBOXYL
LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE |
Robert
Yongxin Zhao |
15- Jul-15 |
15- Jul- 15 |
12- Nov -15 |
US20150322
137 |
HUMAN
ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR ANTIGEN-BINDING FRAGMENT
THEREOF |
Not
Available |
28- Jan- 13 |
28- Jan -14 |
12- Nov -15 |
US20150322
022 |
THERAPEUTIC
CATECHOLS |
RUTGERS,
THE STATE UNIVERSITY OF NEW JERSEY |
12- May- 14 |
11- May -15 |
12- Nov -15 |
US20150322
008 |
INDOLE
CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST |
ACTELION
PHARMACEUTICALS LTD |
12- Dec- 12 |
11- Dec -13 |
12- Nov -15 |
US20150320
842 |
A
COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL INFECTION COMPRISING
SAMHD1 OR A NUCLEIC ACID MOLECULE ENCODING THE SAMHD1 |
SNU
R&DB FOUNDATION |
7- Jan- 13 |
7- Jan -13 |
12- Nov -15 |
US20150320
801 |
USE
OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS |
Not
Available |
6- May-
14 |
6- May -15 |
12- Nov -15 |
US20150315
612 |
ADENO-ASSOCIATED
VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
30- Sep- 03 |
20- Jul- 15 |
5- Nov -15 |
US20150315
574 |
PRODUCTION
OF STABLE NON-POLYADENYLATED RNAS |
Massachusetts
Institute of Technology |
16- Oct- 12 |
16- Oct -13 |
5- Nov -15 |
US20150314
017 |
DISULFUR
BRIDGE LINKERS FOR CONJUGATION OF A CELL- BINDING MOLECULE |
Dr.
Robert Yongxin Zhao |
15- Jul-15 |
15- Jul- 15 |
5- Nov -15 |
US20150313
960 |
NOVEL
DEPSIPEPTIDE AND USES THEREOF |
Not
Available |
3- Dec-
12 |
1- Jul- 15 |
5- Nov -15 |
US20150313
929 |
USE
OF TYLVALOSIN AS ANTIVIRAL AGENT |
CAMBRIDGE
UNIVERSITY TECHNICAL SERVICES |
13- Jul-06 |
8- Jun -15 |
5- Nov -15 |
US20150313
909 |
ANTIVIRAL
COMPOUNDS AND METHODS |
Biotron
Limited |
26- Jun- 03 |
6- Feb -15 |
5- Nov -15 |
US20150309
018 |
SYSTEM
AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS |
NANOMEDICAL
DIAGNOSTICS, INC. |
28- Apr- 14 |
28- Apr -14 |
29- Oct- 15 |
US20150307
936 |
SYSTEM
AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS |
Nanomedical
Diagnostics, Inc. |
28- Apr- 14 |
10- Apr -15 |
29- Oct- 15 |
US20150307
935 |
NON-MASS
DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID DETECTION |
Not
Available |
6- Aug-
09 |
13- Jul- 15 |
29- Oct- 15 |
US20150307
849 |
HIGHLY
EFFICIENT INFLUENZA MATRIX (M1) PROTEINS |
Not
Available |
11- Jul-03 |
23- Feb -15 |
29- Oct- 15 |
US20150307
572 |
BIOACTIVE
PEPTIDES AND METHODS OF USING SAME |
Not
Available |
12- Jul-07 |
23- Feb -15 |
29- Oct- 15 |
US20150307
530 |
NOVEL
MUCOLYTIC AGENTS |
PARION
SCIENCES, INC. |
31- Aug- 12 |
30- Aug -13 |
29- Oct- 15 |
US20150306
213 |
HMGB1-DERIVED
PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS |
The
Regents of the University of California |
27- Jul-10 |
9- Mar -15 |
29- Oct- 15 |
US20150306
212 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
12- Jun -15 |
29- Oct- 15 |
US20150306
205 |
VACCINE
COMPOSITION FOR NAIVE SUBJECTS |
Not
Available |
17- Dec- 12 |
17- Dec -13 |
29- Oct- 15 |
US20150306
137 |
METHODS
OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE
REDUCTIVE POTENTIAL WATER SOLUTION |
OCULUS
INNOVATIVE SCIENCES, INC. |
20- Jan- 06 |
7- Jul- 15 |
29- Oct- 15 |
US20150301
055 |
CIRCULATING
BIOMARKERS FOR DISEASE |
Not
Available |
6- Apr-
10 |
1- Jul- 15 |
22- Oct- 15 |
US20150299
728 |
TC-83-DERIVED
ALPHAVIRUS VECTORS, PARTICLES AND METHODS |
Not
Available |
18- May- 04 |
6- Jul- 15 |
22- Oct- 15 |
US20150299
707 |
CONSTRUCTION
OF POOL OF INTERFERING NUCLEIC ACIDS COVERING ENTIRE RNA TARGET SEQUENCE AND
RELATED COMPOSITIONS |
BIOMICS
BIOTECHNOLOGIES CO., LTD. |
7-Jul- 08 |
2- Jul- 15 |
22- Oct- 15 |
US20150299
667 |
INFLUENZA
VIRUS AND TYPE 1 DIABETES |
ISTITUTO
ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE |
10- Oct- 12 |
10- Oct -13 |
22- Oct- 15 |
US20150299
271 |
TREATING
CANCER WITH VIRAL NUCLEIC ACID |
Not
Available |
20- Feb- 07 |
6- Jul- 15 |
22- Oct- 15 |
US20150299
194 |
4-AMINO-IMIDAZOQUINOLINE
COMPOUNDS |
HOFFMANN-LA
ROCHE INC. |
22- Apr- 14 |
22- Apr -15 |
22- Oct- 15 |
US20150299
142 |
3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PYRAZINE-2-CARBOXAMIDE COMPOUNDS |
PARION
SCIENCES, INC. |
17- Dec- 12 |
8- Jan -15 |
22- Oct- 15 |
US20150297
700 |
Novel
Adenovirus Vectors |
Not
Available |
10- Apr- 07 |
27- Apr -15 |
22- Oct- 15 |
US20150297
677 |
COMPOSITIONS
AND METHODS FOR INHIBITING VIRAL ENTRY |
Children
Medical Center Corporation |
13- Dec- 12 |
12- Dec -13 |
22- Oct- 15 |
US20150297
668 |
ANALOGS
OF C5a AND METHODS OF USING SAME |
BOARD
PF REGENTS OF THE UNIVERSITY OF NEBRASKA |
29- Jun- 10 |
29- Jun -11 |
22- Oct- 15 |
US20150291
609 |
MERTK-SPECIFIC
PYRIMIDINE COMPOUNDS |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150291
606 |
MERTK-SPECIFIC
PYRROLOPYRIMIDINE COMPOUNDS |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150291
605 |
MERTK-SPECIFIC
PYRAZOLOPYRIMIDINE COMPOUNDS |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150291
531 |
THERAPEUTIC
HYDROXYQUINOLONES |
RUTGERS,
THE STATE UNIVERSITY OF NEW JERSEY |
9- Nov-
12 |
8- Nov -13 |
15- Oct- 15 |
US20150290
235 |
USE
OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE
OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL
MALIGNANCIES OR VIRAL INFECTIONS |
Not
Available |
23- Nov- 12 |
8- Nov -13 |
15- Oct- 15 |
US20150290
234 |
TARGETED
INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS |
Not
Available |
23- Mar- 07 |
21- Apr -15 |
15- Oct- 15 |
US20150290
212 |
THERAPEUTIC
USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE
ACTIVITY |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150290
197 |
THERAPEUTIC
USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE
ACTIVITY |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150290
194 |
THERAPEUTIC
USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY |
Not
Available |
11- Apr- 14 |
3- Apr -15 |
15- Oct- 15 |
US20150290
189 |
CHEMICALLY
AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER
ACTIVITY |
PARION
SCIENCES, INC. |
27- Jun- 11 |
12- Jan -15 |
15- Oct- 15 |
US20150290
134 |
TECHNOLOGY
FOR PREPARATION OF MACROMOLECULAR MICROSPHERES |
Not
Available |
24- Jan- 06 |
21- Apr -15 |
15- Oct- 15 |
US20150289
573 |
SELF
SANITIZING FACE MASKS AND METHOD OF MANUFACTURE |
Not
Available |
1- Jun-
07 |
26- Jun -15 |
15- Oct- 15 |
US20150284
475 |
BISPECIFIC
ANTIBODY |
Not
Available |
21- Nov- 12 |
21- Nov -12 |
8- Oct-
15 |
US20150284
451 |
COMPOSITIONS
AND METHODS FOR INHIBITING PATHOGEN INFECTION |
Not
Available |
29- Oct- 12 |
29- Oct -13 |
8- Oct-
15 |
US20150284
416 |
NOVEL
LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES |
SUZHOU
M-CONJ BIOTECH CO., LTD |
16- Jun- 15 |
16- Jun -15 |
8- Oct-
15 |
US20150283
531 |
Microspotting
Device |
Not
Available |
18- Apr- 12 |
17- Apr -13 |
8- Oct-
15 |
US20150283
233 |
Compositions
and Methods for Enhancing Immune Responses |
Not
Available |
15- Jun- 12 |
17- Jun -13 |
8- Oct-
15 |
US20150283
221 |
ATTENUATED
LISTERIA MONOCYTOGENES MUTANT AS A VACCINE VECTOR FOR THE DELIVERY OF EXOGENEOUS
ANTIGENS |
The
Board of Trustees of the University of Illinois |
7- Apr- 14 |
7- Apr -15 |
8- Oct- 15 |
US20150275
183 |
Human
Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl
Peptidase As Its Virus Receptor |
Not
Available |
23- Sep- 12 |
23- Sep -13 |
1- Oct-
15 |
US20150274
698 |
Hydrazide
Containing Nuclear Transport Modulators And Uses Thereof |
Not
Available |
29- Jul-11 |
10- Jun -15 |
1- Oct-
15 |
US20150272
988 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Advanced
Inhalation Therapies (AIT) Ltd. |
7- Mar-
12 |
7- Mar -13 |
1- Oct-
15 |
US20150267
245 |
PRESERVATION
OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA |
GenTegra,
LLC |
14- Mar- 13 |
14- Mar -14 |
24- Sep -15 |
US20150267
202 |
ANTISENSE
ANTIVIRAL COMPOUND AND METHOD FOR TREATING ss/RNA VIRAL INFECTION |
Not
Available |
16- Sep- 04 |
6- Nov -14 |
24- Sep -15 |
US20150267
194 |
DOUBLE-STRANDED
OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF |
Quark
Pharmaceutical, Inc. |
12- Sep- 12 |
12- Sep -13 |
24- Sep -15 |
US20150266
929 |
VIRUS-LIKE
PARTICLES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS |
Not
Available |
17- May- 02 |
4- May -15 |
24- Sep -15 |
US20150266
901 |
ALKYLOXY
SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES |
Not
Available |
9- Feb-
05 |
8- Jun -15 |
24- Sep -15 |
US20150266
882 |
PYRAZOLO[4,3-D]PYRIMIDINES
AS KINASE INHIBITORS |
Not
Available |
19- Oct- 12 |
18- Oct -13 |
24- Sep -15 |
US20150265
721 |
Compounds
and Methods for Modulating an Immune Response |
Not
Available |
23- Mar- 09 |
23- Dec -14 |
24- Sep -15 |
US20150265
697 |
HIGH-YIELD
TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR GENERATING VIRUS-LIKE PARTICLES |
Academia
Sinica |
5- Sep-
06 |
11- Feb -15 |
24- Sep -15 |
US20150265
696 |
Compositions
And Methods For Treating And Preventing Porcine Reproductive And Respiratory
Syndrome |
Not
Available |
24- Apr- 12 |
23- Feb -15 |
24- Sep -15 |
US20150259
427 |
GITR
BINDING MOLECULES AND USES THEREFOR |
Not
Available |
25- Mar- 05 |
23- Mar -15 |
17- Sep -15 |
US20150259
399 |
ANTIBODIES
AND PROCESSES FOR PREPARING THE SAME |
Not
Available |
16- May- 08 |
18- Mar -15 |
17- Sep -15 |
US20150259
340 |
NOVEL
KINASE INHIBITORS |
Not
Available |
19- Oct- 12 |
18- Oct -13 |
17- Sep -15 |
US20150259
292 |
HETEROCYCLIC
MODULATORS OF LIPID SYNTHESIS |
Not
Available |
8- Mar-
11 |
19- Mar -15 |
17- Sep -15 |
US20150258
191 |
ARRANGING
INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION |
Novartis
AG |
3- Dec-
09 |
13- Mar -15 |
17- Sep -15 |
US20150252
439 |
Methods
and Compositions for Prostate Cancer Metastasis |
Not
Available |
25- Mar- 11 |
20- May -15 |
10- Sep -15 |
US20150252
080 |
FUSION
PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND
METHODS OF MAKING AND USE THEREOF |
Not
Available |
7- Sep- 12 |
9- Sep -13 |
10- Sep -15 |
US20150250
896 |
HYDROPHILIC
LINKERS AND THEIR USES FOR CONJUGATION OF DRUGS TO A CELL BINDING MOLECULES |
Hangzhou
DAC Biotech Co., Ltd. |
24- Nov- 12 |
24- Nov -12 |
10- Sep -15 |
US20150247
190 |
METHODS
AND SYSTEMS FOR MICROFLUIDICS IMAGING AND ANALYSIS |
Not
Available |
5- Oct-
12 |
4- Oct -13 |
3- Sep -15 |
US20150246
110 |
ADJUVANTED
INFLUENZA VACCINES INCLUDING CYTOKINE- INDUCING AGENTS |
Novartis
AG |
4- Nov-
05 |
14- May -15 |
3- Sep -15 |
US20150246
091 |
COMPOUNDS
AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION |
Not
Available |
2- Nov-
07 |
15- May -15 |
3- Sep -15 |
US20150246
015 |
Esters of
Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders |
Not
Available |
3- Oct-
12 |
3- Oct -13 |
3- Sep -15 |
US20150239
940 |
COMPOSITIONS
AND METHODS FOR VIRUS INHIBITION |
AUTOIMMUNE
TECHNOLOGIES, LLC |
4- Nov-
03 |
13- May -15 |
27- Aug -15 |
US20150239
875 |
SUBSTITUTED
PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE
ACTIVITY |
Not
Available |
21- Feb- 14 |
12- Feb -15 |
27- Aug -15 |
US20150238
550 |
AAV
Vectors Targeted to Oligodendrocytes |
Not
Available |
28- Sep- 12 |
27- Sep -13 |
27- Aug -15 |
US20150238
489 |
HETEROCYCLYL
CARBOXAMIDES FOR TREATING VIRAL DISEASES |
Not
Available |
31- Aug- 12 |
30- Aug -13 |
27- Aug -15 |
US20150232
957 |
MODIFIED
OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING
NUCLEIC ACIDS |
Not
Available |
4- Apr- 12 |
4- Apr -13 |
20- Aug -15 |
US20150232
881 |
CRISPR-RELATED
METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
EDITAS
MEDICINE, INC. |
7- Nov-
13 |
7- Nov -14 |
20- Aug -15 |
US20150232
878 |
Construct |
Not
Available |
28- Mar- 06 |
20- Oct -14 |
20- Aug -15 |
US20150232
454 |
THERAPEUTIC
HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES |
RUTGERS,
THE STATE UNIVERSITY OF NEW JERSEY |
11- Sep- 12 |
11- Sep -13 |
20- Aug -15 |
US20150231
232 |
OUTER
MEMBRANE VESICLES |
Not
Available |
18- Sep- 12 |
18- Sep -13 |
20- Aug -15 |
US20150225
432 |
COMPOUNDS
AND COMPOSITIONS AS TLR ACTIVITY MODULATORS |
Novartis
AG |
2- Sep-
09 |
24- Apr -15 |
13- Aug -15 |
US20150218
162 |
SUBSTITUTED
IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES |
Not
Available |
18- Jun- 04 |
13- Apr -15 |
6- Aug -15 |
US20150218
109 |
C-REL
INHIBITORS AND USES THEREOF |
Not
Available |
21- Sep- 12 |
19- Sep -13 |
6- Aug -15 |
US20150216
973 |
METHOD
FOR THE INDUCTION OF AN IMMUNE RESPONSE |
Not
Available |
8- Aug-
12 |
8- Aug -13 |
6- Aug -15 |
US20150211
006 |
CHIRAL
CONTROL |
Not
Available |
13- Jul-12 |
12- Jul- 13 |
30- Jul- 15 |
US20150210
733 |
NUCLEIC
ACID CHEMICAL MODIFICATIONS |
Not
Available |
2- Mar-
09 |
22- Jan -15 |
30- Jul- 15 |
US20150210
655 |
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS |
ASTRAZENECA
AB |
24- Jan- 14 |
21- Jan -15 |
30- Jul- 15 |
US20150203
847 |
CHEMICAL
MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION |
Not
Available |
23- Sep- 08 |
31- Dec -14 |
23- Jul- 15 |
US20150203
816 |
MEANS
AND METHODS FOR INFLUENCING THE STABILITY OF CELLS |
Not
Available |
4- Dec-
09 |
26- Mar -15 |
23- Jul- 15 |
US20150202
284 |
METHOD
OF MAKING A VACCINE |
The
United States of America, as represented by the Secretary, Dept. of Health
& Human Services |
11- Oct- 08 |
20- Jan -15 |
23- Jul- 15 |
US20150196
619 |
EV576 FOR
USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT |
Not
Available |
8- Jan- 10 |
2- Jan -15 |
16- Jul- 15 |
US20150196
578 |
COMBINATION
THERAPY TREATMENT FOR VIRAL INFECTIONS |
Not
Available |
14- Oct- 09 |
10- Dec -14 |
16- Jul- 15 |
US20150196
032 |
ANTIVIRAL
COMPOSITIONS |
Long
Island University |
30- May- 07 |
19- Mar -15 |
16- Jul- 15 |
US20150191
704 |
POXVIRUS-PLASMODIUM
RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND
METHODS OF MAKING AND USING SAME |
Not
Available |
30- Dec- 13 |
19- Dec -14 |
9- Jul- 15 |
US20150191
607 |
Anti-fouling
Paints and Coatings |
REACTIVE
SURFACES, LTD |
3-Jul- 03 |
4- Dec -13 |
9- Jul- 15 |
US20150184
231 |
BIOAGENT
DETECTION OLIGONUCLEOTIDES |
Not
Available |
27- Dec- 11 |
27- Dec -12 |
2- Jul- 15 |
US20150183
837 |
IMMUNOGENIC
COMPOSITIONS AND METHODS OF USE THEREOF |
Not
Available |
17- Dec- 07 |
13- Feb -15 |
2- Jul- 15 |
US20150182
636 |
GENETICALLY
MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR
TREATMENT OF BIOLOGICAL OR CHEMICAL AGENTS |
Not
Available |
21- Apr- 08 |
13- Mar -15 |
2- Jul- 15 |
US20150182
588 |
SYNTHETIC
MEMBRANE-RECEIVER COMPLEXES |
Not
Available |
18- Nov- 13 |
23- Dec -14 |
2- Jul- 15 |
US20150176
027 |
ADENO-ASSOCIATED
VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR |
Not
Available |
17- Dec- 01 |
16- Jan -15 |
25- Jun- 15 |
US20150175
656 |
CRYSTALLINE
TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS |
Not
Available |
20- Mar- 09 |
5- Mar -15 |
25- Jun- 15 |
US20150174
257 |
METHODS
AND REAGENTS FOR EFFICIENT AND TARGETED GENE TRANSFER TO MONOCYTES AND MACROPHAGES |
Not
Available |
29- Apr- 09 |
3- Mar -15 |
25- Jun- 15 |
US20150174
206 |
USES
OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE |
Not
Available |
28- Aug- 03 |
28- Jan -15 |
25- Jun- 15 |
US20150174
198 |
GENE
TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR
PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN |
Not
Available |
28- Oct- 05 |
17- Nov -14 |
25- Jun- 15 |
US20150174
158 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
7- Mar-
12 |
7- Mar -13 |
25- Jun- 15 |
US20150173
366 |
PHYSICAL
ANTIMICROBIAL METHOD |
NMS
TECHNOLOGIES CO., LTD. |
1- Aug-
12 |
16- Jul- 13 |
25- Jun- 15 |
US20150168
405 |
OLIGONUCLEOTIDE
BASED ANALYTE DETECTION METHOD |
Not
Available |
16- Feb- 10 |
24- Feb -15 |
18- Jun- 15 |
US20150166
989 |
PARTICLE-NUCLEIC
ACID CONJUGATES AND THERAPEUTIC USES RELATED THERETO |
Not
Available |
25- Jun- 12 |
27- Feb -13 |
18- Jun- 15 |
US20150166
966 |
REVERSE
GENETICS METHODS FOR VIRUS RESCUE |
Not
Available |
20- Oct- 09 |
1- Oct -14 |
18- Jun- 15 |
US20150166
548 |
NOVEL
COMPOUNDS |
CHIESI
FARMACEUTICI S.p.A. |
16- Dec- 13 |
16- Dec -14 |
18- Jun- 15 |
US20150166
532 |
HOST
TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES |
Not
Available |
11- Apr- 12 |
15- Mar -13 |
18- Jun- 15 |
US20150166
488 |
ARYLALKYL-
AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS |
PARION
SCIENCES, INC. |
13- Dec- 13 |
19- Dec -14 |
18- Jun- 15 |
US20150166
487 |
ARYLALKYL-
AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS |
Parion
Sciences, Inc. |
13- Dec- 13 |
13- Dec -13 |
18- Jun- 15 |
US20150165
019 |
Saccharide
Conjugate Vaccines |
Not
Available |
24- Dec- 04 |
5- Aug -14 |
18- Jun- 15 |
US20150165
009 |
TLR5
LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS RELATED THERETO |
Emory
University |
24- Sep- 10 |
20- Sep -11 |
18- Jun- 15 |
US20150164
800 |
REGULATING
THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED
PHOSPHATIDYL SERINE |
Salk
Institute For Biological Studies |
25- Jul-12 |
23- Jul- 13 |
18- Jun- 15 |
US20150159
205 |
METHODS
AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS |
The
United States of America, as represented by the Secretary, Department of
Health and Human |
6- Aug-
12 |
6- Aug -12 |
11- Jun- 15 |
US20150159
173 |
METHOD
OF INCREASING THE FUNCTION OF AN AAV VECTOR |
The
Trustees of the University of Pennsylvania |
7- Apr-
05 |
18- Feb -15 |
11- Jun- 15 |
US20150157
636 |
METHODS
FOR TREATING VIRAL DISORDERS |
Not
Available |
24- Sep- 09 |
18- Feb -15 |
11- Jun- 15 |
US20150152
149 |
Peptides
Having Activity of Inhibiting Infections of Respiratory Viruses and Use of
the Same |
Not
Available |
9- May-
13 |
21- Feb -14 |
4- Jun-
15 |
US20150150
963 |
VACCINATION
WITH INTERLEUKIN-4 ANTAGONISTS |
THE
AUSTRALIAN NATIONAL UNIVERSITY |
5- Jun-
12 |
5- Jun -13 |
4- Jun-
15 |
US20150150
893 |
ANDROGRAPHOLIDE
ANALOGS AND THEIR USE FOR MEDICATION |
Not
Available |
18- Jun- 12 |
31- May -13 |
4- Jun-
15 |
US20150150
878 |
Methods
For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The
Viruses' Glycoproteins |
Not
Available |
4- Apr-
12 |
4- Apr -13 |
4- Jun-
15 |
US20150148
402 |
MODIFIED
SMALL INTERFERING RNA MOLECULES AND METHODS OF USE |
NOVARTIS
AG |
1- Oct-
04 |
9- May -14 |
28- May -15 |
US20150147
346 |
REPLIKIN
SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES
AGAINST PRION AND NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE |
Not
Available |
2- May- 12 |
1- May -13 |
28- May -15 |
US20150141
625 |
IMMUNE
RESPONSE MODIFIER CONJUGATES |
Not
Available |
22- Feb- 06 |
20- Jan -15 |
21- May -15 |
US20150141
387 |
PHARMACEUTICAL
PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT |
Not
Available |
18- Dec- 08 |
14- Jan -15 |
21- May -15 |
US20150140
121 |
Compositions
and Methods for Tight Junction Modulation |
Not
Available |
8- Jun-
12 |
10- Jun -13 |
21- May -15 |
US20150139
949 |
ANTI-VIRAL
COMBINATION THERAPY |
Not
Available |
6- Apr-
11 |
19- May -14 |
21- May -15 |
US20150133
633 |
MODIFICATION
OF PEPTIDES USING A BIS(THIOETHER)ARYLBRIDGE APPROACH |
Not
Available |
18- May- 12 |
17- May -13 |
14- May -15 |
US20150133
402 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
20- Jun- 07 |
7- Nov -14 |
14- May -15 |
US20150133
391 |
CELL-FREE
NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF |
Not
Available |
7- Nov-
13 |
7- Nov -14 |
14- May -15 |
US20150132
339 |
ADJUVANTED
FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS |
Not
Available |
7- Mar-
12 |
7- Mar -13 |
14- May -15 |
US20150132
337 |
COMBINATION
GAS VACCINES AND THERAPEUTICS |
Not
Available |
17- Sep- 08 |
13- Nov -14 |
14- May -15 |
US20150132
220 |
Compositions
and Imaging Methods Comprising Detectably Labeled
Phosphatidylethanolamine-Binding Peptides |
Not
Available |
15- Jul-02 |
8- Jan -15 |
14- May -15 |
US20150126
722 |
OLIGONUCLEOTIDE
COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS |
Not
Available |
24- Dec- 03 |
4- Jun -14 |
7- May -15 |
US20150125
540 |
RELEASE
OF AGENTS FROM CELLS |
Not
Available |
15- Oct- 09 |
5- Jan -15 |
7- May -15 |
US20150125
502 |
DISINFECTING
COMPOSITION AND WIPES WITH REDUCED CONTACT TIME |
Not
Available |
6- Nov-
13 |
4- Nov -14 |
7- May -15 |
US20150125
483 |
FUSION
PROTEINS OF CILIATE GRANULE LATTICE PROTEINS, GRANULAR PROTEIN PARTICLES
THEREOF, AND USES THEREFOR |
Tetragenetics,
Inc. |
27- May- 11 |
29- May -12 |
7- May -15 |
US20150125
475 |
IMMUNOLOGICALLY
USEFUL ARGININE SALTS |
Not
Available |
7- Mar-
12 |
7- Mar -13 |
7- May -15 |
US20150125
384 |
MODULAR
NANODEVICES FOR SMART ADAPTABLE VACCINES |
Not
Available |
15- Feb- 07 |
10- Nov -14 |
7- May -15 |
US20150119
445 |
Carbohydrate
Conjugates as Delivery Agents for Oligonucleotides |
Not
Available |
4- Dec-
07 |
22- Jul- 14 |
30- Apr- 15 |
US20150119
444 |
Carbohydrate
Conjugates as Delivery Agents for Oligonucleotides |
Not
Available |
4- Dec-
07 |
11- Jul- 14 |
30- Apr- 15 |
US20150119
426 |
MODULATORS
OF THE RELAXIN RECEPTOR 1 |
Not
Available |
4- May-
12 |
15- Mar -13 |
30- Apr- 15 |
US20150119
364 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
10- Nov -14 |
30- Apr- 15 |
US20150119
318 |
PEPTIDE
COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION |
THE
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND |
30- Oct- 09 |
9- Jul- 14 |
30- Apr- 15 |
US20150118
746 |
INFLUENZA
VIRUS REASSORTMENT METHOD |
Not
Available |
21- May- 10 |
24- Oct -14 |
30- Apr- 15 |
US20150118
319 |
PROTEOLYSIS-RESISTANT
CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR |
Not
Available |
27- Feb- 09 |
5- Nov -14 |
30- Apr- 15 |
US20150118
265 |
MODIFIED
ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF |
Anthrogenesis
Corporation |
13- Mar- 12 |
12- Mar -13 |
30- Apr- 15 |
US20150118
264 |
PHARMACEUTICAL
COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE
PROTEIN OR PEPTIDE ANTIGEN |
CureVac
GMBH |
31- Jan- 12 |
31- Jan -13 |
30- Apr- 15 |
US20150118
222 |
TREATMENT
USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY |
Not
Available |
25- Oct- 13 |
24- Oct -14 |
30- Apr- 15 |
US20150118
201 |
Directed
Evolution and In Vitro Panning of Virus Vectors |
Not
Available |
30- Apr- 08 |
22- Oct -14 |
30- Apr- 15 |
US20150118
183 |
NEGATIVELY
CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION |
CUREVAC
GMBH |
31- Jan- 12 |
31- Jan -13 |
30- Apr- 15 |
US20150111
955 |
AAV
VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER TO CELLS, ORGANS AND
TISSUES |
Not
Available |
17- Feb- 12 |
19- Feb -13 |
23- Apr- 15 |
US20150111
945 |
COMPOSITIONS
AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION |
Not
Available |
20- Jul-09 |
28- Mar -14 |
23- Apr- 15 |
US20150111
893 |
Nuclear
Transport Modulators and Uses Thereof |
Not
Available |
9- May-
12 |
9- May -13 |
23- Apr- 15 |
US20150110
807 |
HDC-SIGN
BINDING PEPTIDES |
Sloan-Kettering
Institute for Cancer Research |
19- Dec- 11 |
10- Dec -12 |
23- Apr- 15 |
US20150105
375 |
METHODS
FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED
2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES
INHIBITORS OF CATHEPSIN C |
Not
Available |
14- Mar- 13 |
18- Dec -14 |
16- Apr- 15 |
US20150104
867 |
ANIMAL
PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS |
Baxter
Healthcare SA |
29- Oct- 04 |
2- May -14 |
16- Apr- 15 |
US20150104
500 |
Methods
and Compositions for Preventing a Condition |
Not
Available |
9- Aug-
10 |
28- Aug -14 |
16- Apr- 15 |
US20150099
770 |
CARBOXYLIC
ACID COMPOUNDS |
Not
Available |
18- May- 12 |
17- May -13 |
9- Apr-
15 |
US20150099
769 |
PYRROLO[3,2-D]PYRIMIDIN-4-ONE
DERIVATIVES AND THEIR USE IN THERAPY |
Not
Available |
6- Dec-
04 |
15- Sep -14 |
9- Apr-
15 |
US20150099
764 |
DENDRIMER
LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE
TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES |
PARION
SCIENCES, INC. |
29- May- 12 |
9- Dec -14 |
9- Apr- 15 |
US20150099
656 |
Multiplex
Immuno Screening Assay |
Not
Available |
4- May-
12 |
3- May -13 |
9- Apr-
15 |
US20150099
263 |
SELECTIVE
DETECTION OF HUMAN RHINOVIRUS |
Not
Available |
5- Dec-
08 |
15- Dec -14 |
9- Apr-
15 |
US20150099
261 |
RESPIRATORY
INFECTION ASSAY |
Not
Available |
9- Dec-
11 |
10- Dec -12 |
9- Apr-
15 |
US20150093
413 |
NUCLEIC
ACID COMPRISING OR CODING FOR A HISTONE STEM- LOOP AND A POLY(A) SEQUENCE OR
A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED
PATHOGENIC ANTIGEN |
CureVac
GmbH |
15- Feb- 12 |
15- Feb -13 |
2- Apr- 15 |
US20150086
576 |
SORTASE-MODIFIED
VHH DOMAINS AND USES THEREOF |
Not
Available |
13- Apr- 12 |
15- Apr -13 |
26- Mar -15 |
US20150080
447 |
Sceletium
Extract and Uses Thereof |
H.
L. Hall & Sons Limited |
20- Mar- 09 |
15- Jul- 14 |
19- Mar -15 |
US20150080
396 |
Novel Pyrimidine
Derivatives and Their Use in the Treatment of Cancer and Further Diseases |
ASTRAZENECA
AB |
21- May- 09 |
26- Aug -14 |
19- Mar -15 |
US20150080
344 |
PHOSPHONATES
WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS |
Not
Available |
14- Apr- 10 |
29- Sep -14 |
19- Mar -15 |
US20150080
319 |
Inhibition
Of Tace Activity With Cyclic Peptides |
Not
Available |
2- Jun-
11 |
19- Sep -14 |
19- Mar -15 |
US20150079
155 |
Cationic
Liposomal Drug Delivery System for Specific Targeting of Human CD14+
Monocytes in Whole Blood |
Not
Available |
14- Mar- 12 |
14- Mar -13 |
19- Mar -15 |
US20150079
121 |
Human
Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid Constructs And
Vaccines Made Therefrom, And Methods Of Using Same |
Not
Available |
10- Apr- 12 |
10- Apr -13 |
19- Mar -15 |
US20150073
136 |
PYRAZINONE
DERIVATIVES |
Not
Available |
27- Jun- 07 |
17- Nov -14 |
12- Mar -15 |
US20150072
973 |
NOVEL
SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL
COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS |
Not
Available |
13- Aug- 10 |
17- Sep -14 |
12- Mar -15 |
US20150072
023 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
11- Sep- 13 |
11- Sep -14 |
12- Mar -15 |
US20150065
459 |
BORON-CONTAINING
SMALL MOLECULES |
Not
Available |
16- Feb- 05 |
10- Nov -14 |
5- Mar -15 |
US20150065
458 |
Composition
for Inactivating an Enveloped Virus |
Not
Available |
19- May- 06 |
17- Nov -14 |
5- Mar -15 |
US20150064
137 |
USE OF
ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT CELLS |
Kythera
Biopharmaceuticals, Inc. |
17- Apr- 12 |
16- Apr -13 |
5- Mar -15 |
US20150056
636 |
Transgenic
Immunodeficient Mouse Expressing Human SIRP-alpha |
Not
Available |
26- Mar- 12 |
26- Mar -13 |
26- Feb -15 |
US20150056
305 |
DITHIOL
MUCOLYTIC AGENTS |
PARION
SCIENCES, INC. |
23- Aug- 13 |
13- Aug -14 |
26- Feb -15 |
US20150051
206 |
COMPOUNDS
AND COMPOSITIONS AS C-KIT KINASE INHIBITORS |
IRM
LLC |
1- Sep-
11 |
29- Aug -12 |
19- Feb -15 |
US20150050
713 |
Technology
for the Preparation of Microparticles |
Not
Available |
24- Jul-07 |
25- Jul- 14 |
19- Feb -15 |
US20150050
308 |
CORONAVIRUS,
NUCLEIC ACID, PROTEIN, AND METHODS FOR THE GENERATION OF VACCINE, MEDICAMENTS
AND DIAGNOSTICS |
Not
Available |
18- Aug- 03 |
13- Aug -14 |
19- Feb -15 |
US20150050
278 |
SOLUBLE
ENGINEERED MONOMERIC FC |
Not
Available |
16- Mar- 12 |
14- Mar -13 |
19- Feb -15 |
US20150045
412 |
USE
OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE
AND PROMOTING AUTHOPHAGY |
Not
Available |
7- Mar- 12 |
6- Mar -13 |
12- Feb -15 |
US20150044
768 |
METHODS
AND COMPOSITIONS FOR PRODUCTION OF RECOMBINANT PROTEIN IN HBX-EXPRESSING
MAMMALIAN CELLS |
Not
Available |
28- May- 08 |
24- Oct -14 |
12- Feb -15 |
US20150044
305 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Not
Available |
7- Mar-
12 |
7- Mar -13 |
12- Feb -15 |
US20150044
279 |
METHODS
AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE |
Not
Available |
10- Apr- 03 |
6- Oct -14 |
12- Feb -15 |
US20150037
288 |
METHODS
FOR INCREASING THE INFECTIVITY OF VIRUSES |
Not
Available |
26- Jan- 12 |
25- Jan -13 |
5- Feb -15 |
US20150037
281 |
VARIANTS
OF PROTHYMOSIN ALPHA AND METHODS OF USING SAME |
Icahn
School of Medicine at Mount Sinai |
2- Mar-
12 |
1- Mar -13 |
5- Feb -15 |
US20150034
084 |
INHALATION
OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES |
Advanced
Inhalation Therapies (AIT) Ltd. |
7- Mar-
12 |
7- Mar -13 |
5- Feb -15 |
US20150031
038 |
SAMPLE
PREPARATION METHODS |
Not
Available |
6- Sep-
11 |
6- Sep -12 |
29- Jan- 15 |
US20150031
016 |
Mixed
Cell Diagnostic Systems For Detection Of Respiratory, Herpes and Enteric
Viruses |
Diagnostic
Hybrids Inc. |
24- Apr- 98 |
4- Aug -14 |
29- Jan- 15 |
US20150031
014 |
DETECTING
ANALYTES WITH A PH METER |
The
Board of Trustees of the University of Illinois |
25- Jul-13 |
25- Jul- 14 |
29- Jan- 15 |
US20150030
627 |
Trans-complementing,
replication deficient lentiviral vectors and methods for making and using
them |
VIRxSYS.CON390 |
17- Aug- 06 |
8- Oct -14 |
29- Jan- 15 |
US20150030
626 |
IMMUNOMODULATORY
CONJUGATES |
Ascend
Biopharamaceuticals Ltd |
9- Nov-
11 |
9- Nov -12 |
29- Jan- 15 |
Blog: www.Zinglepathy.comEmail Address: rx@zinglepathy.com
Online Health Store: www.ZinglepathyRx.store
Etsy Page - Health Consultation & Astrology Readings: www.zinglepathyrx.
Twitter: @cjzingle
Twitter: @ZinglepathyRx
Telegram Channel: https://t.me/XoanaRa
Telegram Message: https://t.me/
Instagram: @cjzingle
Pinterest: @ZinglepathyRx
Facebook Page: https://www.facebook.
Wow! An amazing amount of work went into this post, thank you. With this information available and this system is still thriving. How to stop this monster is the question.
ReplyDelete